



(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 48/00 (2006.01)  
C12N 15/10 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2020/019766

(22) International Filing Date:

25 February 2020 (25.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/810,320 25 February 2019 (25.02.2019) US

(71) Applicant: EDITAS MEDICINE, INC. [US/US]; 11 Hurley Street, Cambridge, Massachusetts 02141 (US).

(72) Inventors: DINER, Benjamin Aryeh; 40 Grant Street #2, Somerville, Massachusetts 02145 (US). REYON, Deepak; 360 Washington Street #2, Somerville, Massachusetts 02143 (US).

(74) Agent: PROCHNOW, Courtney; Perkins Coie LLP, P.O. Box 1247, Seattle, Washington 98111-1247 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP)

(57) Abstract: CRISPR/RNA-guided nuclease-related compositions and methods for treatment of RHO-associated retinitis pigmentosa, e.g., autosomal-dominant retinitis pigmentosa (adRP).



**CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS  
FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS  
PIGMENTOSA (ADRP)**

**PRIORITY CLAIM**

5           The present application claims the benefit of United States Provisional Patent Application No. 62/810,320, filed February 25, 2019, the subject matter of which is hereby incorporated by reference in its entirety, as if fully set forth herein.

**FIELD**

10           The disclosure relates to CRISPR/RNA-guided nuclease-related methods and components for editing a target nucleic acid sequence, and applications thereof in connection with autosomal dominant retinitis pigmentosa (ADRP).

**BACKGROUND**

15           Retinitis pigmentosa (RP), an inherited retinal dystrophy that affects photoreceptors and retinal pigment epithelium cells, is characterized by progressive retinal deterioration and atrophy, resulting in a gradual loss of vision and ultimately leading to blindness in affected patients. RP can be caused by both homozygous and heterozygous mutations and can present in various forms, for example, as autosomal-dominant RP (adRP), autosomal recessive RP  
20           (arRP) or X-linked RP (X-LRP). Treatment options for RP are limited, and no approved treatment that can arrest or reverse RP progression is currently available.

**SUMMARY**

25           Some aspects of the strategies, methods, compositions, and treatment modalities provided herein address a key unmet need in the field by providing new and effective means of delivering genome editing systems to the affected cells and tissues of subjects suffering from autosomal-dominant retinitis pigmentosa (adRP). Some aspects of this disclosure provide strategies, methods, and compositions for the introduction of genome editing systems targeted to the adRP associated gene rhodopsin into retinal cells. Such strategies, methods,  
30           and compositions are useful, in some embodiments, for editing adRP associated variants of the rhodopsin gene, e.g., for inducing gene editing events that result in loss-of-function of such rhodopsin variants. In some embodiments, such strategies, methods, and compositions are useful as treatment modalities for administration to a subject in need thereof, e.g., to a

subject having an autosomal-dominant form of RP. The strategies, methods, compositions, and treatment modalities provided herein thus represent an important step forward in the development of clinical interventions for the treatment of RP, e.g., for the treatment of adRP.

The *RHO* gene encodes the rhodopsin protein and is expressed in retinal photoreceptor (PR) rod cells. Rhodopsin is a G protein-coupled receptor expressed in the outer segment of rod cells and is a critical element of the phototransduction cascade. Defects in the *RHO* gene are typically characterized by decreased production of wild-type rhodopsin and/or expression of mutant rhodopsin which lead to interruptions in photoreceptor function and corresponding vision loss. Mutations in *RHO* typically result in degeneration of PR rod cells first, followed by degeneration of PR cone cells as the disease progresses. Subjects with *RHO* mutations experience progressive loss of night vision, as well as loss of peripheral visual fields followed by loss of central visual fields. Exemplary *RHO* mutations are provided in **Table A**.

Some aspects of the present disclosure provide strategies, methods, compositions, and treatment modalities for altering a *RHO* gene sequence, e.g., altering the sequence of a wild type and/or of a mutant *RHO* gene, e.g., in a cell or in a patient having adRP, by insertion or deletion of one or more nucleotides mediated by an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) and one or more guide RNAs (gRNAs), resulting in loss of function of the *RHO* gene sequence. This type of alteration is also referred to as “knocking out” the *RHO* gene.

Some aspects of the present disclosure provide strategies, methods, compositions, and treatment modalities for expressing exogenous *RHO*, e.g., in a cell subjected to an RNA-guided nuclease-mediated knock-out of *RHO*, e.g., by delivering an exogenous *RHO* complementary DNA (cDNA) sequence encoding a functional rhodopsin protein (e.g., a wild-type rhodopsin protein).

In certain embodiments, a 5' region of the *RHO* gene (e.g., 5' untranslated region (UTR), exon 1, exon 2, intron 1, the exon 1/intron 1 border or the exon 2/intron 1 border) is targeted by an RNA-guided nuclease to alter the gene. In certain embodiments, any region of the *RHO* gene (e.g., a promoter region, a 5' untranslated region, a 3' untranslated region, an exon, an intron, or an exon/intron border) is targeted by an RNA-guided nuclease to alter the gene. In certain embodiments, a non-coding region of the *RHO* gene (e.g., an enhancer region, a promoter region, an intron, 5' UTR, 3'UTR, polyadenylation signal) is targeted to alter the gene. In certain embodiments, a coding region of the *RHO* gene (e.g., early coding region, an exon) is targeted to alter the gene. In certain embodiments, a region spanning an exon/intron border of the *RHO* gene (e.g., exon 1/intron 1, exon 2/intron 1) is targeted to alter

the gene. In certain embodiments, a region of the *RHO* gene is targeted which, when altered, results in a stop codon and knocking out the *RHO* gene. In certain embodiments, alteration of the mutant *RHO* gene occurs in a mutation-independent manner, which provides the benefit of circumventing the need to develop therapeutic strategies for each *RHO* mutation set forth in **Table A**.

In an embodiment, after treatment, one or more symptoms associated with adRP (e.g., nyctalopia, abnormal electroretinogram, cataract, visual field defect, rod-cone dystrophy, or other symptom(s) known to be associated with adRP) is ameliorated, e.g., progression of adRP is delayed, inhibited, prevented or halted, PR cell degeneration is delayed, inhibited, prevented and/or halted, and/or visual loss is ameliorated, e.g., progression of visual loss is delayed, inhibited, prevented, or halted. In an embodiment, after treatment, progression of adRP is delayed, e.g., PR cell degeneration is delayed. In an embodiment, after treatment, progression of adRP is reversed, e.g., function of existing PR rod cells and cone cells and/or birth of new PR rod cells and cone cells is increased/enhanced and/or visual loss e.g., progression of visual loss is delayed, inhibited, prevented, or halted.

In an embodiment, CRISPR/RNA-guided nuclease-related methods and components and compositions of the disclosure provide for the alteration (e.g., knocking out) of a mutant *RHO* gene associated with adRP, by altering the sequence at a *RHO* target position, e.g., by creating an indel resulting in loss-of-function of the affected *RHO* gene or allele, e.g., a nucleotide substitution resulting in a truncation, nonsense mutation, or other type of loss-of-function of an encoded *RHO* gene product, e.g., of the encoded *RHO* mRNA or RHO protein; a deletion of one or more nucleotides resulting in a truncation, nonsense mutation, or other type of loss-of-function of an encoded *RHO* gene product, e.g., of the encoded *RHO* mRNA or RHO protein, e.g., a single nucleotide, double nucleotide, or other frame-shifting deletion, or a deletion resulting in a premature stop codon; or an insertion resulting in a truncation, nonsense mutation, or other type of loss-of-function of an encoded *RHO* gene product, e.g., of the encoded *RHO* mRNA or RHO protein e.g., a single nucleotide, double nucleotide, or other frame-shifting insertion, or an insertion resulting in a premature stop codon. In some embodiments, CRISPR/RNA-guided nuclease-related methods and components and compositions of the disclosure provide for the alteration (e.g., knocking out) of a mutant *RHO* gene associated with adRP, by altering the sequence at a *RHO* target position, e.g., creating an indel that results in nonsense-mediated decay of an encoded gene product, e.g., an encoded *RHO* transcript.

In one aspect, disclosed herein is a gRNA molecule, e.g., an isolated or non-naturally occurring gRNA molecule, comprising a targeting domain which is complementary with a target domain from the *RHO* gene.

In an embodiment, the targeting domain of the gRNA molecule is configured to  
5 provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to an *RHO* target position, in the *RHO* gene to allow alteration in the *RHO* gene, resulting in disruption (e.g., knocking out) of the *RHO* gene activity, e.g., a loss-of-function of the *RHO* gene, for example, characterized by reduced or abolished expression of a *RHO* gene product (e.g., a *RHO* transcript or a *RHO* protein), or by expression of a dysfunctional  
10 or non-functional *RHO* gene product (e.g., a truncated *RHO* protein or transcript). In an embodiment, the targeting domain is configured such that a cleavage event, e.g., a double strand or single strand break, is positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of an *RHO* target position. The break, e.g., a double strand or single strand break, can be positioned upstream or downstream of an *RHO*  
15 target position, in the *RHO* gene.

In an embodiment, a second gRNA molecule comprising a second targeting domain is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to the *RHO* target position, in the *RHO* gene, to allow alteration in the *RHO* gene, either alone or in combination with the break positioned by said first gRNA molecule.  
20 In an embodiment, the targeting domains of the first and second gRNA molecules are configured such that a cleavage event, e.g., a double strand or single strand break, is positioned, independently for each of the gRNA molecules, within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position. In an embodiment, the breaks, e.g., double strand or single strand breaks, are positioned on both  
25 sides of a nucleotide of a *RHO* target position, in the *RHO* gene. In an embodiment, the breaks, e.g., double strand or single strand breaks, are positioned on one side, e.g., upstream or downstream, of a nucleotide of a *RHO* target position, in the *RHO* gene.

In an embodiment, a single strand break is accompanied by an additional single strand break, positioned by a second gRNA molecule, as discussed below. For example, the  
30 targeting domains are configured such that a cleavage event, e.g., the two single strand breaks, are positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of a *RHO* target position. In an embodiment, the first and second gRNA molecules are configured such, that when guiding a Cas9 nickase, a single strand break will be accompanied by an additional single strand break, positioned by a second

gRNA, sufficiently close to one another to result in alteration of a *RHO* target position, in the *RHO* gene. In an embodiment, the first and second gRNA molecules are configured such that a single strand break positioned by said second gRNA is within 10, 20, 30, 40, or 50 nucleotides of the break positioned by said first gRNA molecule, e.g., when the Cas9 is a nickase. In an embodiment, the two gRNA molecules are configured to position cuts at the same position, or within a few nucleotides of one another, on different strands, e.g., essentially mimicking a double strand break.

In an embodiment, a double strand break can be accompanied by an additional double strand break, positioned by a second gRNA molecule, as is discussed below. For example, the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of a *RHO* target position, in the *RHO* gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position; and the targeting domain of a second gRNA molecule is configured such that a double strand break is positioned downstream of a *RHO* target position, in the *RHO* gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position.

In an embodiment, a double strand break can be accompanied by two additional single strand breaks, positioned by a second gRNA molecule and a third gRNA molecule. For example, the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of a *RHO* target position, in the *RHO* gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position; and the targeting domains of a second and third gRNA molecule are configured such that two single strand breaks are positioned downstream of a *RHO* target position, in the *RHO* gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position. In an embodiment, the targeting domain of the first, second and third gRNA molecules are configured such that a cleavage event, e.g., a double strand or single strand break, is positioned, independently for each of the gRNA molecules.

In an embodiment, a first and second single strand breaks can be accompanied by two additional single strand breaks positioned by a third gRNA molecule and a fourth gRNA molecule. For example, the targeting domain of a first and second gRNA molecule are configured such that two single strand breaks are positioned upstream of a *RHO* target position, in the *RHO* gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position; and the targeting domains of a third

and fourth gRNA molecule are configured such that two single strand breaks are positioned downstream of a *RHO* target position, in the *RHO* gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position.

It is contemplated herein that when multiple gRNAs are used to generate (1) two single stranded breaks in close proximity (2) one double stranded break and two paired nicks flanking a *RHO* target position (e.g., to remove a piece of DNA) or (3) four single stranded breaks, two on each side of a *RHO* target position, that they are targeting the same *RHO* target position. It is further contemplated herein that multiple gRNAs may be used to target more than one *RHO* target position in the same gene.

In some embodiments, the targeting domain of the first gRNA molecule and the targeting domain of the second gRNA molecules are complementary to opposite strands of the target nucleic acid molecule. In some embodiments, the gRNA molecule and the second gRNA molecule are configured such that the PAMs are oriented outward.

In an embodiment, the targeting domain of a gRNA molecule is configured to avoid unwanted target chromosome elements, such as repeat elements, e.g., Alu repeats, in the target domain. The gRNA molecule may be a first, second, third and/or fourth gRNA molecule.

In an embodiment, the *RHO* target position is a target position located in exon 1 or exon 2 of the *RHO* gene and the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from **Table 1**. In some embodiments, the targeting domain is selected from those in **Table 1**. In an embodiment, the *RHO* target position is a target position located in the 5' UTR region of the *RHO* gene and the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of **Table 2**. In some embodiments, the targeting domain is selected from those in **Table 2**. In an embodiment, the target position is a target position located in intron 1 of the *RHO* gene and the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of **Table 3**. In some embodiments, the targeting domain is selected from those in **Table 3**. In an embodiment, the target position is a target position located in the *RHO* gene and the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of **Table 18**. In some embodiments, the targeting domain is selected from those in **Table 18**. In an embodiment,

the gRNA, e.g., a gRNA comprising a targeting domain, which is complementary with the *RHO* gene, is a modular gRNA. In other embodiments, the gRNA is a unimolecular or chimeric gRNA.

In an embodiment, the targeting domain which is complementary with the *RHO* gene is 17 nucleotides or more in length. In an embodiment, the targeting domain is 17 nucleotides in length. In other embodiments, the targeting domain is 18 nucleotides in length. In still other embodiments, the targeting domain is 19 nucleotides in length. In still other embodiments, the targeting domain is 20 nucleotides in length. In still other embodiments, the targeting domain is 21 nucleotides in length. In still other embodiments, the targeting domain is 22 nucleotides in length. In still other embodiments, the targeting domain is 23 nucleotides in length. In still other embodiments, the targeting domain is 24 nucleotides in length. In still other embodiments, the targeting domain is 25 nucleotides in length. In still other embodiments, the targeting domain is 26 nucleotides in length.

A gRNA as described herein may comprise from 5' to 3': a targeting domain (comprising a "core domain", and optionally a "secondary domain"); a first complementarity domain; a linking domain; a second complementarity domain; a proximal domain; and a tail domain. In some embodiments, the proximal domain and tail domain are taken together as a single domain.

In an embodiment, a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting domain of 17, 18, 19 or 20 nucleotides in length.

In another embodiment, a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain of 17, 18, 19 or 20 nucleotides in length.

In another embodiment, a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain of 17, 18, 19 or 20 nucleotides in length.

In another embodiment, a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain of 17, 18, 19 or 20 nucleotides in length.

A cleavage event, e.g., a double strand or single strand break, is generated by an RNA-guided nuclease (e.g., a Cas9 or Cpf1 molecule). The Cas9 molecule may be an enzymatically active Cas9 (eaCas9) molecule, e.g., an eaCas9 molecule that forms a double strand break in a target nucleic acid or an eaCas9 molecule forms a single strand break in a

target nucleic acid (e.g., a nickase molecule). In certain embodiments, the RNA-guided nuclease may be a Cpf1 molecule.

In some embodiments, the RNA-guided nuclease (e.g., eaCas9 molecule or Cpf1 molecule) catalyzes a double strand break.

5 In some embodiments, the eaCas9 molecule comprises HNH-like domain cleavage activity but has no, or no significant, N-terminal RuvC-like domain cleavage activity. In this case, the eaCas9 molecule is an HNH-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at D10, e.g., D10A. In other embodiments, the eaCas9 molecule comprises N-terminal RuvC-like domain cleavage activity but has no, or no significant,  
10 HNH-like domain cleavage activity. In this instance, the eaCas9 molecule is an N-terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at H840, e.g., H840A.

In certain embodiments, the Cas9 molecule may be a self-inactivating Cas9 molecule designed for transient expression of the Cas9 protein.

15 In an embodiment, a single strand break is formed in the strand of the target nucleic acid to which the targeting domain of said gRNA is complementary. In another embodiment, a single strand break is formed in the strand of the target nucleic acid other than the strand to which the targeting domain of said gRNA is complementary.

In another aspect, disclosed herein is a nucleic acid, e.g., an isolated or non-naturally occurring nucleic acid, e.g., DNA, that comprises (a) a sequence that encodes a gRNA  
20 molecule comprising a targeting domain, as disclosed herein.

In an embodiment, the nucleic acid encodes a gRNA molecule, e.g., a first gRNA molecule, comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a *RHO* target position, in the  
25 *RHO* gene to allow alteration in the *RHO* gene. In an embodiment, the nucleic acid encodes a gRNA molecule, e.g., the first gRNA molecule, comprising a targeting domain comprising a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence selected from those set forth in **Tables 1-3** and **18**. In an embodiment, the nucleic acid encodes a gRNA molecule comprising a targeting domain  
30 sequence selected from those set forth in **Tables 1-3** and **18**.

In an embodiment, the nucleic acid encodes a modular gRNA, e.g., one or more nucleic acids encode a modular gRNA. In other embodiments, the nucleic acid encodes a chimeric gRNA. The nucleic acid may encode a gRNA, e.g., the first gRNA molecule, comprising a targeting domain comprising 17 nucleotides or more in length. In one

embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 17 nucleotides in length. In other embodiments, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 18 nucleotides in length. In still other embodiments, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 19 nucleotides in length. In still other embodiments, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 20 nucleotides in length.

In an embodiment, a nucleic acid encodes a gRNA comprising from 5' to 3': a targeting domain (comprising a "core domain", and optionally a "secondary domain"); a first complementarity domain; a linking domain; a second complementarity domain; a proximal domain; and a tail domain. In some embodiments, the proximal domain and tail domain are taken together as a single domain.

In an embodiment, a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting domain of 17, 18, 19 or 20 nucleotides in length.

In an embodiment, a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain of 17, 18, 19 or 20 nucleotides in length.

In an embodiment, a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain of 17, 18, 19 or 20 nucleotides in length.

In an embodiment, a nucleic acid encodes a gRNA comprising e.g., the first gRNA molecule, a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain of 17, 18, 19 or 20 nucleotides in length.

In an embodiment, a nucleic acid comprises (a) a sequence that encodes a gRNA molecule e.g., the first gRNA molecule, comprising a targeting domain that is complementary with a *RHO* target domain in the *RHO* gene as disclosed herein, and further comprising (b) a sequence that encodes an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule).

The Cas9 molecule may be an enzymatically active Cas9 (eaCas9) molecule, e.g., an eaCas9 molecule that forms a double strand break in a target nucleic acid or an eaCas9 molecule forms a single strand break in a target nucleic acid (e.g., a nickase molecule).

A nucleic acid disclosed herein may comprise (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a *RHO* target domain in the *RHO* gene as disclosed herein; (b) a sequence that encodes an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule); (c) a *RHO* cDNA molecule; and further comprises (d)(i) a sequence that encodes a second gRNA molecule described herein having a targeting domain that is complementary to a second target domain of the *RHO* gene, and optionally, (ii) a sequence that encodes a third gRNA molecule described herein having a targeting domain that is complementary to a third target domain of the *RHO* gene; and optionally, (iii) a sequence that encodes a fourth gRNA molecule described herein having a targeting domain that is complementary to a fourth target domain of the *RHO* gene.

In an embodiment, the *RHO* cDNA molecule is a double stranded nucleic acid. In some embodiments, the *RHO* cDNA molecule comprises a nucleotide sequence, e.g., of one or more nucleotides, encoding rhodopsin protein. In certain embodiments, the *RHO* cDNA molecule is not codon modified. In certain embodiments, the *RHO* cDNA molecule is codon modified to provide resistance to hybridization with a gRNA molecule. In certain embodiments, the *RHO* cDNA molecule is codon modified to provide improved expression of the encoded RHO protein (e.g., SEQ ID NOS:13-18). In certain embodiments, the *RHO* cDNA molecule may include a nucleotide sequence comprising exon 1, exon 2, exon 3, exon 4, and exon 5 of the *RHO* gene. In certain embodiments, the *RHO* cDNA may include an intron (e.g., SEQ ID NOS:4-7). In certain embodiments, the *RHO* cDNA molecule may include a nucleotide sequence comprising exon 1, intron 1, exon 2, exon 3, exon 4, and exon 5 of the *RHO* gene. In certain embodiments, the *RHO* cDNA molecule may include one or more of a nucleotide sequence comprising or consisting of the sequences selected from exon 1, intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, and exon 5 of the *RHO* gene. In certain embodiments, the intron comprises one or more truncations at a 5' end of intron 1, a 3' end of intron 1, or both.

In an embodiment, a nucleic acid encodes a second gRNA molecule comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a *RHO* target position, in the *RHO* gene, to allow alteration in the *RHO* gene, either alone or in combination with the break positioned by said first gRNA molecule.

In an embodiment, a nucleic acid encodes a third gRNA molecule comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a *RHO* target position, in the *RHO* gene to allow alteration in the *RHO* gene, either alone or in combination with the break positioned by the first and/or second gRNA molecule.

In an embodiment, a nucleic acid encodes a fourth gRNA molecule comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a *RHO* target position, in the *RHO* gene to allow alteration either alone or in combination with the break positioned by the first gRNA molecule, the second gRNA molecule and the third gRNA molecule.

In an embodiment, the nucleic acid encodes a second gRNA molecule. The second gRNA is selected to target the same *RHO* target position, as the first gRNA molecule. Optionally, the nucleic acid may encode a third gRNA, and further optionally, the nucleic acid may encode a fourth gRNA molecule. The third gRNA molecule and the fourth gRNA molecule are selected to target the same *RHO* target position, as the first and second gRNA molecules.

In an embodiment, the nucleic acid encodes a second gRNA molecule comprising a targeting domain comprising a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence selected from those set forth in **Tables 1-3 and 18**. In an embodiment, the nucleic acid encodes a second gRNA molecule comprising a targeting domain selected from those set forth in **Tables 1-3 and 18**. In an embodiment, when a third or fourth gRNA molecule are present, the third and fourth gRNA molecules may independently comprise a targeting domain comprising a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence selected from those set forth in **Tables 1-3 and 18**. In a further embodiment, when a third or fourth gRNA molecule are present, the third and fourth gRNA molecules may independently comprise a targeting domain selected from those set forth in **Tables 1-3 and 18**.

In an embodiment, the nucleic acid encodes a second gRNA which is a modular gRNA, e.g., wherein one or more nucleic acid molecules encode a modular gRNA. In other embodiments, the nucleic acid encoding a second gRNA is a chimeric gRNA. In other embodiments, when a nucleic acid encodes a third or fourth gRNA, the third and fourth gRNA may be a modular gRNA or a chimeric gRNA. When multiple gRNAs are used, any combination of modular or chimeric gRNAs may be used.

A nucleic acid may encode a second, a third, and/or a fourth gRNA comprising a targeting domain comprising 17 nucleotides or more in length. In an embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 17 nucleotides in length. In other embodiments, the nucleic acid encodes a second gRNA comprising a  
5 targeting domain that is 18 nucleotides in length. In still other embodiments, the nucleic acid encodes a second gRNA comprising a targeting domain that is 19 nucleotides in length. In still other embodiments, the nucleic acid encodes a second gRNA comprising a targeting domain that is 20 nucleotides in length.

10 In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising from 5' to 3': a targeting domain; a first complementarity domain; a linking domain; a second complementarity domain; a proximal domain; and a tail domain. In some embodiments, the proximal domain and tail domain are taken together as a single domain.

In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail  
15 domain, that taken together, are at least 20 nucleotides in length; and a targeting domain of 17, 18, 19 or 20 nucleotides in length.

In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain of  
20 17, 18, 19 or 20 nucleotides in length.

In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain of  
17, 18, 19 or 20 nucleotides in length.

25 In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain of 17, 18, 19 or 20 nucleotides in length.

As described above, a nucleic acid may comprise (a) a sequence encoding a gRNA  
30 molecule comprising a targeting domain that is complementary with a target domain in the *RHO* gene, (b) a sequence encoding an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule), and (c) a *RHO* cDNA molecule sequence. In some embodiments, (a), (b), and (c) are present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., the same adeno-associated virus (AAV) vector. In an embodiment, the nucleic acid molecule is

an AAV vector. Exemplary AAV vectors that may be used in any of the described compositions and methods include an AAV5 vector, a modified AAV5 vector, AAV2 vector, a modified AAV2 vector, an AAV3 vector, a modified AAV3 vector, an AAV6 vector, a modified AAV6 vector, an AAV8 vector and an AAV9 vector.

5 In other embodiments, (a) is present on a first nucleic acid molecule, e.g. a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (b) and (c) are present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecules may be AAV vectors.

10 In other embodiments, (a) and (b) are present on a first nucleic acid molecule, e.g. a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (c) is present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecules may be AAV vectors.

In other embodiments, (a) and (c) are present on a first nucleic acid molecule, e.g. a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (b) is present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. 15 The first and second nucleic acid molecules may be AAV vectors.

In other embodiments, (a) is present on a first nucleic acid molecule, e.g. a first vector, e.g., a first viral vector, e.g., a first AAV vector; (b) is present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector; and (c) 20 is present on a third nucleic acid molecule, e.g., a third vector, e.g., a third vector, e.g., a third AAV vector. The first, second, and third nucleic acid molecules may be AAV vectors.

In other embodiments, the nucleic acid may further comprise (d)(i) a sequence that encodes a second gRNA molecule as described herein. In some embodiments, the nucleic acid comprises (a), (b), (c), and (d)(i). Each of (a), (b), (c), and (d)(i) may be present on the 25 same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., the same adeno-associated virus (AAV) vector. In an embodiment, the nucleic acid molecule is an AAV vector.

In other embodiments, (a) and (d)(i) are on different vectors. For example, (a) may be present on a first nucleic acid molecule, e.g. a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (d)(i) may be present on a second nucleic acid molecule, e.g., a second 30 vector, e.g., a second vector, e.g., a second AAV vector. In an embodiment, the first and second nucleic acid molecules are AAV vectors.

In other embodiments, (b) and (d)(i) are on different vectors. For example, (b) may be present on a first nucleic acid molecule, e.g. a first vector, e.g., a first viral vector, e.g., a

first AAV vector; and (d)(i) may be present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. In an embodiment, the first and second nucleic acid molecules are AAV vectors.

5 In other embodiments, (c) and (d)(i) are on different vectors. For example, (c) may be present on a first nucleic acid molecule, e.g. a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (d)(i) may be present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. In an embodiment, the first and second nucleic acid molecules are AAV vectors.

10 In another embodiment, (a) and (d)(i) are present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, (a) and (d)(i) are encoded on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and a second and third of (a) and (d)(i) are encoded on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.

15 In another embodiment, (b) and (d)(i) are present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, (b) and (d)(i) are encoded on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and a second and third of (b) and (d)(i) are encoded on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.

20 In another embodiment, (c) and (d)(i) are present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, (c) and (d)(i) are encoded on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and a second and third of (c) and (d)(i) are encoded on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.

25 In another embodiment, each of (a), (b), and (d)(i) are present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, one of (a), (b), and (d)(i) is encoded on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and a second and third of (a), (b), and (d)(i) is

encoded on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.

In another embodiment, each of (b), (c), and (d)(i) are present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, one of (b), (c), and (d)(i) is encoded on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and a second and third of (b), (c), and (d)(i) is encoded on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.

In another embodiment, each of (a), (c), and (d)(i) are present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, one of (a), (c), and (d)(i) is encoded on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and a second and third of (a), (c), and (d)(i) is encoded on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.

In an embodiment, (a) is present on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, a first AAV vector; and (b), (c), and (d)(i) are present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.

In other embodiments, (b) is present on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (a), (c), and (d)(i) are present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.

In other embodiments, (c) is present on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (a), (b), and (d)(i) are present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.

In other embodiments, (d)(i) is present on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (a), (b), and (c) are present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.

In another embodiment, each of (a), (b), (c), and (d)(i) are present on different nucleic acid molecules, e.g., different vectors, e.g., different viral vectors, e.g., different AAV vector.

For example, (a) may be on a first nucleic acid molecule, (b) on a second nucleic acid molecule, (c) on a third nucleic acid molecule, and (d)(i) on a fourth nucleic acid molecule. The first, second, third, and fourth nucleic acid molecule may be AAV vectors.

In another embodiment, when a third and/or fourth gRNA molecule are present, each of (a), (b), (c), (d)(i), (d)(ii) and (d)(iii) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, each of (a), (b), (c), (d)(i), (d)(ii) and (d)(iii) may be present on the different nucleic acid molecules, e.g., different vectors, e.g., the different viral vectors, e.g., different AAV vectors. In further embodiments, each of (a), (b), (c), (d)(i), (d)(ii) and (d)(iii) may be present on more than one nucleic acid molecule, but fewer than six nucleic acid molecules, e.g., AAV vectors.

The nucleic acids described herein may comprise a promoter operably linked to the sequence that encodes the gRNA molecule of (a), e.g., a promoter described herein. The nucleic acid may further comprise a second promoter operably linked to the sequence that encodes the second, third and/or fourth gRNA molecule of (d), e.g., a promoter described herein. The promoter and second promoter differ from one another. In some embodiments, the promoter and second promoter are the same.

The nucleic acids described herein may further comprise a promoter operably linked to the sequence that encodes the RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) of (b), e.g., a promoter described herein. In certain embodiments, the promoter operably linked to the sequence that encodes the RNA-guided nuclease of (b) comprises a rod-specific promoter. In certain embodiments, the rod-specific promoter may be a human *RHO* promoter. In certain embodiments, the human *RHO* promoter may be a minimal *RHO* promoter (e.g., SEQ ID NO:44).

The nucleic acids described herein may further comprise a promoter operably linked to the *RHO* cDNA molecule of (c), e.g., a promoter described herein. In certain embodiments, the promoter operably linked to the *RHO* cDNA molecule of (c) comprises a rod-specific promoter. In certain embodiments, the rod-specific promoter may be a human *RHO* promoter. In certain embodiments, the human *RHO* promoter may be a minimal *RHO* promoter (e.g., SEQ ID NO:44). In certain embodiments, the nucleic acids may further comprise a 3' UTR nucleotide sequence downstream of the *RHO* cDNA molecule. In certain embodiments, the 3' UTR nucleotide sequence downstream of the *RHO* cDNA molecule may comprise a *RHO* gene 3' UTR nucleotide sequence. In certain embodiments, the 3' UTR nucleotide sequence downstream of the *RHO* cDNA molecule may comprise a 3' UTR

nucleotide sequence of an mRNA encoding a highly expressed protein. For example, in certain embodiments, the 3' UTR nucleotide sequence downstream of the *RHO* cDNA molecule may comprise an  $\alpha$ -globin 3' UTR nucleotide sequence. In certain embodiments, the 3' UTR nucleotide sequence downstream of the *RHO* cDNA molecule may comprise a  $\beta$ -globin 3' UTR nucleotide sequence. In certain embodiments, the 3' UTR nucleotide sequence comprises one or more truncations at a 5' end of said 3' UTR nucleotide sequence, a 3' end of said 3' UTR nucleotide sequence, or both.

In another aspect, disclosed herein is a composition comprising (a) a gRNA molecule comprising a targeting domain that is complementary with a target domain in the *RHO* gene, as described herein. The composition of (a) may further comprise (b) an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule as described herein). Cpf1 is also sometimes referred to as Cas12a. A composition of (a) and (b) may further comprise (c) a *RHO* cDNA molecule. A composition of (a), (b), and (c) may further comprise (d) a second, third and/or fourth gRNA molecule, e.g., a second, third and/or fourth gRNA molecule described herein.

In another aspect, disclosed herein is a method of altering a cell, e.g., altering the structure, e.g., altering the sequence, of a target nucleic acid of a cell, comprising contacting said cell with: (a) a gRNA that targets the *RHO* gene, e.g., a gRNA as described herein; (b) an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule as described herein); and (c) a *RHO* cDNA molecule; and optionally, (d) a second, third and/or fourth gRNA that targets *RHO* gene, e.g., a gRNA.

In some embodiments, the method comprises contacting said cell with (a) and (b).

In some embodiments, the method comprises contacting said cell with (a), (b), and (c).

In some embodiments, the method comprises contacting said cell with (a), (b), (c) and (d).

The gRNA of (a) and optionally (d) may comprise a targeting domain sequence selected from those set forth in **Tables 1-3** and **18**, or may comprise a targeting domain sequence that differs by no more than 1, 2, 3, 4, or 5 nucleotides from a targeting domain sequence set forth in any of **Tables 1-3** and **18**.

In some embodiments, the method comprises contacting a cell from a subject suffering from or likely to develop adRP. The cell may be from a subject having a mutation at a *RHO* target position.

In some embodiments, the cell being contacted in the disclosed method is a cell from the eye of the subject, e.g., a retinal cell, e.g., a photoreceptor cell. The contacting may be

performed *ex vivo* and the contacted cell may be returned to the subject's body after the contacting step. In other embodiments, the contacting step may be performed *in vivo*.

In some embodiments, the method of altering a cell as described herein comprises acquiring knowledge of the presence of a mutation in the *RHO* gene, in said cell, prior to the contacting step. Acquiring knowledge of a mutation in the *RHO* gene, in the cell may be by  
 5 sequencing the *RHO* gene, or a portion of the *RHO* gene.

In some embodiments, the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses at least one of (a), (b), and (c). In some embodiments, the contacting step of the method comprises contacting the  
 10 cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses each of (a), (b), and (c). In another embodiment, the contacting step of the method comprises delivering to the cell an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) of (b) and a nucleic acid which encodes a gRNA (a), a *RHO* cDNA (c), and optionally, a second gRNA (d)(i), and further optionally, a third gRNA (d)(iv) and/or fourth gRNA (d)(iii).

In some embodiments, the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses at least one of (a), (b), (c) and (d). In some embodiments, the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses each of (a), (b), and (c). In another embodiment, the contacting step of the method comprises delivering to  
 20 the cell an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) of (b), a nucleic acid which encodes a gRNA (a) and a *RHO* cDNA molecule (c), and optionally, a second gRNA (d)(i), and further optionally, a third gRNA (d)(iv) and/or fourth gRNA (d)(iii).

In an embodiment, contacting comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, e.g., an AAV5 vector, a modified AAV5 vector, an AAV2  
 25 vector, a modified AAV2 vector, an AAV3 vector, a modified AAV3 vector, an AAV6 vector, a modified AAV6 vector, an AAV8 vector or an AAV9 vector.

In an embodiment, contacting comprises delivering to the cell an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) of (b), as a protein or an mRNA, and a nucleic acid which encodes (a) and (c) and optionally (d).

In an embodiment, contacting comprises delivering to the cell an RNA-guided  
 30 nuclease (e.g., Cas9 or Cpf1 molecule) of (b), as a protein or an mRNA, said gRNA of (a), as an RNA, and optionally said second gRNA of (d), as an RNA, and the *RHO* cDNA molecule (c) as a DNA.

In an embodiment, contacting comprises delivering to the cell a gRNA of (a) as an RNA, optionally said second gRNA of (d) as an RNA, and a nucleic acid that encodes the RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) of (b), and the *RHO* cDNA molecule (c) as a DNA.

5 In another aspect, disclosed herein is a method of treating a subject suffering from or likely to develop adRP, e.g., altering the structure, e.g., sequence, of a target nucleic acid of the subject, comprising contacting the subject (or a cell from the subject) with:

- (a) a gRNA that targets the *RHO* gene, e.g., a gRNA disclosed herein;
- (b) an RNA-guided nuclease, e.g., a Cas9 or Cpf1 molecule disclosed herein; and
- 10 (c) a *RHO* cDNA molecule; and

optionally, (d)(i) a second gRNA that targets the *RHO* gene, e.g., a second gRNA disclosed herein, and

further optionally, (d)(ii) a third gRNA, and still further optionally, (d)(iii) a fourth gRNA that target the *RHO* gene, e.g., a third and fourth gRNA disclosed herein.

15 In some embodiments, contacting comprises contacting with (a) and (b).

In some embodiments, contacting comprises contacting with (a), (b), and (c).

In some embodiments, contacting comprises contacting with (a), (b), (c), and (d)(i).

In some embodiments, contacting comprises contacting with (a), (b), (c), (d)(i) and (d)(ii).

20 In some embodiments, contacting comprises contacting with (a), (b), (c), (d)(i), (d)(ii) and (d)(iii).

The gRNA of (a) or (d) (e.g., (d)(i), (d)(ii), or (d)(iii)) may comprise a targeting domain sequence selected from any of those set forth in **Tables 1-3** and **18**, or may comprise a targeting domain sequence that differs by no more than 1, 2, 3, 4, or 5 nucleotides from a targeting domain sequence set forth in any of **Tables 1-3** and **18**.

25

In an embodiment, the method comprises acquiring knowledge of the presence of a mutation in the *RHO* gene, in said subject.

In an embodiment, the method comprises acquiring knowledge of the presence of a mutation in the *RHO* gene, in said subject by sequencing the *RHO* gene or a portion of the *RHO* gene.

30

In an embodiment, the method comprises altering a *RHO* target position in a *RHO* gene resulting in knocking out the *RHO* gene and providing exogenous *RHO* cDNA.

When the method comprises altering a *RHO* target position and providing exogenous *RHO* cDNA, an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) of (b), at least one guide

RNA (e.g., a guide RNA of (a) and a *RHO* cDNA molecule (c) are included in the contacting step.

In an embodiment, a cell of the subject is contacted *ex vivo* with (a), (b), (c) and optionally (d). In an embodiment, said cell is returned to the subject's body.

5 In an embodiment, a cell of the subject is contacted is *in vivo* with (a), (b), (c) and optionally (d).

In an embodiment, the cell of the subject is contacted *in vivo* by intravenous delivery of (a), (b), (c) and optionally (d).

10 In an embodiment, contacting comprises contacting the subject with a nucleic acid, e.g., a vector, e.g., an AAV vector, described herein, e.g., a nucleic acid that encodes at least one of (a), (b), (c) and optionally (d).

In an embodiment, contacting comprises delivering to said subject said RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) of (b), as a protein or mRNA, and a nucleic acid which encodes (a), a *RHO* cDNA molecule of (c) and optionally (d).

15 In an embodiment, contacting comprises delivering to the subject the RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) of (b), as a protein or mRNA, the gRNA of (a), as an RNA, a *RHO* cDNA molecule of (c) and optionally the second gRNA of (d), as an RNA.

In an embodiment, contacting comprises delivering to the subject the gRNA of (a), as an RNA, optionally said second gRNA of (d), as an RNA, a nucleic acid that encodes the RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) of (b), and a *RHO* cDNA molecule of (c).

In an embodiment, a cell of the subject is contacted *ex vivo* with (a), (b), (c), and optionally (d). In an embodiment, said cell is returned to the subject's body.

25 In an embodiment, a cell of the subject is contacted is *in vivo* with (a), (b), (c) and optionally (d). In an embodiment, the cell of the subject is contacted *in vivo* by intravenous delivery of (a), (b), (c) and optionally (d).

In an embodiment, contacting comprises contacting the subject with a nucleic acid, e.g., a vector, e.g., an AAV vector, described herein, e.g., a nucleic acid that encodes at least one of (a), (b), (c) and optionally (d).

30 In an embodiment, contacting comprises delivering to said subject said RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) of (b), as a protein or mRNA, and a nucleic acid which encodes (a), (c) and optionally (d).

In an embodiment, contacting comprises delivering to the subject the RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) of (b), as a protein or mRNA, the gRNA of (a), as an

RNA, and optionally the second gRNA of (d), as an RNA, and further optionally the *RHO* cDNA molecule of (c) as a DNA.

In an embodiment, contacting comprises delivering to the subject the gRNA of (a), as an RNA, optionally said second gRNA of (d), as an RNA, and a nucleic acid that encodes the RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) of (b), and the *RHO* cDNA molecule of (c) as a DNA.

In another aspect, disclosed herein is a reaction mixture comprising a, gRNA, a nucleic acid, or a composition described herein, and a cell, e.g., a cell from a subject having, or likely to develop adRP, or a subject having a mutation in the *RHO* gene.

In another aspect, disclosed herein is a kit comprising, (a) gRNA molecule described herein, or nucleic acid that encodes the gRNA, and one or more of the following:

(b) an RNA-guided nuclease molecule, e.g., a Cas9 or Cpf1 molecule described herein, or a nucleic acid or mRNA that encodes the RNA-guided nuclease;

(c) a *RHO* cDNA molecule;

(d)(i) a second gRNA molecule, e.g., a second gRNA molecule described herein or a nucleic acid that encodes (d)(i);

(d)(ii) a third gRNA molecule, e.g., a second gRNA molecule described herein or a nucleic acid that encodes (d)(ii);

(d)(iii) a fourth gRNA molecule, e.g., a second gRNA molecule described herein or a nucleic acid that encodes (d)(iii).

In an embodiment, the kit comprises nucleic acid, e.g., an AAV vector, that encodes one or more of (a), (b), (c), (d)(i), (d)(ii), and (d)(iii).

In certain embodiments, the vector or nucleic acid may include a sequence set forth in one or more of SEQ ID NOs:8-11.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Headings, including numeric and alphabetical headings and subheadings, are for organization and presentation and are not intended to be limiting.

Other features and advantages of the disclosure will be apparent from the detailed description, drawings, and from the claims.

### DESCRIPTION OF THE DRAWINGS

5 The accompanying drawings exemplify certain aspects and embodiments of the present disclosure. The depictions in the drawings are intended to provide illustrative, and schematic rather than comprehensive, examples of certain aspects and embodiments of the present disclosure. The drawings are not intended to be limiting or binding to any particular theory or model, and are not necessarily to scale. Without limiting the foregoing, nucleic  
10 acids and polypeptides may be depicted as linear sequences, or as schematic, two- or three dimensional structures; these depictions are intended to be illustrative, rather than limiting or binding to any particular model or theory regarding their structure.

**Fig. 1** illustrates the genome editing strategy implemented in certain embodiments of the disclosure. Step 1 includes knocking out (“KO”) or alteration of the *RHO* gene, for  
15 example, in the *RHO* target position of exon 1. Knocking out the *RHO* gene results in loss of function of the endogenous *RHO* gene (e.g., a mutant *RHO* gene). Step 2 includes replacing the *RHO* gene with an exogenous *RHO* cDNA including a minimal *RHO* promoter and a *RHO* cDNA.

**Fig. 2** is a schematic of an exemplary dual AAV delivery system that may be used for  
20 a variety of applications, including without limitation, the alteration of the *RHO* target position, according to certain embodiments of the disclosure. Vector 1 shows an AAV5 genome, which encodes ITRs, a GRK1 promoter, and a Cas9 molecule flanked by NLS sequences. Vector 2 shows an AAV5 genome, which encodes ITRs, a minimal *RHO* promoter, a *RHO* cDNA molecule, a U6 promoter, and a gRNA. In certain embodiments, the  
25 AAV vectors may be delivered via subretinal injection.

**Fig. 3** is a schematic of an exemplary dual AAV delivery system that may be used for a variety of applications, including without limitation, the alteration of the *RHO* target position, according to certain embodiments of the disclosure. Vector 1 shows an AAV5 genome, which encodes a minimal *RHO* promoter and a Cas9 molecule. Vector 2 shows an  
30 AAV5 genome, which encodes a minimal *RHO* promoter, a *RHO* cDNA molecule, a U6 promoter, and a gRNA. In certain embodiments, the AAV vectors may be delivered via subretinal injection.

**Fig. 4** depicts indels of the *RHO* gene in HEK293 cells formed by dose-dependent gene editing using ribonucleoproteins (RNPs) comprising RHO-3, RHO-7, or RHO-10

gRNAs (**Table 17**) and Cas9. Increasing concentrations of RNP were delivered to HEK293 cells. Indels of the *RHO* gene were assessed using next generation sequencing (NGS). Data from RNP comprising RHO-3 gRNA, RHO-10 gRNA, or RHO-7 gRNA are represented by circles, squares, and triangles, respectively. Data from control plasmid (expressing Cas9 with scrambled gRNA that does not target a sequence within the human genome) are represented by X.

**Fig. 5** shows details characterizing the predicted gRNA *RHO* alleles generated by RHO-3, RHO-7, or RHO-10 gRNAs (**Table 17**). As shown in the schematic of the human *RHO* cDNA and corresponding exons at the bottom of **Fig. 5**, RHO-3, RHO-10, and RHO-7 gRNAs are predicted to cut the *RHO* cDNA at Exon 1, the Exon 2/Intron 2 border, and the Exon 1/Intron 1 border, respectively. The target site positions for RHO-3, RHO-10, and RHO-7 gRNAs are located at bases encoding amino acids (AA) 96, 174, and 120 of the *RHO* protein, respectively. The protein lengths for each resulting construct for the predicted -1, -2, and -3 frame shifts are set forth. For RHO-3, a 1 base deletion at position 96 results in a truncated protein that is 95 amino acids long, a 2 base deletion at position 96 results in a truncated protein that is 120 amino acids long, a 3 base deletion at position 96 results in a truncated protein that is 347 amino acids long. For RHO-10, a 1 base deletion at position 174 results in a truncated protein that is 215 amino acids long, a 2 base deletion at position 174 results in a truncated protein that is 328 amino acids long, a 3 base deletion at position 174 results in a truncated protein that is 347 amino acids long. For RHO-7, a 1 base deletion at position 120 results in a truncated protein that is 142 amino acids long, a 2 base deletion at position 120 results in a truncated protein that is 142 amino acids long, a 3 base deletion at position 120 results in a truncated protein that is 347 amino acids long. **Fig 6.** provides schematics of the predicted truncated proteins.

**Fig. 6** shows schematics of the predicted *RHO* alleles generated by RHO-3, RHO-7, or RHO-10 gRNAs (**Table 17**). *RHO* alleles were predicted based on deletions of 1, 2, or 3 base pairs at the RHO-3, RHO-7, or RHO-10 cut sites. *RHO* Exons are represented by dark grey, stop codons are represented by black, missense protein is represented by stripes, deletions are represented by light grey.

**Figs. 7A and 7B** show the viability of HEK293 cells expressing wild-type or mock-edited *RHO* alleles. Schematics of *RHO* alleles predicted to be generated by RHO-3, RHO-7, and RHO-10 gRNAs (**Table 17**) having 1 base pair (bp), 2bp or 3bp deletions are illustrated in **Fig. 6**. *RHO* mutations predicted to be generated from RHO-3, RHO-7, and RHO-10 gRNAs (i.e., mock-edited *RHO* alleles) were generated using either WT-*RHO* cDNA or

RHO cDNA expressing the P23H RHO variant. Wild-type RHO, mock-edited RHO alleles, or RHO alleles expressing the P23H RHO variant were cloned into mammalian expression plasmids, lipofected into HEK293 cells and assessed for cell viability after 48 hours using the ATPLite Luminescence Assay by Perkin Elmer. **Fig. 7A** shows viability depicted by luminescence of cells with modified WT RHO alleles. **Fig. 7B** shows viability depicted by luminescence of cells with modified P23H RHO alleles. The upper dotted line represents the level of luminescence from WT RHO alleles and the lower dotted line represents the level of luminescence from the P23H RHO alleles.

**Fig. 8** shows editing of rod photoreceptors in non-human primate (NHP) explants using RHO-9 gRNA (**Table 1**). RNA from a rod-specific mRNA (neural retina leucine zipper (NRL)) was extracted from the explants and measured to determine the percentage of rods present in the explants. RNA from beta actin (ACTB) was also measured to determine the total number of cells. The x-axis shows the delta between ACTB and NRL RNA levels as measured by RT-PCR, which is a measure for the percentage of rods in the explant at the time of lysing the explants. Indels of the *RHO* gene were assessed using next generation sequencing (NGS). Each circle represents data from a different explant.

**Fig. 9** shows a schematic of the plasmid for the dual luciferase system used for optimizing the RHO replacement vector.

**Fig. 10** depicts the ratio of firefly/renilla luciferase luminescence using the dual luciferase system to test the effects of different lengths of the RHO promoter on RHO expression. The lengths of the RHO promoter that were tested ranged from 3.0 Kb to 250 bp.

**Figs. 11A and 11B** depict the effects on RHO mRNA and RHO protein expression of adding various 3' UTRs to the RHO replacement vector. The HBA1 3' UTR (SEQ ID NO:38), short HBA1 3' UTR (SEQ ID NO:39), TH 3' UTR (SEQ ID NO:40), COL1A1 3'UTR (SEQ ID NO:41), ALOX15 3'UTR (SEQ ID NO:42), and minUTR (SEQ ID NO:56) were tested. **Fig. 11A** shows results using RT-qPCR to measure RHO mRNA expression. **Fig. 11B** shows results using a RHO ELISA assay to measure RHO protein expression.

**Fig. 12** depicts the effects on RHO protein expression of inserting different RHO introns into RHO cDNA in the RHO replacement vector. The various RHO cDNA sequences with inserted introns (i.e., Introns 1-4) are set forth in SEQ ID NOs: 4-7, respectively.

**Fig. 13** depicts the effects on RHO protein expression of using wild-type or different codon optimized RHO constructs in the RHO replacement vector. The various codon optimized RHO cDNA sequences (i.e., Codon 1-6) are set forth in SEQ ID NOs: 13-18, respectively. The RHO cDNAs were under the control of a CMV or EFS promoter.

**Figs. 14A and 14B** depict *in vivo* editing of the RHO gene and knock down of Cas9 using a self-limiting Cas9 vector system (“SD”). **Fig. 14A** shows successful knockdown of Cas9 levels using the self-limiting Cas9 vector system (i.e., “SD Cas9 + Rho”). **Fig. 14B** shows successful editing using the self-limiting Cas9 vector system (i.e., “SD Cas9”).

**Fig. 15** depicts RHO expression in human explants. Explants were transduced with “shRNA”: transduction of retinal explants with shRNA targeting the RHO gene and a replacement vector providing a RHO cDNA (as published in Cideciyan 2018); “Vector A”: a two-vector system (Vector 1 comprising saCas9 driven by the minimal RHO promoter (250 bp), and Vector 2 comprising a codon-optimized RHO cDNA (codon-6) and comprising a HBA1 3’ UTR under the control of the minimal 250 bp RHO promoter, as well as as the RHO-9 gRNA (**Table 1**) under the control of a U6 promoter); “Vector B”: a two-vector system identical to “Vector A” except for Vector 2 comprising a wt RHO cDNA; and “UTC”: untransduced control.

**Fig. 16** is a schematic of an exemplary AAV vector (SEQ ID NO:11) according to certain embodiments of the disclosure. The schematic shows an AAV5 genome comprising and encoding an ITR (SEQ ID NO:92), a first U6 promoter (SEQ ID NO:78), a first RHO-7 gRNA (comprising a RHO-7 gRNA targeting domain (SEQ ID NO:606) (DNA) and SEQ ID NO:12), a second U6 promoter (SEQ ID NO:78), a second RHO-7 gRNA (comprising a RHO-7 gRNA targeting domain (SEQ ID NO:606) (DNA) and SEQ ID NO:12), a minimum RHO Promoter (250 bp) (SEQ ID NO:44), an SV40 Intron (SEQ ID NO:94), a codon optimized RHO cDNA (SEQ ID NO:18), HBA1 3’ UTR (SEQ ID NO:38), a minipolyA (SEQ ID NO:56), and a right ITR (SEQ ID NO:93). In certain embodiments, the AAV vector may be delivered via subretinal injection.

**Fig. 17** is a schematic of an exemplary AAV vector (SEQ ID NO:10) according to certain embodiments of the disclosure. The schematic shows an AAV5 genome comprising and encoding an ITR (SEQ ID NO:92), a minimum RHO Promoter (250 bp) (SEQ ID NO:44), an SV40 Intron (SEQ ID NO:94), an NLS sequence, an *S. aureus* Cas9 sequence, an SV40 NLS, an HBA1 3’ UTR (SEQ ID NO:38), and a right ITR (SEQ ID NO:93). In certain embodiments, the AAV vector may be delivered via subretinal injection.

**Fig. 18** is a schematic of an exemplary AAV vector (SEQ ID NO:9) according to certain embodiments of the disclosure. The schematic shows an AAV5 genome comprising and encoding an ITR (SEQ ID NO:92), a minimum RHO Promoter, an SV40 SA/SD, an NLS, an *S. aureus* Cas9 sequence, an SV40 NLS, a minipolyA (SEQ ID NO:56), and a right

ITR (SEQ ID NO:93). In certain embodiments, the AAV vector may be delivered via subretinal injection.

## DETAILED DESCRIPTION

### Definitions

5 “Domain”, as used herein, is used to describe segments of a protein or nucleic acid. Unless otherwise indicated, a domain is not required to have any specific functional property.

Calculations of homology or sequence identity between two sequences (the terms are used interchangeably herein) are performed as follows. The sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The optimal alignment is determined as the best score using the GAP program in the GCG software package with a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frame shift gap penalty of 5. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences.

20 “Modulator”, as used herein, refers to an entity, e.g., a drug, that can alter the activity (e.g., enzymatic activity, transcriptional activity, or translational activity), amount, distribution, or structure of a subject molecule or genetic sequence. In an embodiment, modulation comprises cleavage, e.g., breaking of a covalent or non-covalent bond, or the forming of a covalent or non-covalent bond, e.g., the attachment of a moiety, to the subject molecule. In an embodiment, a modulator alters the, three dimensional, secondary, tertiary, or quaternary structure, of a subject molecule. A modulator can increase, decrease, initiate, or eliminate a subject activity.

“Polypeptide”, as used herein, refers to a polymer of amino acids having less than 100 amino acid residues. In an embodiment, it has less than 50, 20, or 10 amino acid residues.

30 “Replacement”, or “replaced”, as used herein with reference to a modification of a molecule does not require a process limitation but merely indicates that the replacement entity is present.

“*RHO* target position,” as that term is used herein, refers to a target position, e.g., one or more nucleotides, in or near the *RHO* gene, that are targeted for alteration using the

methods described herein. In certain embodiments, alteration of the *RHO* target position, e.g., by substitution, deletion, or insertion, may result in disruption (e.g., “knocking out”) of the *RHO* gene. In certain embodiments, the *RHO* target position may be located in a 5’ region of the *RHO* gene (e.g., 5’ UTR, exon 1, exon 2, intron 1, the exon 1/intron 1 border, or the exon 2/intron 1 border), a non-coding region of the *RHO* gene (e.g., an enhancer region, a promoter region, an intron, 5’ UTR, 3’UTR, polyadenylation signal), or a coding region of the *RHO* gene (e.g., early coding region, an exon (e.g., exon 1, exon 2, exon 3, exon 4, exon 5), or an exon/intron border (e.g., exon 1/intron1, exon 2/intron 1) of the *RHO* gene.

“Small molecule”, as used herein, refers to a compound having a molecular weight less than about 2 kD, e.g., less than about 2 kD, less than about 1.5 kD, less than about 1 kD, or less than about 0.75 kD.

“Subject”, as used herein, may mean either a human or non-human animal. The term includes, but is not limited to, mammals (e.g., humans, other primates, pigs, rodents (e.g., mice and rats or hamsters), rabbits, guinea pigs, cows, horses, cats, dogs, sheep, and goats). In an embodiment, the subject is a human. In other embodiments, the subject is poultry.

“Treat”, “treating” and “treatment”, as used herein, mean the treatment of a disease in a mammal, e.g., in a human, including (a) inhibiting the disease, i.e., arresting or preventing its development; (b) relieving the disease, i.e., causing regression of the disease state; and (c) curing the disease.

“X” as used herein in the context of an amino acid sequence, refers to any amino acid (e.g., any of the twenty natural amino acids) unless otherwise specified.

### **Autosomal-dominant retinitis pigmentosa (adRP)**

Retinitis pigmentosa (RP) affects between 50,000 and 100,000 people in the United States. RP is a group of inherited retinal dystrophies that affect photoreceptors and retinal pigment epithelium cells. The disease causes retinal deterioration and atrophy, and is characterized by progressive deterioration of vision, ultimately resulting in blindness.

Typical disease onset is during the teenage years, although some subjects may present in early adulthood. Subjects initially present with poor night vision and declining peripheral vision. In general, visual loss proceeds from the peripheral visual field inwards. The majority of subjects are legally blind by the age of 40. The central visual field may be spared through the late stages of the disease, so that some subjects may have normal visual acuity within a small visual field into their 70’s. However, the majority of subjects lose their central vision as well between the age of 50 and 80 (Berson 1990). Upon examination, a subject

may have one or more of bone spicule pigmentation, narrowing of the visual fields and retinal atrophy.

There are over 60 genes and hundreds of mutations that cause RP. Autosomal dominant RP (adRP), accounts for 15-25% of RP. Autosomal recessive RP (arRP) accounts for 5-20% of RP. X-linked RP (X-LRP) accounts for 5-15% of RP (Daiger 2007). In general, adRP often has the latest presentation, arRP has a moderate presentation and X-LRP has the earliest presentation.

Autosomal-dominant retinitis pigmentosa (adRP) is caused by heterozygous mutations in the rhodopsin (*RHO*) gene. Mutations in the *RHO* gene account for 25-30% of cases of adRP.

The *RHO* gene encodes the rhodopsin protein. Rhodopsin is a G protein-coupled receptor expressed in the outer segment of retinal photoreceptor (PR) rod cells and is a critical element of the phototransduction cascade. Light absorbed by rhodopsin causes 11-cis retinal to isomerize into all-trans retinal. This conformational change allows rhodopsin to couple with transducin, which is the first step in the visual signaling cascade. Heterozygous mutations in the *RHO* gene cause a decreased production of wild-type rhodopsin and/or expression of mutant rhodopsin. This leads to poor function of the phototransduction cascade and declining function in rod PR cells. Over time, there is atrophy of rod PR cells and eventually atrophy of cone PR cells as well. This causes the typical phenotypic progression of cumulative vision loss experienced by RP subjects. Subjects with *RHO* mutations experience progressive loss of peripheral visual fields followed by loss of central visual fields (the latter measured by decreases in visual acuity).

Exemplary *RHO* mutations are provided in **Table A**.

**Table A: RHO Mutations (Group A Mutations)**

| Number | Mutation   |
|--------|------------|
| 1      | Pro23His   |
| 2      | Pro23Leu   |
| 3      | Thr58Arg   |
| 4      | Pro347Thr  |
| 5      | Pro347Ala  |
| 6      | Pro347Ser  |
| 7      | Pro347Gly  |
| 8      | Pro347Leu  |
| 9      | Pro347Arg  |
| 10     | Thr 4 Lys  |
| 11     | Asn 15 Ser |

|    |              |
|----|--------------|
| 12 | Thr 17 Met   |
| 13 | Gln 28 His   |
| 14 | Leu 40 Arg   |
| 15 | Met 44 Thr   |
| 16 | Phe 45 Leu   |
| 17 | Leu 46 Arg   |
| 18 | Gly 51 Arg   |
| 19 | Gly 51 Val   |
| 20 | Gly 51 Ala   |
| 21 | Pro 53 Arg   |
| 22 | Thr 58 Arg   |
| 23 | Gln 64 stop  |
| 24 | Val 87 Asp   |
| 25 | Gly 89 Asp   |
| 26 | Gly 106 Arg  |
| 27 | Gly 106 Trp  |
| 28 | Gly 109 Arg  |
| 29 | Cys 110 Tyr  |
| 30 | Cys 110 Phe  |
| 31 | Gly 114 Asp  |
| 32 | Gly 114 Val  |
| 33 | Leu 125 Arg  |
| 34 | Ser 127 Phe  |
| 35 | Leu 131 Pro  |
| 36 | Arg 135 Gly  |
| 37 | Arg 135 Trp  |
| 38 | Arg 135 Leu  |
| 39 | Arg 135 Pro  |
| 40 | Tyr 136 stop |
| 41 | Val 137 Met  |
| 42 | Cys 140 Ser  |
| 43 | Ala 164 Val  |
| 44 | Ala 164 Glu  |
| 45 | Cys 167 Arg  |
| 46 | Cys 167 Trp  |
| 47 | Pro 171 Glu  |
| 48 | Pro 171 Ser  |
| 49 | Pro 171 Leu  |
| 50 | Pro 171 Gln  |
| 51 | Tyr 178 Asn  |
| 52 | Tyr 178 Cys  |
| 53 | Pro 180 Ala  |
| 54 | Glu 181 Lys  |
| 55 | Gly 182 Ser  |
| 56 | Gln 184 Pro  |
| 57 | Ser 186 Pro  |
| 58 | Ser 186 Trp  |
| 59 | Cys 187 Tyr  |

|    |              |
|----|--------------|
| 60 | Gly 188 Arg  |
| 61 | Gly 188 Glu  |
| 62 | Asp 190 Asn  |
| 63 | Asp 190 Tyr  |
| 64 | Asp 190 Gly  |
| 65 | Thr 193 Met  |
| 66 | Met 207 Arg  |
| 67 | Val 209 Met  |
| 68 | His 211 Arg  |
| 69 | His 211 Pro  |
| 70 | Pro 215 Thr  |
| 71 | Met 216 Arg  |
| 72 | Met 216 Lys  |
| 73 | Phe 220 Cys  |
| 74 | Cys 222 Arg  |
| 75 | Pro 267 Leu  |
| 76 | Pro 267 Arg  |
| 77 | Ser 270 Arg  |
| 78 | Thr 289 Pro  |
| 79 | Lys 296 Glu  |
| 80 | Lys 296 Met  |
| 81 | Ser 297 Arg  |
| 82 | Gln 312 stop |
| 83 | Leu 328 Pro  |
| 84 | Thr 342 Met  |
| 85 | Gln 344 stop |
| 86 | Val 345 Leu  |
| 87 | Val 345 Met  |
| 88 | Ala 346 Pro  |
| 89 | stop 349 Glu |
| 90 | Glu 150 Lys  |
| 91 | Gly 174 Ser  |
| 92 | Glu 249 ter  |
| 93 | Gly 284 Ser  |

Treatment for RP is limited and there is currently no approved treatment that substantially reverses or halts the progression of disease in adRP. In an embodiment, Vitamin A supplementation may delay onset of disease and slow progression. The Argus II  
5 retinal implant was approved for use in the United States in 2013. The Argus II retinal implant is an electrical implant that offers minimal improvement in vision in subjects with RP. For example, the best visual acuity achieved in trials by the device was 20/1260. However, legal blindness is defined as 20/200 vision.

## Overview

As provided herein, the inventors have designed a therapeutic strategy that provides an alteration that comprises disrupting the mutant *RHO* gene by the insertion or deletion of one or more nucleotides mediated by an RNA-guided nuclease (e.g., Cas9 or Cpf1) as described below and providing a functional *RHO* cDNA. This type of alteration is also referred to as “knocking out” the mutant *RHO* gene and results in a loss of function of the mutant *RHO* gene. While not wishing to be bound by theory, knocking out the mutant *RHO* gene and providing a functional exogenous *RHO* cDNA maintains appropriate levels of rhodopsin protein in PR rod cells. This therapeutic strategy has the benefit of disrupting all known mutant alleles related to adRP, for example, the *RHO* mutations in **Table A**.

In certain embodiments, the 5' UTR region (e.g., 5' UTR, exon 1, exon 2, intron 1, exon 1/intron 1, or exon 2/intron 1 border) of a mutant *RHO* gene, is targeted to alter (i.e., knockout (e.g., eliminate expression of)) the mutant *RHO* gene.

In certain embodiments, the coding region (e.g., an exon, e.g., an early coding region) of the mutant *RHO* gene, is targeted to alter (i.e., knockout (e.g., eliminate expression of)) the mutant *RHO* gene. For example, the early coding region of the mutant *RHO* gene includes the sequence immediately following a start codon, within a first exon of the coding sequence, or within 500 bp of the start codon (e.g., less than 500, 450, 400, 350, 300, 250, 200, 150, 100 or 50 bp).

In certain embodiments, a non-coding region of the mutant *RHO* gene (e.g., an enhancer region, a promoter region, an intron, 5' UTR, 3'UTR, polyadenylation signal) is targeted to alter (i.e., knockout (e.g., eliminate expression of)) the mutant *RHO* gene.

In certain embodiments, an exon/intron border of the mutant *RHO* gene (e.g., exon 1/intron 1, exon 2/intron 1) is targeted to alter (i.e., knockout (e.g., eliminate expression of)) the mutant *RHO* gene. In certain embodiments, targeting an exon/intron border provides the benefit of being able to use an exogenous *RHO* cDNA molecule that is not codon-modified to be resistant to cutting by a gRNA.

**Fig. 1** shows a schematic of one embodiment of a therapeutic strategy to knockout an endogenous *RHO* gene and provide an exogenous *RHO* cDNA. In one embodiment, CRISPR/RNA-guided nuclease genome editing systems may be used to alter (i.e., knockout (e.g., eliminate expression of)) exon 1 or exon 2 of the *RHO* gene. In certain embodiments, the *RHO* gene may be mutated *RHO* gene. In certain embodiments, the mutated *RHO* gene may comprise one or more *RHO* mutations in **Table A**. Alteration of exon 1 or exon 2 of the *RHO* gene results in disruption of the endogenous mutated *RHO* gene.

In certain embodiments, the therapeutic strategy may be accomplished using a dual-vector system. In certain aspects, the disclosure focuses on AAV vectors encoding CRISPR/RNA-guided nuclease genome editing systems and a replacement *RHO* cDNA, and on the use of such vectors to treat adRP disease. Exemplary vector genomes are schematized in **Fig. 2**, which illustrates certain fixed and variable elements of these vectors: inverted terminal repeats (ITRs), at least one gRNA sequence and a promoter sequences to drive its expression, an RNA-guided nuclease (e.g., Cas9) coding sequence and another promoter to drive its expression, nuclear localization signal (NLS) sequences, and a *RHO* cDNA sequence and another promoter to drive its expression. Each of these elements is discussed in detail herein. Additional exemplary vector genomes are schematized in **Fig. 3**, which illustrates certain fixed and variable elements of these vectors: at least one gRNA sequence and a promoter sequence to drive its expression (e.g., U6 promoter), an RNA-guided nuclease (e.g., *S. aureus* Cas9) coding sequence and another promoter to drive its expression (e.g., minimal *RHO* promoter), and a *RHO* cDNA sequence and another promoter to drive its expression (e.g., minimal *RHO* promoter). Additional exemplary vectors and sequences for use with the strategies described herein are set forth in **Figs. 16-18** and SEQ ID NOs:8-11.

In certain embodiments, the AAV vector used herein may be a self-limiting vector system as described in WO2018/106693, published on June 14, 2018, and entitled Systems and Methods for One-Shot guide RNA (ogRNA) Targeting of Endogenous and Source DNA, the entire contents of which are incorporated herein by reference.

As shown in **Fig. 1**, in certain embodiments, a dual vector system may be used to knockout expression of mutant *RHO* gene and deliver an exogenous *RHO* cDNA to restore expression of wild-type rhodopsin protein. In certain embodiments, one AAV vector genome may comprise ITRs and an RNA-guided nuclease coding sequence and promoter sequence to drive its expression and one or more NLS sequences. In certain embodiments, a second AAV vector genome may comprise ITRs, a *RHO* cDNA sequence and a promoter to drive its expression, one gRNA sequence and promoter sequence to drive its expression.

While not wishing to be bound by theory, knocking out the *RHO* gene and replacing it with functional exogenous *RHO* cDNA maintains appropriate levels of rhodopsin protein in PR rod cells. Restoring appropriate levels of functional rhodopsin protein in rod PR cells maintains the phototransduction cascade and may delay or prevent PR cell death in subjects with adRP.

In some embodiments, a method disclosed herein is characterized by knocking out a variant of the *RHO* gene that is associated with adRP, e.g., a *RHO* mutant gene or allele

described herein, and restoring wild-type *RHO* protein expression in a subject in need thereof, e.g., in a subject suffering from or predisposed to adRP. For example, in some embodiments, the methods provided herein are characterized by knocking out a mutant *RHO* allele in a subject having a mutant and a wild-type *RHO* allele, and restoring expression of wild-type rhodopsin protein in rod PR cells. In some embodiments, such methods feature knocking out the mutant allele while leaving the wild-type allele intact. In other embodiments, such methods feature knocking out both the mutant and the wild-type allele. In some embodiments, the methods are characterized by knocking out a mutant allele of the *RHO* gene and providing an exogenous wild-type protein, e.g., via expression of a cDNA encoding wild-type RHO protein. In some embodiments, knocking out expression of a mutant allele (and, optionally, a wild-type allele), and restoring wild-type RHO protein expression, e.g., via expression of an exogenous *RHO* cDNA, in a subject in need thereof, e.g., a subject suffering from or predisposed to adRP, ameliorates at least one symptom associated with adRP. In some embodiments, such an amelioration includes, for example, improving the subject's vision. In some embodiments, such an amelioration includes, for example, delaying adRP disease progression, e.g., as compared to an expected progression without clinical intervention. In some embodiments, such an amelioration includes, for example, arresting adRP disease progression. In some embodiments, such an amelioration includes, for example, preventing or delaying the onset of adRP disease in a subject.

In an embodiment, a method described herein comprises treating allogenic or autologous retinal cells *ex vivo*. In an embodiment, *ex vivo* treated allogenic or autologous retinal cells are introduced into the subject.

In an embodiment, a method described herein comprises treating an embryonic stem cell, an induced pluripotent stem cell or a cell derived from an iPS cell, a hematopoietic stem cell, a neuronal stem cell or a mesenchymal stem cell *ex vivo*. In an embodiment, *ex vivo* treated embryonic stem cells, induced pluripotent stem cells, hematopoietic stem cells, neuronal stem cells or a mesenchymal stem cells are introduced into the subject. In an embodiment, the cell is an induced pluripotent stem cells (iPS) cell or a cell derived from an iPS cell, e.g., an iPS cell generated from the subject, modified to knock out one or more mutated *RHO* genes and express functional exogenous *RHO* DNA and differentiated into a retinal progenitor cell or a retinal cell, e.g., retinal photoreceptor cell, and injected into the eye of the subject, e.g., subretinally, e.g., in the submacular region of the retina.

In an embodiment, a method described herein comprises treating autologous stem cells *ex vivo*. In an embodiment, *ex vivo* treated autologous stem cells are returned to the subject.

5 In an embodiment, the subject is treated *in vivo*, e.g., by a viral (or other mechanism) that targets cells from the eye (e.g., a retinal cell, e.g., a photoreceptor cell, e.g., a cone photoreceptor cell, e.g., a rod photoreceptor cell, e.g., a macular cone photoreceptor cell).

10 In an embodiment, the subject is treated *in vivo*, e.g., by a viral (or other mechanism) that targets a stem cell (e.g., an embryonic stem cell, an induced pluripotent stem cell or a cell derived from an iPS cell, a hematopoietic stem cell, a neuronal stem cell or a mesenchymal stem cell).

In an embodiment, treatment is initiated in a subject prior to disease onset. In a particular embodiment, treatment is initiated in a subject who has tested positive for one or more mutations in the *RHO* gene.

In an embodiment, treatment is initiated in a subject after disease onset.

15 In an embodiment, treatment is initiated in an early stage of adRP disease. In an embodiment, treatment is initiated after a subject presents with gradually declining vision. In an embodiment, repair of the *RHO* gene after adRP onset but early in the disease course will prevent progression of the disease.

20 In an embodiment, treatment is initiated in a subject in an advanced stage of disease. While not wishing to be bound by theory, it is held that advanced stage treatment will likely preserve a subject's visual acuity (in the central visual field), which is important for subject function and performance of activities of daily living.

25 In an embodiment, treatment of a subject prevents disease progression. While not wishing to be bound by theory, it is held that initiation of treatment for subjects at all stages of disease (e.g., prophylactic treatment, early stage adRP, and advanced stage adRP) will prevent RP disease progression and be of benefit to subjects.

In an embodiment, treatment is initiated after determination that the subject, e.g., an infant or newborn, teenager, or adult, is positive for a mutation in the *RHO* gene, e.g., a mutation described herein.

30 In an embodiment, treatment is initiated after determination that the subject is positive for a mutation in the *RHO* gene, e.g., a mutation described herein, but prior to manifestation of a symptom of the disease.

In an embodiment, treatment is initiated after determination that the subject is positive for a mutation in the *RHO* gene, e.g., a mutation described herein, and after manifestation of a symptom of the disease.

5 In an embodiment, treatment is initiated in a subject at the appearance of a decline in visual fields.

In an embodiment, treatment is initiated in a subject at the appearance of declining peripheral vision.

In an embodiment, treatment is initiated in a subject at the appearance of poor night vision and/or night blindness.

10 In an embodiment, treatment is initiated in a subject at the appearance of progressive visual loss.

In an embodiment, treatment is initiated in a subject at the appearance of progressive constriction of the visual field.

15 In an embodiment, treatment is initiated in a subject at the appearance of one or more indications consistent with adRP upon examination of a subject. Exemplary indications include, but are not limited to, bone spicule pigmentation, narrowing of the visual fields, retinal atrophy, attenuated retinal vasculature, loss of retinal pigment epithelium, pallor of the optic nerve, and/or combinations thereof.

20 In an embodiment, a method described herein comprises subretinal injection, submacular injection, suprachoroidal injection, or intravitreal injection, of gRNA or other components described herein, e.g., an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) and a *RHO* cDNA molecule.

25 In an embodiment, a gRNA or other components described herein, e.g., an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) and a *RHO* cDNA molecule are delivered, e.g., to a subject, by AAV, lentivirus, nanoparticle, or parvovirus, e.g., a modified parvovirus designed to target cells from the eye (e.g., a retinal cell, e.g., a photoreceptor cell, e.g., a cone photoreceptor cell, e.g., a rod photoreceptor cell, e.g., a macular cone photoreceptor cell).

30 In an embodiment, a gRNA or other components described herein, e.g., an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) and a *RHO* cDNA molecule are delivered, e.g., to a subject, by AAV, lentivirus, nanoparticle, or parvovirus, e.g., a modified parvovirus designed to target stem cells (e.g., an embryonic stem cell, an induced pluripotent stem cell or a cell derived from an iPS cell, a hematopoietic stem cell, a neuronal stem cell or a mesenchymal stem cell).

In an embodiment, a gRNA or other components described herein, e.g., an RNA-guided nuclease (e.g., Cas9 or Cpf1 molecule) and a *RHO* cDNA molecule are delivered, *ex vivo*, by electroporation.

In an embodiment, CRISPR/RNA-guided nuclease components are used to knock out  
5 the mutant *RHO* gene which gives rise to the disease.

### I. gRNA Molecules

The terms guide RNA and gRNA refer to any nucleic acid that promotes the specific association (or “targeting”) of an RNA-guided nuclease such as a Cas9 or a Cpf1 to a target  
10 sequence such as a genomic or episomal sequence in a cell. gRNAs can be unimolecular (comprising a single RNA molecule, and referred to alternatively as chimeric), or modular (comprising more than one, and typically two, separate RNA molecules, such as a crRNA and a tracrRNA, which are usually associated with one another, for example by duplexing). gRNAs and their component parts are described throughout the literature (see, e.g., Briner  
15 2014, which is incorporated by reference; see also Cotta-Ramusino).

In bacteria and archaea, type II CRISPR systems generally comprise an RNA-guided nuclease protein such as Cas9, a CRISPR RNA (crRNA) that includes a 5' region that is complementary to a foreign sequence, and a trans-activating crRNA (tracrRNA) that includes a 5' region that is complementary to, and forms a duplex with, a 3' region of the crRNA.  
20 While not intending to be bound by any theory, it is thought that this duplex facilitates the formation of — and is necessary for the activity of — the RNA-guided nuclease/gRNA complex. As type II CRISPR systems were adapted for use in gene editing, it was discovered that the crRNA and tracrRNA could be joined into a single unimolecular or chimeric gRNA, for example by means of a four nucleotide (e.g., GAAA) “tetraloop” or “linker” sequence  
25 bridging complementary regions of the crRNA (at its 3' end) and the tracrRNA (at its 5' end) (Mali 2013; Jiang 2013; Jinek 2012; all incorporated by reference herein).

Guide RNAs, whether unimolecular or modular, include a targeting domain that is fully or partially complementary to the target domain within a target sequence (e.g., a double-stranded DNA sequence in the genome of a cell where editing is desired). In certain  
30 embodiments, a *RHO* target sequence encompasses, comprises, or is proximal to a *RHO* target position. Targeting domains are referred to by various names in the literature, including without limitation “guide sequences” (Hsu 2013, incorporated by reference herein), “complementarity regions” (Cotta-Ramusino), “spacers” (Briner 2014), and generically as “crRNAs” (Jiang 2013). Irrespective of the names they are given, targeting domains are

typically 10-30 nucleotides in length, preferably 16-24 nucleotides in length (for example, 16, 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides in length), and are at or near the 5' terminus of in the case of a Cas9 gRNA, and at or near the 3' terminus in the case of a Cpf1 gRNA. The nucleic acid sequence complementary to the target domain, i.e., the nucleic acid sequence on the complementary DNA strand of the double-stranded DNA that comprises the target domain, is referred to herein as the "protospacer."

The "protospacer-adjacent motif" (PAM) sequence takes its name from its sequential relationship to the "protospacer" sequence. Together with protospacer sequences, PAM sequences define target sequences and/or target positions for specific RNA-guided nuclease/gRNA combinations. Various RNA-guided nucleases may require different sequential relationships between PAMs and protospacers.

For example, in general, Cas9 nucleases recognize PAM sequences that are 3' of the protospacer:

```
5' ----[ protospacer ] [PAM] -----3'
3' ----[ target domain ] -----5'
```

For another example, in general, Cpf1 recognizes PAM sequences that are 5' of the protospacer:

```
5' ----[PAM] [ protospacer ] -----3'
3' -----[ target domain ] -----5'
```

In some embodiments described herein, *RHO* protospacers and exemplary suitable targeting domains are described. Those of ordinary skill in the art will be aware of additional suitable guide RNA targeting domains that can be used to target an RNA-guided nuclease to a given protospacer, e.g., targeting domains that comprise additional or less nucleotides, or that comprise one or more nucleotide mismatches when hybridized to a target domain.

In addition to the targeting domains, gRNAs typically (but not necessarily, as discussed below) include a plurality of domains that influence the formation or activity of gRNA/Cas9 complexes. For example, as mentioned above, the duplexed structure formed by first and secondary complementarity domains of a gRNA (also referred to as a repeat:anti-repeat duplex) interacts with the recognition (REC) lobe of Cas9 and may mediate the formation of Cas9/gRNA complexes (Nishimasu 2014; Nishimasu 2015; both incorporated by reference herein). It should be noted that the first and/or second complementarity domains can contain one or more poly-A tracts, which can be recognized by RNA polymerases as a termination signal. The sequence of the first and second complementarity domains are, therefore, optionally modified to eliminate these tracts and promote the complete in vitro

transcription of gRNAs, for example through the use of A-G swaps as described in Briner 2014, or A-U swaps. These and other similar modifications to the first and second complementarity domains are within the scope of the present disclosure.

Along with the first and second complementarity domains, Cas9 gRNAs typically include two or more additional duplexed regions that are necessary for nuclease activity in vivo but not necessarily in vitro (Nishimasu 2015). A first stem-loop near the 3' portion of the second complementarity domain is referred to variously as the "proximal domain," (Cotta-Ramusino) "stem loop 1" (Nishimasu 2014; Nishimasu 2015) and the "nexus" (Briner 2014). One or more additional stem loop structures are generally present near the 3' end of the gRNA, with the number varying by species: *S. pyogenes* gRNAs typically include two 3' stem loops (for a total of four stem loop structures including the repeat:anti-repeat duplex), while *S. aureus* and other species have only one (for a total of three). A description of conserved stem loop structures (and gRNA structures more generally) organized by species is provided in Briner 2014.

Skilled artisans will appreciate that gRNAs can be modified in a number of ways, some of which are described below, and these modifications are within the scope of disclosure. For economy of presentation in this disclosure, gRNAs may be presented by reference solely to their targeting domain sequences.

#### gRNA modifications

The activity, stability, or other characteristics of gRNAs can be altered through the incorporation of chemical and/or sequential modifications. As one example, transiently expressed or delivered nucleic acids can be prone to degradation by, e.g., cellular nucleases. Accordingly, the gRNAs described herein can contain one or more modified nucleosides or nucleotides which introduce stability toward nucleases. While not wishing to be bound by theory it is also believed that certain modified gRNAs described herein can exhibit a reduced innate immune response when introduced into a population of cells, particularly the cells of the present invention. As noted above, the term "innate immune response" includes a cellular response to exogenous nucleic acids, including single stranded nucleic acids, generally of viral or bacterial origin, which involves the induction of cytokine expression and release, particularly the interferons, and cell death.

One common 3' end modification is the addition of a poly A tract comprising one or more (and typically 5-200) adenine (A) residues. The poly A tract can be contained in the nucleic acid sequence encoding the gRNA, or can be added to the gRNA during chemical

synthesis, or following in vitro transcription using a polyadenosine polymerase (e.g., *E. coli* Poly(A)Polymerase). In vivo, poly-A tracts can be added to sequences transcribed from DNA vectors through the use of polyadenylation signals. Examples of such signals are provided in Maeder.

5           Some exemplary gRNA modifications useful in the context of the present RNA-guided nuclease technology are provided herein, and the skilled artisan will be able to ascertain additional suitable modifications that can be used in conjunction with the gRNAs and treatment modalities disclosed herein based on the present disclosure. Suitable gRNA modifications include, without limitations, those described in U.S. Patent Application No. US 10 2017/0073674 A1 and International Publication No. WO 2017/165862 A1, the entire contents of each of which are incorporated by reference herein.

## II. Methods for Designing gRNAs

Methods for designing gRNAs are described herein, including methods for selecting, 15 designing and validating target domains. Exemplary targeting domains are also provided herein. Targeting domains discussed herein can be incorporated into the gRNAs described herein.

Methods for selection and validation of target sites as well as off-target analyses are described, e.g., in Mali 2013; Hsu 2013; Fu 2014; Heigwer 2014; Bae 2014; Xiao 2014.

20           For example, a software tool can be used to optimize the choice of gRNA within a user's target site, e.g., to minimize total off-target activity across the genome. Off target activity may be other than cleavage. For each possible gRNA choice using *S. pyogenes* Cas9, the tool can identify all off-target sites (preceding either NAG or NGG PAMs) across the genome that contain up to certain number (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of mismatched 25 base-pairs. The cleavage efficiency at each off-target site can be predicted, e.g., using an experimentally-derived weighting scheme. Each possible gRNA is then ranked according to its total predicted off-target cleavage; the top-ranked gRNAs represent those that are likely to have the greatest on-target and the least off-target cleavage. Other functions, e.g., automated reagent design for CRISPR construction, primer design for the on-target Surveyor assay, and 30 primer design for high-throughput detection and quantification of off-target cleavage via next-gen sequencing, can also be included in the tool.

The targeting domains discussed herein can be incorporated into the gRNAs described herein.

### Exemplary Protospacers and Targeting Domains

Guide RNAs targeting various positions within the *RHO* gene for use with *S. aureus* Cas9 were identified. Following identification, the gRNAs were ranked into three tiers. The gRNAs in tier 1 were selected based on cutting in exon 1 and exon 2 of the *RHO* gene. Tier 1 guides exhibited > 9% editing in T-cells. For selection of tier 2 gRNAs, selection was based on cutting in the 5' UTR of the *RHO* gene. Tier 2 gRNAs exhibited > 10% editing in T-cells. Tier 3 gRNAs were selected based cutting in intron 1 of the *RHO* gene. Tier 3 gRNAs exhibit > 10% editing in T-cells.

**Table 1** provides targeting domains for an exon 1 or exon 2 *RHO* target position in the *RHO* gene selected according to the first-tier parameters. The targeting domains were selected based on cutting in exon 1 or exon 2 of the *RHO* gene and exhibiting > 9% editing in T-cells. It is contemplated herein that the targeting domain hybridizes to the strand complementary to the target domain sequence provided through complementary base pairing. Any of the targeting domains in the table can be used with a *S. aureus* Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a *S. aureus* Cas9 single-stranded break nucleases (nickases).

**Table 1**

| Tier 1                      |         |                       |                                               |                                               |
|-----------------------------|---------|-----------------------|-----------------------------------------------|-----------------------------------------------|
| Location in <i>RHO</i> gene | gRNA ID | Indel Fraction Window | Targeting Domain (RNA)                        | Targeting Domain (DNA)/ Protospacer           |
| utr5_0;<br>cds_0            | RHO-1   | 0.2284375             | GUCAGCCACAAGG<br>GCCACAGCC<br>(SEQ ID NO:100) | GTCAGCCACAAGG<br>GCCACAGCC<br>(SEQ ID NO:600) |
| cds_0                       | RHO-2   | 0.134454179           | CCGAAGACGAAGU<br>AUCCAUGCA<br>(SEQ ID NO:101) | CCGAAGACGAAGT<br>ATCCATGCA<br>(SEQ ID NO:601) |
| cds_0                       | RHO-3   | 0.174725089           | AGUAUCCAUGCAG<br>AGAGGUGUA<br>(SEQ ID NO:102) | AGTATCCATGCAG<br>AGAGGTGTA<br>(SEQ ID NO:602) |
| cds_0                       | RHO-4   | 0.093809401           | CUAGGUUGAGCAG<br>GAUGUAGUU<br>(SEQ ID NO:103) | CTAGGTTGAGCAG<br>GATGTAGTT<br>(SEQ ID NO:603) |
| cds_0                       | RHO-5   | 0.109343522           | CAUGGCUCAGCCA<br>GGUAGUACU<br>(SEQ ID NO:104) | CATGGCTCAGCCA<br>GGTAGTACT<br>(SEQ ID NO:604) |
| cds_0                       | RHO-6   | 0.112374147           | ACGGGUGUGGUAC<br>GCAGCCCCU<br>(SEQ ID NO:105) | ACGGGTGTGGTAC<br>GCAGCCCCT<br>(SEQ ID NO:605) |

|                    |        |             |                                                |                                               |
|--------------------|--------|-------------|------------------------------------------------|-----------------------------------------------|
| cds_0;<br>intron_0 | RHO-7  | 0.297946972 | CCCACACCCGGCU<br>CAUACCGCC<br>(SEQ ID NO:106)  | CCCACACCCGGCT<br>CATACCGCC<br>(SEQ ID NO:606) |
| cds_0;<br>intron_0 | RHO-8  | 0.118235744 | CCCUGGGCGGU<br>GAGCCGGGU<br>(SEQ ID NO:107)    | CCCTGGGCGGTAT<br>GAGCCGGGT<br>(SEQ ID NO:607) |
| cds_1              | RHO-9  | 0.270630335 | CCAUCAUGGGCGU<br>UGCCUUCAC<br>(SEQ ID NO:108)  | CCATCATGGGCGT<br>TGCCTTCAC<br>(SEQ ID NO:608) |
| cds_1;<br>intron_1 | RHO-10 | 0.567902679 | GUGCCAUAUACCUG<br>GACCAGCCG<br>(SEQ ID NO:109) | GTGCCATTACCTG<br>GACCAGCCG<br>(SEQ ID NO:609) |
| cds_1;<br>intron_1 | RHO-11 | 0.106516652 | UUACCUGGACCAG<br>CCGGCGAGU<br>(SEQ ID NO:110)  | TTACCTGGACCAG<br>CCGGCGAGT<br>(SEQ ID NO:610) |

**Table 2** provides targeting domains for a 5' UTR *RHO* target position in the *RHO* gene selected according to the second-tier parameters. The targeting domains were selected based on cutting in the 5' UTR region of the *RHO* gene and exhibiting > 10% editing in T-cells. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a *S. aureus* Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a *S. aureus* Cas9 single-stranded break nucleases (nickases).

**Table 2**

| Tier 2                            |         |                             |                                               |                                               |
|-----------------------------------|---------|-----------------------------|-----------------------------------------------|-----------------------------------------------|
| Location<br>in <i>RHO</i><br>gene | gRNA ID | Indel<br>Fraction<br>Window | Targeting Domain<br>(RNA)                     | Targeting Domain<br>(DNA)/Protospacer         |
| utr5_0                            | RHO-12  | 0.459024462                 | GCAUUCUUGGGUGG<br>GAGCAGCC<br>(SEQ ID NO:111) | GCATTCTTGGGTGG<br>GAGCAGCC<br>(SEQ ID NO:611) |
| utr5_0                            | RHO-13  | 0.20572897                  | GCUCAGCCACUCAG<br>GGCUCCAG<br>(SEQ ID NO:112) | GCTCAGCCACTCAG<br>GGCTCCAG<br>(SEQ ID NO:612) |
| utr5_0                            | RHO-14  | 0.409641098                 | UGACCCGUGGCUGC<br>UCCACCC<br>(SEQ ID NO:113)  | TGACCCGTGGCTGC<br>TCCACCC<br>(SEQ ID NO:613)  |
| utr5_0                            | RHO-15  | 0.134736551                 | AGCUCAGGCCUUCG<br>CAGCAUUC<br>(SEQ ID NO:114) | AGCTCAGGCCTTCG<br>CAGCATTC<br>(SEQ ID NO:614) |

**Table 3** provides targeting domains for an intron 1 *RHO* target position in the *RHO* gene selected according to the third-tier parameters. The targeting domains were selected based on cutting in intron 1 of the *RHO* gene and exhibiting > 10% editing in T-cells. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a *S. aureus* Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a *S. aureus* Cas9 single-stranded break nucleases (nickases).

**Table 3**

| Tier 3                      |         |                               |                                               |                                               |
|-----------------------------|---------|-------------------------------|-----------------------------------------------|-----------------------------------------------|
| Location in <i>RHO</i> gene | gRNA ID | Indel Fraction Window Average | Targeting Domain (RNA)                        | Targeting Domain/Protospacer (DNA)            |
| intron_0                    | RHO-16  | 0.107449452                   | UAGCAGAAGAAUG<br>CAUCCUAAU<br>(SEQ ID NO:115) | TAGCAGAAGAATG<br>CATCCTAAT<br>(SEQ ID NO:615) |
| intron_0                    | RHO-17  | 0.107559427                   | ACACGCUGAGGAG<br>AGCUGGGCA<br>(SEQ ID NO:116) | ACACGCTGAGGAG<br>AGCTGGGCA<br>(SEQ ID NO:616) |
| intron_0                    | RHO-18  | 0.116786532                   | GCAAUAACUCC<br>CCCAUUCCC<br>(SEQ ID NO:117)   | GCAAATAACTTCCC<br>CCATTCCC<br>(SEQ ID NO:617) |
| intron_0                    | RHO-19  | 0.129975835                   | AGACCCAGGCUGG<br>GCACUGAGG<br>(SEQ ID NO:118) | AGACCCAGGCTGG<br>GCACTGAGG<br>(SEQ ID NO:618) |
| intron_0                    | RHO-20  | 0.130270513                   | CUAGGUCUCCUGG<br>CUGUGAUCC<br>(SEQ ID NO:119) | CTAGGTCTCCTGGC<br>TGTGATCC<br>(SEQ ID NO:619) |
| intron_0                    | RHO-21  | 0.132448578                   | CCAGAAGGUGGGU<br>GUGCCACUU<br>(SEQ ID NO:120) | CCAGAAGGTGGGT<br>GTGCCACTT<br>(SEQ ID NO:620) |
| intron_0                    | RHO-22  | 0.140129895                   | AACAAGGAACUCU<br>GCCCCACAU<br>(SEQ ID NO:121) | AACAAGGAACTCT<br>GCCCCACAT<br>(SEQ ID NO:621) |
| intron_0                    | RHO-23  | 0.142141636                   | CAGGAUUGAACUG<br>GGAACCCGG<br>(SEQ ID NO:122) | CAGGATTGAACTG<br>GGAACCCGG<br>(SEQ ID NO:622) |
| intron_0                    | RHO-24  | 0.147082642                   | GGGCGUCACACAG<br>GGACGGGTG<br>(SEQ ID NO:123) | GGGCGTCACACAG<br>GGACGGGTG<br>(SEQ ID NO:623) |
| intron_0                    | RHO-25  | 0.14820997                    | CUGUGAUCCAGGA<br>AUAUCUCUG                    | CTGTGATCCAGGA<br>ATATCTCTG                    |

|          |        |             |                                               |                                               |
|----------|--------|-------------|-----------------------------------------------|-----------------------------------------------|
|          |        |             | (SEQ ID NO:124)                               | (SEQ ID NO:624)                               |
| intron_0 | RHO-26 | 0.150900653 | UUGCAUUUAACAG<br>GAAACAGA<br>(SEQ ID NO:125)  | TTGCATTTAACAGG<br>AAACAGA<br>(SEQ ID NO:625)  |
| intron_0 | RHO-27 | 0.151929784 | GGAGUGCACCCUC<br>CUUAGGCAG<br>(SEQ ID NO:126) | GGAGTGCACCCTCC<br>TTAGGCAG<br>(SEQ ID NO:626) |
| intron_0 | RHO-28 | 0.152980769 | CAUCUGUCCUGCU<br>CACCACCCC<br>(SEQ ID NO:127) | CATCTGTCCTGCTC<br>ACCACCCC<br>(SEQ ID NO:627) |
| intron_0 | RHO-29 | 0.156913097 | GAGGGGAGGCAGA<br>GGAUGCCAG<br>(SEQ ID NO:128) | GAGGGGAGGCAGA<br>GGATGCCAG<br>(SEQ ID NO:628) |
| intron_0 | RHO-30 | 0.166237876 | CUCAGGGAAUCUC<br>UGGCCAUUG<br>(SEQ ID NO:129) | CTCAGGGAATCTCT<br>GGCCATTG<br>(SEQ ID NO:629) |
| intron_0 | RHO-31 | 0.166367333 | UGCACUCCCCCU<br>AGACAGGGA<br>(SEQ ID NO:130)  | TGCACTCCCCCTA<br>GACAGGGA<br>(SEQ ID NO:630)  |
| intron_0 | RHO-32 | 0.172983706 | UGCUGUUUGUGCA<br>GGGCUGGCA<br>(SEQ ID NO:131) | TGCTGTTTGTGCAG<br>GGCTGGCA<br>(SEQ ID NO:631) |
| intron_0 | RHO-33 | 0.185512517 | ACUGGGACAUUCC<br>UAACAGUGA<br>(SEQ ID NO:132) | ACTGGGACATTCCT<br>AACAGTGA<br>(SEQ ID NO:632) |
| intron_0 | RHO-34 | 0.190420346 | AUCAGGGGGUCAG<br>GAUUGAACU<br>(SEQ ID NO:133) | ATCAGGGGGTCAG<br>GATTGAACT<br>(SEQ ID NO:633) |
| intron_0 | RHO-35 | 0.194765615 | CUCCUCUCUGGGG<br>GCCCAAGCU<br>(SEQ ID NO:134) | CTCCTCTCTGGGGG<br>CCCAAGCT<br>(SEQ ID NO:634) |
| intron_0 | RHO-36 | 0.197589827 | CUGCAUCUCAGCA<br>GAGAUAUUC<br>(SEQ ID NO:135) | CTGCATCTCAGCAG<br>AGATATTC<br>(SEQ ID NO:635) |
| intron_0 | RHO-37 | 0.199499884 | UGUUUCCCUUGGA<br>GCAGCUGUG<br>(SEQ ID NO:136) | TGTTTCCCTTGGAG<br>CAGCTGTG<br>(SEQ ID NO:636) |
| intron_0 | RHO-38 | 0.212418288 | GCGCUCUGGGCCC<br>AUAAGGGAC<br>(SEQ ID NO:137) | GCGCTCTGGGCCCA<br>TAAGGGAC<br>(SEQ ID NO:637) |
| intron_0 | RHO-39 | 0.215235707 | AGGAUUGAACUGG<br>GAACCCGGU<br>(SEQ ID NO:138) | AGGATTGAACTGG<br>GAACCCGGT<br>(SEQ ID NO:638) |
| intron_0 | RHO-40 | 0.21710799  | CCUAGGAGAGGCC<br>CCCACAUGU<br>(SEQ ID NO:139) | CCTAGGAGAGGCC<br>CCCACATGT<br>(SEQ ID NO:639) |
| intron_0 | RHO-41 | 0.217881646 | AUCACUCAGUUCU<br>GGCCAGAAG<br>(SEQ ID NO:140) | ATCACTCAGTTCTG<br>GCCAGAAG<br>(SEQ ID NO:640) |

|          |        |             |                                                |                                               |
|----------|--------|-------------|------------------------------------------------|-----------------------------------------------|
| intron_0 | RHO-42 | 0.227315789 | AGAGCUGGGCAA<br>GAAAUUCCA<br>(SEQ ID NO:141)   | AGAGCTGGGCAA<br>GAAATTCCA<br>(SEQ ID NO:641)  |
| intron_0 | RHO-43 | 0.230358178 | CCACCCCAUGAAG<br>UCCAUAAGG<br>(SEQ ID NO:142)  | CCACCCCATGAAGT<br>TCCATAGG<br>(SEQ ID NO:642) |
| intron_0 | RHO-44 | 0.231888098 | CCACCCUGAGCUU<br>GGCCCCCA<br>(SEQ ID NO:143)   | CCACCCTGAGCTTG<br>GGCCCCCA<br>(SEQ ID NO:643) |
| intron_0 | RHO-45 | 0.234285631 | CAGAGGAAGAAGA<br>AGGAAUAUGA<br>(SEQ ID NO:144) | CAGAGGAAGAAGA<br>AGGAAATGA<br>(SEQ ID NO:644) |
| intron_0 | RHO-46 | 0.240341645 | AAACAGCAGCCCG<br>GCUAUCACC<br>(SEQ ID NO:145)  | AAACAGCAGCCCG<br>GCTATCACC<br>(SEQ ID NO:645) |
| intron_0 | RHO-47 | 0.242233765 | GGAUUGAACUGGG<br>AACCCGGUA<br>(SEQ ID NO:146)  | GGATTGAACTGGG<br>AACCCGGTA<br>(SEQ ID NO:646) |
| intron_0 | RHO-48 | 0.242660421 | UGUGUGUGUGUGU<br>GUUUAGCAG<br>(SEQ ID NO:147)  | TGTGTGTGTGTGTG<br>TTAGCAG<br>(SEQ ID NO:647)  |
| intron_0 | RHO-49 | 0.251755576 | UCACACAGGGACG<br>GGUGCAGAG<br>(SEQ ID NO:148)  | TCACACAGGGACG<br>GGTGCAGAG<br>(SEQ ID NO:648) |
| intron_0 | RHO-50 | 0.252241304 | GUGUGUGUGUGUG<br>UGUGUUUAG<br>(SEQ ID NO:149)  | GTGTGTGTGTGTGT<br>GTGTTTAG<br>(SEQ ID NO:649) |
| intron_0 | RHO-51 | 0.255029622 | UGAGCUUGGGCCC<br>CCAGAGAGG<br>(SEQ ID NO:150)  | TGAGCTTGGGCCCC<br>CAGAGAGG<br>(SEQ ID NO:650) |
| intron_0 | RHO-52 | 0.263525952 | AAUAUCUCUGCUG<br>AGAUGCAGG<br>(SEQ ID NO:151)  | AATATCTCTGCTGA<br>GATGCAGG<br>(SEQ ID NO:651) |
| intron_0 | RHO-53 | 0.2666129   | GGAGAGGGGAAGA<br>GACUCAUUU<br>(SEQ ID NO:152)  | GGAGAGGGGAAGA<br>GACTCATTT<br>(SEQ ID NO:652) |
| intron_0 | RHO-54 | 0.287053205 | AGAACUGAGUGAU<br>CUGUGAUUA<br>(SEQ ID NO:153)  | AGAACTGAGTGAT<br>CTGTGATTA<br>(SEQ ID NO:653) |
| intron_0 | RHO-55 | 0.291326632 | CCACUCUCCCUAU<br>GGAACUUA<br>(SEQ ID NO:154)   | CCACTCTCCCTATG<br>GAACTTCA<br>(SEQ ID NO:654) |
| intron_0 | RHO-56 | 0.292218928 | AUAAGGGACACGA<br>AUCAGAUCA<br>(SEQ ID NO:155)  | ATAAGGGACACGA<br>ATCAGATCA<br>(SEQ ID NO:655) |
| intron_0 | RHO-57 | 0.305482452 | UGGAUUUUCCAUA<br>CUCCAGUCA<br>(SEQ ID NO:156)  | TGGATTTTCCATTC<br>TCCAGTCA<br>(SEQ ID NO:656) |

|          |        |             |                                                |                                                |
|----------|--------|-------------|------------------------------------------------|------------------------------------------------|
| intron_0 | RHO-58 | 0.310447227 | GUGCAGGAGCCCCG<br>GGAGCAUGG<br>(SEQ ID NO:157) | GTGCAGGAGCCCCG<br>GGAGCATGG<br>(SEQ ID NO:657) |
| intron_0 | RHO-59 | 0.31581459  | GGGUGGUGAGCAG<br>GACAGAUGU<br>(SEQ ID NO:158)  | GGGTGGTGAGCAG<br>GACAGATGT<br>(SEQ ID NO:658)  |
| intron_0 | RHO-60 | 0.329433399 | CAGCUCUCCCUCA<br>GUGCCCAGC<br>(SEQ ID NO:159)  | CAGCTCTCCCTCAG<br>TGCCCAGC<br>(SEQ ID NO:659)  |
| intron_0 | RHO-61 | 0.337601649 | CCUGCUGGGGCGU<br>CACACAGGG<br>(SEQ ID NO:160)  | CCTGCTGGGGCGTC<br>ACACAGGG<br>(SEQ ID NO:660)  |
| intron_0 | RHO-62 | 0.341369802 | CACACACACACAA<br>AACUCCCUA<br>(SEQ ID NO:161)  | CACACACACACAA<br>AACTCCCTA<br>(SEQ ID NO:661)  |
| intron_0 | RHO-63 | 0.342930279 | ACUUACGGGUGGU<br>UGUUCUCUG<br>(SEQ ID NO:162)  | ACTTACGGGTGGTT<br>GTTCTCTG<br>(SEQ ID NO:662)  |
| intron_0 | RHO-64 | 0.347123022 | CACAGGGAAGACC<br>CAAUGACUG<br>(SEQ ID NO:163)  | CACAGGGAAGACC<br>CAATGACTG<br>(SEQ ID NO:663)  |
| intron_0 | RHO-65 | 0.3604802   | AGCACAGACCCCA<br>CUGCCUAAG<br>(SEQ ID NO:164)  | AGCACAGACCCCA<br>CTGCCTAAG<br>(SEQ ID NO:664)  |
| intron_0 | RHO-66 | 0.396256305 | ACCUGAGGACAGG<br>GGCUGAGAG<br>(SEQ ID NO:165)  | ACCTGAGGACAGG<br>GGCTGAGAG<br>(SEQ ID NO:665)  |
| intron_0 | RHO-67 | 0.397224629 | CAACAAUGGCCAG<br>AGAUUCCCU<br>(SEQ ID NO:166)  | CAACAATGGCCAG<br>AGATTCCT<br>(SEQ ID NO:666)   |
| intron_0 | RHO-68 | 0.40353484  | UGCUGCCUCGGUC<br>CCAUUCUCA<br>(SEQ ID NO:167)  | TGCTGCCTCGGTCC<br>CATTCTCA<br>(SEQ ID NO:667)  |
| intron_0 | RHO-69 | 0.416729506 | UGCUGCCUGGCCA<br>CAUCCCUAA<br>(SEQ ID NO:168)  | TGCTGCCTGGCCAC<br>ATCCCTAA<br>(SEQ ID NO:668)  |

### III. RNA-Guided Nucleases

RNA-guided nucleases according to the present disclosure include, without limitation, naturally-occurring Class 2 CRISPR nucleases such as Cas9, and Cpf1, as well as other  
5 nucleases derived or obtained therefrom. In functional terms, RNA-guided nucleases are defined as those nucleases that: (a) interact with (e.g., complex with) a gRNA; and (b) together with the gRNA, associate with, and optionally cleave or modify, a target region of a DNA that includes (i) a sequence complementary to the targeting domain of the gRNA and, optionally, (ii) an additional sequence referred to as a “protospacer adjacent motif,” or

“PAM,” which is described in greater detail below. As the following examples will illustrate, RNA-guided nucleases can be defined, in broad terms, by their PAM specificity and cleavage activity, even though variations may exist between individual RNA-guided nucleases that share the same PAM specificity or cleavage activity. Skilled artisans will appreciate that some aspects of the present disclosure relate to systems, methods and compositions that can be implemented using any suitable RNA-guided nuclease having a certain PAM specificity and/or cleavage activity. For this reason, unless otherwise specified, the term RNA-guided nuclease should be understood as a generic term, and not limited to any particular type (e.g., Cas9 vs. Cpf1), species (e.g., *S. pyogenes* vs. *S. aureus*) or variation (e.g., full-length vs. truncated or split; naturally-occurring PAM specificity vs. engineered PAM specificity).

Turning to the PAM sequence, this structure takes its name from its sequential relationship to the “protospacer” sequence that is complementary to gRNA targeting domains (or “spacers”). Together with protospacer sequences, PAM sequences define target regions or sequences for specific RNA-guided nuclease / gRNA combinations.

Various RNA-guided nucleases may require different sequential relationships between PAMs and protospacers. In general, Cas9s recognize PAM sequences that are 5’ of the protospacer as visualized relative to the top or complementary strand.

In addition to recognizing specific sequential orientations of PAMs and protospacers, RNA-guided nucleases generally recognize specific PAM sequences. *S. aureus* Cas9, for example, recognizes a PAM sequence of NNGRRT, wherein the N sequences are immediately 3’ of the region recognized by the gRNA targeting domain. *S. pyogenes* Cas9 recognizes NGG PAM sequences. It should also be noted that engineered RNA-guided nucleases can have PAM specificities that differ from the PAM specificities of similar nucleases (such as the naturally occurring variant from which an RNA-guided nuclease is derived, or the naturally occurring variant having the greatest amino acid sequence homology to an engineered RNA-guided nuclease). Modified Cas9s that recognize alternate PAM sequences are described below.

RNA-guided nucleases are also characterized by their DNA cleavage activity: naturally-occurring RNA-guided nucleases typically form DSBs in target nucleic acids, but engineered variants have been produced that generate only SSBs (discussed above; see also Ran 2013, incorporated by reference herein), or that do not cut at all.

The terms “RNA-guided nuclease” and “RNA-guided nuclease molecule” are used interchangeably herein. In some embodiments, the RNA-guided nuclease is a RNA-guided DNA endonuclease enzyme. In some embodiments, the RNA-guided nuclease is a CRISPR

nuclease. Examples of RNA-guided nucleases suitable for use in the context of the methods, strategies, and treatment modalities provided herein are listed in **Table 4** below, and the methods, compositions, and treatment modalities disclosed herein can, in some embodiments, make use of any combination of RNA-guided nucleases disclosed herein, or known to those of ordinary skill in the art.

**Table 4. RNA-Guided Nucleases**

| Nuclease          | Length (a.a.) | PAM               | Reference                                                         |
|-------------------|---------------|-------------------|-------------------------------------------------------------------|
| SpCas9            | 1368          | NGG               | Cong <i>et al.</i> , Science. 2013;339(6121):819-23               |
| SaCas9            | 1053          | NNGRRT            | Ran <i>et al.</i> , Nature. 2015;520(7546):186-91.                |
| (KKH) SaCas9      | 1067          | NNNRRT            | Kleinstiver <i>et al.</i> , Nat Biotechnol. 2015;33(12):1293-1298 |
| AsCpfI (AsCas12a) | 1353          | TTTV              | Zetsche <i>et al.</i> , Nat Biotechnol. 2017;35(1):31-34.         |
| LbCpfI (LbCas12a) | 1274          | TTTV              | Zetsche <i>et al.</i> , Cell. 2015;163(3):759-71.                 |
| CasX              | 980           | TTC               | Burstein <i>et al.</i> , Nature. 2017;542(7640):237-241.          |
| CasY              | 1200          | TA                | Burstein <i>et al.</i> , Nature. 2017;542(7640):237-241.          |
| Cas12h1           | 870           | RTR               | Yan <i>et al.</i> , Science. 2019;363(6422):88-91.                |
| Cas12i1           | 1093          | TTN               | Yan <i>et al.</i> , Science. 2019;363(6422):88-91.                |
| Cas12c1           | unknown       | TG                | Yan <i>et al.</i> , Science. 2019;363(6422):88-91.                |
| Cas12c2           | unknown       | TN                | Yan <i>et al.</i> , Science. 2019;363(6422):88-91.                |
| eSpCas9           | 1423          | NGG               | Chen <i>et al.</i> , Nature. 2017;550(7676):407-410.              |
| Cas9-HF1          | 1367          | NGG               | Chen <i>et al.</i> , Nature. 2017;550(7676):407-410.              |
| HypaCas9          | 1404          | NGG               | Chen <i>et al.</i> , Nature. 2017;550(7676):407-410.              |
| dCas9-FokI        | 1623          | NGG               | U.S. Patent No. 9,322,037                                         |
| Sniper-Cas9       | 1389          | NGG               | Lee <i>et al.</i> , Nat Commun. 2018;9(1):3048.                   |
| xCas9             | 1786          | NGG, NG, GAA, GAT | Wang <i>et al.</i> , Plant Biotechnol J. 2018; pbi.13053.         |
| AaCas12b          | 1129          | TTN               | Teng <i>et al.</i> Cell Discov. 2018;4:63.                        |
| evoCas9           | 1423          | NGG               | Casini <i>et al.</i> , Nat Biotechnol. 2018;36(3):265-271.        |
| SpCas9-NG         | 1423          | NG                | Nishimasu <i>et al.</i> , Science. 2018;361(6408):1259-1262.      |
| VRQR              | 1368          | NGA               | Li <i>et al.</i> , The CRISPR Journal, 2018; 01:01                |
| VRER              | 1372          | NGCG              | Kleinstiver <i>et al.</i> , Nature. 2016;529(7587):490-5.         |

|                |      |              |                                                             |
|----------------|------|--------------|-------------------------------------------------------------|
| NmeCas9        | 1082 | NNNNGA<br>TT | Amrani <i>et al.</i> , Genome Biol. 2018;19(1):214.         |
| CjCas9         | 984  | NNNNRY<br>AC | Kim <i>et al.</i> , Nat Commun. 2017;8:14500.               |
| BhCas12b       | 1108 | ATTN         | Strecker <i>et al.</i> , Nat Commun. 2019 Jan 22;10(1):212. |
| BhCas12b<br>V4 | 1108 | ATTN         | Strecker <i>et al.</i> , Nat Commun. 2019 Jan 22;10(1):212. |

In one embodiment, the RNA-guided nuclease is a *Acidaminococcus* sp. Cpf1 RR variant (AsCpf1-RR). In another embodiment, the RNA-guided nuclease is a Cpf1 RVR variant

5 Exemplary suitable methods for designing targeting domains and guide RNAs, as well as for the use of the various Cas nucleases in the context of genome editing approaches, are known to those of skill in the art. Some exemplary methods are disclosed herein, and additional suitable methods will be apparent to the skilled artisan based on the present disclosure. The disclosure is not limited in this respect.

10

#### IV. *RHO* genomic sequence and complementary DNA sequences

The *RHO* genomic sequence is known to those of ordinary skill in the art. An exemplary *RHO* genomic sequence is provided below for ease of reference:

AGAGTCATCCAGCTGGAGCCCTGAGTGGCTGAGCTCAGGCCTTCGCAGCATTCTTGGGTGGG  
 15 AGCAGCCACGGGTCAGCCACAAGGGCCACAGCCATGAATGGCACAGAAGGCCCTAACTTCTA  
 CGTGCCCTTCTCCAATGCGACGGGTGTGGTACGCAGCCCCTTCGAGTACCCACAGTACTACC  
 TGGCTGAGCCATGGCAGTTCTCCATGCTGGCCGCCTACATGTTTCTGCTGATCGTGCTGGGC  
 TTCCCCATCAACTTCCTCACGCTCTACGTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCT  
 CAACTACATCCTGCTCAACCTAGCCGTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCA  
 20 GCACCCTCTACACCTCTCTGCATGGATACTTCGTCTTCGGGCCCACAGGATGCAATTTGGAG  
 GGCTTCTTTGCCACCCTGGGCGGTATGAGCCGGGTGTGGGTGGGGTGTGCAGGAGCCCGGGA  
 GCATGGAGGGGTCTGGGAGAGTCCCGGGCTTGGCGGTGGTGGCTGAGAGGCCTTCTCCCTTC  
 TCCTGTCCTGTCAATGTTATCCAAAGCCCTCATATATTCAGTCAACAAACACCATTTCATGGT  
 GATAGCCGGGCTGCTGTTTGTGCAGGGCTGGCACTGAACACTGCCTTGATCTTATTTGGAGC  
 25 AATATGCGCTTGTCTAATTTACAGCAAGAAAAGTGGAGCTGAGGCTCAAAGAAGTCAAGCGC  
 CCTGCTGGGGCGTCACACAGGGACGGGTGCAGAGTTGAGTTGGAAGCCCGCATCTATCTCGG  
 GCCATGTTTGCAGCACCAAGCCTCTGTTTCCCTTGAGCAGCTGTGCTGAGTCAGACCCAGG

CTGGGCACTGAGGGAGAGCTGGGCAAGCCAGACCCCTCCTCTCTGGGGGCCCAAGCTCAGGG  
TGGGAAGTGGATTTTCCATTCTCCAGTCATTGGGTCTTCCCTGTGCTGGGCAATGGGCTCGG  
TCCCCTCTGGCATCCTCTGCCTCCCCTCTCAGCCCCCTGTCCTCAGGTGCCCCCTCCAGCCTCC  
CTGCCGCGTTCCAAGTCTCCTGGTGTGAGAACCGCAAGCAGCCGCTCTGAAGCAGTTCCTT  
5 TTTGCTTTAGAATAATGTCTTGCATTTAACAGGAAAACAGATGGGGTGCTGCAGGGATAACA  
GATCCCACCTTAACAGAGAGGAAAACTGAGGCAGGGAGAGGGGAAGAGACTCATTTAGGGATG  
TGGCCAGGCAGCAACAAGAGCCTAGGTCTCCTGGCTGTGATCCAGGAATATCTCTGCTGAGA  
TGCAGGAGGAGACGCTAGAAGCAGCCATTGCAAAGCTGGGTGACGGGGAGAGCTTACCGCCA  
GCCACAAGCGTCTCTCTGCCAGCCTTGCCCTGTCTCCCCCATGTCCAGGCTGCTGCCTCGGT  
10 CCCATTCTCAGGGAATCTCTGGCCATTGTTGGGTGTTTGTGTCATTCAATAATCACAGATCA  
CTCAGTTCTGGCCAGAAGGTGGGTGTGCCACTTACGGGTGGTTGTTCTCTGCAGGGTCAGTC  
CCAGTTTACAAATATTGTCCCTTTCACTGTTAGGAATGTCCCAGTTTGGTTGATTAACATA  
TGGCCACTCTCCCTATGGAACCTCATGGGGTGGTGAGCAGGACAGATGTCTGAATTCCATCA  
TTTCCTTCTTCTTCTCTGGGCAAAACATTGCACATTGCTTCATGGCTCCTAGGAGAGGCCC  
15 CCACATGTCCGGGTATTTTCATTTCCCGAGAAGGGAGAGGGAGGAAGGACTGCCAATTCTGG  
GTTTCCACCACCTCTGCATTCCCTTCCCAACAAGGAACTCTGCCCCACATTAGGATGCATTCT  
TCTGCTAAACACACACACACACACACACACACACACACACACACACACACACACACACA  
CACACACAAAACCTCCCTACCGGGTTCCCAGTTCAATCCTGACCCCCTGATCTGATTCTGTGTC  
CCTTATGGGCCCAGAGCGCTAAGCAAATAACTTCCCCCATTCCTGGAATTTCTTTGCCAG  
20 CTCTCCTCAGCGTGTGGTCCCTCTGCCCCTTCCCCCTCCTCCAGCACCAAGCTCTCTCCTT  
CCCCAAGGCCTCCTCAAATCCCTCTCCCACTCCTGGTTGCCTTCCTAGCTACCCTCTCCCTG  
TCTAGGGGGGAGTGCACCTCCTTAGGCAGTGGGGTCTGTGCTGACCGCCTGCTGACTGCCT  
TGCAGGTGAAATTGCCCTGTGGTCTTGGTGGTCTGGCCATCGAGCGGTACGTGGTGGTGT  
GTAAGCCCATGAGCAACTTCCGCTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACC  
25 TGGGTCTATGGCGCTGGCCTGCGCCGACCCCCACTCGCCGGCTGGTCCAGGTAATGGCACTG  
AGCAGAAGGGAAGAAGCTCCGGGGGCTCTTTGTAGGGTCCTCCAGTCAGGACTCAAACCCAG  
TAGTGTCTGGTTCCAGGCACTGACCTTGTATGTCTCCTGGCCCAAATGCCCACTCAGGGTAG  
GGGTGTAGGGCAGAAGAAGAAACAGACTCTAATGTTGCTACAAGGGCTGGTCCCATCTCCTG  
AGCCCCATGTCAAACAGAATCCAAGACATCCCAACCCTTCACCTTGGCTGTGCCCCAATCC  
30 TCAACTAAGCTAGGCGCAAATTCGAATCCTCTTTGGTCTAGTACCCCGGGGGCAGCCCCCTC  
TAACCTTGGGCCTCAGCAGCAGGGGAGGCCACACCTTCCTAGTGCAGGTGGCCATATTGTGG  
CCCCTTGGAACCTGGGTCCCACTCAGCCTCTAGGCGATTGTCTCCTAATGGGGCTGAGATGAG  
ACACAGTGGGGACAGTGGTTTGGACAATAGGACTGGTGACTCTGGTCCCCAGAGGCCTCATG  
TCCCTCTGTCTCCAGAAAATTCCCACTCTCACTTCCCTTTCCTCCTCAGTCTTGCTAGGGTC

CATTTCTTACCCCTTGCTGAATTTGAGCCCACCCCCTGGACTTTTTCCCCATCTTCTCCAAT  
CTGGCCTAGTTCTATCCTCTGGAAGCAGAGCCGCTGGACGCTCTGGGTTTCCTGAGGCCCCGT  
CCACTGTCACCAATATCAGGAACCATTGCCACGTCCTAATGACGTGCGCTGGAAGCCTCTAG  
TTTCCAGAAGCTGCACAAAGATCCCTTAGATACTCTGTGTGTCCATCTTTGGCCTGGAAAAT  
5 ACTCTCACCCCTGGGGCTAGGAAGACCTCGGTTTGTACAAACTTCCTCAAATGCAGAGCCTGA  
GGGCTCTCCCCACCTCCTCACCAACCCTCTGCGTGGCATAGCCCTAGCCTCAGCGGGCAGTG  
GATGCTGGGGCTGGGCATGCAGGGAGAGGCTGGGTGGTGTCTGTTAACGCAGCCACCAA  
ACAATGAAGCGACACTGATTCCACAAGGTGCATCTGCATCCCCATCTGATCCATTCCATCCT  
GTCACCCAGCCATGCAGACGTTTATGATCCCCTTTTCCAGGGAGGGAATGTGAAGCCCCAGA  
10 AAGGGCCAGCGCTCGGCAGCCACCTTGGCTGTTCCCAAGTCCCTCACAGGCAGGGTCTCCCT  
ACCTGCCTGTCCTCAGGTACATCCCCGAGGGCCTGCAGTGCTCGTGTGGAATCGACTACTAC  
ACGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCTATCTACATGTTCTGTTCCACTTCAC  
CATCCCCATGATTATCATCTTTTTCTGCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGTAC  
GGGCCGGGGGTGGGCGGCCTCACGGCTCTGAGGGTCCAGCCCCAGCATGCATCTGCGGCT  
15 CCTGCTCCCTGGAGGAGCCATGGTCTGGACCCGGGTCCCCTGTCCTGCAGGCCGCTGCCCAG  
CAGCAGGAGTCAGCCACCACACAGAAGGCAGAGAAGGAGGTACCCCGCATGGTCATCATCAT  
GGTCATCGCTTTCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCACCC  
ACCAGGGCTCCAACCTCGGTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCC  
GCCATCTACAACCCTGTCATCTATATCATGATGAACAAGCAGGTGCCTACTGCGGGTGGGAG  
20 GGCCCCAGTGCCCCAGGCCACAGGCGCTGCCTGCCAAGGACAAGCTACTTCCAGGGCAGGG  
GAGGGGGCTCCATCAGGGTTACTGGCAGCAGTCTTGGGTGAGCAGTCCCAATGGGGAGTGTG  
TGAGAAATGCAGATTCTGGCCCCACTCAGAACTGCTGAATCTCAGGGTGGGCCAGGAACC  
TGCATTTCCAGCAAGCCCTCCACAGGTGGCTCAGATGCTCACTCAGGTGGGAGAAGCTCCAG  
TCAGCTAGTTCTGGAAGCCCAATGTCAAAGTCAGAAGGACCCAAGTCGGGAATGGGATGGGC  
25 CAGTCTCCATAAAGCTGAATAAGGAGCTAAAAAGTCTTATTCTGAGGGGTAAAGGGGTAAAG  
GGTTCCTCGGAGAGGTACCTCCGAGGGGTAAACAGTTGGGTAAACAGTCTCTGAAGTCAGCT  
CTGCCATTTTCTAGCTGTATGGCCCTGGGCAAGTCAATTTCTTCTCTGTGCTTTGGTTTCC  
TCATCCATAGAAAGGTAGAAAGGGCAAAACACCAAACCTCTTGATTACAAGAGATAATTTAC  
AGAACACCCTTGGCACACAGAGGGCACCATGAAATGTCACGGGTGACACAGCCCCCTTGTGC  
30 TCAGTCCCTGGCATCTCTAGGGGTGAGGAGCGTCTGCCTAGCAGGTTCCCTCCAGGAAGCTG  
GATTTGAGTGGATGGGGCGCTGGAATCGTGAGGGGCAGAAGCAGGCAAAGGGTCGGGGCGAA  
CCTCACTAACGTGCCAGTTCCAAGCACACTGTGGGCAGCCCTGGCCCTGACTCAAGCCTCTT  
GCCTTCCAGTTCCGGAAGTGCATGCTCACCACCATCTGCTGCGGCAAGAACCCACTGGGTGA  
CGATGAGGCCTCTGCTACCGTGTCCAAGACGGAGACGAGCCAGGTGGCCCCGGCCTAAGACC

TGCCTAGGACTCTGTGGCCGACTATAGGCGTCTCCCATCCCCTACACCTTCCCCCAGCCACA  
 GCCATCCCACCAGGAGCAGCGCCTGTGCAGAATGAACGAAGTCACATAGGCTCCTTAATTTT  
 TTTTTTTTTTTTAAAGAAATAATTAATGAGGCTCCTCACTCACCTGGGACAGCCTGAGAAGGG  
 ACATCCACCAAGACCTACTGATCTGGAGTCCCACGTTCCCCAAGGCCAGCGGGATGTGTGCC  
 5 CCTCCTCCTCCCAACTCATCTTTCAGGAACACGAGGATTCTTGCTTTCTGGAAAAGTGTCCC  
 AGCTTAGGGATAAGTGTCTAGCACAGAATGGGGCACACAGTAGGTGCTTAATAAATGCTGGA  
 TGGATGCAGGAAGGAATGGAGGAATGAATGGGAAGGGAGAACATATCTATCCTCTCAGACCC  
 TCGCAGCAGCAGCAACTCATACTTGGCTAATGATATGGAGCAGTTGTTTTTCCCTCCCTGGG  
 CCTCACTTTCTTCTCCTATAAAATGGAAATCCCAGATCCCTGGTCCTGCCGACACGCAGCTA  
 10 CTGAGAAGACCAAAAGAGGTGTGTGTGTGTCTATGTGTGTGTTTCAGCACTTTGTAAATAGC  
 AAGAAGCTGTACAGATTCTAGTTAATGTTGTGAATAACATCAATTAATGTAAGTGTAAAT  
 ACTATGATTATCACCTCCTGATAGTGAACATTTTGAGATTGGGCATTCAGATGATGGGGTTT  
 CACCCAACCTTGGGGCAGGTTTTTAAAAATTAGCTAGGCATCAAGGCCAGACCAGGGCTGGG  
 GGTTGGGCTGTAGGCAGGGACAGTCACAGGAATGCAGAATGCAGTCATCAGACCTGAAAAAA  
 15 CAACACTGGGGGAGGGGGACGGTGAAGGCCAAGTTCCCAATGAGGGTGAGATTGGGCCTGGG  
 GTCTCACCCCTAGTGTGGGGCCCCAGGTCCCGTGCCTCCCCTTCCCAATGTGGCCTATGGAG  
 AGACAGGCCTTTCTCTCAGCCTCTGGAAGCCACCTGCTCTTTTGCTCTAGCACCTGGGTCCC  
 AGCATCTAGAGCATGGAGCCTCTAGAAGCCATGCTCACCCGCCACATTTAATTAACAGCTG  
 AGTCCCTGATGTCATCCTTATCTCGAAGAGCTTAGAAACAAAGAGTGGGAAATTCCACTGGG  
 20 CCTACCTTCCTTGGGGATGTTTCATGGGCCCCAGTTTCCAGTTTCCCTTGCCAGACAAGCCCA  
 TCTTCAGCAGTTGCTAGTCCATTCTCCATTCTGGAGAATCTGCTCCAAAAAGCTGGCCACAT  
 CTCTGAGGTGTCAGAAATTAAGCTGCCTCAGTAACTGCTCCCCCTTCTCCATATAAGCAAAGC  
 CAGAAGCTCTAGCTTTACCCAGCTCTGCCTGGAGACTAAGGCAAATTGGGCCATTAAAAGCT  
 CAGCTCCTATGTTGGTATTAACGGTGGTGGGTTTTGTTGCTTTCACACTCTATCCACAGGAT  
 25 AGATTGAAACTGCCAGCTTCCACCTGATCCCTGACCTGGGATGGCTGGATTGAGCAATGAG  
 CAGAGCCAAGCAGCACAGAGTCCCCTGGGGCTAGAGGTGGAGGAGGCAGTCCTGGGAATGGG  
 AAAAACCCCA (SEQ ID NO:1)

The *RHO* genomic sequence can be annotated as follows:

|        |                                                     |
|--------|-----------------------------------------------------|
| mRNA   | 1..456,2238..2406,3613..3778,3895..4134,4970..6706  |
| 30 CDS | 96..456,2238..2406,3613..3778,3895..4134,4970..5080 |

Exemplary target domains, described in more detail elsewhere herein, are provided below in **Table 5** for the purpose of illustration:

**Table 5**

| Reference ID | Position of target domain in <i>RHO</i> genomic sequence (SEQ ID NO:1) |
|--------------|------------------------------------------------------------------------|
| RHO-1        | 74..95                                                                 |
| RHO-2        | 391..412                                                               |
| RHO-3        | 381..402                                                               |
| RHO-4        | 312..333                                                               |
| RHO-5        | 178..199                                                               |
| RHO-6        | 144..165                                                               |
| RHO-7        | 453..474                                                               |
| RHO-8        | 448..469                                                               |
| RHO-9        | 2334..2355                                                             |
| RHO-10       | 2395..2416                                                             |
| RHO-11       | 2389..2410                                                             |

A variety of *RHO* cDNA sequences may be used herein. In certain embodiments, the *RHO* cDNA may be delivered to provide an exogenous functional *RHO* cDNA.

5        Provided below is an exemplary nucleic acid sequence of a wild-type *RHO* cDNA:

ATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGGTACG  
 CAGCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCCATGCTGGCCG  
 CCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCACGCTCTACGTCACC  
 GTCCAGCACAGAAGCTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAGCCGTGGCTGA  
 10 CCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCTCTACACCTCTCTGCATGGATACTTCG  
 TCTTCGGGCCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGCGGTGAAATTGCC  
 CTGTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGTAAGCCCATGAGCAA  
 CTTCGCTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACCTGGGTCATGGCGCTGG  
 CCTGCGCCGCACCCCCACTCGCCGGCTGGTCCAGGTACATCCCCGAGGGCCTGCAGTGCTCG  
 15 TGTGGAATCGACTACTACAGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCTATCTACAT  
 GTTCGTGGTCCACTTCACCATCCCCATGATTATCATCTTTTCTGCTATGGGCAGCTCGTCT  
 TCACCGTCAAGGAGGCCGCTGCCCAGCAGCAGGAGTCAGCCACCACACAGAAGGCAGAGAAG  
 GAGGTCACCCGCATGGTCATCATCATGGTCATCGCTTTCCTGATCTGCTGGGTGCCCTACGC  
 CAGCGTGGCATTCTACATCTTCACCCACCAGGGCTCCAACCTTCGGTCCCATCTTCATGACCA  
 20 TCCCAGCGTTCTTTGCCAAGAGCGCCGCCATCTACAACCCTGTCATCTATATCATGATGAAC  
 AAGCAGTTCCGGAAGTGCATGCTCACCACCATCTGCTGCGGCAAGAACCCTGGGTGACGA  
 TGAGGCCTCTGCTACCGTGTCCAAGACGGAGACGAGCCAGGTGGCCCCGGCCTAA (SEQ  
 ID NO:2)

25        In certain embodiments, the *RHO* cDNA may be codon-optimized to increase  
 expression. In certain embodiments, the *RHO* cDNA may be codon-modified to be resistant

to hybridization with a gRNA targeting domain. In certain embodiments, the *RHO* cDNA is not codon-modified to be resistant to hybridization with a gRNA targeting domain.

Provided below are exemplary nucleic acid sequences of codon optimized *RHO*

cDNA:

5 Codon optimized RHO-encoding sequence 1 (Codon 1):

ATGAACGGCACCGAGGGCCCCAACTTCTACGTCCCCTTCTCAGCAACGCCACCGGCGTCTGTCGG  
CAGCCCCCTTCGAGTACCCCCAGTACTACCTGGCCGAGCCCTGGCAGTTTCTCAGCATGCTGGCCG  
CCTACATGTTCTCTGCTGATCGTCTGGGCTTCCCCATCAACTTCCTGACCCCTGTACGTACCC  
GTCCAGCACAAGAAGCTGCGCACCCCCCTGAACTACATCCTGCTGAACCTGGCCGTCGCCGA  
10 CCTGTTTCATGGTCTCTGGGCGGCTTACCAGCACCCCTGTACACCAGCCTGCACGGCTACTTCG  
TCTTCGGCCCCACCGGCTGCAACCTGGAGGGCTTCTTCGCCACCCTGGGCGGCGAGATCGCC  
CTGTGGAGCCTGGTCTGCTCTGGCCATCGAGCGCTACGTCTGCTCTGCAAGCCCATGAGCAA  
CTTCCGCTTCGGCGAGAACCACGCCATCATGGGCGTCGCCCTTACCTGGGTCTATGGCCCTGG  
CCTGCGCCGCCCCCCCCCTGGCCGGCTGGAGCCGCTACATCCCCGAGGGCCTGCAGTGCAGC  
15 TGCGGCATCGACTACTACACCCTGAAGCCCCGAGGTCAACAACGAGAGCTTCGTCTATCTACAT  
GTTCTGTCGTCCACTTACCATCCCCATGATCATCATCTTCTTCTGCTACGGCCAGCTGGTCT  
TCACCGTCAAGGAGGCCGCCGCCAGCAGCAGGAGAGCGCCACCACCCAGAAGGCCGAGAAG  
GAGGTCAACCGCATGGTCATCATCATGGTCTCGCCTTCTGATCTGCTGGGTCCCCTACGC  
CAGCGTCGCCTTCTACATCTTACCCACCAGGGCAGCAACTTCGGCCCCATCTTCATGACCA  
20 TCCCCGCCTTCTTCGCCAAGAGCGCCGCCATCTACAACCCCGTCATCTACATCATGATGAAC  
AAGCAGTTCCGCAACTGCATGCTGACCACCATCTGCTGCGGCAAGAACCCCCCTGGGCGACGA  
CGAGGCCAGCGCCACCGTCAGCAAGACCGAGACCAGCCAGGTGCGCCCCGCCTAA (SEQ  
ID NO:13)

Codon optimized RHO-encoding sequence 2 (Codon 2):

25 ATGAACGGCACCGAGGGCCCCAACTTCTACGTGCCCTTCTCCAACGCCACCGGCGTGGTGCG  
CTCCCCCTTCGAGTACCCCCAGTACTACCTGGCCGAGCCCTGGCAGTTTCTCCATGCTGGCCG  
CCTACATGTTCTCTGCTGATCGTCTGGGCTTCCCCATCAACTTCCTGACCCCTGTACGTGACC  
GTGCAGCACAAGAAGCTGCGCACCCCCCTGAACTACATCCTGCTGAACCTGGCCGTCGCCGA  
CCTGTTTCATGGTCTGGGCGGCTTACCTCCACCCTGTACACCTCCCTGCACGGCTACTTCG  
30 TGTTTCGGCCCCACCGGCTGCAACCTGGAGGGCTTCTTCGCCACCCTGGGCGGCGAGATCGCC  
CTGTGGTCCCTGGTGGTCTGGCCATCGAGCGCTACGTGGTGGTGTGCAAGCCCATGTCCAA  
CTTCCGCTTCGGCGAGAACCACGCCATCATGGGCGTGGCCTTACCTGGGTGATGGCCCTGG  
CCTGCGCCGCCCCCCCCCTGGCCGGCTGGTCCCCTACATCCCCGAGGGCCTGCAGTGTCTCC  
TGCGGCATCGACTACTACACCCTGAAGCCCCGAGGTGAACAACGAGTCCTTCGTGATCTACAT  
35 GTTCGTGGTGCACCTTACCATCCCCATGATCATCATCTTCTTCTGCTACGGCCAGCTGGTGT  
TCACCGTGAAGGAGGCCGCCGCCAGCAGCAGGAGTCCGCCACCACCCAGAAGGCCGAGAAG  
GAGGTGACCCGCATGGTGATCATCATGGTGATCGCCTTCTGATCTGCTGGGTGCCCTACGC  
CTCCGTGGCCTTCTACATCTTACCCACCAGGGCTCCAACCTTCGGCCCCATCTTCATGACCA  
TCCCCGCCTTCTTCGCCAAGTCCGCCGCCATCTACAACCCCGTCATCTACATCATGATGAAC  
40 AAGCAGTTCCGCAACTGCATGCTGACCACCATCTGCTGCGGCAAGAACCCCCCTGGGCGACGA  
CGAGGCCCTCCGCCACCGTGTCCAAGACCGAGACCTCCAGGTGGCCCCCGCCTAA (SEQ  
ID NO:14)

Codon Optimized RHO-encoding sequence 3 (Codon 3):

ATGAACGGCACCGAGGGCCCCAACTTCTACGTCCCCTTCTCAGCAACGCCACCGGCGTCTGTCGG

CAGCCCCCTTCGAGTACCCCCAGTACTACCTGGCCGAGCCCTGGCAGTTCTCTATGCTGGCCG  
 CCTACATGTTCTGCTGATCGTCCTGGGCTTCCCTATCAACTTCCTCACCCCTCTACGTCACC  
 GTCCAGCACAGAAGCTCCGCACCCCTCTCAACTACATCCTCCTTAACCTTGCCGTCGCCGA  
 CCTTTTCATGGTCCTTGGCGGCTTCACCTCTACTCTTTACACTTCTTTGCACGGGTACTTCG  
 5 TGTTCGGTCCTACTGGTTGCAACTTGGAGGGTTTCTTCGCCACTTTGGGTGGTGAGATCGCC  
 TTGTGGTCGTTGGTGGTGTAGCTATCGAGCGATACGTGGTGGTGTGCAAGCCTATGTGAA  
 CTTCCGGTTCGGTGAGAATCATGCTATCATGGGAGTGGCTTTTACTTGGGTGATGGCTTTAG  
 CTTGCGCTGCTCCTCCGTTAGCTGGATGGTCGCGTTATATCCCGGAGGGATTACAGTGCTCA  
 TGCGGAATCGACTATTATACTCTAAAGCCGGAAGTTAATAATGAATCATTTGTTATTTATAT  
 10 GTTTGTTGTTTCATTTTACAATTCCGATGATTATTATTTTTTTTTTGTATGGACAGCTAGTTT  
 TTACAGTTAAGGAAGCAGCAGCACAGCAACAAGAATCAGCAACAACACAAAAGGCAGAAAAA  
 GAAGTTACAAGGATGGTTATTATTATGGTAATTGCATTTCTAATATGTTGGGTACCGTATGC  
 ATCCGTAGCATTTTATATATTTACACATCAAGGGTCCAATTTTGGGCCAATATTTATGACGA  
 TACCAGCGTTTTTTTGCAGAAATCCGCGGCGATATATAATCCAGTAATATATATAATGATGAAT  
 15 AAACAATTTAGAAATTGTATGCTAACGACGATATGTTGTGGGAAAAATCCACTAGGGGATGA  
 TGAAGCGAGTGCACGGTAAGTAAACGGAAACGAGTCAAGTAGCGCCAGCGTAA (SEQ  
 ID NO:15)

**Codon Optimized RHO-encoding sequence 4 (Codon 4):**

ATGAACGGCACCCGAGGGTCCCAATTTCTACGTCCCATTTTCCAACGCCACGGGGGTGGTACG  
 20 CAGCCCTTTCGAATATCCGCAGTACTATCTGGCTGAGCCCTGGCAGTTTTCTATGCTCGCAG  
 CGTACATGTTCTTGCTAATCGTTCTGGGATTTCCAATTAATTTCTCACATTGTATGTCACC  
 GTGCAGCACAGAAGCTACGGACGCCTCTGAACTACATCCTCTTGAATCTAGCCGTCGCTGA  
 CCGTGTATGTTCTCGGCGGTTTCACATCGACCTTGATACGTCACTACATGGGTACTTTG  
 TCTTCGGACCGACAGGCTGCAACCTGGAAGGTTTTTTTCGCAACCCTCGGGGGAGAGATTGCG  
 25 TTGTGGTCCCTAGTGGTACTGGCCATCGAAAGGTATGTTGTGCTGTGTAAGCCCATGAGCAA  
 TTTTCGCTTCGGCGAGAACCACGCTATTATGGGTGTAGCATTTACGTGGGTATGGCGCTCG  
 CCTGCGCTGCACCACCTTTGGCGGGGTGGTCTCGGTACATCCCGGAAGGACTACAGTGTTGCG  
 TGCGGCATTGATTATTACACACTGAAGCCCGAGGTCAATAACGAATCATTCTGTGATCTATAT  
 GTTTGTAGTTCATTTACCATTTCCAATGATCATTATCTTTTTCTGTTACGGTCAGCTCGTCT  
 30 TTACGGTGAAGGAGGCCGCTGCACAGCAGCAGGAATCCGCGACAACCCAGAAGGCCGAGAAG  
 GAAGTAACGAGGATGGTTATTATCATGGTCATTGCTTTCTTGATCTGCTGGGTGCCTTATGC  
 AAGCGTAGCGTTTTACATTTTCACACACCAGGGGTCTAATTTTGGACCGATCTTCATGACCA  
 TTCCCGCCTTTTTTCGCTAAGTCGGCAGCGATCTATAACCCAGTTATTTACATCATGATGAAT  
 AAGCAGTTTTCGCAACTGTATGCTAACGACAATTTGCTGTGGCAAGAATCCTCTGGGTGACGA  
 35 TGAGGCCTCAGCTACCGTCTCCAAGACGGAAACAAGCCAGGTGGCACCGGCGTAA (SEQ  
 ID NO:16)

**Codon Optimized RHO-encoding sequence 5 (Codon 5):**

ATGAATGGGACTGAAGGACCTAATTTCTATGTGCCATTTAGCAATGCTACTGGCGTTGTCAG  
 AAGCCCCCTTCGAATATCCACAATACTATCTGGCCGAACCTTGGCAGTTCAGCATGCTCGCTG  
 40 CCTATATGTTTCTGCTGATTGTGCTGGGCTTTCCCATAAATTTCTCACCCCTGTATGTTACT  
 GTTCAACACAAAAAGCTGCGGACGCCTCTGAACTACATACTGCTGAACCTGGCCGTCGCCGA  
 CCTGTTTATGGTCCTGGGAGGCTTTACAAGCACTCTGTATACAAGCCTGCACGGCTACTTCG  
 TGTTCGGCCCCACAGGCTGCAACCTCGAAGGCTTCTTTGCCACCCTCGGAGGAGAGATTGCC  
 CTGTGGAGCCTGGTGGTGGTGGCCATCGAAAGGTATGTGGTGGTGTGTAACCCATGTCCAA  
 45 TTTTCGGTTCGGCGAGAACCACGCTATTATGGGAGTGGCTTTCACTTGGGTGATGGCCCTGG  
 CCTGCGCCGCCCCACCACTGGCCGGGTGGAGCCGGTACATCCAGAGGGGCTGCAATGTAGC

TGCGGAATCGACTATTATACCCTGAAACCAGAGGTGAACAACGAGAGCTTTGTGATTTATAT  
 GTTTGTGGTGCATTTTACAATTCCTATGATTATCATTTTCTTCTGTTACGGGCAACTGGTGT  
 TTACCGTGAAGGAAGCCGCCGCTCAACAGCAGGAGAGCGCCACAACCCAAAAGGCCGAGAAG  
 GAGGTGACCAGAATGGTGAATTATTATGGTGATCGCTTTTCTGATTTGCTGGGTGCCATACGC  
 5 TAGCGTCGCTTTCTATATTTTCACTCACCAGGGGAGCAACTTCGGCCCCATTTTCATGACAA  
 TCCCTGCCTTTTTTGTAAAAGCGCCGCCATCTATAACCCAGTGATCTACATCATGATGAAC  
 AAACAGTTTAGGAACTGTATGCTCACAACAATCTGCTGTGGAAAGAACCCCTCGGCGATGA  
 CGAAGCCAGCGCCACCGTCAGCAAGACAGAAACAAGCCAGGTGGCCCCTGCCTAA (SEQ  
 ID NO: 17)

10 Codon Optimized RHO-encoding sequence 6 (Codon 6):

ATGAATGGCACAGAGGGCCCTAACTTCTACGTGCCCTTTAGCAATGCCACAGGCGTCGTGCG  
 GAGCCCTTTTGTAGTACCCTCAGTACTATCTGGCCGAGCCTTGGCAGTTTAGCATGCTGGCCG  
 CCTACATGTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTTCTGACCTGTACGTGACC  
 GTGCAGCACAAGAAGCTGCGGACCCCTCTGAACATCATCCTGCTGAATCTGGCCGTGGCCGA  
 15 CCTGTTTATGGTGCTCGGCGGCTTTACCAGCACACTGTACACAAGCCTGCACGGCTACTTCG  
 TGTTTGGCCCCACCGGCTGCAATCTGGAAGGCTTTTTTGCCACACTCGGCGGCGAAATTGCT  
 CTGTGGTCACTGGTGGTGCTGGCCATCGAGAGATACGTGGTCTGTGCAAGCCCATGAGCAA  
 CTTGAGATTCGGCGAGAACCACGCCATCATGGGCGTCGCCTTTACATGGGTTATGGCCCTGG  
 CTTGTGCAGCTCCTCCTCTTGCCGGCTGGTCCAGATATATTCCTGAGGGCTGCAGTGCAGC  
 20 TGCGGCATCGATTACTACACCCTGAAGCCTGAAGTGAACAACGAGAGCTTCGTGATCTACAT  
 GTTTGTGGTGCATTTACGATCCCCATGATCATCATATTCTTTTGCTACGGCCAGCTGGTGT  
 TCACCGTGAAAGAAGCCGCTGCTCAGCAGCAAGAGAGCGCCACAACACAGAAAGCCGAGAAA  
 GAAGTGACCCGGATGGTCATTATCATGGTTATCGCCTTTCTGATCTGTTGGGTGCCCTACGC  
 CAGCGTGGCCTTCTACATCTTTACCCACCAAGGCAGCAACTTCGGCCCCATCTTTATGACAA  
 25 TCCCCGCCTTCTTTGCCAAGAGCGCCGCCATCTACAACCCCGTGATCTATATCATGATGAAC  
 AAGCAGTTCGCAACTGCATGCTGACCACCATCTGCTGCGGAAAGAACCCTCTGGGAGATGA  
 TGAGGCCAGCGCCACCGTGTCTAAGACCGAAACATCTCAGGTGGCCCCTGCATGA (SEQ  
 ID NO: 18)

30 In certain embodiments, the *RHO* cDNA may include a modified 5' UTR, a modified  
 3'UTR, or a combination thereof. For example, in certain embodiments, the *RHO* cDNA  
 may include a truncated 5' UTR, a truncated 3'UTR, or a combination thereof. In certain  
 embodiments, the *RHO* cDNA may include a 3'UTR from a known stable messenger RNA  
 (mRNA). For example, in certain embodiments, the *RHO* cDNA may include a heterologous  
 35 3'-UTR downstream of the *RHO* coding sequence. For example, in some embodiments, the  
*RHO* cDNA may include an  $\alpha$ -globin 3' UTR. In certain embodiments, the *RHO* cDNA may  
 include a  $\beta$ -globin 3' UTR. In certain embodiments, the *RHO* cDNA may include one or  
 more introns. In certain embodiments, the *RHO* cDNA may include a truncation of one or  
 more introns.

40 Exemplary suitable heterologous 3'-UTRs that can be used to stabilize the transcript  
 of the *RHO* cDNA include, but are not limited, to the following:

**HBA1 3'UTR:**

GCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCAGCCCCCTCCTCCCCTT  
CCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGCA (SEQ ID  
NO: 38)

**5 short HBA1 3'UTR:**

GCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCAGCCCCCTCCTCCCCTT  
CCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGA (SEQ ID NO: 39)

**TH 3'UTR:**

10 GTGCACGGCGTCCCTGAGGGGCCCTTCCCAACCTCCCCTGGTCTGCACTGTCCCGGAGCTCA  
GGCCCTGGTGAGGGGCTGGGTCCCGGGTGGCCCCCATGCCCTCCCTGCTGCCAGGCTCCAC  
TGCCCCTGCACCTGCTTCTCAGCGCAACAGCTGTGTGTGCCCGTGGTGAGGTTGTGCTGCCT  
GTGGTGAGGTCTGTCTTGGCTCCCAGGGTCTTGGGGGCTGCTGCACTGCCCTCCGCCCTTC  
CCTGACACTGTCTGCTGCCCCAATCACCGTCACAATAAAGAACTGTGGTCTCTA (SEQ  
ID NO: 40)

**15 COL1A1 3'UTR:**

ACTCCCTCCATCCCAACCTGGCTCCCTCCCACCCAACCAACTTCCCCCAACCCGGAAACA  
GACAAGCAACCCAACTGAACCCCTCAAAAGCCAAAAAATGGGAGACAATTTACATGGAC  
TTTGGAATAATTTTTTTCCTTTGCATTCTCTCAAACCTAGTTTTATCTTTGACCAAC  
CGAACATGACCAAAAACCAAAAGTGCATTCAACCTTACCAAAAAAAAAAAAAAAAAAGAAT  
20 AAATAAATAACTTTTTAAAAAGGAAGCTTGGTCCACTTGCTTGAAGACCCATGCGGGGGTA  
AGTCCCTTTCTGCCCGTTGGGCTTATGAAACCCCAATGCTGCCCTTTCTGCTCCTTTCTCCA  
CACCCCTTGGGGCCTCCCTCCACTCCTTCCCAATCTGTCTCCCCAGAAGACACAGGAA  
ACAATGTATTTGTCTGCCAGCAATCAAAGGCAATGCTCAAACACCCAAGTGGCCCCACCCT  
CAGCCCGCTCCTGCCCGCCAGCACCCCGAGGCCCTGGGGGACCTGGGGTTCTCAGACTGCC  
25 AAAGAAGCCTTGCCATCTGGCGCTCCCATGGCTCTTGCAACATCTCCCTTCGTTTTTGAGG  
GGGTCATGCCGGGGGAGCCACCAGCCCTCACTGGGTTCGGAGGAGAGTCAGGAAGGGCCAC  
GACAAAGCAGAAACATCGGATTTGGGGAACGCGTGTCAATCCCTTGTGCCGCAGGGCTGGGC  
GGGAGAGACTGTTCTGTTCTTGTGTAACCTGTGTTGCTGAAAGACTACCTCGTTCTTGTCTT  
GATGTGTACCCGGGGCAACTGCCTGGGGGCGGGGATGGGGGAGGGTGGAAGCGGCTCCCCA  
30 TTTTATACCAAAGGTGCTACATCTATGTGATGGGTGGGGTGGGGAGGGAATCACTGGTGCTA  
TAGAAATTGAGATGCCCCCCCAGGCCAGCAAATGTTCTTTTTTGTTCAAAGTCTATTTTTAT  
TCCTTGATATTTTTCTTTTTTTTTTTTTTTTTTTTGTGGATGGGGACTTGTGAATTTTTCTAA  
AGGTGCTATTTAACATGGGAGGAGAGCGTGTGCGGCTCCAGCCCAGCCCGCTGCTCACTTTC  
CACCTCTCTCCACCTGCCTCTGGCTTCTCAGGCCTCTGCTCTCCGACCTCTCTCTCTGAA  
35 ACCCTCCTCCACAGCTGCAGCCCATCCTCCCGGCTCCCTCCTAGTCTGTCTCTGCTCCTCTG  
TCCCCGGGTTTCAGAGACAACTTCCCAAAGCACAAAGCAGTTTTTCCCCCTAGGGGTGGGAG  
GAAGCAAAAGACTCTGTACCTATTTTGTATGTGTATAATAATTTGAGATGTTTTTAATTATT  
TTGATTGCTGGAATAAAGCATGTGGAAATGACCCAAACATAA (SEQ ID NO: 41)

**40 ALOX15 3'UTR:**

GCGTCGCCACCCTTTGGTTATTTTACGCCCCCATCACCCAAGCCACAAGCTGACCCCTTCGTG  
GTTATAGCCCTGCCCTCCCAAGTCCCACCCTCTTCCCATGTCCCACCCTCCCTAGAGGGGCA  
CCTTTTCATGGTCTCTGCACCCAGTGAACACATTTTACTCTAGAGGCATCACCTGGGACCTT  
ACTCCTCTTTCCTTCTTCTCCTTCTCCTATCTTCTTCTCTCTCTCTCTCTCTCTCTCTCA  
45 TTCAGATCTATATGGCAAATAGCCACAATTATATAAATCATTTCAAGACTAGAATAGGGGGA  
TATAATACATATTACTCCACACCTTTTATGAATCAAATATGATTTTTTTTGTGTTGTTAAGA  
CAGAGTCTCACTTTGACACCCAGGCTGGAGTGCAGTGGTGCCATCACACGGCTCACTGCAG  
CCTCAGCGTCTGGGCTCAAATGATCCTCCCACCTCAGCCTCCTGAGTAGCTGGGACTACAG

GCTCATGCCATCATGCCCAGCTAATATTTTTTTATTTTCGTGGAGACGGGGCCTCACTATGT  
TGCCTAGGCTGGAAATAGGATTTTGAACCCAAATTGAGTTTAAACAATAATAAAAAGTTGTTT  
TACGCTAAAGATGGAAAAGAACTAGGACTGAAGTATTTTAAATAAAATATTGGCAAAAGAA  
(SEQ ID NO: 42)

- 5 In certain embodiments, the *RHO* cDNA may include one or more introns. In certain embodiments, the *RHO* cDNA may include a truncation of one or more introns.

Table 6 below provides exemplary sequences of *RHO* cDNA containing introns.

Table 6

| cDNA Identifier                      | <i>RHO</i> cDNA sequence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b><i>RHO</i> cDNA with intron 1</b> | ATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGG<br>TACGCAGCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCCAT<br>GCTGGCCGCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCACG<br>CTCTACGTCAACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTGCTCA<br>ACCTAGCCGCTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCTCTACAC<br>CTCTCTGCATGGATACTTCGTCTTCGGGCCACAGGATGCAATTTGGAGGGCTTCTTT<br>GCCACCTTGGGCGGTATGAGCCGGGTGTGGGTGGGGTGTGCAGGAGCCCGGAGCATG<br>GAGGGTCTGGGAGAGTCCCGGGCTTGGCGGTGGTGGCTGAGAGGCCCTCTCCCTTCT<br>CCTGTCTGTCAATGTTATCCAAAGCCCTCATATATTCAAGTCAACAAACACCATTTCAT<br>GGTGATAGCCGGCTGCTGTTTGTGCAGGGCTGGCACTGAACACTGCCTTGATCTTAT<br>TTGGAGCAATATGCGCTTGTCTAATTTACAGCAAGAAAAGTGAAGTGAAGCTCAAAG<br>AAGTCAAGCGCCCTGCTGGGGCGTCACACAGGGACGGGTGCAGAGTTGAGTTGGAAGC<br>CCGCATCTATCTCGGGCCATGTTTGCAGCACCAAGCCTCTGTTTCCCTTGGAGCAGCT<br>GTGCTGAGTCAGACCCAGGCTGGGCACTGAGGGAGAGCTGGGCAAGCCAGACCCCTCC<br>TCTCTGGGGGCCCAAGCTCAGGGTGGGAAGTGGATTTTCCATTCTCCAGTCATTGGGT<br>CTTCCCTGTGCTGGGCAATGGGCTCGGTCCCTCTGGCATCCCTGCTCCCTCCCTCTCA<br>GCCCCGTCTCTCAGGTGCCCTCCAGCCTCCCTGCCGCGTTCCAAGTCTCCTGGTGTT<br>GAGAACCGCAAGCAGCCGCTCTGAAGCAGTTCTTTTTGCTTTAGAATAATGTCTTGC<br>ATTTAACAGGAAAACAGATGGGGTGTGTCAGGGATAACAGATCCCACTTAACAGAGAG<br>GAAAAGTGAAGCAGGGAGAGGGGAAGAGACTCATTTAGGGATGTGGCCAGGCAGCAAC<br>AAGAGCCTAGGTCTCCTGGCTGTGATCCAGGAATATCTCTGCTGAGATGCAGGAGGAG<br>ACGCTAGAAGCAGCCATTGCAAAGCTGGGTGACGGGGAGAGCTTACCGCCAGCCACAA<br>GCGTCTCTCTGCCAGCCTTGCCCTGTCTCCCCCATGTCCAGGCTGCTGCCTCGGTCCC<br>ATTTCTCAGGGAATCTCTGGCCATTGTTGGGTGTTTGTGTCATTCAATAATCACAGATC<br>ACTCAGTTCTGGCCAGAAGGTGGGTGTGCCACTTACGGGTGGTTGTTCTCTGCAGGGT<br>CAGTCCAGTTTACAAATATTGTCCCTTTCACTGTTAGGAATGTCCAGTTTGGTTGA<br>TTAACTATATGGCCACTCTCCCTATGGAACCTTCATGGGGTGGTGAAGCAGGACAGATGT<br>CTGAATTCCATCATTTCTTCTTCTTCTTCTCTGGGCAAAACATTGCACATTGCTTCATG<br>GCTCCTAGGAGAGGCCCCACATGTCCGGGTATTTTCATTTCCCGAGAAGGGAGAGGG<br>AGGAAGGACTGCCAATTCTGGGTTTCCACCACCTCTGCATTCTTCCCAACAAGGAAC<br>TCTGCCCCACATTAGGATGCATTCTTCTGCTAAACACACACACACACACACACACA<br>CAACACACACACACACACACACACACACACACACACACACACACACACACACACACA<br>GTTCAATCCTGACCCCCCTGATCTGATTCTGTGTCCTTATGGGCCAGAGCGCTAAGCA<br>AATAACTTCCCCCATTCCTTGGAAATTTCTTTGCCAGCTCTCCTCAGCGTGTGGTCCC<br>TCTGCCCCCTTCCCCCTCCTCCAGCACCAAGCTCTCTCCTTCCCCAAGGCCTCCTCAA<br>ATCCCTCTCCCACTCCTGGTTGCCCTTCCTAGCTACCCTCTCCCTGTCTAGGGGGAGT<br>GCACCTCCTTAGGCAGTGGGGTCTGTGCTGACCGCTGCTGACTGCCTTGCAGGTGA<br>AATTGCCCTGTGGTCTTGGTGGTCTTGGCCATCGAGCGGTACGTGGTGGTGTGTAAG<br>CCCATGAGCAACTTCCGCTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACCT<br>GGGTCAATGGCGCTGGCCTGCGCCGACCCCCACTCGCCGGCTGGTCCAGGTACATCCC<br>CGAGGGCTGCAAGTCTGCTGTGGAATCGACTACTACACGCTCAAGCCGGAGGTCAAC<br>AACGAGTCTTTTGTCACTACATGTTCTGTTGGTCCACTTCACCATCCCCATGATTATCA<br>TCTTTTCTGCTATGGGAGCTCGTCTTACCGTCAAGGAGGCGGTGCCAGCAGCA<br>GGAGTCAGCCACCACACAGAAGGCAGAGAAGGAGGTACCCGCATGGTCATCATCATG |

|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                   | <p>GTCATCGCTTTCCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCA<br/>         CCCACCAGGGCTCCAACTTCGGTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAA<br/>         GAGCGCCGCCATCTACAACCCGTGTCATCTATATCATGATGAACAAGCAGTTCCGGAAC<br/>         TGCATGCTCACCACCATCTGCTGCGGCAAGAACCCTAGGGTGACGATGAGGCCTCTG<br/>         CTACCGTGTCCAAGACGGAGACGAGCCAGGTGGCCCCGGCCTAA<br/>         (SEQ ID NO:4)</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>RHO cDNA with<br/>intron 2</b> | <p>ATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTG<br/>         GTACGCAGCCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCC<br/>         ATGCTGGCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTC<br/>         ACGCTCTACGTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTG<br/>         CTCAACCTAGCCGTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCCTC<br/>         TACACCTCTCTGCATGGATACTTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGC<br/>         TTCTTTGCCACCCCTGGGCGGTGAAATTGCCCTGTGGTCCTTGGTGGCTCTGGCCATC<br/>         GAGCGGTACGTGGTGGTGTGTAAGCCCATGAGCAACTTCCGCTTCGGGGAGAACCAT<br/>         GCCATCATGGGCGTTGCCCTTCACCTGGGTGATGGCGCTGGCCTGCGCCGCACCCCCA<br/>         CTCGCCGGCTGGTCCAGTAATGGCACTGAGCAGAAGGGAAGAAGCTCCGGGGGCTC<br/>         TTTGTAGGGTCTCCAGTCAGGACTCAAACCCAGTAGTGTCTGGTTCCAGGCACCTGA<br/>         CCTTGATGTCTCCTGGCCCAAATGCCCACTCAGGGTAGGGGTGTAGGGCAGAAGAA<br/>         GAAACAGACTCTAATGTTGCTACAAGGGCTGGTCCCCTCTCCTGAGCCCCATGTCAA<br/>         ACAGAATCCAAGACATCCCAACCCCTTCACCTTGGCTGTGCCCTAATCCTCAACTAA<br/>         GCTAGGCGCAAATTCCAATCCTCTTTGGTCTAGTACCCCGGGGCGAGCCCCCTCTAA<br/>         CCTTGGGCCTCAGCAGCAGGGGAGGCCACACCTTCCCTAGTGCAGGTGGCCATATTGT<br/>         GGCCCCCTTGGAACCTGGGTCCCCTCAGCCTCTAGGCGATTGTCTCCTAATGGGGCTG<br/>         AGATGAGACACAGTGGGGACAGTGGTTTGGACAATAGGACTGGTGACTCTGGTCCCC<br/>         AGAGGCCTCATGTCCCTCTGTCTCCAGAAAATTCCCCTCTCACTTCCCTTTCTCTCC<br/>         TCAGTCTTGCTAGGGTCCATTTCTTACCCCTTGCTGAATTTGAGCCCCACCCCTGGA<br/>         CTTTTTCCCCATCTTCTCCAATCTGGCCTAGTTCTATCCTCTGGAAGCAGAGCCGCT<br/>         GGACGCTCTGGGTTTCTTGAGGCCCCGTCCACTGTCCCAATATCAGGAACCATTTGCC<br/>         ACGTCCTAATGACGTGCGCTGGAAGCCTCTAGTTTCCAGAAGCTGCACAAAGATCCC<br/>         TTAGATACTCTGTGTGCCATCTTTGGCCTGGAAAATACTCTCAGCCTGGGGCTAGG<br/>         AAGACCTCGGTTTGTACAACTTCTCTCAAATGCAGAGCCTGAGGCTCTCCCCACCT<br/>         CCTCACCAACCCTCTGCGTGGCATAGCCCTAGCCTCAGCGGGCAGTGGATGCTGGGG<br/>         CTGGGCATGCAGGGAGAGGCTGGGTGGTGTCTGTTAAGCAGCCACCAACAAT<br/>         GAAGCGACACTGATTCACACAAGGTGCATCTGCATCCCCATCTGATCCATTCCATCCT<br/>         GTCACCCAGCCATGCAGACGTTTATGATCCCCTTTTCCAGGGAGGGAATGTGAAGCC<br/>         CCAGAAAGGGCCAGCGCTCGGCAGCCACCTTGGCTGTTCCCAAGTCCCTCACAGGCA<br/>         GGGTCTCCCTACCTGCCGTGCTCCTCAGGTACATCCCCGAGGGCCTGCAGTGCTCGTGT<br/>         GGAATCGACTACTACAGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCTATCTAC<br/>         ATGTTCTGTGGTCCACTTCACCATCCCCATGATTATCATCTTTTTCTGCTATGGGCAG<br/>         CTGCTCTTACCCTCAAGGAGGCGCTGCCAGCAGCAGGAGTCAAGCCACACACAG<br/>         AAGGCAGAGAAGGAGGTCAACCGCATGGTCTCATCATGGTCTATCGCTTTCTGATC<br/>         TGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCAACCCAGGGCTCCAAC<br/>         TTCGGTCCCCTCTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATCTAC<br/>         AACCTGTCTATATCATGATGAACAAGCAGTTCCGGAAGTGCATGCTCACCACC<br/>         ATCTGCTGCGGCAAGAACCCTAGGGTGACGATGAGGCCTCTGCTACCGTGTCCAAG<br/>         ACGGAGACGAGCCAGGTGGCCCCGGCCTAA<br/>         (SEQ ID NO:5)</p> |
| <b>RHO cDNA<br/>with intron 3</b> | <p>ATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTG<br/>         GTACGCAGCCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCC<br/>         ATGCTGGCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTC<br/>         ACGCTCTACGTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTG<br/>         CTCAACCTAGCCGTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCCTC<br/>         TACACCTCTCTGCATGGATACTTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGC<br/>         TTCTTTGCCACCCCTGGGCGGTGAAATTGCCCTGTGGTCCTTGGTGGTCTGGCCATC<br/>         GAGCGGTACGTGGTGGTGTGTAAGCCCATGAGCAACTTCCGCTTCGGGGAGAACCAT<br/>         GCCATCATGGGCGTTGCCCTTCACCTGGGTGATGGCGCTGGCCTGCGCCGCACCCCCA<br/>         CTCGCCGGCTGGTCCAGGTACATCCCCGAGGGCCTGCAGTGCTCGTGTGAATTCGAC<br/>         TACTACAGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCTATCATGTTCTCGTG<br/>         GTCCACTTCACCATCCCCATGATTATCATCTTTTTCTGCTATGGGCAGCTCGTCTTC<br/>         ACCGTCAAGGAGGTACGGGCCGGGGGGTGGGCGGCCCTCACGGCTCTGAGGGTCCAGC</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

|                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                          | CCCCAGCATGCATCTGCGGCTCCTGCTCCCTGGAGGAGCCATGGTCTGGACCCGGGT<br>CCCGTGTCTCTGCAGGCCGCTGCCAGCAGCAGGAGTCAGCCACCACAGAAGGCAG<br>AGAAGGAGGTCACCCGCATGGTCATCATCATGGTCATCGCTTTCCTGATCTGCTGGG<br>TGCCCTACGCCAGCGTGGCATTCTACATCTTCACCCACAGGGCTCCAACCTTCGGTC<br>CCATCTTCATGACCATCCAGCGTTCTTTGCCAAGAGCGCCGCCATCTACAACCTTG<br>TCATCTATATCATGATGAACAAGCAGTTCGGAAGTGCATGCTCACCACCATCTGCT<br>GCGGCAAGAACCCACTGGGTGACGATGAGGCCTCTGCTACCGTGTCCAAGACGGAGA<br>CGAGCCAGGTGGCCCCGGCCTAA<br>(SEQ ID NO:6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b><i>RHO</i> cDNA<br/>with intron 4</b> | ATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTG<br>GTACGCAGCCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCC<br>ATGCTGGCCGCCCTACATGTTTCTGCTGATCGTGTGGGCTTCCCCATCAACTTCCTC<br>ACGCTCTACGTACCGTCCAGCACAAGAAGCTGCGCAGCGCTCTCAACTACATCCTG<br>CTCAACCTAGCCGTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCCAGCACCCTC<br>TACACCTCTCTGCATGGATACTTCGTCTTCGGGCCACAGGATGCAATTTGGAGGGC<br>TTCTTTGCCACCCTGGGCGGTGAAATTGCCCTGTGGTCTTGGTGGTCTGGCCATC<br>GAGCGGTACGTGGTGGTGTGTAAGCCCATGAGCAACTTCGCTTCGGGGAGAACCAT<br>GCCATCATGGGCGTTGCCTTCACCTGGGTGATGGCGCTGGCTGCGCCGACCCCCA<br>CTCGCCGGCTGGTCCAGGTACATCCCCGAGGGCCTGCAGTGCTCGTGTGGAATCGAC<br>TACTACACGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCTATCTACATGTTCTGTG<br>GTCCACTTCACCATCCCCATGATTATCATCTTTTCTGCTATGGGCAGCTCGTCTTC<br>ACCGTCAAGGAGGCCGCTGCCAGCAGCAGGAGTCAGCCACCACAGAAGGCAGAG<br>AAGGAGGTCACCCGCATGGTCATCATCATGGTCATCGCTTTCCTGATCTGCTGGGTG<br>CCCTACGCCAGCGTGGCATTCTACATCTTCACCCACCAGGGCTCCAACCTTCGGTCCC<br>ATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATCTACAACCTGTG<br>ATCTATATCATGATGAACAAGCAGGTGCCTACTGCGGGTGGGAGGGCCCCAGTGCCC<br>CAGGCCACAGGCGCTGCCTGCCAAGGACAAGCTACTTCCAGGGCAGGGGAGGGGGC<br>TCCATCAGGGTTACTGGCAGCAGTCTTGGGTGAGCAGTCCCAATGGGGAGTGTGTGA<br>GAAATGCAGATTCTGGCCCCACTCAGAACTGCTGAATCTCAGGGTGGGCCCAGGAA<br>CCTGCATTTCCAGCAAGCCCTCCACAGGTGGCTCAGATGCTCACTCAGGTGGGAGAA<br>GCTCCAGTCAGCTAGTTCTGGAAGCCCAATGTCAAAGTCAGAAAGCAAGTCCGGG<br>AATGGGATGGGCCAGTCTCCATAAAGCTGAATAAGGAGCTAAAAAGTCTTATTCTGA<br>GGGGTAAAGGGGTAAAGGGTTCTCGGAGAGGTACCTCCGAGGGGTAAACAGTTGGG<br>TAAACAGTCTCTGAAGTCAGCTCTGCCATTTTCTAGCTGTATGGCCCTGGGCAAGTC<br>AATTTCTCTTCTCTGTGCTTTGGTTTCTCATCCATAGAAAGGTAGAAAGGGCAAAAC<br>ACCAAACCTCTTGGATTACAAGAGATAATTTACAGAACACCCTTGGCACACAGAGGGC<br>ACCATGAAATGTCACGGGTGACACAGCCCCCTTGTGCTCAGTCCCTGGCATCTCTAG<br>GGGTGAGGAGCGTCTGCCTAGCAGGTTCCCTCCAGGAAGCTGGATTTGAGTGGATGG<br>GGCGCTGGAATCGTGAGGGGCAGAAGCAGGCAAAGGTCGGGGCGAACCTCACTAAC<br>GTGCCAGTTCCAAGCACACTGTGGGCAGCCCTGGCCCTGACTCAAGCCTCTTGCCCTT<br>CCAGTTCCGGAAGTGCATGCTCACCACCATCTGCTGCGGCAAGAACCCTGAGGTGA<br>CGATGAGGCCTCTGCTACCGTGTCCAAGACGGAGACGAGCCAGGTGGCCCCGGCCTA<br>A<br>(SEQ ID NO:7) |

## V. Genome Editing Approaches

In some embodiments, the *RHO* gene is altered using one of the approaches discussed herein.

5

### NHEJ-mediated knock-out of *RHO*

Some aspects of this disclosure provide strategies, methods, compositions, and treatment modalities that are characterized by targeting an RNA-guided nuclease, e.g., a Cas9 or Cpf1 nuclease to a *RHO* target sequence, e.g., a target sequence described herein and/or

using a guide RNA described herein, wherein the RNA-guided nuclease cuts the *RHO* genomic DNA at or near the *RHO* target sequence, resulting in NHEJ-mediated repair of the cut genomic DNA. The outcome of this NHEJ-mediated repair is typically the creation of an indel at the cut site, which in turn results in a loss-of-function of the cut *RHO* gene. A loss-  
5 of-function can be characterized by a decrease or a complete abolishment of expression of a gene product, e.g., in the case of the *RHO* gene: a *RHO* gene product, for example, a *RHO* transcript or a RHO protein, or by expression of a gene product that does not exhibit a function of the wild-type gene product. In some embodiments, a loss-of-function of the *RHO* gene is characterized by expression of a lower level of functional RHO protein. In some  
10 embodiments, a loss-of-function of the *RHO* gene is characterized by abolishment of expression of RHO protein from the *RHO* gene. In some embodiments, a loss-of-function of a mutant *RHO* gene or allele is characterized by decreased expression, or abolishment of expression, of the encoded mutant RHO protein.

As described herein, nuclease-induced non-homologous end-joining (NHEJ) can be  
15 used to introduce indels at a target position. Nuclease-induced NHEJ can also be used to remove (e.g., delete) genomic sequence including the mutation at a target position in a gene of interest.

While not wishing to be bound by theory, it is believed that, in an embodiment, the genomic alterations associated with the methods described herein rely on nuclease-induced  
20 NHEJ and the error-prone nature of the NHEJ repair pathway. NHEJ repairs a double-strand break in the DNA by joining together the two ends; however, generally, the original sequence is restored only if two compatible ends, exactly as they were formed by the double-strand break, are perfectly ligated. The DNA ends of the double-strand break are frequently the subject of enzymatic processing, resulting in the addition or removal of nucleotides, at one or  
25 both strands, prior to rejoining of the ends. This results in the presence of insertion and/or deletion (indel) mutations in the DNA sequence at the site of the NHEJ repair.

The indel mutations generated by NHEJ are unpredictable in nature; however, at a given break site certain indel sequences are favored and are over represented in the population, likely due to small regions of microhomology. The lengths of deletions can vary  
30 widely; most commonly in the 1-50 bp range, but they can easily reach greater than 100-200 bp. Insertions tend to be shorter and often include short duplications of the sequence immediately surrounding the break site. However, it is possible to obtain large insertions, and in these cases, the inserted sequence has often been traced to other regions of the genome or to plasmid DNA present in the cells.

Because NHEJ is a mutagenic process, it can also be used to delete small sequence motifs as long as the generation of a specific final sequence is not required. If a double-strand break is targeted near to a specific sequence motif, the deletion mutations caused by the NHEJ repair often span, and therefore remove, the unwanted nucleotides. For the  
5 deletion of larger DNA segments, introducing two double-strand breaks, one on each side of the sequence, can result in NHEJ between the ends with removal of the entire intervening sequence. Both of these approaches can be used to delete specific DNA sequences; however, the error-prone nature of NHEJ may still produce indel mutations at the site of deletion.

Both double strand cleaving RNA-guided nucleases and single strand, or nickase,  
10 RNA-guided nucleases can be used in the methods and compositions described herein to generate break-induced indels.

Some exemplary methods featuring NHEJ-mediated knock-out of the *RHO* gene are provided herein, as are some exemplary suitable guide RNAs, RNA-guided nucleases, delivery methods, and other aspects related to such methods. Additional suitable methods,  
15 guide RNAs, RNA-guided nucleases, delivery methods, etc., will be apparent to those of ordinary skill in the art based on the present disclosure.

#### HDR Repair and Template Nucleic Acids

As described herein, in certain embodiments, nuclease-induced homology directed  
20 repair (HDR) can be used to alter a target position of a mutant *RHO* gene (e.g., knock out) and replace the mutant *RHO* gene with a wild-type *RHO* sequence. While not wishing to be bound by theory, it is believed that alteration of the target position occurs by homology-directed repair (HDR) with a donor template or template nucleic acid. For example, the donor template or the template nucleic acid provides for alteration of the target position. It is  
25 contemplated that a plasmid donor can be used as a template for homologous recombination. It is further contemplated that a single stranded donor template can be used as a template for alteration of the target position by alternate methods of homology directed repair (e.g., single strand annealing) between the cut sequence and the donor template. Donor template-effected alteration of a target sequence depends on cleavage by an RNA-guided nuclease molecule.  
30 Cleavage by RNA-guided nuclease molecule can comprise a double strand break or two single strand breaks.

Mutant *RHO* genes that can be replaced with wild-type *RHO* by HDR using a template nucleic acid include mutant *RHO* genes comprising point mutations, mutation hotspots or sequence insertions. In an embodiment, a mutant *RHO* gene having a point

mutation or a mutation hotspot (e.g., a mutation hotspot of less than about 30 bp, e.g., less than 25, 20, 15, 10 or 5 bp) can be altered (e.g., knocked out) by either a single double-strand break or two single strand breaks. In an embodiment, a mutant *RHO* gene having a point mutation or a mutation hotspot (e.g., a mutation hotspot greater than about 30 bp, e.g., more than 35, 40, 45, 50, 75, 100, 150, 200, 250, 300, 400 or 500 bp) or an insertion can be altered (e.g., knocked out) by (1) a single double-strand break, (2) two single strand breaks, (3) two double stranded breaks with a break occurring on each side of the target position, or (4) four single stranded breaks with a pair of single stranded breaks occurring on each side of the target position.

Mutant *RHO* genes that can be altered (e.g., knocked out) by HDR and replaced with a template nucleic acid include, but are not limited to, those in **Table A**, such as P23, e.g., P23H or P23L, T58, e.g., T58R and P347, e.g., P347T, P347A, P347S, P347G, P347L or P347R.

#### Double strand break mediated alteration

In an embodiment, double strand cleavage is affected by an RNA-guided nuclease. In certain embodiments, the RNA-guided nuclease may be a Cas9 molecule having cleavage activity associated with an HNH-like domain and cleavage activity associated with an RuvC-like domain, e.g., an N-terminal RuvC-like domain, e.g., a wild type Cas9. Such embodiments require only a single gRNA.

#### Single strand break mediated alteration

In other embodiments, two single strand breaks, or nicks, are affected by a Cas9 molecule having nickase activity, e.g., cleavage activity associated with an HNH-like domain or cleavage activity associated with an N-terminal RuvC-like domain. Such embodiments require two gRNAs, one for placement of each single strand break. In an embodiment, the Cas9 molecule having nickase activity cleaves the strand to which the gRNA hybridizes, but not the strand that is complementary to the strand to which the gRNA hybridizes. In an embodiment, the Cas9 molecule having nickase activity does not cleave the strand to which the gRNA hybridizes, but rather cleaves the strand that is complementary to the strand to which the gRNA hybridizes.

In an embodiment, the nickase has HNH activity, e.g., a Cas9 molecule having the RuvC activity inactivated, e.g., a Cas9 molecule having a mutation at D10, e.g., the D10A mutation. D10A inactivates RuvC; therefore, the Cas9 nickase has (only) HNH activity and

will cut on the strand to which the gRNA hybridizes (the complementary strand, which does not have the NGG PAM on it). In other embodiments, a Cas9 molecule having an H840, e.g., an H840A, mutation can be used as a nickase. H840A inactivates HNH; therefore, the Cas9 nickase has (only) RuvC activity and cuts on the non-complementary strand (the strand that  
 5 has the NGG PAM and whose sequence is identical to the gRNA).

In an embodiment, in which a nickase and two gRNAs are used to position two single strand nicks, one nick is on the + strand and one nick is on the – strand of the target nucleic acid. The PAMs are outwardly facing. The gRNAs can be selected such that the gRNAs are separated by, from about 0-50, 0-100, or 0-200 nucleotides. In an embodiment, there is no  
 10 overlap between the target domains that are complementary to the targeting domains of the two gRNAs. In an embodiment, the gRNAs do not overlap and are separated by as much as 50, 100, or 200 nucleotides. In an embodiment, the use of two gRNAs can increase specificity, e.g., by decreasing off-target binding (Ran 2013).

In an embodiment, a single nick can be used to induce HDR. It is contemplated  
 15 herein that a single nick can be used to increase the ratio of HR to NHEJ at a given cleavage site.

#### Placement of the double strand break or a single strand break relative to the target position

The double strand break or single strand break in one of the strands should be  
 20 sufficiently close to the target position such that alteration occurs. In an embodiment, the distance is not more than 50, 100, 200, 300, 350 or 400 nucleotides. While not wishing to be bound by theory, it is believed that the break should be sufficiently close to the target position such that the break is within the region that is subject to exonuclease-mediated removal during end resection.

In an embodiment, in which a gRNA (unimolecular (or chimeric) or modular gRNA) and RNA-guided nuclease induce a double strand break for the purpose of inducing HDR-mediated replacement, the cleavage site is between 0-200 bp (e.g., 0-175, 0 to 150, 0 to 125, 0 to 100, 0 to 75, 0 to 50, 0 to 25, 25 to 200, 25 to 175, 25 to 150, 25 to 125, 25 to 100, 25 to 75, 25 to 50, 50 to 200, 50 to 175, 50 to 150, 50 to 125, 50 to 100, 50 to 75, 75 to 200, 75 to  
 25 175, 75 to 150, 75 to 125, 75 to 100 bp) away from the target position. In an embodiment, the cleavage site is between 0-100 bp (e.g., 0 to 75, 0 to 50, 0 to 25, 25 to 100, 25 to 75, 25 to 50, 50 to 100, 50 to 75 or 75 to 100 bp) away from the target position.  
 30

In an embodiment, in which two gRNAs (independently, unimolecular (or chimeric) or modular gRNA) complexing with Cas9 nickases induce two single strand breaks for the

purpose of inducing HDR-mediated replacement, the closer nick is between 0-200 bp (e.g., 0-175, 0 to 150, 0 to 125, 0 to 100, 0 to 75, 0 to 50, 0 to 25, 25 to 200, 25 to 175, 25 to 150, 25 to 125, 25 to 100, 25 to 75, 25 to 50, 50 to 200, 50 to 175, 50 to 150, 50 to 125, 50 to 100, 50 to 75, 75 to 200, 75 to 175, 75 to 150, 75 to 125, 75 to 100 bp) away from the target position and the two nicks will ideally be within 25-55 bp of each other (e.g., 25 to 50, 25 to 45, 25 to 40, 25 to 35, 25 to 30, 30 to 55, 30 to 50, 30 to 45, 30 to 40, 30 to 35, 35 to 55, 35 to 50, 35 to 45, 35 to 40, 40 to 55, 40 to 50, 40 to 45 bp) and no more than 100 bp away from each other (e.g., no more than 90, 80, 70, 60, 50, 40, 30, 20, 10 or 5 bp away from each other). In an embodiment, the cleavage site is between 0-100 bp (e.g., 0 to 75, 0 to 50, 0 to 25, 25 to 100, 25 to 75, 25 to 50, 50 to 100, 50 to 75 or 75 to 100 bp) away from the target position.

In one embodiment, two gRNAs, e.g., independently, unimolecular (or chimeric) or modular gRNA, are configured to position a double-strand break on both sides of a target position. In an alternate embodiment, three gRNAs, e.g., independently, unimolecular (or chimeric) or modular gRNA, are configured to position a double strand break (i.e., one gRNA complexes with a cas9 nuclease) and two single strand breaks or paired single stranded breaks (i.e., two gRNAs complex with Cas9 nickases) on either side of the target position. In another embodiment, four gRNAs, e.g., independently, unimolecular (or chimeric) or modular gRNA, are configured to generate two pairs of single stranded breaks (i.e., two pairs of two gRNAs complex with Cas9 nickases) on either side of the target position. The double strand break(s) or the closer of the two single strand nicks in a pair will ideally be within 0-500 bp of the target position (e.g., no more than 450, 400, 350, 300, 250, 200, 150, 100, 50 or 25 bp from the target position). When nickases are used, the two nicks in a pair are within 25-55 bp of each other (e.g., between 25 to 50, 25 to 45, 25 to 40, 25 to 35, 25 to 30, 50 to 55, 45 to 55, 40 to 55, 35 to 55, 30 to 55, 30 to 50, 35 to 50, 40 to 50, 45 to 50, 35 to 45, or 40 to 45 bp) and no more than 100 bp away from each other (e.g., no more than 90, 80, 70, 60, 50, 40, 30, 20 or 10 bp).

#### Length of the homology arms

The homology arm should extend at least as far as the region in which end resection may occur, e.g., in order to allow the resected single stranded overhang to find a complementary region within the donor template. The overall length could be limited by parameters such as plasmid size or viral packaging limits. In an embodiment, a homology arm does not extend into repeated elements, e.g., ALU repeats, LINE repeats.

Exemplary homology arm lengths include a least 50, 100, 250, 500, 750 or 1000 nucleotides.

Target position, as used herein, refers to a site on a target nucleic acid (e.g., the *RHO* gene) that is modified by a Cas9 molecule-dependent process. For example, the target position can be a modified Cas9 molecule cleavage of the target nucleic acid and template nucleic acid directed modification, e.g., alteration, of the target position. In an embodiment, a target position can be a site between two nucleotides, e.g., adjacent nucleotides, on the target nucleic acid into which one or more nucleotides is added. The target position may comprise one or more nucleotides that are altered, e.g., knocked out, by a template nucleic acid. In an embodiment, the target position is within a target domain (e.g., the sequence to which the gRNA binds). In an embodiment, a target position is upstream or downstream of a target domain (e.g., the sequence to which the gRNA binds).

A template nucleic acid, as that term is used herein, refers to a nucleic acid sequence which can be used in conjunction with an RNA-guided nuclease molecule and a gRNA molecule to alter the structure of a target position. In an embodiment, the target nucleic acid is modified to have some or all of the sequence of the template nucleic acid, typically at or near cleavage site(s). In an embodiment, the template nucleic acid is single stranded. In an alternate embodiment, the template nucleic acid is double stranded. In an embodiment, the template nucleic acid is DNA, e.g., double stranded DNA. In an alternate embodiment, the template nucleic acid is single stranded DNA. In an embodiment, the template nucleic acid is encoded on the same vector backbone, e.g. AAV genome, plasmid DNA, as the Cas9 and gRNA. In an embodiment, the template nucleic acid is excised from a vector backbone *in vivo*, e.g., it is flanked by gRNA recognition sequences.

In an embodiment, the template nucleic acid alters the structure of the target position by participating in a homology directed repair event. In an embodiment, the template nucleic acid alters the sequence of the target position. In an embodiment, the template nucleic acid results in the incorporation of a modified, or non-naturally occurring base into the target nucleic acid.

Typically, the template sequence undergoes a breakage-mediated or -catalyzed recombination with the target sequence. In an embodiment, the template nucleic acid includes a sequence that corresponds to a site on the target sequence that is cleaved by an *ea*Cas9 mediated cleavage event. In an embodiment, the template nucleic acid includes a sequence that corresponds to both, a first site on the target sequence that is cleaved in a first

Cas9 mediated event, and a second site on the target sequence that is cleaved in a second Cas9 mediated event.

In an embodiment, the template nucleic acid can include sequence which results in an alteration in the coding sequence of a translated sequence, e.g., one which results in the substitution of one amino acid for another in a protein product, e.g., transforming a mutant allele into a wild type allele, transforming a wild type allele into a mutant allele, and/or introducing a stop codon, insertion of an amino acid residue, deletion of an amino acid residue, or a nonsense mutation.

In other embodiments, the template nucleic acid can include sequence which results in an alteration in a non-coding sequence, e.g., an alteration in an exon or in a 5' or 3' non-translated or non-transcribed region. Such alterations include an alteration in a control element, e.g., a promoter, enhancer, and an alteration in a cis-acting or trans-acting control element.

A template nucleic acid having homology with a target position in the *RHO* gene can be used to alter the structure of a target sequence. The template sequence can be used to alter an unwanted structure, e.g., an unwanted or mutant nucleotide.

A template nucleic acid comprises the following components:

[5' homology arm]-[replacement sequence]-[3' homology arm].

The homology arms provide for recombination into the chromosome, thus replacing the undesired element, e.g., a mutation or signature, with the replacement sequence. In an embodiment, the homology arms flank the most distal cleavage sites.

In an embodiment, the 3' end of the 5' homology arm is the position next to the 5' end of the replacement sequence. In an embodiment, the 5' homology arm can extend at least 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, or 2000 nucleotides 5' from the 5' end of the replacement sequence.

In an embodiment, the 5' end of the 3' homology arm is the position next to the 3' end of the replacement sequence. In an embodiment, the 3' homology arm can extend at least 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, or 2000 nucleotides 3' from the 3' end of the replacement sequence.

### Exemplary Template Nucleic Acids

Exemplary template nucleic acids (also referred to herein as donor constructs) comprise one or more nucleotides of a *RHO* gene. In certain embodiments, the template nucleic acid comprises a *RHO* cDNA molecule. In certain embodiments, the template

nucleic acid sequence may be codon modified to be resistant to hybridization with a gRNA molecule.

**Table 7** below provides exemplary template nucleic acids. In an embodiment, the template nucleic acid includes the 5' homology arm and the 3' homology arm of a row from **Table 7**. In other embodiments, a 5' homology arm from the first column can be combined with a 3' homology arm from **Table 7**. In each embodiment, a combination of the 5' and 3' homology arms include a replacement sequence, e.g., a cytosine (C) residue.

**Table 7**

| <b>5' homology arm (the number of nucleotides from SEQ ID NO: 5'H, beginning at the 3' end of SEQ ID NO: 5'H)</b> | <b>Replacement Sequence=C</b> | <b>3' homology arm (the number of nucleotides from SEQ ID NO: 3'H, beginning at the 5' end of SEQ ID NO: 3'H)</b> |
|-------------------------------------------------------------------------------------------------------------------|-------------------------------|-------------------------------------------------------------------------------------------------------------------|
| 10 or more                                                                                                        |                               | 10 or more                                                                                                        |
| 20 or more                                                                                                        |                               | 20 or more                                                                                                        |
| 50 or more                                                                                                        |                               | 50 or more                                                                                                        |
| 100 or more                                                                                                       |                               | 100 or more                                                                                                       |
| 150 or more                                                                                                       |                               | 150 or more                                                                                                       |
| 200 or more                                                                                                       |                               | 200 or more                                                                                                       |
| 250 or more                                                                                                       |                               | 250 or more                                                                                                       |
| 300 or more                                                                                                       |                               | 300 or more                                                                                                       |
| 350 or more                                                                                                       |                               | 350 or more                                                                                                       |
| 400 or more                                                                                                       |                               | 400 or more                                                                                                       |
| 450 or more                                                                                                       |                               | 450 or more                                                                                                       |
| 500 or more                                                                                                       |                               | 500 or more                                                                                                       |
| 550 or more                                                                                                       |                               | 550 or more                                                                                                       |
| 600 or more                                                                                                       |                               | 600 or more                                                                                                       |
| 650 or more                                                                                                       |                               | 650 or more                                                                                                       |
| 700 or more                                                                                                       |                               | 700 or more                                                                                                       |
| 750 or more                                                                                                       |                               | 750 or more                                                                                                       |
| 800 or more                                                                                                       |                               | 800 or more                                                                                                       |
| 850 or more                                                                                                       |                               | 850 or more                                                                                                       |
| 900 or more                                                                                                       |                               | 900 or more                                                                                                       |

|                                                                 |  |                                                                 |
|-----------------------------------------------------------------|--|-----------------------------------------------------------------|
| 1000 or more                                                    |  | 1000 or more                                                    |
| 1100 or more                                                    |  | 1100 or more                                                    |
| 1200 or more                                                    |  | 1200 or more                                                    |
| 1300 or more                                                    |  | 1300 or more                                                    |
| 1400 or more                                                    |  | 1400 or more                                                    |
| 1500 or more                                                    |  | 1500 or more                                                    |
| 1600 or more                                                    |  | 1600 or more                                                    |
| 1700 or more                                                    |  | 1700 or more                                                    |
| 1800 or more                                                    |  | 1800 or more                                                    |
| 1900 or more                                                    |  | 1900 or more                                                    |
| 1200 or more                                                    |  | 1200 or more                                                    |
| At least 50 but not long enough to include a repeated element.  |  | At least 50 but not long enough to include a repeated element.  |
| At least 100 but not long enough to include a repeated element. |  | At least 100 but not long enough to include a repeated element. |
| At least 150 but not long enough to include a repeated element. |  | At least 150 but not long enough to include a repeated element. |
| 5 to 100 nucleotides                                            |  | 5 to 100 nucleotides                                            |
| 10 to 150 nucleotides                                           |  | 10 to 150 nucleotides                                           |
| 20 to 150 nucleotides                                           |  | 20 to 150 nucleotides                                           |

#### Examples of gRNAs in Genome Editing Methods

gRNA molecules as described herein can be used with RNA-guided nuclease molecules (e.g., Cas9 or Cpf1 molecules) that generate a double strand break or a single strand break to alter the sequence of a target nucleic acid, e.g., a target position or target genetic signature. The skilled artisan will be able to ascertain additional suitable gRNA molecules that can be used in conjunction with the methods and treatment modalities disclosed herein based on the present disclosure. Suitable gRNA molecules include, without limitations, those described in U.S. Patent Application No. US 2017/0073674 A1 and International Publication No. WO 2017/165862 A1, the entire contents of each of which are incorporated by reference herein.

## VI. Target Cells

RNA-guided nuclease molecules (e.g., Cas9 or Cpf1 molecules) and gRNA molecules, e.g., a Cas9 or Cpf1 molecule/gRNA molecule complex can be used to manipulate a cell, e.g., to edit a target nucleic acid, in a wide variety of cells

5 In some embodiments, a cell is manipulated by editing (e.g., altering) one or more target genes, e.g., as described herein. In some embodiments, the expression of one or more target genes (e.g., one or more target genes described herein) is modulated, e.g., *in vivo*. In other embodiments, the expression of one or more target genes (e.g., one or more target genes described herein) is modulated, e.g., *ex vivo*.

10 The RNA-guided nuclease molecules (e.g., Cas9 or Cpf1 molecules), gRNA molecules, and *RHO* cDNA molecules described herein can be delivered to a target cell. In an embodiment, the target cell is a cell from the eye, e.g., a retinal cell, e.g., a photoreceptor cell. In an embodiment, the target cell is a cone photoreceptor cell or cone cell. In an embodiment, the target cell is a rod photoreceptor cell or rod cell. In an embodiment, the target cell is a macular cone photoreceptor cell. In an exemplary embodiment, cone photoreceptors in the macula are targeted, i.e., cone photoreceptors in the macula are the target cells.

A suitable cell can also include a stem cell such as, by way of example, an embryonic stem cell, an induced pluripotent stem cell, a hematopoietic stem cell, a neuronal stem cell and a mesenchymal stem cell. In an embodiment, the cell is an induced pluripotent stem cells (iPS) cell or a cell derived from an iPS cell, e.g., an iPS cell generated from the subject, modified to alter (e.g., knock out) the mutant *RHO* gene and deliver exogenous *RHO* cDNA to the cell and differentiated into a retinal progenitor cell or a retinal cell, e.g., retinal photoreceptor, and injected into the eye of the subject, e.g., subretinally, e.g., in the submacular region of the retina.

## VII. Delivery, Formulations and Routes of Administration

The components, e.g., an RNA-guided nuclease molecule (e.g., Cas9 or Cpf1 molecule), gRNA molecule, and *RHO* cDNA molecule can be delivered or formulated in a variety of forms, see, e.g., **Tables 8-9**. In an embodiment, one RNA-guided nuclease molecule (e.g., Cas9 or Cpf1 molecule), one or more (e.g., 1, 2, 3, 4, or more) gRNA molecules, and the sequence of the *RHO* cDNA molecule are delivered, e.g., by an AAV vector. In an embodiment, the sequence encoding the RNA-guided nuclease molecule (e.g., Cas9 or Cpf1 molecule), the sequence(s) encoding the one or more (e.g., 1, 2, 3, 4, or more)

gRNA molecules, and the sequence of the *RHO* cDNA molecule are present on the same nucleic acid molecule, e.g., an AAV vector. In an embodiment, the sequence encoding the RNA-guided nuclease molecule (e.g., Cas9 or Cpf1 molecule) is present on a first nucleic acid molecule, e.g., an AAV vector, and the sequence(s) encoding the one or more (e.g., 1, 2, 3, 4, or more) gRNA molecules and the sequence of the *RHO* cDNA molecule are present on a second nucleic acid molecule, e.g., an AAV vector. In an embodiment, the sequence encoding the RNA-guided nuclease molecule (e.g., Cas9 or Cpf1 molecule) is present on a first nucleic acid molecule, e.g., an AAV vector, and the sequence(s) encoding the one or more (e.g., 1, 2, 3, 4, or more) gRNA molecules are present on a second nucleic acid molecule, e.g., an AAV vector, and the sequence of the *RHO* cDNA molecule is present on a third nucleic acid molecule, e.g., an AAV vector.

When an RNA-guided nuclease molecule (e.g., Cas9 or Cpf1 molecule), gRNA, or *RHO* cDNA component is delivered encoded in DNA the DNA will typically include a control region, e.g., comprising a promoter, to effect expression. Useful promoters for RNA-guided nuclease molecule (e.g., Cas9 or Cpf1 molecule) sequences include CMV, EFS, EF-1a, MSCV, PGK, CAG, hGRK1, hCRX, hNRL, and hRCVRN control promoters. Useful promoters for gRNAs include H1, EF-1a and U6 promoters. Useful promoters for *RHO* cDNA sequences include CMV, EFS, EF-1a, MSCV, PGK, CAG, hGRK1, hCRX, hNRL, and hRCVRN control promoters. In certain embodiments, useful promoters for *RHO* cDNA and RNA-guided nuclease molecule sequences include a *RHO* promoter sequence. In certain embodiments, the *RHO* promoter sequence may be a minimal *RHO* promoter sequence. In certain embodiments, a minimal *RHO* promoter sequence may comprise the sequence set forth in SEQ ID NO:44. In some embodiments, a minimal *RHO* promoter comprises no more than 100 bp, no more than 200 bp, no more than 250 bp, no more than 300 bp, no more than 400 bp, no more than 500 bp, no more than 600 bp, no more than 700 bp, no more than 800 bp, no more than 900bp, or no more than 1000 bp of the endogenous *RHO* promoter region, e.g., the region of up to 3000 bp upstream from the *RHO* transcription start site. In some embodiments, the minimal *RHO* promoter comprises no more than 100 bp, no more than 200 bp, no more than 250 bp, no more than 300 bp, no more than 400 bp, no more than 500 bp, or no more than 600 bp of the sequence proximal to the transcription start site of the endogenous *RHO* gene, and the distal enhancer region of the *RHO* promoter, or a fragment thereof. In certain embodiments, the minimal *RHO* cDNA promoter may be a rod-specific promoter. In certain embodiments, the *RHO* cDNA promoter may be a human opsin promoter. *RHO* promoters, and engineered promoter variants, suitable for use in the context of the methods,

compositions, and treatment modalities provided herein include, for example, those described in Pellissier 2014; and those described in International Patent Applications PCT/NL2014/050549, PCT/US2016/050809, and PCT/US2016/019725, the entire contents of each of which are incorporated by reference herein.

5 In an embodiment, the promoter is a constitutive promoter. In another embodiment, the promoter is a tissue specific promoter. Promoters with similar or dissimilar strengths can be selected to tune the expression of components. Sequences encoding an RNA-guided nuclease molecule can comprise a nuclear localization signal (NLS), e.g., an SV40 NLS. In an embodiment, the sequence encoding an RNA-guided nuclease molecule comprises at least  
10 two nuclear localization signals. In an embodiment, a promoter for an RNA-guided nuclease molecule, a gRNA molecule, or a *RHO* cDNA molecule can be, independently, inducible, tissue specific, or cell specific. To detect the expression of an RNA-guided nuclease, an affinity tag can be used. Useful affinity tag sequences include, but are not limited to, 3xFlag tag, single Flag tag, HA tag, Myc tag or HIS tag. Exemplary affinity tag sequences are  
15 disclosed in **Table 12**. To regulate RNA-guided nuclease expression, e.g., in mammalian cells, polyadenylation signals (poly(A) signals) can be used. Exemplary polyadenylation signals are disclosed in **Table 13**.

**Table 8** provides examples of the form in which the components can be delivered to a target cell.

20

**Table 8**

| Elements                        |                  |                 |                                                                                                                                                                                                                                                 |
|---------------------------------|------------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RNA-guided nuclease molecule(s) | gRNA molecule(s) | <i>RHO</i> cDNA | Comments                                                                                                                                                                                                                                        |
| DNA                             | DNA              | DNA             | In this embodiment, an RNA-guided nuclease and a gRNA are transcribed from DNA. In this embodiment, they are encoded on separate molecules. In this embodiment, the <i>RHO</i> cDNA is provided as a separate DNA molecule.                     |
| DNA                             | DNA              |                 | In this embodiment, an RNA-guided nuclease and a gRNA are transcribed from DNA. In this embodiment, they are encoded on separate molecules. In this embodiment, the <i>RHO</i> cDNA is provided on the same DNA molecule that encodes the gRNA. |

|         |     |     |                                                                                                                                                                                                                                                                |
|---------|-----|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DNA     |     | DNA | In this embodiment, an RNA-guided nuclease and a gRNA are transcribed from DNA, here from a single molecule. In this embodiment, the <i>RHO</i> cDNA is provided as a separate DNA molecule.                                                                   |
| DNA     | DNA | DNA | In this embodiment, an RNA-guided nuclease and a gRNA are transcribed from DNA. In this embodiment, they are encoded on separate molecules. In this embodiment, the <i>RHO</i> cDNA is provided on the same DNA molecule that encodes the RNA-guided nuclease. |
| DNA     | RNA | DNA | In this embodiment, an RNA-guided nuclease, is transcribed from DNA, and a gRNA is provided as in vitro transcribed or synthesized RNA. In this embodiment, the <i>RHO</i> cDNA is provided as a separate DNA molecule.                                        |
| DNA     | RNA | DNA | In this embodiment, an RNA-guided nuclease is transcribed from DNA, and a gRNA is provided as in vitro transcribed or synthesized RNA. In this embodiment, the <i>RHO</i> cDNA is provided on the same DNA molecule that encodes the RNA-guided nuclease.      |
| mRNA    | RNA | DNA | In this embodiment, an RNA-guided nuclease is translated from in vitro transcribed mRNA, and a gRNA is provided as in vitro transcribed or synthesized RNA. In this embodiment, the <i>RHO</i> cDNA is provided as a DNA molecule.                             |
| mRNA    | DNA | DNA | In this embodiment, an RNA-guided nuclease is translated from in vitro transcribed mRNA, and a gRNA is transcribed from DNA. In this embodiment, the <i>RHO</i> cDNA is provided as a separate DNA molecule.                                                   |
| mRNA    | DNA |     | In this embodiment, an RNA-guided nuclease is translated from in vitro transcribed mRNA, and a gRNA is transcribed from DNA. In this embodiment, the <i>RHO</i> cDNA is provided on the same DNA molecule that encodes the gRNA.                               |
| Protein | DNA | DNA | In this embodiment, an RNA-guided nuclease is provided as a protein, and a gRNA is transcribed from DNA. In this embodiment, the <i>RHO</i> cDNA is provided as a separate DNA molecule.                                                                       |
| Protein | DNA |     | In this embodiment, an RNA-guided nuclease is provided as a protein, and a                                                                                                                                                                                     |

|         |     |     |                                                                                                                                                                                                       |
|---------|-----|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |     |     | gRNA is transcribed from DNA. In this embodiment, the <i>RHO</i> cDNA is provided on the same DNA molecule that encodes the gRNA.                                                                     |
| Protein | RNA | DNA | In this embodiment, an RNA-guided nuclease is provided as a protein, and a gRNA is provided as transcribed or synthesized RNA. In this embodiment, the <i>RHO</i> cDNA is provided as a DNA molecule. |

**Table 9** summarizes various delivery methods for the components of an RNA-guided nuclease system, e.g., the Cas9 or Cpf1 molecule component, the gRNA molecule component, and the *RHO* cDNA molecule component as described herein.

5

**Table 9**

| Delivery Vector/Mode                                                                  |                                     | Delivery into Non-Dividing Cells | Duration of Expression | Genome Integration           | Type of Molecule Delivered |
|---------------------------------------------------------------------------------------|-------------------------------------|----------------------------------|------------------------|------------------------------|----------------------------|
| <b>Physical (e.g., electroporation, particle gun, Calcium Phosphate transfection)</b> |                                     | YES                              | Transient              | NO                           | Nucleic Acids and Proteins |
| <b><i>Viral</i></b>                                                                   | <b>Retrovirus</b>                   | NO                               | Stable                 | YES                          | RNA                        |
|                                                                                       | <b>Lentivirus</b>                   | YES                              | Stable                 | YES/NO with modifications    | RNA                        |
|                                                                                       | <b>Adenovirus</b>                   | YES                              | Transient              | NO                           | DNA                        |
|                                                                                       | <b>Adeno-Associated Virus (AAV)</b> | YES                              | Stable                 | NO                           | DNA                        |
|                                                                                       | <b>Vaccinia Virus</b>               | YES                              | Very Transient         | NO                           | DNA                        |
|                                                                                       | <b>Herpes Simplex Virus</b>         | YES                              | Stable                 | NO                           | DNA                        |
| <b><i>Non-Viral</i></b>                                                               | <b>Cationic Liposomes</b>           | YES                              | Transient              | Depends on what is delivered | Nucleic Acids and Proteins |
|                                                                                       | <b>Polymeric Nanoparticles</b>      | YES                              | Transient              | Depends on what is delivered | Nucleic Acids and Proteins |
| <b><i>Biological Non-Viral</i></b>                                                    | <b>Attenuated Bacteria</b>          | YES                              | Transient              | NO                           | Nucleic Acids              |

|                          |                                                              |     |           |    |               |
|--------------------------|--------------------------------------------------------------|-----|-----------|----|---------------|
| <b>Delivery Vehicles</b> | <b>Engineered Bacteriophages</b>                             | YES | Transient | NO | Nucleic Acids |
|                          | <b>Mammalian Virus-like Particles</b>                        | YES | Transient | NO | Nucleic Acids |
|                          | <b>Biological liposomes: Erythrocyte Ghosts and Exosomes</b> | YES | Transient | NO | Nucleic Acids |

**Table 10** describes exemplary promoter sequences that can be used in AAV vectors for RNA-guided nuclease (e.g., Cas9 or Cpf1) expression.

#### 5 **Table 10. RNA-Guided Nuclease Promoter Sequences**

| <b>Promoter</b>                  | <b>Length (bp)</b> | <b>DNA Sequence</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|----------------------------------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CMV                              | 617                | CATTGATTATTGACTAGTTATTAATAGTAATCAAT<br>TACGGGGTCATTAGTTCATAGCCCATATATGGAGT<br>TCCGCGTTACATAACTTACGGTAAATGGCCCGCCT<br>GGCTGACCGCCCCAACGACCCCCGCCCATTTGACGTC<br>AATAATGACGTATGTTCCCATAGTAACGCCAATAG<br>GGACTTTCCATTGACGTCAATGGGTGGACTATTTA<br>CGGTAAACTGCCCACTTGGCAGTACATCAAGTGTA<br>TCATATGCCAAGTACGCCCCCTATTGACGTCAATG<br>ACGGTAAATGGCCCGCCTGGCATTATGCCCAGTAC<br>ATGACCTTATGGGACTTTTCTACTTGGCAGTACAT<br>CTACGTATTAGTCATCGCTATTACCATGGTGATGC<br>GGTTTTGGCAGTACATCAATGGGCGTGGATAGCGG<br>TTTGACTCACGGGGATTTCCAAGTCTCCACCCCAT<br>TGACGTCAATGGGAGTTTGTGTTTGGCACCAAATC<br>AACGGGACTTTTCCAAAATGTCGTAACAACCTCCGCC<br>CCATTGACGCAAATGGGCGGTAGGCGTGTACGGTG<br>GGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACC<br>GTCAGATCCGCTAGAGATCCGC<br>(SEQ ID NO:45) |
| EFS                              | 252                | TCGAGTGGCTCCGGTGCCCGTCAGTGGGCAGAGCG<br>CACATCGCCACAGTCCCCGAGAAGTTGGGGGGAG<br>GGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGG<br>CGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTG<br>GTCCTCGCCTTTTTCCCGAGGGTGGGGGAGAACCGT<br>ATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTT<br>CGCAACGGGTTTGGCGCCAGAACACAGGTGTCGTG<br>ACCGCGG<br>(SEQ ID NO:46)                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Human GRK1<br>(rhodopsin kinase) | 292                | GGGCCCCAGAAGCCTGGTGGTTGTTTGTCTTCTC<br>AGGGGAAAAGTGAGGCGGCCCTTGGAGGAAGGGG<br>CCGGGCAGAATGATCTAATCGGATTCCAAGCAGCT<br>CAGGGGATTGTCTTTTTCTAGCACCTTCTTGCCAC<br>TCCTAAGCGTCCTCCGTGACCCCGGCTGGGATTTC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

|                                                                                                                  |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                  |     | GCCTGGTGCTGTGTCAGCCCCGGTCTCCCAGGGGC<br>TTCCCAGTGGTCCCCAGGAACCTCGACAGGGCCC<br>GGTCTCTCTCGTCCAGCAAGGGCAGGGACGGGCCA<br>CAGGCCAAGGGC<br>(SEQ ID NO:47)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Human CRX (cone rod homeobox transcription factor)                                                               | 113 | GCCTGTAGCC TTAATCTCTC CTAGCAGGGG<br>GTTTGGGGGA GGGAGGAGGA GAAAGAAAGG<br>GCCCCCTTATG GCTGAGACAC AATGACCCAG<br>CCACAAGGAG GGATTACCGG GCG<br>(SEQ ID NO:48)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Human NRL (neural retina leucine zipper transcription factor enhance upstream of the human TK terminal promoter) | 281 | AGGTAGGAAG TGGCCTTTAA CTCCATAGAC<br>CCTATTTAAA CAGCTTCGGA CAGGTTTAAA<br>CATCTCCTTG GATAATTCTT AGTATCCCTG<br>TTCCCCTCTC TACTCAGGGA TGATAGCTCT<br>AAGAGGTGTT AGGGGATTAG GCTGAAAATG<br>TAGGTCACCC CTCAGCCATC TGGGAAGTAG<br>AATGAGTGAG AGAGGAGAGA GGGGCAGAGA<br>CACACACATT CGCATATTAA GGTGACGCGT<br>GTGGCCTCGA ACACCGAGCG ACCCTGCAGC<br>GACCCGCTTA A<br>(SEQ ID NO:49)                                                                                                                                                                                                                                                                                           |
| Human RCVRN (recoverin)                                                                                          | 235 | ATTTTAATCT CACTAGGGTT CTGGGAGCAC<br>CCCCCCCCAC CGCTCCCGCC CTCCACAAAG<br>CTCCTGGGCC CCTCCTCCCT TCAAGGATTG<br>CGAAGAGCTG GTCGCAAATC CTCCTAAGCC<br>ACCAGCATCT CGGTCTTCAG CTCACACCAG<br>CCTTGAGCCC AGCCTGCGGC CAGGGGACCA<br>CGCACGTCCC ACCCACCCAG CGACTCCCCA<br>GCCGCTGCCC ACTCTTCCTC ACTCA<br>(SEQ ID NO:50)                                                                                                                                                                                                                                                                                                                                                    |
| Human rhodopsin promoter                                                                                         | 516 | CCACGTCAGA ATCAAACCCT CACCTTAACC<br>TCATTAGCGT TGGGCATAAT CACCAGGCCA<br>AGCGCCTTAA ACTACGAGAG GCCCCATCCC<br>ACCCGCCCTG CCTTAGCCCT GCCACGTGTG<br>CCAAACGCTG TTAGACCCAA CACCACCCAG<br>GCCAGGTAGG GGGCTGGAGC CCAGGTGGGC<br>ATTTGAGTCA CCAACCCCCA GGCAGTCTCC<br>CTTTTCCTGG ATCCTGAGTA CCTCTCCTCC<br>CTGACCTCAG GCTTCCTCCT AGTGTACCT<br>TGGCCCCCTCT TAGAAGCCAA TTAGGCCCTC<br>AGTTTCTGCA GCGGGGATTA ATATGATTAT<br>GAACACCCCC AATCTCCCAG ATGCTGATTC<br>AGCCAGGAGC TTAGGAGGGG GAGGTCACTT<br>TATAAGGGTC TGGGGGGGTC AGAACCCAGA<br>GTCATCCAGC TGGAGCCCTG AGTGGCTGAG<br>CTCAGGCCTT CGCAGCATTC TTGGGTGGGA<br>GCAGCCACGG GTCAGCCACA AGGGCCACCA<br>CCATGG<br>(SEQ ID NO:43) |
| Minimal Human rhodopsin promoter                                                                                 | 249 | GTCACCTTGGCCCCCTCTTAGAAGCCAATTAGGCC<br>TCAGTTTCTGCAGCGGGGATTAATATGATTATGAA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

|  |  |                                                                                                                                                                                                                            |
|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  |  | CACCCCCAATCTCCCAGATGCTGATTGAGCCAGGA<br>GCTTAGGAGGGGGAGGTCACCTTATAAGGGTCTGG<br>GGGGGTCAGAACCCAGAGTCATCCAGCTGGAGCCC<br>TGAGTGGCTGAGCTCAGGCCTTCGCAGCATTCTTG<br>GGTGGGAGCAGCCACGGGTCAGCCACAAGGGCCAC<br>AGCC<br>(SEQ ID NO: 44) |
|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Table 11** describes exemplary promoter sequences that can be used in AAV vectors for *RHO* cDNA.

5 **Table 11. *RHO* cDNA Promoter Sequences**

| Promoter                            | Length (bp) | DNA Sequence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CMV                                 | 617         | CATTGATTATTGACTAGTTATTAATAGTAATCAATTA<br>CGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCG<br>CGTTACATAACTTACGGTAAATGGCCCGCTGGCTGA<br>CCGCCCCAACGACCCCCGCCCATTTGACGTCAATAATGA<br>CGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCA<br>TTGACGTCAATGGGTGGACTATTTACGGTAAACTGCC<br>CACTTGGCAGTACATCAAGTGTATCATATGCCAAGTA<br>CGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGC<br>CTGGCATTATGCCCAGTACATGACCTTATGGGACTTT<br>CCTACTTGGCAGTACATCTACGTATTAGTCATCGCTA<br>TTACCATGGTGATGCGGTTTTGGCAGTACATCAATGG<br>GCGTGGATAGCGGTTTTGACTCACGGGGATTTCCAAGT<br>CTCCACCCCATTTGACGTCAATGGGAGTTTGTGTTTGGC<br>ACCAAATCAACGGGACTTTCCAAATGTGCTAACAA<br>CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTA<br>CGGTGGGAGGTCTATATAAGCAGAGCTGGTTTAGTGA<br>ACCGTCAGATCCGCTAGAGATCCGC<br>(SEQ ID NO: 45) |
| EFS                                 | 252         | TCGAGTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCA<br>CATCGCCACAGTCCCCGAGAAGTTGGGGGGAGGGGT<br>CGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGG<br>GTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCC<br>TTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGC<br>AGTAGTCGCCGTGAACGTTCTTTTTTCGCAACGGGTTT<br>GCCGCCAGAACACAGGTGTCGTGACCGCGG<br>(SEQ ID NO: 46)                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Human GRK1<br>(rhodopsin<br>kinase) | 292         | GGGCCCCAGAACCTGGTGGTTGTTTGTCTTCTCAG<br>GGGAAAAGTGAGGCGGCCCTTGGAGGAAGGGGCCGG<br>GCAGAATGATCTAATCGGATTCCAAGCAGCTCAGGGG<br>ATTGTCTTTTTCTAGCACCTTCTTGCCACTCCTAAGC<br>GTCTCCGTGACCCCGGTGGGATTTGCGCTGGTGCT<br>GTGTCAGCCCCGGTCTCCAGGGGCTTCCCAGTGGTC<br>CCCAGGAACCTCGACAGGGCCCGGTCTCTCTCGTCC<br>AGCAAGGGCAGGGACGGGCCACAGGCCAAGGGC<br>(SEQ ID NO: 47)                                                                                                                                                                                                                                                                                                                                                                                   |

|                                                                                                                                          |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Human CRX<br>(cone rod<br>homeobox<br>transcription<br>factor)                                                                           | 113 | GCCTGTAGCC TTAATCTCTC CTAGCAGGGG<br>GTTTGGGGGA GGGAGGAGGA GAAAGAAAGG<br>GCCCCTTATG GCTGAGACAC AATGACCCAG<br>CCACAAGGAG GGATTACCGG GCG<br>(SEQ ID NO: 48)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Human NRL<br>(neural retina<br>leucine zipper<br>transcription<br>factor enhance<br>upstream of the<br>human TK<br>terminal<br>promoter) | 281 | AGGTAGGAAG TGGCCTTTAA CTCCATAGAC<br>CCTATTTAAA CAGCTTCGGA CAGGTTTAAA<br>CATCTCCTTG GATAATTCCT AGTATCCCTG<br>TTCCCACTCC TACTCAGGGA TGATAGCTCT<br>AAGAGGTGTT AGGGGATTAG GCTGAAAATG<br>TAGGTCACCC CTCAGCCATC TGGGAACCTAG<br>AATGAGTGAG AGAGGAGAGA GGGGCAGAGA<br>CACACACATT CGCATATTAA GGTGACGCGT<br>GTGGCCTCGA ACACCGAGCG ACCCTGCAGC<br>GACCCGCTTA A<br>(SEQ ID NO: 49)                                                                                                                                                                                                                                                                                          |
| Human RCVRN<br>(recoverin)                                                                                                               | 235 | ATTTTAATCT CACTAGGGTT CTGGGAGCAC<br>CCCCCCCCAC CGCTCCCGCC CTCCACAAAG<br>CTCCTGGGCC CCTCCTCCCT TCAAGGATTG<br>CGAAGAGCTG GTCGCAAATC CTCCTAAGCC<br>ACCAGCATCT CGGTCTTCAG CTCACACCAG<br>CCTTGAGCCC AGCCTGCGGC CAGGGGACCA<br>CGCACGTCCC ACCCACCCAG CGACTCCCCA<br>GCCGCTGCCC ACTCTTCCTC ACTCA<br>(SEQ ID NO: 50)                                                                                                                                                                                                                                                                                                                                                    |
| Human<br>rhodopsin<br>promoter                                                                                                           | 516 | CCACGTCAGA ATCAAACCCT CACCTTAACC<br>TCATTAGCGT TGGGCATAAT CACCAGGCCA<br>AGCGCCTTAA ACTACGAGAG GCCCCATCCC<br>ACCCGCCCTG CCTTAGCCCT GCCACGTGTG<br>CCAAACGCTG TTAGACCCAA CACCACCCAG<br>GCCAGGTAGG GGGCTGGAGC CCAGGTGGGC<br>ATTTGAGTCA CCAACCCCCA GGCAGTCTCC<br>CTTTTCCTGG ATCCTGAGTA CCTCTCCTCC<br>CTGACCTCAG GCTTCCTCCT AGTGTCACCT<br>TGGCCCCTCT TAGAAGCCAA TTAGGCCCTC<br>AGTTTCTGCA GCGGGGATTA ATATGATTAT<br>GAACACCCCC AATCTCCCAG ATGCTGATTG<br>AGCCAGGAGC TTAGGAGGGG GAGGTCACCT<br>TATAAGGGTC TGGGGGGGTC AGAACCAGAG<br>GTCATCCAGC TGGAGCCCTG AGTGGCTGAG<br>CTCAGGCCTT CGCAGCATTC TTGGGTGGGA<br>GCAGCCACGG GTCAGCCACA AGGGCCACCA<br>CCATGG<br>(SEQ ID NO: 43) |

|                                  |     |                                                                                                                                                                                                                                                                                                       |
|----------------------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Minimal Human rhodopsin promoter | 249 | GTCACCTTGGCCCCCTCTTAGAAGCCAATTAGGCCCTC<br>AGTTTCTGCAGCGGGGATTAATATGATTATGAACACC<br>CCCAATCTCCCAGATGCTGATTGAGCCAGGAGCTTAG<br>GAGGGGGAGGTCACTTTATAAGGGTCTGGGGGGGTCA<br>GAACCCAGAGTCATCCAGCTGGAGCCCTGAGTGGCTG<br>AGCTCAGGCCTTCGCAGCATTCTTGGGTGGGAGCAGC<br>CACGGGTCAGCCACAAGGGCCACAGCC<br>(SEQ ID NO: 44) |
|----------------------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Table 12** describes exemplary affinity tag sequences that can be used in AAV vectors, e.g., for RNA-guided nuclease (e.g., Cas9 or Cpf1) expression.

#### 5 Table 12. Exemplary Affinity Tag Sequences

| Affinity tag             | Amino Acid Sequence                    |
|--------------------------|----------------------------------------|
| <b>3XFlag tag</b>        | DYKDHDGDYKDHDIDYKDDDDK (SEQ ID NO: 51) |
| <b>Flag tag (single)</b> | DYKDDDDK (SEQ ID NO: 52)               |
| <b>HA tag</b>            | YPYDVPDYA (SEQ ID NO: 53)              |
| <b>Myc tag</b>           | EQKLISEEDL (SEQ ID NO: 54)             |
| <b>HIS tag</b>           | HHHHHH (SEQ ID NO: 55)                 |

**Table 13** describes exemplary polyadenylation (polyA) sequences that can be used in AAV vectors, e.g., for RNA-guided nuclease (e.g., Cas9 or Cpf1) expression.

#### 10 Table 13. Exemplary PolyA Sequences

| PolyA             | DNA sequence                                                                                                                                                                                                                                                                                       |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Mini polyA</b> | TAGCAATAAA GGATCGTTTA TTTTCATTGG<br>AAGCGTGTGT TGGTTTTTTG ATCAGGCGCG<br>(SEQ ID NO: 56)                                                                                                                                                                                                            |
| <b>bGH polyA</b>  | GCTGCAGGAT GACCGGTCAT CATCACCATC<br>ACCATTGAGT TTAAACCCGC TGATCAGCCT<br>CGACTGTGCC TTCTAGTTGC CAGCCATCTG<br>TTGTTTGCCC CTCCCCCGTG CCTTCCTTGA<br>CCCTGGAAGG TGCCACTCCC ACTGTCCTTT<br>CCTAATAAAA TGAGGAAATT GCATCGCATT<br>GTCTGAGTAG GTGTCATTCT ATTCTGGGGG<br>GTGGGGTGGG GCAGGACA<br>(SEQ ID NO: 57) |
| <b>SV40 polyA</b> | ATGCTTTATT TGTGAAATTT GTGATGCTAT<br>TGCTTTATTT GTAACCATTA TAAGCTGCAA<br>TAAACAAGTT AACAACAACA ATTGCATTCA<br>TTTTATGTTT CAGGTTTCAGG GGGAGGTGTG<br>GGAGGTTTTT TAAA<br>(SEQ ID NO: 58)                                                                                                                |

**Table 14** describes exemplary Inverted Terminal Repeat (ITR) sequences that can be used in AAV vectors.

**Table 14. Sequences of ITRs from Exemplary AAV Serotypes**

| <b>AAV Serotype</b> | <b>Left ITR Sequence</b>                                                                                                                                                                                 | <b>Right ITR Sequence</b>                                                                                                                                                                                 |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>AAV1</b>         | TTGCCCCTC CCTCTCTGCG<br>CGCTCGCTCG CTCGGTGGGG<br>CCTGCGGACC AAAGGTCCGC<br>AGACGGCAGA GCTCTGCTCT<br>GCCGGCCCCA CCGAGCGAGC<br>GAGCGCGCAG AGAGGGAGTG<br>GGCAACTCCA TCACTAGGGG<br>TAA (SEQ ID NO: 59)        | TTACCCCTAG TGATGGAGTT<br>GCCCCACTCCC TCTCTGCGCG<br>CTCGCTCGCT CGGTGGGGCC<br>GGCAGAGCAG AGCTCTGCCG<br>TCTGCGGACC TTTGGTCCGC<br>AGGCCCCACC GAGCGAGCGA<br>GCGCGCAGAG AGGGAGTGGG<br>CAA<br>(SEQ ID NO: 68)    |
| <b>AAV2</b>         | TTGGCCACTC CCTCTCTGCG<br>CGCTCGCTCG CTCACTGAGG<br>CCGGGCGACC AAAGGTCCGC<br>CGACGCCCCG GCTTTGCCCCG<br>GGCGGCCTCA GTGAGCGAGC<br>GAGCGCGCAG AGAGGGAGTG<br>GCCAACTCCA TCACTAGGGG<br>TTCCT<br>(SEQ ID NO: 60) | AGGAACCCCT AGTGATGGAG<br>TTGGCCACTC CCTCTCTGCG<br>CGCTCGCTCG CTCACTGAGG<br>CCGCCCCGGC AAAGCCCCGGG<br>CGTCGGGCGA CCTTTGGTCTG<br>CCCGGCCTCA GTGAGCGAGC<br>GAGCGCGCAG AGAGGGAGTG<br>GCCAA<br>(SEQ ID NO: 69) |
| <b>AAV3B</b>        | TGGCCACTCC CTCTATGCGC<br>ACTCGCTCGC TCGGTGGGGC<br>CTGGCGACCA AAGGTCCGCA<br>GACGGACGTG CTTTGCACGT<br>CCGGCCCCAC CGAGCGAGCG<br>AGTGCGCATA GAGGGAGTGG<br>CCAATCCAT CACTAGAGGT<br>AT<br>(SEQ ID NO: 61)      | ATACCTCTAG TGATGGAGTT<br>GGCCACTCCC TCTATGCGCA<br>CTCGCTCGCT CGGTGGGGCC<br>GGACGTGCAA AGCACGTCCG<br>TCTGGCGACC TTTGGTCCGC<br>AGGCCCCACC GAGCGAGCGA<br>GTGCGCATAG AGGGAGTGGC CA<br>(SEQ ID NO: 70)         |
| <b>AAV4</b>         | TTGGCCACTC CCTCTATGCG<br>CGCTCGCTCA CTCACTCGGC<br>CCTGGAGACC AAAGGTCTCC<br>AGACTGCCGG CCTCTGGCCG<br>GCAGGGCCGA GTGAGTGAGC<br>GAGCGCGCAT AGAGGGAGTG<br>GCCAACTCCA TCATCTAGGT<br>TTGCCC<br>(SEQ ID NO: 62) | GGGCAAACCT AGATGATGGA<br>GTTGGCCACT CCCTCTATGC<br>GCGCTCGCTC ACTCACTCGG<br>CCCTGCCGGC CAGAGGCCGG<br>CAGTCTGGAG ACCTTTGGTC<br>TCCAGGGCCG AGTGAGTGAG<br>CGAGCGCGCA TAGAGGGAGT<br>GGCCAA<br>(SEQ ID NO: 71)  |
| <b>AAV5</b>         | CTCTCCCCC TGTCGCGTTC<br>GCTCGCTCGC TGGCTCGTTT<br>GGGGGGGTGG CAGCTCAAAG<br>AGCTGCCAGA CGACGGCCCT<br>CTGGCCGTCG CCCCCCAA<br>CGAGCCAGCG AGCGAGCGAA                                                          | TTGCTTGAGA GTGTGGCACT<br>CTCCCCCTG TCGCGTTCGC<br>TCGCTCGCTG GCTCGTTTGG<br>GGGGGCGACG GCCAGAGGGC<br>CGTCGTCTGG CAGCTCTTTG<br>AGCTGCCACC CCCCCAAACG                                                         |

|             |                                                                                                                                                                                                        |                                                                                                                                                                                                        |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             | CGCGACAGGG GGGAGAGTGC<br>CACACTCTCA<br>AGCAA<br>(SEQ ID NO:63)                                                                                                                                         | AGCCAGCGAG CGAGCGAACG<br>CGACAGGGGG GAGAG<br>(SEQ ID NO:72)                                                                                                                                            |
| <b>AAV6</b> | ATACCCCTAG TGATGGAGTT<br>GCCCCTCCC TCTATGCGCG<br>CTCGCTCGCT CGGTGGGGCC<br>GGCAGAGCAG AGCTCTGCCG<br>TCTGCGGACC TTTGGTCCGC<br>AGGCCCCACC GAGCGAGCGA<br>GCGCGCATAG AGGGAGTGGG<br>CAA<br>(SEQ ID NO:64)    | TTGCCCACTC CCTCTATGCG<br>CGCTCGCTCG CTCGGTGGGG<br>CCTGCGGACC AAAGGTCCGC<br>AGACGGCAGA GCTCTGCTCT<br>GCCGGCCCCA CCGAGCGAGC<br>GAGCGCGCAT AGAGGGAGTG<br>GGCAACTCCA TCACTAGGGG<br>TAT<br>(SEQ ID NO:73)   |
| <b>AAV7</b> | TTGGCCACTC CCTCTATGCG<br>CGCTCGCTCG CTCGGTGGGG<br>CCTGCGGACC AAAGGTCCGC<br>AGACGGCAGA GCTCTGCTCT<br>GCCGGCCCCA CCGAGCGAGC<br>GAGCGCGCAT AGAGGGAGTG<br>GCCAACTCCA TCACTAGGGG<br>TACCG<br>(SEQ ID NO:65) | CGGTACCCCT AGTGATGGAG<br>TTGGCCACTC CCTCTATGCG<br>CGCTCGCTCG CTCGGTGGGG<br>CCGGCAGAGC AGAGCTCTGC<br>CGTCTGCGGA CCTTTGGTCC<br>GCAGGCCCCA CCGAGCGAGC<br>GAGCGCGCAT AGAGGGAGTG<br>GCCAA<br>(SEQ ID NO:74) |
| <b>AAV8</b> | CAGAGAGGGA GTGGCCAAC<br>CCATCACTAG GGGTAGCGCG<br>AAGCGCCTCC CACGCTGCCG<br>CGTCAGCGCT GACGTAAATT<br>ACGTCATAGG GGAGTGGTCC<br>TGTATTAGCT GTCACGTGAG<br>TGCTTTTGCG GCATTTTGCG<br>ACACC<br>(SEQ ID NO:66)  | GGTGTGCGAA AATGCCGCAA<br>AAGCACTCAC GTGACAGCTA<br>ATACAGGACC ACTCCCCTAT<br>GACGTAATTT ACGTCAGCGC<br>TGACGCGGCA GCGTGGGAGG<br>CGCTTCGCGC TACCCCTAGT<br>GATGGAGTTG GCCACTCCCT<br>CTCTG<br>(SEQ ID NO:75) |
| <b>AAV9</b> | CAGAGAGGGA GTGGCCAAC<br>CCATCACTAG GGGTAATCGC<br>GAAGCGCCTC CCACGCTGCC<br>GCGTCAGCGC TGACGTAGAT<br>TACGTCATAG GGGAGTGGTC<br>CTGTATTAGC TGTCACGTGA<br>GTGCTTTTGC GACATTTTGC<br>GACAC<br>(SEQ ID NO:67)  | GTGTGCGAAA ATGTGCGAAA<br>AGCACTCACG TGACAGCTAA<br>TACAGGACCA CTCCCCTATG<br>ACGTAATCTA CGTCAGCGCT<br>GACGCGGCAG CGTGGGAGGC<br>GCTTCGCGAT TACCCCTAGT<br>GATGGAGTTG GCCACTCCCT<br>CTCTG<br>(SEQ ID NO:76) |
| <b>AAV</b>  | TGCAGGCAGCTGCGCGCTCGCTCG<br>CTCACTGAGGCCGCCGGGCAAAG<br>CCCGGGCGTCGGGCGACCTTTGGT<br>CGCCGGCCTCAGTGAGCGAGCGA<br>GCGCGCAGAGAGGGAGTGGCCAAC<br>TCCATCACTAGGGGTTCCCT<br>(SEQ ID NO:92)                       | AGGAACCCCTAGTGATGGAGTTGG<br>CCACTCCCTCTCTGCGCGCTCGCT<br>CGCTCACTGAGGCCGGGCGACCAA<br>AGGTCGCCCAGCGCCCGGGCTTTG<br>CCCGGGCGGCCTCAGTGAGCGAGC<br>GAGCGCGCAGCTGCCTGCA<br>(SEQ ID NO:93)                      |

Additional exemplary sequences for the recombinant AAV genome components described herein are provided below.

Exemplary U6 promoter sequence:

AAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAA  
 GGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATA  
 CGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAATG  
 5 GACTATCATATGCTTACCGTAACTTGAAAGTATTTGATTTCTTGGCTTTATATATCTTGTG  
 GAAAGGACGAAACACC (SEQ ID NO:78).

Exemplary gRNA targeting domain sequences are described herein, e.g., in **Tables 1-3, and 18**.

10 Skilled artisans will understand that it may be advantageous in some embodiments to add a 5' G to a gRNA targeting domain sequence, e.g., when the gRNA is driven by a U6 promoter.

Exemplary gRNA scaffold domain sequences:

GTTTTAGTACTCTGGAAACAGAATCTACTAAAACAAGGCAAAATGCCGTGTTTATCTCGTCA  
 ACTTGTTGGCGAGATTTTTT (SEQ ID NO:79);  
 15 GTTATAGTACTCTGGAAACAGAATCTACTATAACAAGGCAAAATGCCGTGTTTATCTCGTCA  
 ACTTGTTGGCGAGA (SEQ ID NO:12).

Exemplary N-ter NLS nucleotide sequence:

CCGAAGAAAAAGCGCAAGGTCGAAGCGTCC (SEQ ID NO:81).

Exemplary N-ter NLS amino acid sequence: PKKKRKV (SEQ ID NO:82).

20 Exemplary Cas9 nucleotide sequences as described herein.

Exemplary Cas9 amino acid sequences as described herein.

Exemplary Cpf1 nucleotide sequences as described herein.

Exemplary Cpf1 amino acid sequences as described herein.

Exemplary C-ter NLS sequence: CCCAAGAAGAAGAGGAAAGTC (SEQ ID NO:83).

25 Exemplary C-ter NLS amino acid sequence: PKKKRKV (SEQ ID NO:84).

Exemplary poly(A) signal sequence:

TAGCAATAAAGGATCGTTTATTTTCATTGGAAGCGTGTGTTGGTTTTTTTGATCAGGCGCG  
 (SEQ ID NO:56).

Exemplary 3xFLAG nucleotide sequence:

30 GACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGA  
 CAAG (SEQ ID NO:86).

Exemplary 3xFLAG amino acid sequence:

DYKDHDGDYKDHDIDYKDDDDK (SEQ ID NO:51).

Exemplary spacer sequences:

CAGATCTGAATTCGGTACC (SEQ ID NO:77);

GGTACCGCTAGCGCTTAAGTCGCGATGTACGGGCCAGATATACGCGTTGA (SEQ ID NO:80);

5 TCCAAGCTTCGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCGTTAACTCTAGATT  
TAAATGCATGCTGGGGAGAGATCT (SEQ ID NO:85);

CGACTTAGTTCGATCGAAGG (SEQ ID NO:87).

Exemplary SV40 intron sequence:

TCTAGAGGATCCGGTACTCGAGGAACTGAAAAACCAGAAAGTTAACTGGTAAGTTTAGTCTT  
10 TTTGTCTTTTATTTTCAAGTCCCGGATCCGGTGGTGGTGCAAATCAAAGAACTGCTCCTCAGT  
GGATGTTGCCTTTACTTCTAGGCCTGTACGGAAGTGTTAC (SEQ ID NO:94).

In certain aspects, the present disclosure focuses on AAV vectors encoding CRISPR/RNA-guided nuclease genome editing systems and a *RHO* cDNA molecule, and on the use of such vectors to treat adRP. Exemplary AAV vector genomes are schematized in **Fig. 2**, which illustrate certain fixed and variable elements of these vectors: a first AAV vector comprising ITRs, an RNA-guided nuclease (e.g., Cas9) coding sequence and a promoter to drive its expression, with the RNA-guided nuclease coding sequence flanked by NLS sequences; and a second AAV vector comprising ITRs, one *RHO* cDNA sequence and a minimal *RHO* promoter to drive its expression and one gRNA sequence and promoter sequences to drive its expression. Additional exemplary AAV vector genomes are also set forth in **Figs. 3 and 16-18**. Exemplary AAV vector genome sequences are set forth in SEQ ID NOs: 8-11.

Turning first to the gRNA utilized in the nucleic acids or AAV vectors of the present disclosure, one or more gRNAs may be used to cut the 5' region of a mutant *RHO* gene (e.g., 5' UTR, exon 1, exon 2, intron 1, exon 1/intron border). In certain embodiments, cutting in the 5' region of the mutant *RHO* gene results in knocking out or loss of function of the mutant *RHO* gene. In certain embodiments, one or more gRNAs may be used to cut the coding region of a mutant *RHO* gene (e.g., exon 1, exon 2, exon 3, exon 4, exon 5) or the non-coding region of a mutant *RHO* gene (e.g., 5' UTR, introns, 3' UTR). In certain embodiments, cutting in the coding region or non-coding region of the mutant *RHO* gene may result in knocking out or loss of function of the mutant *RHO* gene.

Targeting domain sequences of exemplary guides (both DNA and RNA sequences) are presented in **Tables 1-3 and 18**.

In some embodiments, the gRNAs used in the present disclosure may be derived from *S. aureus* gRNAs and can be unimolecular or modular, as described below. Exemplary DNA and RNA sequences corresponding to unimolecular *S. aureus* gRNAs are shown below:

**DNA:** [N]<sub>16</sub>-

5 24 GTTTTAGTACTCTGGAAACAGAACTCTACTAAAACAAGGCAAAATGCCGTGTTTATCTCGTC  
AACTTGTTGGCGAGATTTTTT (SEQ ID NO:88) and

**RNA:** [N]<sub>16</sub>-

24 GUUUUAGUACUCUGGAAACAGAAUCUACUAAAACAAGGCAAAAUGCCGUGUUUAUCUCGUC  
AACUUGUUGGCGAGAUUUUUU (SEQ ID NO:89).

10

**DNA:** [N]<sub>16</sub>-

24 GTTATAGTACTCTGGAAACAGAACTCTACTATAACAAGGCAAAATGCCGTGTTTATCTCGTC  
AACTTGTTGGCGAGATTTTTT (SEQ ID NO:90) and

**RNA:** [N]<sub>16</sub>-

15 24 GUUAUAGUACUCUGGAAACAGAAUCUACUAUAAACAAGGCAAAAUGCCGUGUUUAUCUCGUC  
AACUUGUUGGCGAGAUUUUUU (SEQ ID NO:91).

It should be noted that the targeting domain can have any suitable length. gRNAs used in the various embodiments of this disclosure preferably include targeting domains of between 16 and 24 (inclusive) bases in length at their 5' ends, and optionally include a 3' U6 termination sequence as illustrated.

In some instances, modular guides can be used. In the exemplary unimolecular gRNA sequences above, a 5' portion corresponding to a crRNA (underlined) is connected by a GAAA linker to a 3' portion corresponding to a tracrRNA (double underlined). Skilled artisans will appreciate that two-part modular gRNAs can be used that correspond to the underlined and double underlined sections.

Skilled artisans will appreciate that the exemplary gRNA designs set forth herein can be modified in a variety of ways, which are described below or are known in the art; the incorporation of such modifications is within the scope of this disclosure.

Expression of the one or more gRNAs in the AAV vector may be driven by a pair of U6 promoters, such as a human U6 promoter. An exemplary U6 promoter sequence, as set forth in Maeder, is SEQ ID NO:78.

Turning next to RNA-guided nucleases, in some embodiments the RNA-guided nuclease may be a Cas9 or Cpf1 protein. In certain embodiments, the Cas9 protein is *S.*

*pyogenes* Cas9. In certain embodiments, the Cas9 protein is *S. aureus* Cas9. In further embodiments of this disclosure an Cas9 sequence is modified to include two nuclear localization sequences (NLSs) at the C- and N-termini of the Cas9 protein, and a mini-polyadenylation signal (or Poly-A sequence). Exemplary Cas9 sequences and Cpf1  
5 sequences are provided herein. These sequences are exemplary in nature and are not intended to be limiting. The skilled artisan will appreciate that modifications of these sequences may be possible or desirable in certain applications; such modifications are described below, or are known in the art, and are within the scope of this disclosure.

Skilled artisans will also appreciate that polyadenylation signals are widely used and  
10 known in the art, and that any suitable polyadenylation signal can be used in the embodiments of this disclosure. Exemplary polyadenylation signals are set forth in SEQ ID NOs:56-58.

Cas9 expression may be driven, in certain vectors of this disclosure, by one of three promoters: cytomegalovirus (CMV) (i.e., SEQ ID NO:45), elongation factor-1 (EFS) (i.e.,  
15 SEQ ID NO:46), or human g-protein receptor coupled kinase-1 (hGRK1) (i.e., SEQ ID NO:47), which is specifically expressed in retinal photoreceptor cells. Modifications of the sequences of the promoters may be possible or desirable in certain applications, and such modifications are within the scope of this disclosure. In certain embodiments, Cas9 expression may be driven by a *RHO* promoter described herein (e.g., a minimum *RHO*  
20 Promoter (250 bp) SEQ ID NO:44).

Turning next to *RHO* cDNA, in some embodiments the *RHO* cDNA molecule may be wild-type *RHO* cDNA (e.g., SEQ ID NO:2). In certain embodiments, the *RHO* cDNA molecule may be a codon-modified cDNA to be resistant to hybridizing with a gRNA. In certain embodiments, the *RHO* cDNA molecule is not codon-modified to be resistant to  
25 hybridizing with a gRNA. In certain embodiments, the *RHO* cDNA molecule may be a codon-optimized cDNA to provide increased expression of rhodopsin protein (e.g., SEQ ID NOs:13-18). In certain embodiments, the *RHO* cDNA may comprise a modified 3' UTR, for example, a 3' UTR from a highly expressed, stable transcript, such as alpha- or beta-globin. Exemplary 3' UTRs are set forth in SEQ ID NOs:38-42. In certain embodiments, the *RHO*  
30 cDNA may include one or more introns (e.g., SEQ ID NOs:4-7). In certain embodiments, the *RHO* cDNA may include a truncation of one or more introns.

In certain embodiments, *RHO* cDNA expression may be driven by a rod-specific promoter. In certain embodiments, *RHO* cDNA expression may be driven by a *RHO* promoter described herein (e.g., a minimum *RHO* Promoter (250 bp) SEQ ID NO:44).

AAV genomes according to the present disclosure generally incorporate inverted terminal repeats (ITRs) derived from the AAV5 serotype. Exemplary left and right ITRs are SEQ ID NO:63 (AAV5 Left ITR) and SEQ ID NO:72 (AAV5 Right ITR), respectively. In certain embodiments, exemplary left and right ITRs are SEQ ID NO:92 (AAV Left ITR) and  
5 SEQ ID NO:93 (AAV Right ITR), respectively. It should be noted, however, that numerous modified versions of the AAV5 ITRs are used in the field, and the ITR sequences shown herein are exemplary and are not intended to be limiting. Modifications of these sequences are known in the art, or will be evident to skilled artisans, and are thus included in the scope of this disclosure.

10 The gRNA, RNA-guided nuclease, and *RHO* cDNA promoters are variable and can be selected from the lists presented herein. For clarity, this disclosure encompasses nucleic acids and/or AAV vectors comprising any combination of these elements, though certain combinations may be preferred for certain applications.

In various embodiments, a first nucleic acid or AAV vector may encode the  
15 following: left and right AAV ITR sequences (e.g., AAV5 ITRs), a promoter (e.g., CMV, hGRK1, EFS, *RHO* promoter) to drive expression of an RNA-guided nuclease (e.g., Cas9 encoded by a Cas9 nucleic acid molecule or Cpf1 encoded by a Cpf1 nucleic acid), NLS sequences flanking the RNA-guided nuclease nucleic acid molecule, and a second nucleic acid or AAV vector may encode the following: left and right AAV ITR sequences (e.g.,  
20 AAV5 ITRs), a U6 promoter to drive expression of a guide RNA comprising a targeting domain sequence (e.g., a sequence according to a sequence in **Tables 1-3** or **18**), and a *RHO* promoter (e.g., minimal *RHO* promoter) to drive expression of a *RHO* cDNA molecule.

The nucleic acid or AAV vector may also comprise a Simian virus 40 (SV40) splice donor/splice acceptor (SD/SA) sequence element. In certain embodiments, the SV40 SD/SA  
25 element may be positioned between the promoter and the RNA-guided nuclease gene (e.g., Cas9 or Cpf1 gene). In certain embodiments, a Kozak consensus sequence may precede the start codon of the RNA-guided nuclease (e.g., Cas9 or Cpf1) to ensure robust RNA-guided nuclease (e.g., Cas9 or Cpf1) expression.

In some embodiments, the nucleic acid or AAV vector shares at least 80%, 85%,  
30 90%, 95%, 96%, 97%, 98%, 99% or greater sequence identity with one of the nucleic acids or AAV vectors recited above.

It should be noted that these sequences described above are exemplary and can be modified in ways that do not disrupt the operating principles of elements they encode. Such modifications, some of which are discussed below, are within the scope of this disclosure.

Without limiting the foregoing, skilled artisans will appreciate that the DNA, RNA or protein sequences of the elements of this disclosure may be varied in ways that do not interrupt their function, and that a variety of similar sequences that are substantially similar (e.g., greater than 90%, 95%, 96%, 97%, 98% or 99% sequence similarity, or in the case of short  
5 sequences such as gRNA targeting domains, sequences that differ by no more than 1, 2 or 3 nucleotides) can be utilized in the various systems, methods and AAV vectors described herein. Such modified sequences are within the scope of this disclosure.

The AAV genomes described above can be packaged into AAV capsids (for example, AAV5 capsids), which capsids can be included in compositions (such as pharmaceutical  
10 compositions) and/or administered to subjects. An exemplary pharmaceutical composition comprising an AAV capsid according to this disclosure can include a pharmaceutically acceptable carrier such as balanced saline solution (BSS) and one or more surfactants (e.g., Tween20) and/or a thermosensitive or reverse-thermosensitive polymer (e.g., pluronic). Other pharmaceutical formulation elements known in the art may also be suitable for use in  
15 the compositions described here.

Compositions comprising AAV vectors according to this disclosure can be administered to subjects by any suitable means, including without limitation injection, for example, subretinal injection. The concentration of AAV vector within the composition is selected to ensure, among other things, that a sufficient AAV dose is administered to the  
20 retina of the subject, taking account of dead volume within the injection apparatus and the relatively limited volume that can be safely administered to the retina. Suitable doses may include, for example,  $1 \times 10^{11}$  viral genomes (vg)/mL,  $2 \times 10^{11}$  viral genomes (vg)/mL,  $3 \times 10^{11}$  viral genomes (vg)/mL,  $4 \times 10^{11}$  viral genomes (vg)/mL,  $5 \times 10^{11}$  viral genomes (vg)/mL,  $6 \times 10^{11}$  viral genomes (vg)/mL,  $7 \times 10^{11}$  viral genomes (vg)/mL,  $8 \times 10^{11}$  viral genomes  
25 (vg)/mL,  $9 \times 10^{11}$  viral genomes (vg)/mL,  $1 \times 10^{12}$  vg/mL,  $2 \times 10^{12}$  viral genomes (vg)/mL,  $3 \times 10^{12}$  viral genomes (vg)/mL,  $4 \times 10^{12}$  viral genomes (vg)/mL,  $5 \times 10^{12}$  viral genomes (vg)/mL,  $6 \times 10^{12}$  viral genomes (vg)/mL,  $7 \times 10^{12}$  viral genomes (vg)/mL,  $8 \times 10^{12}$  viral genomes (vg)/mL,  $9 \times 10^{12}$  viral genomes (vg)/mL,  $1 \times 10^{13}$  vg/mL,  $2 \times 10^{13}$  viral genomes (vg)/mL,  $3 \times 10^{13}$  viral genomes (vg)/mL,  $4 \times 10^{13}$  viral genomes (vg)/mL,  $5 \times 10^{13}$  viral genomes  
30 (vg)/mL,  $6 \times 10^{13}$  viral genomes (vg)/mL,  $7 \times 10^{13}$  viral genomes (vg)/mL,  $8 \times 10^{13}$  viral genomes (vg)/mL, or  $9 \times 10^{13}$  viral genomes (vg)/mL. Any suitable volume of the composition may be delivered to the subretinal space. In some instances, the volume is selected to form a bleb in the subretinal space, for example 1 microliter, 10 microliters, 50 microliters, 100 microliters, 150 microliters, 200 microliters, 250 microliters, 300 microliters, etc.

Any region of the retina may be targeted, though the fovea (which extends approximately 1 degree out from the center of the eye) may be preferred in certain instances due to its role in central visual acuity and the relatively high concentration of cone photoreceptors there relative to peripheral regions of the retina. Alternatively or additionally, injections may be targeted to parafoveal regions (extending between approximately 2 and 10 degrees off center), which are characterized by the presence of both rod and cone photoreceptor cells. In addition, injections into the parafoveal region may be made at comparatively acute angles using needle paths that cross the midline of the retina. For instance, injection paths may extend from the nasal aspect of the sclera near the limbus through the vitreal chamber and into the parafoveal retina on the temporal side, from the temporal aspect of the sclera to the parafoveal retina on the nasal side, from a portion of the sclera located superior to the cornea to an inferior parafoveal position, and/or from an inferior portion of the sclera to a superior parafoveal position. The use of relatively small angles of injection relative to the retinal surface may advantageously reduce or limit the potential for spillover of vector from the bleb into the vitreous body and, consequently, reduce the loss of the vector during delivery. In other cases, the macula (inclusive of the fovea) can be targeted, and in other cases, additional retinal regions can be targeted, or can receive spillover doses.

To mitigate ocular inflammation and associated discomfort, one or more corticosteroids may be administered before, during, and/or after administration of the composition comprising AAV vectors. In certain embodiments, the corticosteroid may be an oral corticosteroid. In certain embodiments, the oral corticosteroid may be prednisone. In certain embodiments, the corticosteroid may be administered as a prophylactic, prior to administration of the composition comprising AAV vectors. For example, the corticosteroid may be administered the day prior to administration, or 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days prior to administration of the composition comprising AAV vectors. In certain embodiments, the corticosteroid may be administered for 1 week to 10 weeks after administration of the composition comprising AAV vectors (e.g., 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, or 10 weeks after administration of the composition comprising AAV vectors). In certain embodiments, the corticosteroid treatment may be administered prior to (e.g., the day prior to administration, or 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days prior to administration) and after administration of the composition comprising AAV vectors (e.g., 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, or 10 weeks after administration). For example,

the corticosteroid treatment may be administered beginning 3 days prior to until 6 weeks after administration of the AAV vector.

Suitable doses of corticosteroids may include, for example, 0.1 mg/kg/day to 10 mg/kg/day (e.g., 0.1 mg/kg/day, 0.2 mg/kg/day, 0.3 mg/kg/day, 0.4 mg/kg/day, 0.5 mg/kg/day, 0.6 mg/kg/day, 0.7 mg/kg/day, 0.8 mg/kg/day, 0.9 mg/kg/day, or 1.0 mg/kg/day). In certain embodiments, the corticosteroid may be administered at an elevated dose during the corticosteroid treatment, followed by a tapered dose of the corticosteroid. For example, 0.5 mg/kg/day corticosteroid may be administered for 4 weeks, followed by a 15-day taper (0.4 mg/kg/day for 5 days, and then 0.2 mg/kg/day for 5 days, and then 0.1 mg/kg/day for 5 days). The corticosteroid dose may be increased if there is an increase in vitreous inflammation by 1+ on the grading scale following surgery (e.g., within 4 weeks after surgery). For example, if there is an increase in vitreous inflammation by 1+ on the grading scale while the patient is receiving a 0.5 mg/kg/day dose (e.g., within 4 weeks after surgery), the corticosteroid dose may be increased to 1 mg/kg/day. If any inflammation is present within 4 weeks after surgery, the taper may be delayed.

For pre-clinical development purposes, systems, compositions, nucleotides and vectors according to this disclosure can be evaluated ex vivo using a retinal explant system, or in vivo using an animal model such as a mouse, rabbit, pig, nonhuman primate, etc. Retinal explants are optionally maintained on a support matrix, and AAV vectors can be delivered by injection into the space between the photoreceptor layer and the support matrix, to mimic subretinal injection. Tissue for retinal explantation can be obtained from human or animal subjects, for example mouse.

Explants are particularly useful for studying the expression of gRNAs, RNA-guided nucleases, and rhodopsin protein following viral transduction, and for studying genome editing over comparatively short intervals. These models also permit higher throughput than may be possible in animal models and can be predictive of expression and genome editing in animal models and subjects. Small (mouse, rat) and large animal models (such as rabbit, pig, nonhuman primate) can be used for pharmacological and/or toxicological studies and for testing the systems, nucleotides, vectors and compositions of this disclosure under conditions and at volumes that approximate those that will be used in clinic. Because model systems are selected to recapitulate relevant aspects of human anatomy and/or physiology, the data obtained in these systems will generally (though not necessarily) be predictive of the behavior of AAV vectors and compositions according to this disclosure in human and animal subjects.

DNA-based Delivery of an RNA-guided nuclease molecule, a gRNA molecule, and/or a *RHO* expression cassette

DNA encoding RNA-guided nuclease molecules (e.g., Cas9 or Cpf1 molecules), gRNA molecules, and/or *RHO* cDNA molecules can be administered to subjects or delivered  
5 into cells by art-known methods or as described herein. For example, RNA-guided nuclease (e.g., Cas9 or Cpf1) encoding DNA, gRNA-encoding DNA, and/or *RHO* cDNA can be delivered, e.g., by vectors (e.g., viral or non-viral vectors), non-vector based methods (e.g., using naked DNA or DNA complexes), or a combination thereof.

In some embodiments, the RNA-guided nuclease (e.g., Cas9 or Cpf1)-encoding DNA,  
10 gRNA-encoding DNA, and/or *RHO* cDNA is delivered by a vector (e.g., viral vector/virus or plasmid).

A vector can comprise a sequence that encodes an RNA-guided nuclease-encoding DNA, gRNA-encoding DNA, and/or *RHO* cDNA molecule. A vector can also comprise a sequence encoding a signal peptide (e.g., for nuclear localization, nucleolar localization,  
15 mitochondrial localization), fused, e.g., to an RNA-guided nuclease sequence. For example, a vector can comprise a nuclear localization sequence (e.g., from SV40) fused to the sequence encoding the RNA-guided nuclease (e.g., Cas9 or Cpf1) molecule.

One or more regulatory/control elements, e.g., a promoter, an enhancer, an intron, a polyadenylation signal, a Kozak consensus sequence, internal ribosome entry sites (IRES), a  
20 2A sequence, and splice acceptor or donor can be included in the vectors. In some embodiments, the promoter is recognized by RNA polymerase II (e.g., a CMV promoter). In other embodiments, the promoter is recognized by RNA polymerase III (e.g., a U6 promoter). In some embodiments, the promoter is a regulated promoter (e.g., inducible promoter). In other embodiments, the promoter is a constitutive promoter. In some embodiments, the  
25 promoter is a tissue specific promoter. In some embodiments, the promoter is a viral promoter. In other embodiments, the promoter is a non-viral promoter.

In some embodiments, the vector or delivery vehicle is a viral vector (e.g., for generation of recombinant viruses). In some embodiments, the virus is a DNA virus (e.g., dsDNA or ssDNA virus). In other embodiments, the virus is an RNA virus (e.g., an ssRNA  
30 virus). Exemplary viral vectors/viruses include, e.g., retroviruses, lentiviruses, adenovirus, adeno-associated virus (AAV), vaccinia viruses, poxviruses, and herpes simplex viruses.

In some embodiments, the virus infects dividing cells. In other embodiments, the virus infects non-dividing cells. In some embodiments, the virus infects both dividing and non-dividing cells. In some embodiments, the virus can integrate into the host genome. In

some embodiments, the virus is engineered to have reduced immunity, e.g., in human. In some embodiments, the virus is replication-competent. In other embodiments, the virus is replication-defective, e.g., having one or more coding regions for the genes necessary for additional rounds of virion replication and/or packaging replaced with other genes or deleted.

5 In some embodiments, the virus causes transient expression of the RNA-guided nuclease molecule, the gRNA molecule, and/or the *RHO* cDNA molecule. In other embodiments, the virus causes long-lasting, e.g., at least 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 9 months, 1 year, 2 years, or permanent expression, of the RNA-guided nuclease molecule, the gRNA molecule, and/or the *RHO* cDNA molecule. The packaging capacity of  
10 the viruses may vary, e.g., from at least about 4 kb to at least about 30 kb, e.g., at least about 5 kb, 10 kb, 15 kb, 20 kb, 25 kb, 30 kb, 35 kb, 40 kb, 45 kb, or 50 kb.

In some embodiments, the RNA-guided nuclease-encoding DNA, gRNA-encoding DNA, and/or *RHO* cDNA is delivered by a recombinant retrovirus. In some embodiments, the retrovirus (e.g., Moloney murine leukemia virus) comprises a reverse transcriptase, e.g.,  
15 that allows integration into the host genome. In some embodiments, the retrovirus is replication-competent. In other embodiments, the retrovirus is replication-defective, e.g., having one of more coding regions for the genes necessary for additional rounds of virion replication and packaging replaced with other genes, or deleted.

In some embodiments, the RNA-guided nuclease-encoding DNA, gRNA-encoding DNA, and/or *RHO* cDNA is delivered by a recombinant lentivirus. For example, the  
20 lentivirus is replication-defective, e.g., does not comprise one or more genes required for viral replication.

In some embodiments, the RNA-guided nuclease-encoding DNA, gRNA-encoding DNA, and/or *RHO* cDNA is delivered by a recombinant adenovirus. In some embodiments,  
25 the adenovirus is engineered to have reduced immunity in human.

In some embodiments, the RNA-guided nuclease-encoding DNA, gRNA-encoding DNA, and/or *RHO* cDNA is delivered by a recombinant AAV. In some embodiments, the AAV can incorporate its genome into that of a host cell, e.g., a target cell as described herein. In some embodiments, the AAV is a self-complementary adeno-associated virus (scAAV),  
30 e.g., a scAAV that packages both strands which anneal together to form double stranded DNA. AAV serotypes that may be used in the disclosed methods, include AAV1, AAV2, modified AAV2 (e.g., modifications at Y444F, Y500F, Y730F and/or S662V), AAV3, modified AAV3 (e.g., modifications at Y705F, Y731F and/or T492V), AAV4, AAV5, AAV6, modified AAV6 (e.g., modifications at S663V and/or T492V), AAV8, AAV 8.2,

AAV9, AAV rh 10, and pseudotyped AAV, such as AAV2/8, AAV2/5 and AAV2/6 can also be used in the disclosed methods.

In some embodiments, the RNA-guided nuclease-encoding DNA, gRNA-encoding DNA, and/or *RHO* cDNA is delivered by a hybrid virus, e.g., a hybrid of one or more of the  
5 viruses described herein.

A Packaging cell is used to form a virus particle that is capable of infecting a host or target cell. Such a cell includes a 293 cell, which can package adenovirus, and a  $\psi$ 2 cell or a PA317 cell, which can package retrovirus. A viral vector used in gene therapy is usually generated by a producer cell line that packages a nucleic acid vector into a viral particle. The  
10 vector typically contains the minimal viral sequences required for packaging and subsequent integration into a host or target cell (if applicable), with other viral sequences being replaced by an expression cassette encoding the protein to be expressed. For example, an AAV vector used in gene therapy typically only possesses inverted terminal repeat (ITR) sequences from the AAV genome which are required for packaging and gene expression in the host or target  
15 cell. The missing viral functions are supplied in trans by the packaging cell line. Henceforth, the viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences. The cell line is also infected with adenovirus as a helper. The helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid. The helper plasmid is not packaged in  
20 significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV.

In an embodiment, the viral vector has the ability of cell type and/or tissue type recognition. For example, the viral vector can be pseudotyped with a different/alternative viral envelope glycoprotein; engineered with a cell type-specific receptor (e.g., genetic  
25 modification of the viral envelope glycoproteins to incorporate targeting ligands such as a peptide ligand, a single chain antibody, a growth factor); and/or engineered to have a molecular bridge with dual specificities with one end recognizing a viral glycoprotein and the other end recognizing a moiety of the target cell surface (e.g., ligand-receptor, monoclonal antibody, avidin-biotin and chemical conjugation).

In an embodiment, the viral vector achieves cell type specific expression. For  
30 example, a tissue-specific promoter can be constructed to restrict expression of the transgene (Cas 9 and gRNA) in only the target cell. The specificity of the vector can also be mediated by microRNA-dependent control of transgene expression. In an embodiment, the viral vector has increased efficiency of fusion of the viral vector and a target cell membrane. For

example, a fusion protein such as fusion-competent hemagglutinin (HA) can be incorporated to increase viral uptake into cells. In an embodiment, the viral vector has the ability of nuclear localization. For example, a virus that requires the breakdown of the cell wall (during cell division) and therefore will not infect a non-dividing cell can be altered to incorporate a nuclear localization peptide in the matrix protein of the virus thereby enabling the transduction of non-proliferating cells.

In some embodiments, the RNA-guided nuclease-encoding DNA, gRNA-encoding DNA, and/or *RHO* cDNA is delivered by a non-vector based method (e.g., using naked DNA or DNA complexes). For example, the DNA can be delivered, e.g., by organically modified silica or silicate (Ormosil), electroporation, gene gun, sonoporation, magnetofection, lipid-mediated transfection, dendrimers, inorganic nanoparticles, calcium phosphates, or a combination thereof.

In some embodiments, the RNA-guided nuclease-encoding DNA, gRNA-encoding DNA, and/or *RHO* cDNA is delivered by a combination of a vector and a non-vector based method. For example, a virosome comprises a liposome combined with an inactivated virus (e.g., HIV or influenza virus), which can result in more efficient gene transfer, e.g., in a respiratory epithelial cell than either a viral or a liposomal method alone.

In an embodiment, the delivery vehicle is a non-viral vector. In an embodiment, the non-viral vector is an inorganic nanoparticle (e.g., attached to the payload to the surface of the nanoparticle). Exemplary inorganic nanoparticles include, e.g., magnetic nanoparticles (e.g.,  $\text{Fe}_3\text{MnO}_2$ ), or silica. The outer surface of the nanoparticle can be conjugated with a positively charged polymer (e.g., polyethylenimine, polylysine, polyserine) which allows for attachment (e.g., conjugation or entrapment) of payload. In an embodiment, the non-viral vector is an organic nanoparticle (e.g., entrapment of the payload inside the nanoparticle). Exemplary organic nanoparticles include, e.g., SNALP liposomes that contain cationic lipids together with neutral helper lipids which are coated with polyethylene glycol (PEG) and protamine and nucleic acid complex coated with lipid coating.

Exemplary lipids for gene transfer are shown below in **Table 15**.

**Table 15: Lipids Used for Gene Transfer**

| <b>Lipid</b>                                                                                                     | <b>Abbreviation</b> | <b>Feature</b> |
|------------------------------------------------------------------------------------------------------------------|---------------------|----------------|
| 1,2-Dioleoyl-sn-glycero-3-phosphatidylcholine                                                                    | DOPC                | Helper         |
| 1,2-Dioleoyl-sn-glycero-3-phosphatidylethanolamine                                                               | DOPE                | Helper         |
| Cholesterol                                                                                                      |                     | Helper         |
| <i>N</i> -[1-(2,3-Dioleoyloxy)propyl] <i>N,N,N</i> -trimethylammonium chloride                                   | DOTMA               | Cationic       |
| 1,2-Dioleoyloxy-3-trimethylammonium-propane                                                                      | DOTAP               | Cationic       |
| Diocetadecylamidoglycylspermine                                                                                  | DOGS                | Cationic       |
| <i>N</i> -(3-Aminopropyl)- <i>N,N</i> -dimethyl-2,3-bis(dodecyloxy)-1-propanaminium bromide                      | GAP-DLRIE           | Cationic       |
| Cetyltrimethylammonium bromide                                                                                   | CTAB                | Cationic       |
| 6-Lauroxyhexyl ornithinate                                                                                       | LHON                | Cationic       |
| 1-(2,3-Dioleoyloxypropyl)-2,4,6-trimethylpyridinium                                                              | 2Oc                 | Cationic       |
| 2,3-Dioleoyloxy- <i>N</i> -[2(sperminocarboxamido-ethyl)]- <i>N,N</i> -dimethyl-1-propanaminium trifluoroacetate | DOSPA               | Cationic       |
| 1,2-Dioleoyl-3-trimethylammonium-propane                                                                         | DOPA                | Cationic       |
| <i>N</i> -(2-Hydroxyethyl)- <i>N,N</i> -dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide                  | MDRIE               | Cationic       |
| Dimyristoxypropyl dimethyl hydroxyethyl ammonium bromide                                                         | DMRI                | Cationic       |
| 3β-[ <i>N</i> -( <i>N,N'</i> -Dimethylaminoethane)-carbonyl]cholesterol                                          | DC-Chol             | Cationic       |
| Bis-guanidium-tren-cholesterol                                                                                   | BGTC                | Cationic       |
| 1,3-Dioleoyl-2-(6-carboxy-spermyl)-propylamide                                                                   | DOSPER              | Cationic       |
| Dimethyloctadecylammonium bromide                                                                                | DDAB                | Cationic       |
| Diocetadecylamidoglycylspermidin                                                                                 | DSL                 | Cationic       |
| rac-[2,3-Dioctadecyloxypropyl(2-hydroxyethyl)]-dimethylammonium chloride                                         | CLIP-1              | Cationic       |
| rac-[2,3-Dihexadecyloxypropyl-oxy-methyloxy)ethyl]trimethylammonium bromide                                      | CLIP-6              | Cationic       |
| Ethyl dimyristoylphosphatidylcholine                                                                             | EDMPC               | Cationic       |
| 1,2-Distearyloxy- <i>N,N</i> -dimethyl-3-aminopropane                                                            | DSDMA               | Cationic       |
| 1,2-Dimyristoyl-trimethylammonium propane                                                                        | DMTAP               | Cationic       |
| <i>O,O'</i> -Dimyristyl- <i>N</i> -lysyl aspartate                                                               | DMKE                | Cationic       |
| 1,2-Distearoyl-sn-glycero-3-ethylphosphocholine                                                                  | DSEPC               | Cationic       |
| <i>N</i> -Palmitoyl D-erythro-sphingosyl carbonyl-spermine                                                       | CCS                 | Cationic       |
| <i>N</i> - <i>t</i> -Butyl- <i>N</i> 0-tetradecyl-3-tetradecylaminopropionamidine                                | diC14-amidine       | Cationic       |
| Octadecenolyoxy[ethyl-2-heptadecenyl-3 hydroxyethyl]imidazolinium chloride                                       | DOTIM               | Cationic       |
| <i>N</i> 1-Cholesteryl-oxy-carbonyl-3,7-diazanonane-1,9-diamine                                                  | CDAN                | Cationic       |
| 2-(3-[Bis(3-amino-propyl)-amino]propylamino)- <i>N</i> -ditetradecylcarbonylme-ethyl-acetamide                   | RPR209120           | Cationic       |

Exemplary polymers for gene transfer are shown below in **Table 16**.

**Table 16: Polymers Used for Gene Transfer**

| Polymer                                          | Abbreviation |
|--------------------------------------------------|--------------|
| Poly(ethylene)glycol                             | PEG          |
| Polyethylenimine                                 | PEI          |
| Dithiobis(succinimidylpropionate)                | DSP          |
| Dimethyl-3,3'-dithiobispropionimide              | DTBP         |
| Poly(ethylene imine) biscarbamate                | PEIC         |
| Poly(L-lysine)                                   | PLL          |
| Histidine modified PLL                           |              |
| Poly( <i>N</i> -vinylpyrrolidone)                | PVP          |
| Poly(propylenimine)                              | PPI          |
| Poly(amidoamine)                                 | PAMAM        |
| Poly(amido ethylenimine)                         | SS-PAEI      |
| Triethylenetetramine                             | TETA         |
| Poly( $\beta$ -aminoester)                       |              |
| Poly(4-hydroxy-L-proline ester)                  | PHP          |
| Poly(allylamine)                                 |              |
| Poly( $\alpha$ -[4-aminobutyl]-L-glycolic acid)  | PAGA         |
| Poly(D,L-lactic-co-glycolic acid)                | PLGA         |
| Poly( <i>N</i> -ethyl-4-vinylpyridinium bromide) |              |
| Poly(phosphazene)s                               | PPZ          |
| Poly(phosphoester)s                              | PPE          |
| Poly(phosphoramidate)s                           | PPA          |
| Poly( <i>N</i> -2-hydroxypropylmethacrylamide)   | pHPMA        |
| Poly (2-(dimethylamino)ethyl methacrylate)       | pDMAEMA      |
| Poly(2-aminoethyl propylene phosphate)           | PPE-EA       |
| Chitosan                                         |              |
| Galactosylated chitosan                          |              |
| <i>N</i> -Dodacylated chitosan                   |              |
| Histone                                          |              |
| Collagen                                         |              |
| Dextran-spermine                                 | D-SPM        |

In an embodiment, the vehicle has targeting modifications to increase target cell  
 5 update of nanoparticles and liposomes, e.g., cell specific antigens, monoclonal antibodies,  
 single chain antibodies, aptamers, polymers, sugars, and cell penetrating peptides. In an  
 embodiment, the vehicle uses fusogenic and endosome-destabilizing peptides/polymers. In  
 an embodiment, the vehicle undergoes acid-triggered conformational changes (e.g., to  
 accelerate endosomal escape of the cargo). In an embodiment, a stimuli-cleavable polymer is  
 10 used, e.g., for release in a cellular compartment. For example, disulfide-based cationic  
 polymers that are cleaved in the reducing cellular environment can be used.

In an embodiment, the delivery vehicle is a biological non-viral delivery vehicle. In an embodiment, the vehicle is an attenuated bacterium (e.g., naturally or artificially engineered to be invasive but attenuated to prevent pathogenesis and expressing the transgene (e.g., *Listeria monocytogenes*, certain *Salmonella strains*, *Bifidobacterium longum*, and modified *Escherichia coli*), bacteria having nutritional and tissue-specific tropism to target specific tissues, bacteria having modified surface proteins to alter target tissue specificity). In an embodiment, the vehicle is a genetically modified bacteriophage (e.g., engineered phages having large packaging capacity, less immunogenic, containing mammalian plasmid maintenance sequences and having incorporated targeting ligands). In an embodiment, the vehicle is a mammalian virus-like particle. For example, modified viral particles can be generated (e.g., by purification of the “empty” particles followed by *ex vivo* assembly of the virus with the desired cargo). The vehicle can also be engineered to incorporate targeting ligands to alter target tissue specificity. In an embodiment, the vehicle is a biological liposome. For example, the biological liposome is a phospholipid-based particle derived from human cells (e.g., erythrocyte ghosts, which are red blood cells broken down into spherical structures derived from the subject (e.g., tissue targeting can be achieved by attachment of various tissue or cell-specific ligands), or secretory exosomes –subject (i.e., patient) derived membrane-bound nanovesicle (30 -100 nm) of endocytic origin (e.g., can be produced from various cell types and can therefore be taken up by cells without the need of for targeting ligands).

In an embodiment, one or more nucleic acid molecules (e.g., DNA molecules) other than the components of an RNA-guided nuclease system, e.g., the Cas9 or Cpf1 molecule component, the gRNA molecule component, and/or the *RHO* cDNA molecule component described herein, are delivered. In an embodiment, the nucleic acid molecule is delivered at the same time as one or more of the components of the RNA-guided nuclease system are delivered. In an embodiment, the nucleic acid molecule is delivered before or after (e.g., less than about 30 minutes, 1 hour, 2 hours, 3 hours, 6 hours, 9 hours, 12 hours, 1 day, 2 days, 3 days, 1 week, 2 weeks, or 4 weeks) one or more of the components of the RNA-guided nuclease system are delivered. In an embodiment, the nucleic acid molecule is delivered by a different means than one or more of the components of the RNA-guided nuclease system, e.g., the Cas9 or Cpf1 molecule component, the gRNA molecule component, and/or the *RHO* cDNA molecule component are delivered. The nucleic acid molecule can be delivered by any of the delivery methods described herein. For example, the nucleic acid molecule can be delivered by a viral vector, e.g., an integration-deficient lentivirus, and the RNA-guided

nuclease molecule component, the gRNA molecule component, and/or the *RHO* cDNA molecule component can be delivered by electroporation, e.g., such that the toxicity caused by nucleic acids (e.g., DNAs) can be reduced. In an embodiment, the nucleic acid molecule encodes a therapeutic protein, e.g., a protein described herein. In an embodiment, the nucleic acid molecule encodes an RNA molecule, e.g., an RNA molecule described herein.

#### Delivery of RNA encoding an RNA-guided nuclease molecule

RNA encoding RNA-guided nuclease molecules (e.g., Cas9 or Cpf1 molecules described herein), gRNA molecules, and/or *RHO* cDNA molecules can be delivered into cells, e.g., target cells described herein, by art-known methods or as described herein. For example, RNA-guided nuclease molecules (e.g., Cas9 or Cpf1 molecules described herein), gRNA molecules, and/or *RHO* cDNA molecules can be delivered, e.g., by microinjection, electroporation, lipid-mediated transfection, peptide-mediated delivery, or a combination thereof.

#### Delivery RNA-guided nuclease molecule protein

RNA-guided nuclease molecules (e.g., Cas9 or Cpf1 molecules described herein) can be delivered into cells by art-known methods or as described herein. For example, RNA-guided nuclease protein molecules can be delivered, e.g., by microinjection, electroporation, lipid-mediated transfection, peptide-mediated delivery, or a combination thereof. Delivery can be accompanied by DNA encoding a gRNA and/or *RHO* cDNA or by a gRNA and/or *RHO* cDNA.

#### Routes of Administration

Systemic modes of administration include oral and parenteral routes. Parenteral routes include, by way of example, intravenous, intraarterial, intraosseous, intramuscular, intradermal, subcutaneous, intranasal and intraperitoneal routes. Components administered systemically may be modified or formulated to target the components to the eye.

Local modes of administration include, by way of example, intraocular, intraorbital, subconjunctival, intravitreal, subretinal or transscleral routes. In an embodiment, significantly smaller amounts of the components (compared with systemic approaches) may exert an effect when administered locally (for example, intravitreally) compared to when administered systemically (for example, intravenously). Local modes of administration can reduce or eliminate the incidence of potentially toxic side effects that may occur when therapeutically

effective amounts of a component are administered systemically.

In an embodiment, components described herein are delivered by subretinally, e.g., by subretinal injection. Subretinal injections may be made directly into the macular, e.g., submacular injection.

5 In an embodiment, components described herein are delivered by intravitreal injection. Intravitreal injection has a relatively low risk of retinal detachment risk. In an embodiment, nanoparticle or viral, e.g., AAV vector, e.g., an AAV5 vector, e.g., a modified AAV5 vector, an AAV2 vector, e.g., a modified AAV2 vector, is delivered intravitreally.

10 Methods for administration of agents to the eye are known in the medical arts and can be used to administer components described herein. Exemplary methods include intraocular injection (e.g., retrobulbar, subretinal, submacular, intravitreal and intrachoroidal), iontophoresis, eye drops, and intraocular implantation (e.g., intravitreal, sub-Tenons and sub-conjunctival).

Administration may be provided as a periodic bolus (for example, subretinally,  
15 intravenously or intravitreally) or as continuous infusion from an internal reservoir (for example, from an implant disposed at an intra- or extra-ocular location (see, U.S. Pat. Nos. 5,443,505 and 5,766,242)) or from an external reservoir (for example, from an intravenous bag). Components may be administered locally, for example, by continuous release from a sustained release drug delivery device immobilized to an inner wall of the eye or via targeted  
20 transscleral controlled release into the choroid (see, for example, PCT/US00/00207, PCT/US02/14279, Ambati 2000a, and Ambati 2000b. A variety of devices suitable for administering components locally to the inside of the eye are known in the art. See, for example, U.S. Pat. Nos. 6,251,090, 6,299,895, 6,416,777, 6,413,540, and PCT/US00/28187.

In addition, components may be formulated to permit release over a prolonged period  
25 of time. A release system can include a matrix of a biodegradable material or a material which releases the incorporated components by diffusion. The components can be homogeneously or heterogeneously distributed within the release system. A variety of release systems may be useful, however, the choice of the appropriate system will depend upon rate of release required by a particular application. Both non-degradable and degradable release  
30 systems can be used. Suitable release systems include polymers and polymeric matrices, non-polymeric matrices, or inorganic and organic excipients and diluents such as, but not limited to, calcium carbonate and sugar (for example, trehalose). Release systems may be natural or synthetic. However, synthetic release systems are preferred because generally they are more reliable, more reproducible and produce more defined release profiles. The release

system material can be selected so that components having different molecular weights are released by diffusion through or degradation of the material.

Representative synthetic, biodegradable polymers include, for example: polyamides such as poly(amino acids) and poly(peptides); polyesters such as poly(lactic acid),  
 5 poly(glycolic acid), poly(lactic-co-glycolic acid), and poly(caprolactone); poly(anhydrides); polyorthoesters; polycarbonates; and chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof.

Representative synthetic, non-degradable polymers include, for example: polyethers such as  
 10 poly(ethylene oxide), poly(ethylene glycol), and poly(tetramethylene oxide); vinyl polymers- polyacrylates and polymethacrylates such as methyl, ethyl, other alkyl, hydroxyethyl methacrylate, acrylic and methacrylic acids, and others such as poly(vinyl alcohol), poly(vinyl pyrrolidone), and poly(vinyl acetate); poly(urethanes); cellulose and its derivatives such as alkyl, hydroxyalkyl, ethers, esters, nitrocellulose, and various cellulose acetates;  
 15 polysiloxanes; and any chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof.

Poly(lactide-co-glycolide) microsphere can also be used for intraocular injection. Typically the microspheres are composed of a polymer of lactic acid and glycolic acid, which  
 20 are structured to form hollow spheres. The spheres can be approximately 15-30 microns in diameter and can be loaded with components described herein.

#### Bi-Modal or Differential Delivery of Components

Separate delivery of the components of an RNA-guided nuclease system, e.g., the  
 25 RNA-guided nuclease molecule component (e.g., Cas9 or Cpf1 molecule component), the gRNA molecule component, and the *RHO* cDNA molecule component, and more particularly, delivery of the components by differing modes, can enhance performance, e.g., by improving tissue specificity and safety.

In an embodiment, the RNA-guided nuclease molecule component, the gRNA  
 30 molecule component, and the *RHO* cDNA molecule component, are delivered by different modes, or as sometimes referred to herein as differential modes. Different or differential modes, as used herein, refer modes of delivery that confer different pharmacodynamic or pharmacokinetic properties on the subject component molecule, e.g., an RNA-guided nuclease molecule, gRNA molecule, or *RHO* cDNA molecule. For example, the modes of delivery

can result in different tissue distribution, different half-life, or different temporal distribution, e.g., in a selected compartment, tissue, or organ.

Some modes of delivery, e.g., delivery by a nucleic acid vector that persists in a cell, or in progeny of a cell, e.g., by autonomous replication or insertion into cellular nucleic acid, result in more persistent expression of and presence of a component. Examples include viral, e.g., adeno- associated virus or lentivirus, delivery.

By way of example, the components, e.g., an RNA-guided nuclease molecule, a gRNA molecule, and a *RHO* cDNA molecule can be delivered by modes that differ in terms of resulting half-life or persistence of the delivered component the body, or in a particular compartment, tissue or organ. In an embodiment, a gRNA molecule can be delivered by such modes. The RNA-guided nuclease molecule component can be delivered by a mode which results in less persistence or less exposure to the body or a particular compartment or tissue or organ. The *RHO* cDNA molecule component may be delivered by a mode that difference from that mode of the gRNA molecule component and the RNA-guided nuclease molecule component.

More generally, in an embodiment, a first mode of delivery is used to deliver a first component and a second mode of delivery is used to deliver a second component. The first mode of delivery confers a first pharmacodynamic or pharmacokinetic property. The first pharmacodynamic property can be, e.g., distribution, persistence, or exposure, of the component, or of a nucleic acid that encodes the component, in the body, a compartment, tissue or organ. The second mode of delivery confers a second pharmacodynamic or pharmacokinetic property. The second pharmacodynamic property can be, e.g., distribution, persistence, or exposure, of the component, or of a nucleic acid that encodes the component, in the body, a compartment, tissue or organ.

In an embodiment, the first pharmacodynamic or pharmacokinetic property, e.g., distribution, persistence or exposure, is more limited than the second pharmacodynamic or pharmacokinetic property.

In an embodiment, the first mode of delivery is selected to optimize, e.g., minimize, a pharmacodynamic or pharmacokinetic property, e.g., distribution, persistence or exposure.

In an embodiment, the second mode of delivery is selected to optimize, e.g., maximize, a pharmacodynamic or pharmacokinetic property, e.g., distribution, persistence or exposure.

In an embodiment, the first mode of delivery comprises the use of a relatively persistent element, e.g., a nucleic acid, e.g., a plasmid or viral vector, e.g., an AAV or

lentivirus. As such vectors are relatively persistent product transcribed from them would be relatively persistent.

In an embodiment, the second mode of delivery comprises a relatively transient element, e.g., an RNA or protein.

5 In an embodiment, the first component comprises gRNA, and the delivery mode is relatively persistent, e.g., the gRNA is transcribed from a plasmid or viral vector, e.g., an AAV or lentivirus. Transcription of these genes would be of little physiological consequence because the genes do not encode for a protein product, and the gRNAs are incapable of acting in isolation. The second component, an RNA-guided nuclease molecule, is delivered in a  
10 transient manner, for example as mRNA or as protein, ensuring that the full RNA-guided nuclease molecule/gRNA molecule complex is only present and active for a short period of time.

Furthermore, the components can be delivered in different molecular form or with different delivery vectors that complement one another to enhance safety and tissue  
15 specificity.

Use of differential delivery modes can enhance performance, safety and efficacy. E.g., the likelihood of an eventual off-target modification can be reduced. Delivery of immunogenic components, e.g., RNA-guided nuclease molecules, by less persistent modes can reduce immunogenicity, as peptides from the bacterially-derived Cas enzyme are  
20 displayed on the surface of the cell by MHC molecules. A two-part delivery system can alleviate these drawbacks.

Differential delivery modes can be used to deliver components to different, but overlapping target regions. The formation active complex is minimized outside the overlap of the target regions. Thus, in an embodiment, a first component, e.g., a gRNA molecule is  
25 delivered by a first delivery mode that results in a first spatial, e.g., tissue, distribution. A second component, e.g., an RNA-guided nuclease molecule is delivered by a second delivery mode that results in a second spatial, e.g., tissue, distribution. In an embodiment, the first mode comprises a first element selected from a liposome, nanoparticle, e.g., polymeric nanoparticle, and a nucleic acid, e.g., viral vector. The second mode comprises a second  
30 element selected from the group. In an embodiment, the first mode of delivery comprises a first targeting element, e.g., a cell specific receptor or an antibody, and the second mode of delivery does not include that element. In embodiment, the second mode of delivery comprises a second targeting element, e.g., a second cell specific receptor or second antibody.

When the RNA-guided nuclease molecule is delivered in a virus delivery vector, a liposome, or polymeric nanoparticle, there is the potential for delivery to and therapeutic activity in multiple tissues, when it may be desirable to only target a single tissue. A two-part delivery system can resolve this challenge and enhance tissue specificity. If the gRNA molecule and the RNA-guided nuclease molecule are packaged in separated delivery vehicles with distinct but overlapping tissue tropism, the fully functional complex is only formed in the tissue that is targeted by both vectors.

#### Ex vivo delivery

In some embodiments, components described in **Table 8** are introduced into cells which are then introduced into the subject. Methods of introducing the components can include, e.g., any of the delivery methods described in **Table 9**.

### **VIII. Modified Nucleosides, Nucleotides, and Nucleic Acids**

In some embodiments of the present disclosure, modified nucleosides and/or modified nucleotides can be present in nucleic acids, e.g., in a gRNA molecule provided herein. Some exemplary nucleoside, nucleotide, and nucleic acid modifications useful in the context of the present RNA-guided nuclease technology are provided herein, and the skilled artisan will be able to ascertain additional suitable modifications that can be used in conjunction with the nucleosides, nucleotides, and nucleic acids and treatment modalities disclosed herein based on the present disclosure. Suitable nucleoside, nucleotide, and nucleic acid modifications include, without limitation, those described in U.S. Patent Application No. US 2017/0073674 A1 and International Publication No. WO 2017/165862 A1, the entire contents of each of which are incorporated by reference herein.

### **Examples**

The following Examples are merely illustrative and are not intended to limit the scope or content of the disclosure in any way.

#### Example 1: Screening of gRNAs for editing *RHO* alleles in T cells

Approximately 430 gRNAs targeting various positions within the *RHO* gene for use with Cas9 were designed and screened for editing activity in T cells. Briefly, SA Cas9 and guide RNA were complexed at a 1:2 ratio (RNP complex) and delivered to T cells via

electroporation. Three days after electroporation, gDNA was extracted from T cells and the target site was PCR amplified from the gDNA. Sequencing analysis of the *RHO* PCR gene product was evaluated by next generation sequencing (NGS). **Table 18** below provides the RNA and DNA sequences of the targeting domains of the gRNAs that exhibited > 0.1% editing in T cells. These data indicate that gRNA comprising targeting domains set forth in **Table 18** and Cas9 support editing of the *RHO* gene.

#### Example 2: Dose-dependent editing of *RHO* alleles in HEK293 cells

Three gRNAs whose target sites are predicted to be within exon 1 or exon 2 of the *RHO* gene, RHO-3, RHO-7, and RHO-10 (**Table 17**), were selected for further optimization and testing for dose-dependent editing with Cas9. Briefly, increasing concentrations of control plasmid (expressing Cas9 with scrambled gRNA that does not target a sequence within the human genome) or plasmids expressing Cas9 and gRNA were delivered to HEK293 cells by electroporation. Three days after electroporation, gDNA was extracted from HEK293 cells and the gRNA target site was PCR amplified from the gDNA. Sequencing analysis of the *RHO* PCR gene product was evaluated by NGS. The increasing concentration of Cas9/gRNA plasmid supported an increase in indels at the *RHO* gene to 80% (**Fig. 4**). Sequencing analysis indicated that increasing the plasmid concentration resulted in an increase in indels.

**Table 17: gRNAs Targeting *RHO* Gene**

| gRNA ID       | Targeting Domain (RNA)                    | Targeting Domain (DNA)/<br>Protospacer    |
|---------------|-------------------------------------------|-------------------------------------------|
| <b>RHO-3</b>  | AGUAUCCAUGCAGAGAGGUGUA<br>(SEQ ID NO:102) | AGTATCCATGCAGAGAGGTGTA<br>(SEQ ID NO:602) |
| <b>RHO-7</b>  | CCCACACCCGGCUCAUACCGCC<br>(SEQ ID NO:106) | CCCACACCCGGCTCATACCGCC<br>(SEQ ID NO:606) |
| <b>RHO-10</b> | GUGCCAUUACCGGACCAGCCG<br>(SEQ ID NO:109)  | GTGCCATTACCTGGACCAGCCG<br>(SEQ ID NO:609) |

Specificity of the gRNA (*i.e.*, RHO-3, RHO-7, RHO-10) and Cas9 ribonucleoprotein complexes was evaluated using two different assays that are well-known to skilled artisans for profiling CRISPR-Cas9 specificity, the Digenome-seq (digested genome sequencing) and GUIDE-seq assays. No apparent off target editing was detected under physiological conditions for RNP comprising RHO-3, RHO-7, or RHO-10 gRNA complexed with Cas9 (data not shown).

Example 3: Characterization of novel *RHO* alleles generated by simulation of on-targeted editing by RHO-3, RHO-7, and RHO-10 gRNAs

The cut sites generated by on-targeted editing of RHO-3, RHO-7, or RHO-10 gRNA (see targeting domains in **Table 17**) of *RHO* alleles were predicted. **Fig. 5** illustrates the predicted cutting locations of RHO-3, RHO-7, or RHO-10 gRNAs on the *RHO* human cDNA and resulting lengths of RHO protein. RHO-3 is predicted to target Exon 1, RHO-10 is predicted to target the boundary of Exon 2 and Intron 2, and RHO-7 is predicted to target the boundary of Exon 1 and Intron 1 of *RHO* cDNA. Deletions of 1 or 2 base pairs at the RHO-3, RHO-10, or RHO-7 target sites are predicted to cause frameshifts in the *RHO* cDNA resulting in abnormal RHO proteins. **Fig. 6** shows schematics of the predicted *RHO* alleles resulting from editing by RHO-3, RHO-10, or RHO-7 gRNAs.

The effects of the alleles generated by on-targeted editing by RHO-3, RHO-7, or RHO-10 gRNA were characterized to determine whether editing using these gRNAs could result in potentially deleterious *RHO* alleles. Briefly, wild-type (WT) or mock-edited *RHO* alleles were cloned into mammalian expression plasmids under the control of a CMV promoter and lipofected into HEK293 cells. Mock-edited *RHO* alleles included each of the mutated alleles shown in **Fig. 6** (i.e., RHO-3 (-1, -2, or -3 bp), RHO-10 (-1, -2, or -3 bp), or RHO-7 (-1 bp, -2 bp, -3 bp)). The well-known P23H *RHO* variant leading to a dominant form of retinitis pigmentosa was also cloned and tested. After 48 hours of overexpression, cell viability for WT and each mock-edited allele was assessed using ATPLite Luminescence Assay (Perkin Elmer).

While WT RHO overexpression induced relatively no cytotoxicity with respect to the vector control (pUC19 plasmid, upper dotted line), P23H RHO resulted in 50% cell death (lower dotted line), as expected (**Fig. 7A**). Furthermore, expression of the frameshifting of one- or two-base pair deletions at the RHO-3, RHO-7, or RHO-10 gRNA target sites did not induce significant loss in cell viability with respect to WT RHO (**Fig. 7A**, see RHO-3 1 and 2 bp del; RHO-10 1 and 2 bp del; and RHO-7 1 and 2 bp del). However, for in-frame three-base pair deletions at RHO-3 and RHO-10 target sites, there was a significant loss in cell viability, resulting in levels of cell death comparable to that of P23H RHO (**Fig. 7A**, see RHO-3 3 bp del and RHO-10 3 bp del). This was not the case for all gRNAs as a three-base pair deletion at the RHO-7 sequence resulted in a non-cytotoxic RHO allele (**Fig. 7A**, see RHO-7 3bp del).

Next, to determine whether the RHO-3, RHO-7, and RHO-10 mock-edited *RHO* alleles could reduce toxicity of the P23H variant of *RHO*, mock-edited RHO-3, RHO-7, and RHO-10 *RHO* alleles shown in **Fig. 6** and containing the P23H mutation were cloned into mammalian expression plasmids under the control of a CMV promoter and lipofected into HEK293 cells. After 48 hours of overexpression, cell viability for WT and each mock-edited allele was assessed using ATPLite Luminescence Assay (Perkin Elmer).

Expression of the frameshifting of one- or two-base pair deletions at the RHO-3, RHO-7, or RHO-10 gRNA target sites reduced toxicity of the P23H variant of *RHO* and did not induce significant loss in cell viability with respect to WT *RHO* (**Fig. 7B**, see RHO-3 1 and 2 bp del, RHO-10 1 and 2 bp del and RHO-7 1 and 2 bp del). The in-frame three-base pair deletions at RHO-3 and RHO-10 target sites did not reduce toxicity of the P23H variant of *RHO* as there was a significant loss in cell viability, resulting in levels of cell death comparable to that of P23H *RHO* (**Fig. 7B**, see RHO-3 3 bp del and RHO-10 3 bp del). However, the three-base pair deletion at the RHO-7 target sequence reduced toxicity of the P23H variant of *RHO* and resulted in a non-cytotoxic *RHO* allele (**Fig. 7B**, see RHO-7 3bp del).

These data indicate that out-of-frame *RHO* edits produced by RHO-3, RHO-7, or RHO-10 gRNA were productive and non-toxic while the effect of in-frame edits were gRNA/locus dependent.

#### Example 4: Editing of non-human primate explants by ribonucleoproteins comprising Cas9 and gRNA targeting the *RHO* gene

The ability of ribonucleoproteins comprising RHO-9 gRNA targeting the *RHO* gene and Cas9 to edit explants from non-human primates (NHP) was assessed. The RHO-9 gRNA (comprising the targeting domain sequence set forth in SEQ ID NO:108 (RNA) (SEQ ID NO:608 (DNA), **Table 1**) is cross-reactive and can edit both human and NHP *RHO* sequences.

Briefly, retinal explants from NHP donors were harvested and transferred to a membrane on a trans-well chamber in a 24 well plate. 300 µl of retinal media was added to the 24 well plate (i.e., Neurobasal-A media (no phenol red) (470 mL) containing B27 (with VitA) 50X (20 mL), Antibiotic- Antimycotic (5 mL), and GlutaMAX 1% (5 mL)). Transduction with dual AAV comprising RHO-9 gRNA, SA Cas9, and Replacement *RHO* occurred after 24-48 hours. AAVs were diluted to the desired titer ( $10^{12}$  vg/ml) with the retinal media to obtain the final concentration in a total of 100 µl. The diluted/titered AAV

was added dropwise on top of the explant in the 24 well plate. 300 µl of retinal media was replenished every 72 hours. After 2-4 weeks, explants were lysed to obtain DNA, RNA and protein for molecular biology analysis. To measure the percentage of rods in the explants, a rod-specific mRNA (neural retina leucine zipper (NRL)) was extracted from the explants and measured. The housekeeping RNA (beta actin (ACTB)) was also measured to determine the total number of cells.

As shown in **Fig. 8**, each data point represents a single explant, which can contain differing numbers of rod photoreceptors. The x-axis shows the delta between ACTB and NRL RNA levels as measured by RT-qPCR, which is a measure for the percentage of rods in the explant at the time of lysing the explants. A correlation between significant editing and high percentage of rods was shown, demonstrating that robust editing levels can be achieved in explants with a substantial number of rods (**Fig. 8**). These data show that gRNA targeting RHO can efficiently edit non-human primate explants.

#### Example 5: Optimization of RHO replacement vector

Various components of the RHO replacement vector (e.g., promoter, UTRs, RHO sequence) were optimized to identify the optimal RHO replacement vector for maximal expression of RHO mRNA and RHO protein. First, a dual luciferase system was designed to test the impact that different lengths of the RHO promoter have on RHO expression. The components of the luciferase system included a Renilla luciferase driven by CMV in the backbone to normalize for plasmid concentrations and transfection efficiencies (**Fig. 9**).

Briefly, plasmids containing different lengths of the RHO promoter and the *RHO* gene tagged with a firefly luciferase separated by a self-cleaving T2A peptide (100 ng/10,000 cells) were transfected into HEK293 cells along with a plasmid expressing NRL, CRX, and NONo (100 ng/10,000) to turn on expression from the RHO promoters (see Yadav 2014, the entire contents of which are incorporated herein by reference). 72 hours later the cells were lysed and both transfection efficiency (Firefly) and experimental variable (NanoLuc) were analyzed. The Nano-Glo® Dual-Luciferase® Reporter Assay System (Promega Corporation, Cat# N1521) was used to measure luminescence. Luminescence from both Firefly and NanoLuc were measured. As shown in **Fig. 10**, promoters of different lengths were shown to be functional, including the minimal 250 bp RHO promoter (SEQ ID NO:44).

Next, varying 3' UTRs were tested to determine whether 3' UTRs can improve expression of RHO mRNA and RHO protein. Briefly, 3' UTRs from highly stable transcripts and genes were cloned downstream of CMV RHO (i.e., HBA1 3' UTR (SEQ ID NO:38),

short HBA1 3' UTR (SEQ ID NO:39), TH 3' UTR (SEQ ID NO:40), COL1A1 3'UTR (SEQ ID NO:41), ALOX15 3'UTR (SEQ ID NO:42), and minUTR (SEQ ID NO:56)). Vectors (500 ng) were transfected into HEK293 cells (80,000 cells/well). 72 hours later the cells were lysed, and RHO mRNA and protein expression levels were determined using RHO RT-qPCR and RHO ELISA assays, respectively. **Fig. 11A** shows that incorporation of 3' UTRs from stable transcripts into the RHO replacement vector improved RHO mRNA expression levels. **Fig. 11B** shows that incorporation of 3' UTRs from stable transcripts into the RHO replacement vector also improved RHO protein expression levels.

Next, incorporation of sequences of RHO introns 1, 2, 3, or 4 were added to RHO cDNA (i.e., SEQ ID NOs:4-7, respectively) in the RHO replacement vector to determine the impact on RHO protein expression. Vectors (500 and 250 ng) were transfected into HEK293 cells (80,000/well). 72 hours later the cells were lysed, and RHO protein expression was determined using RHO ELISA. **Fig. 12** shows that addition of introns affects RHO protein expression.

Lastly, different codon optimized RHO cDNA constructs (i.e., SEQ ID NOs:13-18) were tested to determine the impact of codon optimization on RHO expression. Vectors (500 and 250 ng) were transfected into HEK293 cells (80,000/well). 72 hours later the cells were lysed and RHO protein expression was determined using a RHO ELISA. **Fig. 13** shows that codon optimization of the RHO cDNA impacts RHO protein expression.

#### Example 6: *In vivo* editing using self-limiting Cas9 vector system to reduce Cas9 levels after successful editing

The ability of a dual vector system expressing Cas9 and gRNAs to edit the RHO genome and to render Cas9 vector expression non-functional was tested *in vivo*. The self-limiting vector system has previously been published (see WO2018/106693, published on June 14, 2018, and entitled Systems and Methods for One-Shot guide RNA (ogRNA) Targeting of Endogenous and Source DNA, the entire contents of which are incorporated herein by reference). Briefly, a Cas9 vector system was generated in which the Cas9 vector comprised a target site for the RHO gRNA within the Cas9 cDNA (SD Cas9). Six weeks after administration of the SD Cas9 and RHO vectors, Cas9 protein levels, Cas9 AAV, and editing of *RHO* was assessed.

**Fig. 14A** indicates that the SD Cas9 vector system demonstrated successful silencing of Cas9 levels. **Fig. 14B** indicates that the vector system carrying the SD Cas9 system

resulted in robust editing at the *RHO* locus, albeit at slightly lower levels as compared to a vector system encoding a wild-type Cas9 sequence.

Example 7: Editing of human explants by ribonucleoproteins comprising gRNA targeting the

5 *RHO* gene and Cas9

The ability of ribonucleoproteins comprising RHO-9 gRNA (**Table 1**) targeting the *RHO* gene and Cas9 to edit human explants was assessed. Briefly, retinal explants from one human donor were harvested and transferred to a membrane on a trans-well chamber in a 24 well plate. 300 µl of retinal media was added to the 24 well plate (i.e., Neurobasal-A media (no phenol red) (470 mL) containing B27 (with VitA) 50X (20 mL), Antibiotic- Antimycotic (5 mL), and GlutaMAX 1% (5 mL)). Different “knock-down and replace” strategies were compared: “shRNA”: transduction of retinal explants with shRNA targeting the *RHO* gene and a replacement vector providing a *RHO* cDNA (as published in Cideciyan 2018); “Vector A”: a two-vector system (Vector 1 comprising saCas9 driven by the minimal *RHO* promoter (250 bp), and Vector 2 comprising a codon-optimized *RHO* cDNA (Codon 6 (SEQ ID NO:18)) and comprising a HBA1 3’ UTR under the control of the minimal 250 bp *RHO* promoter, as well as a the *RHO*-9 gRNA under the control of a U6 promoter); “Vector B”: a two-vector system identical to “Vector A” except for Vector 2 comprising a wt *RHO* cDNA; and “UTC”: untransduced control. The respective AAVs were diluted to the desired titer ( $1 \times 10^{12}$  vg/ml) with the retinal media to obtain the final concentration in a total of 100 µl. The diluted/titered AAV was added dropwise on top of the explant in the 24 well plate. 300 µl of retinal media was replenished every 72 hours. After 4 weeks, explants were lysed to obtain protein for molecular biology analysis. The ratio of *RHO* protein:total protein was measured. Data indicate that Vector A (comprising the minimal 250 bp promoter, *RHO* cDNA, HBA1 3’ UTR, and *RHO*-9 gRNA), resulted in robust expression of *RHO* protein (**Fig. 15**).

Example 8: Administration of a gene editing system to a patient in need thereof

A human patient presenting with adRP is administered a gene editing system comprising two AAV5-based expression vectors.

30 Vector 1 comprises a nucleic acid sequence encoding an *S. aureus* Cas9 protein, flanked on each site by a nuclear localization sequence under the control of a GRK1 promoter or under the control of a *RHO* minimal promoter (e.g., 250 bp *RHO* promoter).

Vector 2 comprises a nucleic acid sequence encoding one or more guide RNAs, each under the control of a U6 promoter. The targeting domain of the one or more guide RNAs, independently, is selected from the following sequences:

RHO-1: GUCAGCCACAAGGGCCACAGCC (SEQ ID NO:100)

5 RHO-2: CCGAAGACGAAGUAUCCAUGCA (SEQ ID NO:101)

RHO-3: AGUAUCCAUGCAGAGAGGUGUA (SEQ ID NO:102)

RHO-4: CUAGGUUGAGCAGGAUGUAGUU (SEQ ID NO:103)

RHO-5: CAUGGCUCAGCCAGGUAGUACU (SEQ ID NO:104)

RHO-6: ACGGGUGUGGUACGCAGCCCCU (SEQ ID NO:105)

10 RHO-7: CCCACACCCGGCUCAUACCGCC (SEQ ID NO:106)

RHO-8: CCCUGGGCGGUAGAGCCGGGU (SEQ ID NO:107)

RHO-9: CCAUCAUGGGCGUUGCCUUCAC (SEQ ID NO:108)

RHO-10: GUGCCAUUACCUGGACCAGCCG (SEQ ID NO:109)

RHO-11: UUACCUGGACCAGCCGGCGAGU (SEQ ID NO:110)

15 The nucleic acid sequence encoding the guide RNA is under the control of a U6 promoter. Vector 2 further comprises a nucleic acid comprising an upstream sequence encoding a *RHO* 5'-UTR, a *RHO* cDNA, and a downstream sequence encoding an HBA1 3'-UTR under the control of a minimal *RHO* promoter sequence that comprises a portion of the *RHO* distal enhancer and a portion of the *RHO* proximal promoter region. The [promoter]-

20 [5'UTR]-[cDNA]-[3'UTR] sequence of Vector 2 is as follows:

CCACGTCAGAATCAAACCCTCACCTTAACCTCATTAGCGTTGGGCATAATCACCAGGCCAAG  
CGCCTTAAACTACGAGAGGCCCCATCCCACCCGCCCTGCCTTAGCCCTGCCACGTGTGCCAA  
ACGCTGTTAGACCCAACACCACCCAGGCCAGGTAGGGGGCTGGAGCCCAGGTGGGCATTTGA  
GTCACCAACCCCCAGGCAGTCTCCCTTTTCTGGATCCTGAGTACCTCTCCTCCCTGACCTC  
25 AGGCTTCCTCCTAGTGTCACCTTGGCCCCCTCTTAGAAGCCAATTAGGCCCTCAGTTTCTGCA  
GCGGGGATTAATATGATTATGAACACCCCCAATCTCCAGATGCTGATTCAGCCAGGAGCTT  
AGGAGGGGGAGGTCACTTTATAAGGGTCTGGGGGGGTGAGAACCAGAGTCATCCAGCTGGA  
GCCCTGAGTGGCTGAGCTCAGGCCTTCGCAGCATTCTTGGGTGGGAGCAGCCACGGGTCAGC  
CACAAGGGCCACCACC

30 ATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGGTACG  
CAGCCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCCATGCTGGCCG  
CCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCACGCTCTACGTCACC  
GTCCAGCACAGAAGCTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAGCCGTGGCTGA  
CCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCTCTACACCTCTCTGCATGGATACTTCG  
35 TCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGCGGTGAAATTGCC  
CTGTGGTCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGTAAGCCCATGAGCAA  
CTTCCGCTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACCTGGGTGATGGCGCTGG  
CCTGCGCCGCACCCCCACTCGCCGGCTGGTCCAGGTACATCCCCGAGGGCCTGCAGTGCTCG  
TGTGGAATCGACTACTACGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCTATCTACAT  
40 GTTCGTGGTCCACTTCACCATCCCCATGATTATCATCTTTTTCTGCTATGGGCAGCTCGTCT

TCACCGTCAAGGAGGCCGCTGCCCAGCAGCAGGAGTCAGCCACCACACAGAAGGCAGAGAAG  
 GAGGTCACCCGCATGGTCATCATCATGGTCATCGCTTTCCTGATCTGCTGGGTGCCCTACGC  
 CAGCGTGGCATTCTACATCTTCACCCACCAGGGCTCCAACCTTCGGTCCCATCTTCATGACCA  
 TCCCAGCGTTCTTTGCCAAGAGCGCCGCCATCTACAACCCTGTCATCTATATCATGATGAAC  
 5 AAGCAGTTCCGGAAGTGCATGCTCACCACCATCTGCTGCGGCAAGAACCCACTGGGTGACGA  
 TGAGGCCTCTGCTACCGTGTCCAAGACGGAGACGAGCCAGGTGGCCCCGGCCTAAGCTGGAG  
 CCTCGGTGGCCATGCTTCTTGCCCCCTGGGCCTCCCCCAGCCCCCTCCTCCCCTTCCTGCAC  
 CCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGCA (SEQ ID NO:8)

Where a guide RNA is used that comprises a targeting domain that binds to a wild-  
 10 type *RHO* sequence present in the *RHO* cDNA, a codon-modified version of the *RHO* cDNA  
 may be substituted for the *RHO* cDNA comprised in the nucleic acid construct above.

Vector 1 and Vector 2 are packaged into viral particles according to methods known  
 in the art, and delivered to the patient via subretinal injection at a dose of about 300  
 microliters of  $1 \times 10^{11}$  -  $3 \times 10^{11}$  viral genomes (vg)/mL. The patient is monitored post-  
 15 administration, and periodically subjected to an assessment of one or more symptoms  
 associated with adRP. For example, the patient is periodically subjected to an assessment of  
 rod photoreceptor function, e.g., by scotopic microperimetry. About one year after  
 administration of Vector 1 and Vector 2, the patient shows an amelioration of at least one  
 adRP associated symptom, e.g. a stabilization of rod function, characterized by improved rod  
 20 function compared to the expected level of rod function in the patient, or in an appropriate  
 control group, in the absence of a clinical intervention.

**Table 18: gRNAs Providing > 0.1% Editing of *RHO* Alleles in HEK293T Cells**

| gRNA ID | Targeting Domain (RNA)                    | Targeting Domain (DNA)/<br>Protospacer     |
|---------|-------------------------------------------|--------------------------------------------|
| RHO-1   | GUCAGCCACAAGGGCCACAGCC<br>(SEQ ID NO:100) | GTCAGCCACAAGGGCCACAGCC<br>(SEQ ID NO:600)  |
| RHO-2   | CCGAAGACGAAGUAUCCAUGCA<br>(SEQ ID NO:101) | CCGAAGACGAAGTATCCATGCA<br>(SEQ ID NO:601)  |
| RHO-3   | AGUAUCCAUGCAGAGAGGUGUA<br>(SEQ ID NO:102) | AGTATCCATGCAGAGAGGTGTA<br>(SEQ ID NO:602)  |
| RHO-4   | CUAGGUUGAGCAGGAUGUAGUU<br>(SEQ ID NO:103) | CTAGGTTGAGCAGGATGTAGTT<br>(SEQ ID NO:603)  |
| RHO-5   | CAUGGCUCAGCCAGGUAGUACU<br>(SEQ ID NO:104) | CATGGCTCAGCCAGGTAGTACT<br>(SEQ ID NO:604)  |
| RHO-6   | ACGGGUGUGGUACGCAGCCCCU<br>(SEQ ID NO:105) | ACGGGTGTGGTACGCAGCCCCCT<br>(SEQ ID NO:605) |
| RHO-7   | CCCACACCCGGCUCAUACCGCC<br>(SEQ ID NO:106) | CCCACACCCGGCTCATACCGCC<br>(SEQ ID NO:606)  |
| RHO-8   | CCUGGGCGGUAUGAGCCGGGU<br>(SEQ ID NO:107)  | CCCTGGGCGGTATGAGCCGGGT<br>(SEQ ID NO:607)  |
| RHO-9   | CCAUCAUGGGCGUUGCCUUCAC<br>(SEQ ID NO:108) | CCATCATGGGCGTTGCCTTCAC<br>(SEQ ID NO:608)  |

|        |                                            |                                            |
|--------|--------------------------------------------|--------------------------------------------|
| RHO-10 | GUGCCAUUACCGUGGACCAGCCG<br>(SEQ ID NO:109) | GTGCCATTACCTGGACCAGCCG<br>(SEQ ID NO:609)  |
| RHO-11 | UUACCGUGGACCAGCCGGCGAGU<br>(SEQ ID NO:110) | TTACCTGGACCAGCCGGCGAGT<br>(SEQ ID NO:610)  |
| RHO-12 | GCAUUCUUGGGUGGGAGCAGCC<br>(SEQ ID NO:111)  | GCATTCTTGGGTGGGAGCAGCC<br>(SEQ ID NO:611)  |
| RHO-13 | GCUCAGCCACUCAGGGCUCCAG<br>(SEQ ID NO:112)  | GCTCAGCCACTCAGGGCTCCAG<br>(SEQ ID NO:612)  |
| RHO-14 | UGACCCGUGGCUGCUCCACCC<br>(SEQ ID NO:113)   | TGACCCGTGGCTGCTCCACCC<br>(SEQ ID NO:613)   |
| RHO-15 | AGCUCAGGCCUUCGCAGCAUUC<br>(SEQ ID NO:114)  | AGCTCAGGCCTTCGCAGCATTC<br>(SEQ ID NO:614)  |
| RHO-17 | ACACGCUGAGGAGAGCUGGGCA<br>(SEQ ID NO:116)  | ACACGCTGAGGAGAGCTGGGCA<br>(SEQ ID NO:616)  |
| RHO-18 | GCAAUAACUCCCCCAUUCCC<br>(SEQ ID NO:117)    | GCAAATAACTTCCCCCATTCCT<br>(SEQ ID NO:617)  |
| RHO-19 | AGACCCAGGCUGGGCACUGAGG<br>(SEQ ID NO:118)  | AGACCCAGGCTGGGCACTGAGG<br>(SEQ ID NO:618)  |
| RHO-20 | CUAGGUCUCCUGGCUGUGAUCC<br>(SEQ ID NO:119)  | CTAGGTCTCCTGGCTGTGATCC<br>(SEQ ID NO:619)  |
| RHO-21 | CCAGAAGGUGGGUGUGCCACUU<br>(SEQ ID NO:120)  | CCAGAAGGTGGGTGTGCCACTT<br>(SEQ ID NO:620)  |
| RHO-24 | GGGCGUCACACAGGGACGGGUG<br>(SEQ ID NO:123)  | GGGCGTCACACAGGGACGGGTG<br>(SEQ ID NO:623)  |
| RHO-25 | CUGUGAUCCAGGAUAUCUCUG<br>(SEQ ID NO:124)   | CTGTGATCCAGGAATATCTCTG<br>(SEQ ID NO:624)  |
| RHO-26 | UUGCAUUUAACAGGAAAACAGA<br>(SEQ ID NO:125)  | TTGCATTTAACAGGAAAACAGA<br>(SEQ ID NO:625)  |
| RHO-27 | GGAGUGCACCCUCCUAGGCAG<br>(SEQ ID NO:126)   | GGAGTGCACCCCTCCTTAGGCAG<br>(SEQ ID NO:626) |
| RHO-28 | CAUCUGUCCUGCUCACCACCCC<br>(SEQ ID NO:127)  | CATCTGTCCTGCTCACCACCCC<br>(SEQ ID NO:627)  |
| RHO-29 | GAGGGGAGGCAGAGGAUGCCAG<br>(SEQ ID NO:128)  | GAGGGGAGGCAGAGGATGCCAG<br>(SEQ ID NO:628)  |
| RHO-30 | CUCAGGGAAUCUCUGGCCAUUG<br>(SEQ ID NO:129)  | CTCAGGGAATCTCTGGCCATTG<br>(SEQ ID NO:629)  |
| RHO-31 | UGCACUCCCCCUAGACAGGGA<br>(SEQ ID NO:130)   | TGCACTCCCCCTAGACAGGGA<br>(SEQ ID NO:630)   |
| RHO-32 | UGCUGUUUGUGCAGGGCUGGCA<br>(SEQ ID NO:131)  | TGCTGTTTGTGCAGGGCTGGCA<br>(SEQ ID NO:631)  |
| RHO-33 | ACUGGGACAUCCUAACAGUGA<br>(SEQ ID NO:132)   | ACTGGGACATTCCTAACAGTGA<br>(SEQ ID NO:632)  |
| RHO-35 | CUCCUCUCUGGGGGCCCAAGCU<br>(SEQ ID NO:134)  | CTCCTCTCTGGGGGCCCAAGCT<br>(SEQ ID NO:634)  |
| RHO-36 | CUGCAUCUCAGCAGAGAUUUC<br>(SEQ ID NO:135)   | CTGCATCTCAGCAGAGATATTC<br>(SEQ ID NO:635)  |
| RHO-37 | UGUUUCCCUUGGAGCAGCUGUG<br>(SEQ ID NO:136)  | TGTTTCCCTTGGAGCAGCTGTG<br>(SEQ ID NO:636)  |
| RHO-40 | CCUAGGAGAGGCCCCCAUGU<br>(SEQ ID NO:139)    | CCTAGGAGAGGCCCCCACATGT<br>(SEQ ID NO:639)  |

|        |                                           |                                           |
|--------|-------------------------------------------|-------------------------------------------|
| RHO-41 | AUCACUCAGUUCUGGCCAGAAG<br>(SEQ ID NO:140) | ATCACTCAGTTCTGGCCAGAAG<br>(SEQ ID NO:640) |
| RHO-42 | AGAGCUGGGCAAAGAAAUCCA<br>(SEQ ID NO:141)  | AGAGCTGGGCAAAGAAATCCA<br>(SEQ ID NO:641)  |
| RHO-43 | CCACCCCAUGAAGUCCAUAGG<br>(SEQ ID NO:142)  | CCACCCCATGAAGTTCCATAGG<br>(SEQ ID NO:642) |
| RHO-44 | CCACCCUGAGCUUGGGCCCCCA<br>(SEQ ID NO:143) | CCACCCTGAGCTTGGGCCCCCA<br>(SEQ ID NO:643) |
| RHO-45 | CAGAGGAAGAAGAAGGAAUGA<br>(SEQ ID NO:144)  | CAGAGGAAGAAGAAGGAAATGA<br>(SEQ ID NO:644) |
| RHO-46 | AAACAGCAGCCCGGCUAUCACC<br>(SEQ ID NO:145) | AAACAGCAGCCCGGCTATCACC<br>(SEQ ID NO:645) |
| RHO-49 | UCACACAGGGACGGGUGCAGAG<br>(SEQ ID NO:148) | TCACACAGGGACGGGTGCAGAG<br>(SEQ ID NO:648) |
| RHO-51 | UGAGCUUGGGCCCCCAGAGAGG<br>(SEQ ID NO:150) | TGAGCTTGGGCCCCCAGAGAGG<br>(SEQ ID NO:650) |
| RHO-52 | AAUAUCUCUGCUGAGAUGCAGG<br>(SEQ ID NO:151) | AATATCTCTGCTGAGATGCAGG<br>(SEQ ID NO:651) |
| RHO-53 | GGAGAGGGGAAGAGACUCAUUU<br>(SEQ ID NO:152) | GGAGAGGGGAAGAGACTCATTT<br>(SEQ ID NO:652) |
| RHO-54 | AGAACUGAGUGAUCUGUGAUUA<br>(SEQ ID NO:153) | AGAACTGAGTGATCTGTGATTA<br>(SEQ ID NO:653) |
| RHO-55 | CCACUCUCCCUAUGGAACUUCA<br>(SEQ ID NO:154) | CCACTCTCCCTATGGAACCTCA<br>(SEQ ID NO:654) |
| RHO-57 | UGGAUUUUCCAUUCUCCAGUCA<br>(SEQ ID NO:156) | TGGATTTTCCATTCTCCAGTCA<br>(SEQ ID NO:656) |
| RHO-58 | GUGCAGGAGCCCGGGAGCAUGG<br>(SEQ ID NO:157) | GTGCAGGAGCCCGGGAGCATGG<br>(SEQ ID NO:657) |
| RHO-59 | GGGUGGUGAGCAGGACAGAUGU<br>(SEQ ID NO:158) | GGGTGGTGAGCAGGACAGATGT<br>(SEQ ID NO:658) |
| RHO-60 | CAGCUCUCCUCAGUGCCCAGC<br>(SEQ ID NO:159)  | CAGCTCTCCCTCAGTGCCCAGC<br>(SEQ ID NO:659) |
| RHO-61 | CCUGCUGGGGCGUCACACAGGG<br>(SEQ ID NO:160) | CCTGCTGGGGCGTCACACAGGG<br>(SEQ ID NO:660) |
| RHO-63 | ACUUACGGGUGGUUGUUCUCUG<br>(SEQ ID NO:162) | ACTTACGGGTGGTTGTTCTCTG<br>(SEQ ID NO:662) |
| RHO-64 | CACAGGGAAGACCCAAUGACUG<br>(SEQ ID NO:163) | CACAGGGAAGACCCAATGACTG<br>(SEQ ID NO:663) |
| RHO-65 | AGCACAGACCCACUGCCUAAG<br>(SEQ ID NO:164)  | AGCACAGACCCCACTGCCTAAG<br>(SEQ ID NO:664) |
| RHO-66 | ACCUGAGGACAGGGGCGAGAG<br>(SEQ ID NO:165)  | ACCTGAGGACAGGGGCTGAGAG<br>(SEQ ID NO:665) |
| RHO-67 | CAACAAUGGCCAGAGAUUCCCU<br>(SEQ ID NO:166) | CAACAATGGCCAGAGATTCCCT<br>(SEQ ID NO:666) |
| RHO-68 | UGCUGCCUCGGUCCCAUUCUCA<br>(SEQ ID NO:167) | TGCTGCCTCGGTCCCATTCTCA<br>(SEQ ID NO:667) |
| RHO-69 | UGCUGCCUGGCCACAUCCCUAA<br>(SEQ ID NO:168) | TGCTGCCTGGCCACATCCCTAA<br>(SEQ ID NO:668) |
| RHO-70 | GCCACUCUCCCUAUGGAACUUC<br>(SEQ ID NO:169) | GCCACTCTCCCTATGGAACCTC<br>(SEQ ID NO:669) |

|        |                                            |                                            |
|--------|--------------------------------------------|--------------------------------------------|
| RHO-71 | GAGGGAGGAAGGACUGCCAAUU<br>(SEQ ID NO:170)  | GAGGGAGGAAGGACTGCCAATT<br>(SEQ ID NO:670)  |
| RHO-72 | GAGGGUAGCUAGGAAGGCAACC<br>(SEQ ID NO:171)  | GAGGGTAGCTAGGAAGGCAACC<br>(SEQ ID NO:671)  |
| RHO-73 | GGAAGGCAACCAGGAGUGGGAG<br>(SEQ ID NO:172)  | GGAAGGCAACCAGGAGTGGGAG<br>(SEQ ID NO:672)  |
| RHO-74 | GCUGAGAUGCAGGAGGAGACGC<br>(SEQ ID NO:173)  | GCTGAGATGCAGGAGGAGACGC<br>(SEQ ID NO:673)  |
| RHO-75 | AGGCUGGAGGGGCACCUGAGGA<br>(SEQ ID NO:174)  | AGGCTGGAGGGGCACCTGAGGA<br>(SEQ ID NO:674)  |
| RHO-76 | AGGAAGGCAACCAGGAGUGGGA<br>(SEQ ID NO:175)  | AGGAAGGCAACCAGGAGTGGGA<br>(SEQ ID NO:675)  |
| RHO-77 | CCGGGAGCAUGGAGGGGUCUGG<br>(SEQ ID NO:176)  | CCGGGAGCATGGAGGGGTCTGG<br>(SEQ ID NO:676)  |
| RHO-78 | GGAUAAACAGAUCCACUUAACA<br>(SEQ ID NO:177)  | GGATAACAGATCCCACTTAACA<br>(SEQ ID NO:677)  |
| RHO-79 | AGGCAGAGGAUGCCAGAGGGGA<br>(SEQ ID NO:178)  | AGGCAGAGGATGCCAGAGGGGA<br>(SEQ ID NO:678)  |
| RHO-80 | GGGCCCCAAGCUCAGGGUGGGAA<br>(SEQ ID NO:179) | GGGCCCCAAGCTCAGGGTGGGAA<br>(SEQ ID NO:679) |
| RHO-81 | UAACUAUAUGGCCACUCUCCCU<br>(SEQ ID NO:180)  | TAACTATATGGCCACTCTCCCT<br>(SEQ ID NO:680)  |
| RHO-82 | UCCACUUAACAGAGAGGAAAA<br>(SEQ ID NO:181)   | TCCCACTTAACAGAGAGGAAAA<br>(SEQ ID NO:681)  |
| RHO-83 | GAAUGCAGAGGUGGUGGAAACC<br>(SEQ ID NO:182)  | GAATGCAGAGGTGGTGGAAACC<br>(SEQ ID NO:682)  |
| RHO-84 | GGGAGACAGGGCAAGGCTGGCA<br>(SEQ ID NO:183)  | GGGAGACAGGGCAAGGCTGGCA<br>(SEQ ID NO:683)  |
| RHO-85 | CACCACCCCAUGAAGUCCAUA<br>(SEQ ID NO:184)   | CACCACCCCATGAAGTTCCATA<br>(SEQ ID NO:684)  |
| RHO-86 | GCCAUUAUAGUUAUCAAACAAA<br>(SEQ ID NO:185)  | GCCATATAGTTAATCAACAAA<br>(SEQ ID NO:685)   |
| RHO-87 | GUAGCUAGGAAGGCAACCAGGA<br>(SEQ ID NO:186)  | GTAGCTAGGAAGGCAACCAGGA<br>(SEQ ID NO:686)  |
| RHO-88 | CACAUUGCUUCAUGGCUCCUAG<br>(SEQ ID NO:187)  | CACATTGCTTCATGGCTCCTAG<br>(SEQ ID NO:687)  |
| RHO-89 | CUGAGCUUGGGCCCCCAGAGAG<br>(SEQ ID NO:188)  | CTGAGCTTGGGCCCCCAGAGAG<br>(SEQ ID NO:688)  |
| RHO-90 | ACCGAGCCCAUUGCCCAGCACA<br>(SEQ ID NO:189)  | ACCGAGCCCATTGCCCAGCACA<br>(SEQ ID NO:689)  |
| RHO-91 | CUCAAAGAAGUCAAGCGCCUG<br>(SEQ ID NO:190)   | CTCAAAGAAGTCAAGCGCCCTG<br>(SEQ ID NO:690)  |
| RHO-92 | GCUACCCUCUCCUGUCUAGGG<br>(SEQ ID NO:191)   | GCTACCCTCTCCCTGTCTAGGG<br>(SEQ ID NO:691)  |
| RHO-93 | ACCCUGAGCUUGGGCCCCCAGA<br>(SEQ ID NO:192)  | ACCCTGAGCTTGGGCCCCCAGA<br>(SEQ ID NO:692)  |
| RHO-94 | GGCAGAGGGACCACACGCUGAG<br>(SEQ ID NO:193)  | GGCAGAGGGACCACACGCTGAG<br>(SEQ ID NO:693)  |
| RHO-95 | UCUGACUCAGCACAGCUGCUCC<br>(SEQ ID NO:194)  | TCTGACTCAGCACAGCTGCTCC<br>(SEQ ID NO:694)  |

|         |                                            |                                            |
|---------|--------------------------------------------|--------------------------------------------|
| RHO-96  | CUCUCAGCCACCACCGCCAAGC<br>(SEQ ID NO:195)  | CTCTCAGCCACCACCGCCAAGC<br>(SEQ ID NO:695)  |
| RHO-97  | AGGGAUGUGGCCAGGCAGCAAC<br>(SEQ ID NO:196)  | AGGGATGTGGCCAGGCAGCAAC<br>(SEQ ID NO:696)  |
| RHO-98  | CACCUGAGGACAGGGGCUGAGA<br>(SEQ ID NO:197)  | CACCTGAGGACAGGGGCTGAGA<br>(SEQ ID NO:697)  |
| RHO-99  | GCCCAUGAUGGCAUGGUUCUCC<br>(SEQ ID NO:198)  | GCCCATGATGGCATGGTTCTCC<br>(SEQ ID NO:698)  |
| RHO-100 | GAAGGGGCAGAGGGACCACACG<br>(SEQ ID NO:199)  | GAAGGGGCAGAGGGACCACACG<br>(SEQ ID NO:699)  |
| RHO-101 | AGCACCCUCUACACCUCUCUGC<br>(SEQ ID NO:200)  | AGCACCTCTACACCTCTCTGC<br>(SEQ ID NO:700)   |
| RHO-102 | CUUUGGAUAACAUUGACAGGAC<br>(SEQ ID NO:201)  | CTTTGGATAACATTGACAGGAC<br>(SEQ ID NO:701)  |
| RHO-103 | GGUGAAGCCACCUAGGACCAUG<br>(SEQ ID NO:202)  | GGTGAAGCCACCTAGGACCATG<br>(SEQ ID NO:702)  |
| RHO-104 | UAACAUUGACAGGACAGGAGAA<br>(SEQ ID NO:203)  | TAACATTGACAGGACAGGAGAA<br>(SEQ ID NO:703)  |
| RHO-105 | GGGAGAGGGGAAGAGACUCAUU<br>(SEQ ID NO:204)  | GGGAGAGGGGAAGAGACTCATT<br>(SEQ ID NO:704)  |
| RHO-106 | GCUGUGCUGAGUCAGACCCAGG<br>(SEQ ID NO:205)  | GCTGTGCTGAGTCAGACCCAGG<br>(SEQ ID NO:705)  |
| RHO-107 | UUGAGGAGGCCUUGGGGAAGGA<br>(SEQ ID NO:206)  | TTGAGGAGGCCTTGGGGAAGGA<br>(SEQ ID NO:706)  |
| RHO-108 | GCCCGGGAGCAUGGAGGGGUCU<br>(SEQ ID NO:207)  | GCCCGGGAGCATGGAGGGGTCT<br>(SEQ ID NO:707)  |
| RHO-109 | GUAACUGGGACUGACCCUGCA<br>(SEQ ID NO:208)   | GTAAACTGGGACTGACCCTGCA<br>(SEQ ID NO:708)  |
| RHO-110 | AUAACAUUGACAGGACAGGAGA<br>(SEQ ID NO:209)  | ATAACATTGACAGGACAGGAGA<br>(SEQ ID NO:709)  |
| RHO-111 | GGCAGGGAGGCUGGAGGGGCAC<br>(SEQ ID NO:210)  | GGCAGGGAGGCTGGAGGGGCAC<br>(SEQ ID NO:710)  |
| RHO-112 | GCAAACAUGGCCCCGAGAUAGAU<br>(SEQ ID NO:211) | GCAAACATGGCCCCGAGATAGAT<br>(SEQ ID NO:711) |
| RHO-113 | GGACCGAGCCCAUUGCCCAGCA<br>(SEQ ID NO:212)  | GGACCGAGCCCATTGCCCAGCA<br>(SEQ ID NO:712)  |
| RHO-114 | GCUCUACGUCACCGUCCAGCAC<br>(SEQ ID NO:213)  | GCTCTACGTCACCGTCCAGCAC<br>(SEQ ID NO:713)  |
| RHO-115 | AGCACAGCUGCUGCAAGGGAAA<br>(SEQ ID NO:214)  | AGCACAGCTGCTCCAAGGGAAA<br>(SEQ ID NO:714)  |
| RHO-116 | CUAAAGCAAAAAGGAACUGCUU<br>(SEQ ID NO:215)  | CTAAAGCAAAAAGGAAGTCTT<br>(SEQ ID NO:715)   |
| RHO-117 | GAGAGGAAAACUGAGGCAGGGA<br>(SEQ ID NO:216)  | GAGAGGAAAACUGAGGCAGGGA<br>(SEQ ID NO:716)  |
| RHO-118 | CAUUGCAAAGCUGGGUGACGGG<br>(SEQ ID NO:217)  | CATTGCAAAGCTGGGTGACGGG<br>(SEQ ID NO:717)  |
| RHO-119 | UUGCCACCCUGGGCGGUAUGAG<br>(SEQ ID NO:218)  | TTGCCACCCTGGGCGGTATGAG<br>(SEQ ID NO:718)  |
| RHO-120 | AGCUAGGAAGGCAACCAGGAGU<br>(SEQ ID NO:219)  | AGCTAGGAAGGCAACCAGGAGT<br>(SEQ ID NO:719)  |

|         |                                           |                                            |
|---------|-------------------------------------------|--------------------------------------------|
| RHO-121 | UCUCUGGGGGCCCAAGCUCAGG<br>(SEQ ID NO:220) | TCTCTGGGGGGCCCAAGCTCAGG<br>(SEQ ID NO:720) |
| RHO-122 | AGCACAGGGAAGACCCAAUGAC<br>(SEQ ID NO:221) | AGCACAGGGAAGACCCAAATGAC<br>(SEQ ID NO:721) |
| RHO-123 | GUUGACUGAAUAUAUGAGGGCU<br>(SEQ ID NO:222) | GTTGACTGAATATATGAGGGCT<br>(SEQ ID NO:722)  |
| RHO-124 | UUGUAAACUGGGACUGACCCUG<br>(SEQ ID NO:223) | TTGTAAACTGGGACTGACCCTG<br>(SEQ ID NO:723)  |
| RHO-125 | CACACCCACCUUCUGGCCAGAA<br>(SEQ ID NO:224) | CACACCCACCTTCTGGCCAGAA<br>(SEQ ID NO:724)  |
| RHO-126 | CCAGAGGAAGAAGAAGGAAUG<br>(SEQ ID NO:225)  | CCAGAGGAAGAAGAAGGAAATG<br>(SEQ ID NO:725)  |
| RHO-127 | GAGAUAUUCCUGGAUCACAGCC<br>(SEQ ID NO:226) | GAGATATTCCTGGATCACAGCC<br>(SEQ ID NO:726)  |
| RHO-128 | AGGGGCAGAGGGACCACACGCU<br>(SEQ ID NO:227) | AGGGGCAGAGGGACCACACGCT<br>(SEQ ID NO:727)  |
| RHO-129 | AACUAUAUGGCCACUCUCCCUA<br>(SEQ ID NO:228) | AACTATATGGCCACTCTCCCTA<br>(SEQ ID NO:728)  |
| RHO-130 | GCUGCUUGCGGUUCUACACACC<br>(SEQ ID NO:229) | GCTGCTTGCGGTTCTCAACACC<br>(SEQ ID NO:729)  |
| RHO-131 | CACCAUGAAUGGUGUUUGUUGA<br>(SEQ ID NO:230) | CACCATGAATGGTGTGTTGTTGA<br>(SEQ ID NO:730) |
| RHO-132 | GCAGCCAUUGCAAAGCUGGGUG<br>(SEQ ID NO:231) | GCAGCCATTGCAAAGCTGGGTG<br>(SEQ ID NO:731)  |
| RHO-133 | UGACUCAGCACAGCUGCUCCAA<br>(SEQ ID NO:232) | TGACTCAGCACAGCTGCTCCAA<br>(SEQ ID NO:732)  |
| RHO-134 | CUGGGAGGAGGGGGAAGGGGCA<br>(SEQ ID NO:233) | CTGGGAGGAGGGGGAAGGGGCA<br>(SEQ ID NO:733)  |
| RHO-135 | GAUAACAUUGACAGGACAGGAG<br>(SEQ ID NO:234) | GATAACATTGACAGGACAGGAG<br>(SEQ ID NO:734)  |
| RHO-136 | CCAAACUGGGACAUCCUAACA<br>(SEQ ID NO:235)  | CCAAACTGGGACATTCTTAACA<br>(SEQ ID NO:735)  |
| RHO-137 | AGGAAAACAGAUGGGGUGCUGC<br>(SEQ ID NO:236) | AGGAAAACAGATGGGGTGCTGC<br>(SEQ ID NO:736)  |
| RHO-138 | CGGACAUGUGGGGGCCUCUCCU<br>(SEQ ID NO:237) | CGGACATGTGGGGGCTCTCCT<br>(SEQ ID NO:737)   |
| RHO-139 | GCAAAGAAAUCCAGGGAUUGG<br>(SEQ ID NO:238)  | GCAAAGAAATTCAGGGAATGG<br>(SEQ ID NO:738)   |
| RHO-140 | CCAGGAGACUUGGAACGCGGCA<br>(SEQ ID NO:239) | CCAGGAGACTTGAACGCGGCA<br>(SEQ ID NO:739)   |
| RHO-141 | UGGUCCUUGGUGGUCCUGGCCA<br>(SEQ ID NO:240) | TGGTCCTTGGTGGTCCTGGCCA<br>(SEQ ID NO:740)  |
| RHO-142 | AAUGGAAAAUCCACUCCCACC<br>(SEQ ID NO:241)  | AATGGAAAATCCACTTCCCACC<br>(SEQ ID NO:741)  |
| RHO-143 | GCCCCAAGACGAAGUAUCCAUG<br>(SEQ ID NO:242) | GCCCCAAGACGAAGTATCCATG<br>(SEQ ID NO:742)  |
| RHO-144 | GUGCUGGACGGUGACGUAGAGC<br>(SEQ ID NO:243) | GTGCTGGACGGTGACGTAGAGC<br>(SEQ ID NO:743)  |
| RHO-145 | AGAAACAUGUAGGCGGCCAGCA<br>(SEQ ID NO:244) | AGAAACATGTAGGCGGCCAGCA<br>(SEQ ID NO:744)  |

|         |                                            |                                           |
|---------|--------------------------------------------|-------------------------------------------|
| RHO-146 | CCGCUCGAUGGCCAGGACCACC<br>(SEQ ID NO:245)  | CCGCTCGATGGCCAGGACCACC<br>(SEQ ID NO:745) |
| RHO-147 | UCAGCACAGACCCACUGCCUA<br>(SEQ ID NO:246)   | TCAGCACAGACCCACTGCCTA<br>(SEQ ID NO:746)  |
| RHO-148 | GAAUAUCUCUGCUGAGAUGCAG<br>(SEQ ID NO:247)  | GAATATCTCTGCTGAGATGCAG<br>(SEQ ID NO:747) |
| RHO-149 | GAGUACCCACAGUACUACCUGG<br>(SEQ ID NO:248)  | GAGTACCCACAGTACTACCTGG<br>(SEQ ID NO:748) |
| RHO-150 | CAACCAGGAGUGGGAGAGGGAU<br>(SEQ ID NO:249)  | CAACCAGGAGTGGGAGAGGGAT<br>(SEQ ID NO:749) |
| RHO-151 | UUGAGAACCGCAAGCAGCCGCU<br>(SEQ ID NO:250)  | TTGAGAACCGCAAGCAGCCGCT<br>(SEQ ID NO:750) |
| RHO-152 | GCAAGCCAGACCCUCCUCUCU<br>(SEQ ID NO:251)   | GCAAGCCAGACCCCTCCTCTCT<br>(SEQ ID NO:751) |
| RHO-153 | GAGAGCUGGGCAAAGAAAUUCC<br>(SEQ ID NO:252)  | GAGAGCTGGGCAAAGAAATTCC<br>(SEQ ID NO:752) |
| RHO-154 | CGAGGCAGCAGCCUGGACAUGG<br>(SEQ ID NO:253)  | CGAGGCAGCAGCCTGGACATGG<br>(SEQ ID NO:753) |
| RHO-155 | AGGAAUAUCUCUGCUGAGAUGC<br>(SEQ ID NO:254)  | AGGAATATCTCTGCTGAGATGC<br>(SEQ ID NO:754) |
| RHO-156 | UUCCCGAGAAGGGAGAGGGAGG<br>(SEQ ID NO:255)  | TTCCCGAGAAGGGAGAGGGAGG<br>(SEQ ID NO:755) |
| RHO-157 | UCCUUCUCCUCCUCCUCCUUCUC<br>(SEQ ID NO:256) | TCCTTCCTCCCTCTCCCTTCTC<br>(SEQ ID NO:756) |
| RHO-158 | UGUUUUGCCCAGAGGAAGAAGA<br>(SEQ ID NO:257)  | TGTTTTGCCAGAGGAAGAAGA<br>(SEQ ID NO:757)  |
| RHO-159 | CCGGCUGGUCCAGGUAAUGGCA<br>(SEQ ID NO:258)  | CCGGCTGGTCCAGGTAATGGCA<br>(SEQ ID NO:758) |
| RHO-160 | CAGCACAGGGAAGACCCAAUGA<br>(SEQ ID NO:259)  | CAGCACAGGGAAGACCCAATGA<br>(SEQ ID NO:759) |
| RHO-161 | ACCAGGAGUGGGAGAGGGAUUU<br>(SEQ ID NO:260)  | ACCAGGAGTGGGAGAGGGATTT<br>(SEQ ID NO:760) |
| RHO-162 | GCUGGUGAAGCCACCUAGGACC<br>(SEQ ID NO:261)  | GCTGGTGAAGCCACCTAGGACC<br>(SEQ ID NO:761) |
| RHO-163 | GGCGGUAUGAGCCGGGUGUGGG<br>(SEQ ID NO:262)  | GGCGGTATGAGCCGGGTGTGGG<br>(SEQ ID NO:762) |
| RHO-164 | CAGCCAUUGCAAAGCUGGGUGA<br>(SEQ ID NO:263)  | CAGCCATTGCAAAGCTGGGTGA<br>(SEQ ID NO:763) |
| RHO-165 | ACAUUGACAGGACAGGAGAAGG<br>(SEQ ID NO:264)  | ACATTGACAGGACAGGAGAAGG<br>(SEQ ID NO:764) |
| RHO-166 | UGGGUCUUCCUGUGCUGGGCA<br>(SEQ ID NO:265)   | TGGGTCTTCCCTGTGCTGGGCA<br>(SEQ ID NO:765) |
| RHO-167 | GUACGUGGUGGUGUGUAAGCCC<br>(SEQ ID NO:266)  | GTACGTGGTGGTGTGTAAGCCC<br>(SEQ ID NO:766) |
| RHO-168 | AGCAAUAACUCCCCCAUUC<br>(SEQ ID NO:267)     | AGCAAATAACTTCCCCCATTC<br>(SEQ ID NO:767)  |
| RHO-169 | GGAUUUGAGGAGGCCUUGGGGA<br>(SEQ ID NO:268)  | GGATTTGAGGAGGCCTTGGGGA<br>(SEQ ID NO:768) |
| RHO-170 | CCUGAGCUUGGGCCCCCAGAG<br>(SEQ ID NO:269)   | CCCTGAGCTTGGGCCCCCAGAG<br>(SEQ ID NO:769) |

|         |                                           |                                            |
|---------|-------------------------------------------|--------------------------------------------|
| RHO-171 | CAGAGAUUCCUGAGAAUGGGA<br>(SEQ ID NO:270)  | CAGAGATTCCCTGAGAATGGGA<br>(SEQ ID NO:770)  |
| RHO-172 | GAGUUGGAAGCCCGCAUCUAUC<br>(SEQ ID NO:271) | GAGTTGGAAGCCCGCATCTATC<br>(SEQ ID NO:771)  |
| RHO-173 | AGUCCUCCUCCUCUCCCUUC<br>(SEQ ID NO:272)   | AGTCCTTCCTCCCTCTCCCTTC<br>(SEQ ID NO:772)  |
| RHO-174 | GUUAAUUCAUUUCCCGAGAAGG<br>(SEQ ID NO:273) | GTTATTTTCATTTCCCGAGAAGG<br>(SEQ ID NO:773) |
| RHO-175 | AUUUCAUUUCCCGAGAAGGGAG<br>(SEQ ID NO:274) | ATTTTCATTTCCCGAGAAGGGAG<br>(SEQ ID NO:774) |
| RHO-176 | GACGUAGAGCGUGAGGAAGUUG<br>(SEQ ID NO:275) | GACGTAGAGCGTGAGGAAGTTG<br>(SEQ ID NO:775)  |
| RHO-177 | CAUUUCCCGAGAAGGGAGAGGG<br>(SEQ ID NO:276) | CATTTCCCGAGAAGGGAGAGGG<br>(SEQ ID NO:776)  |
| RHO-178 | GUAGAGCGUGAGGAAGUUGAUG<br>(SEQ ID NO:277) | GTAGAGCGTGAGGAAGTTGATG<br>(SEQ ID NO:777)  |
| RHO-179 | CAGGCCUUCGCAGCAUUCUUGG<br>(SEQ ID NO:278) | CAGGCCTTCGCAGCATTCTTGG<br>(SEQ ID NO:778)  |
| RHO-180 | AGGUAGUACUGUGGGUACUCGA<br>(SEQ ID NO:279) | AGGTAGTACTGTGGGTACTCGA<br>(SEQ ID NO:779)  |
| RHO-181 | AAACAUGUAGGCGGCCAGCAUG<br>(SEQ ID NO:280) | AAACATGTAGGCGGCCAGCATG<br>(SEQ ID NO:780)  |
| RHO-182 | UUUCAUUUCCCGAGAAGGGAGA<br>(SEQ ID NO:281) | TTTCATTTCCCGAGAAGGGAGA<br>(SEQ ID NO:781)  |
| RHO-183 | GGGAAGACCCAAUGACUGGAGA<br>(SEQ ID NO:282) | GGGAAGACCCAATGACTGGAGA<br>(SEQ ID NO:782)  |
| RHO-184 | AAAACUGAGGCAGGGAGAGGGG<br>(SEQ ID NO:283) | AAAACUGAGGCAGGGAGAGGGG<br>(SEQ ID NO:783)  |
| RHO-185 | UGAGUCAGACCCAGGCUGGGCA<br>(SEQ ID NO:284) | TGAGTCAGACCCAGGCTGGGCA<br>(SEQ ID NO:784)  |
| RHO-186 | GGGAUUUGAGGAGGCCUUGGGG<br>(SEQ ID NO:285) | GGGATTTGAGGAGGCCCTTGGGG<br>(SEQ ID NO:785) |
| RHO-187 | UCUGGGGGCCCAAGCUCAGGGU<br>(SEQ ID NO:286) | TCTGGGGGGCCCAAGCTCAGGGT<br>(SEQ ID NO:786) |
| RHO-188 | CGGGCCACAGGAUGCAAUUUG<br>(SEQ ID NO:287)  | CGGGCCACAGGATGCAATTTG<br>(SEQ ID NO:787)   |
| RHO-189 | ACGUAGAGCGUGAGGAAGUUGA<br>(SEQ ID NO:288) | ACGTAGAGCGTGAGGAAGTTGA<br>(SEQ ID NO:788)  |
| RHO-190 | GACCGAGGCAGCAGCCUGGACA<br>(SEQ ID NO:289) | GACCGAGGCAGCAGCCTGGACA<br>(SEQ ID NO:789)  |
| RHO-191 | CAGGCUGGGCACUGAGGGAGAG<br>(SEQ ID NO:290) | CAGGCTGGGCACTGAGGGAGAG<br>(SEQ ID NO:790)  |
| RHO-192 | UAUUUCAUUUCCCGAGAAGGGA<br>(SEQ ID NO:291) | TATTTTCATTTCCCGAGAAGGGA<br>(SEQ ID NO:791) |
| RHO-193 | GUCCCGGGCUUGGCGGUGGUGG<br>(SEQ ID NO:292) | GTCCCGGGCTTGGCGGTGGTGG<br>(SEQ ID NO:792)  |
| RHO-194 | CUGCUGCCUCGGUCCCAUUCUC<br>(SEQ ID NO:293) | CTGCTGCCTCGGTCCCATTCTC<br>(SEQ ID NO:793)  |
| RHO-195 | AGCGUCUCCUCCUGCAUCUCAG<br>(SEQ ID NO:294) | AGCGTCTCCTCCTGCATCTCAG<br>(SEQ ID NO:794)  |

|         |                                            |                                            |
|---------|--------------------------------------------|--------------------------------------------|
| RHO-196 | UCAGACCCAGGCUGGGCACUGA<br>(SEQ ID NO:295)  | TCAGACCCAGGCTGGGCACTGA<br>(SEQ ID NO:795)  |
| RHO-197 | AGCUACCCUCUCCCUGUCUAGG<br>(SEQ ID NO:296)  | AGCTACCCTCTCCCTGTCTAGG<br>(SEQ ID NO:796)  |
| RHO-198 | CAGAGAGGAAAACUGAGGCAGG<br>(SEQ ID NO:297)  | CAGAGAGGAAAACCTGAGGCAGG<br>(SEQ ID NO:797) |
| RHO-199 | GGAGAGGGAAUUGAGGAGGCCU<br>(SEQ ID NO:298)  | GGAGAGGGATTGAGGAGGCCT<br>(SEQ ID NO:798)   |
| RHO-200 | GUCCUUCUCCCUCUCCUUCU<br>(SEQ ID NO:299)    | GTCCTTCCTCCCTCTCCCTTCT<br>(SEQ ID NO:799)  |
| RHO-201 | AGAGAGCUUGGUGCUGGGAGGA<br>(SEQ ID NO:300)  | AGAGAGCTTGGTGCTGGGAGGA<br>(SEQ ID NO:800)  |
| RHO-202 | CCUUCUCGGGAAUGAAUAAC<br>(SEQ ID NO:301)    | CCTTCTCGGGAAATGAAATAAC<br>(SEQ ID NO:801)  |
| RHO-203 | GCGGUUCUACAACACCAGGAGAC<br>(SEQ ID NO:302) | GCGGTTCTCAACACCAGGAGAC<br>(SEQ ID NO:802)  |
| RHO-204 | CUCUGGGGGCCCAAGCUCAGGG<br>(SEQ ID NO:303)  | CTCTGGGGGGCCCAAGCTCAGGG<br>(SEQ ID NO:803) |
| RHO-205 | UGUGCAGGAGCCCGGAGCAUG<br>(SEQ ID NO:304)   | TGTGCAGGAGCCCGGAGCATG<br>(SEQ ID NO:804)   |
| RHO-206 | CAGAGAGGUGUAGAGGGUGCUG<br>(SEQ ID NO:305)  | CAGAGAGGTGTAGAGGGTGCTG<br>(SEQ ID NO:805)  |
| RHO-207 | CUCCCCGAAGCGGAAGUUGCUC<br>(SEQ ID NO:306)  | CTCCCCGAAGCGGAAGTTGCTC<br>(SEQ ID NO:806)  |
| RHO-208 | GCUAGAAGCAGCCAUUGCAAAG<br>(SEQ ID NO:307)  | GCTAGAAGCAGCCATTGCAAAG<br>(SEQ ID NO:807)  |
| RHO-209 | CAAACACCAUUAUGGUGAUAG<br>(SEQ ID NO:308)   | CAAACACCATTTCATGGTGATAG<br>(SEQ ID NO:808) |
| RHO-210 | UCAUUUCCCGAGAAGGGAGAGG<br>(SEQ ID NO:309)  | TCATTTCCCGAGAAGGGAGAGG<br>(SEQ ID NO:809)  |
| RHO-211 | UCACCACCCCAUGAAGUCCAU<br>(SEQ ID NO:310)   | TCACCACCCCATGAAGTTCCAT<br>(SEQ ID NO:810)  |
| RHO-212 | GGGAGUGCACCCUCCUAGGCA<br>(SEQ ID NO:311)   | GGGAGTGCACCCTCCTTAGGCA<br>(SEQ ID NO:811)  |
| RHO-213 | AAUGGCCAGAGAUUCCUGAGA<br>(SEQ ID NO:312)   | AATGGCCAGAGATTCCTTGAGA<br>(SEQ ID NO:812)  |
| RHO-214 | AGAAUGGGACCGAGGCAGCAGC<br>(SEQ ID NO:313)  | AGAATGGGACCGAGGCAGCAGC<br>(SEQ ID NO:813)  |
| RHO-215 | GGCAAGCCAGACCCUCCUCUC<br>(SEQ ID NO:314)   | GGCAAGCCAGACCCCTCCTCTC<br>(SEQ ID NO:814)  |
| RHO-216 | CCCGGGCUUGGCGGUGGUGGCU<br>(SEQ ID NO:315)  | CCCGGGCTTGGCGGTGGTGGCT<br>(SEQ ID NO:815)  |
| RHO-217 | AGCCCGGGAGCAUGGAGGGGUC<br>(SEQ ID NO:316)  | AGCCCGGGAGCATGGAGGGGTC<br>(SEQ ID NO:816)  |
| RHO-218 | CCGGGUUAUUUCAUUUCCCGAG<br>(SEQ ID NO:317)  | CCGGGTATTTCATTTCCCGAG<br>(SEQ ID NO:817)   |
| RHO-219 | GGUGUUUGUUGACUGAAUAUAU<br>(SEQ ID NO:318)  | GGTGTTTGTTGACTGAATATAT<br>(SEQ ID NO:818)  |
| RHO-220 | CCGUCCCUGUGUGACGCCCCAG<br>(SEQ ID NO:319)  | CCGTCCCTGTGTGACGCCCCAG<br>(SEQ ID NO:819)  |

|         |                                           |                                            |
|---------|-------------------------------------------|--------------------------------------------|
| RHO-221 | GGACAGGGGCUGAGAGGGGAGG<br>(SEQ ID NO:320) | GGACAGGGGCTGAGAGGGGAGG<br>(SEQ ID NO:820)  |
| RHO-222 | AGAGGGUGCUGGUGAAGCCACC<br>(SEQ ID NO:321) | AGAGGGTGCTGGTGAAGCCACC<br>(SEQ ID NO:821)  |
| RHO-223 | AUUGCAUCCUGUGGGCCCGAAG<br>(SEQ ID NO:322) | ATTGCATCCTGTGGGCCCGAAG<br>(SEQ ID NO:822)  |
| RHO-224 | CGGGUUAUUUCAUUUCCCGAGA<br>(SEQ ID NO:323) | CGGGTTATTTTCATTTCCCGAGA<br>(SEQ ID NO:823) |
| RHO-225 | GGAAAUGAAAUAACCCGGACAU<br>(SEQ ID NO:324) | GGAAATGAAATAACCCGGACAT<br>(SEQ ID NO:824)  |
| RHO-226 | CUGACUCAGCACAGCUGCUCCA<br>(SEQ ID NO:325) | CTGACTCAGCACAGCTGCTCCA<br>(SEQ ID NO:825)  |
| RHO-227 | GGCACCUGAGGACAGGGGCUGA<br>(SEQ ID NO:326) | GGCACCTGAGGACAGGGGCTGA<br>(SEQ ID NO:826)  |
| RHO-228 | GGAGAGCUGGGCAAAGAAUUC<br>(SEQ ID NO:327)  | GGAGAGCTGGGCAAAGAAATTC<br>(SEQ ID NO:827)  |
| RHO-229 | GGGCGGUAUGAGCCGGGUGUGG<br>(SEQ ID NO:328) | GGGCGGTATGAGCCGGGTGTGG<br>(SEQ ID NO:828)  |
| RHO-230 | CCUCCUCUCCCUUCUCGGGAA<br>(SEQ ID NO:329)  | CCTCCCTCTCCCTTCTCGGGAA<br>(SEQ ID NO:829)  |
| RHO-231 | UCCAGGUAAUGGCACUGAGCAG<br>(SEQ ID NO:330) | TCCAGGTAATGGCACTGAGCAG<br>(SEQ ID NO:830)  |
| RHO-232 | GUGGGGGCCUCUCCUAGGAGCC<br>(SEQ ID NO:331) | GTGGGGGCCTCTCCTAGGAGCC<br>(SEQ ID NO:831)  |
| RHO-233 | GAUGGCAUGGUUCUCCCCGAAG<br>(SEQ ID NO:332) | GATGGCATGGTTCTCCCCGAAG<br>(SEQ ID NO:832)  |
| RHO-234 | CGUCGCAUUGGAGAAGGGCACG<br>(SEQ ID NO:333) | CGTCGCATTGGAGAAGGGCACG<br>(SEQ ID NO:833)  |
| RHO-235 | UGGGUGGGGUGUGCAGGAGCCC<br>(SEQ ID NO:334) | TGGGTGGGGTGTGCAGGAGCCC<br>(SEQ ID NO:834)  |
| RHO-236 | CUGGACGGUGACGUAGAGCGUG<br>(SEQ ID NO:335) | CTGGACGGTGACGTAGAGCGTG<br>(SEQ ID NO:835)  |
| RHO-237 | GAGGAAAACUGAGGCAGGGAGA<br>(SEQ ID NO:336) | GAGGAAAACUGAGGCAGGGAGA<br>(SEQ ID NO:836)  |
| RHO-238 | CUGAACACUGCCUUGAUCUUAU<br>(SEQ ID NO:337) | CTGAACACTGCCTTGATCTTAT<br>(SEQ ID NO:837)  |
| RHO-239 | CAUUACCUGGACCAGCCGGCGA<br>(SEQ ID NO:338) | CATTACCTGGACCAGCCGGCGA<br>(SEQ ID NO:838)  |
| RHO-240 | GGAGAGAGCUUGGUGCUGGGAG<br>(SEQ ID NO:339) | GGAGAGAGCTTGGTGCTGGGAG<br>(SEQ ID NO:839)  |
| RHO-241 | AGAAUAAUGUCUUGCAUUUAAC<br>(SEQ ID NO:340) | AGAATAATGTCTTGCAATTTAAC<br>(SEQ ID NO:840) |
| RHO-242 | CUAGGAAGGCAACCAGGAGUGG<br>(SEQ ID NO:341) | CTAGGAAGGCAACCAGGAGTGG<br>(SEQ ID NO:841)  |
| RHO-243 | UCUCCAGACCCCUCCAUGCUC<br>(SEQ ID NO:342)  | TCTCCAGACCCCTCCATGCTC<br>(SEQ ID NO:842)   |
| RHO-244 | ACAGGGGCUGAGAGGGGAGGCA<br>(SEQ ID NO:343) | ACAGGGGCTGAGAGGGGAGGCA<br>(SEQ ID NO:843)  |
| RHO-245 | GGGGCAGAGGGACCACACGCTG<br>(SEQ ID NO:344) | GGGGCAGAGGGACCACACGCTG<br>(SEQ ID NO:844)  |

|         |                                           |                                            |
|---------|-------------------------------------------|--------------------------------------------|
| RHO-246 | AGGGGAGGCAGAGGAUGCCAGA<br>(SEQ ID NO:345) | AGGGGAGGCAGAGGATGCCAGA<br>(SEQ ID NO:845)  |
| RHO-247 | UGGUCCAGGUAAUGGCACUGAG<br>(SEQ ID NO:346) | TGGTCCAGGTAATGGCACTGAG<br>(SEQ ID NO:846)  |
| RHO-248 | CCGGACAUGUGGGGGCCUCUCC<br>(SEQ ID NO:347) | CCGGACATGTGGGGGCCTCTCC<br>(SEQ ID NO:847)  |
| RHO-249 | GCAGGCCAGCGCCAUGACCCAG<br>(SEQ ID NO:348) | GCAGGCCAGCGCCATGACCCAG<br>(SEQ ID NO:848)  |
| RHO-250 | CUAGCUACCCUCUCCUGUCUA<br>(SEQ ID NO:349)  | CTAGCTACCCTCTCCCTGTCTA<br>(SEQ ID NO:849)  |
| RHO-251 | GCUUUGGAUAACAUGACAGGA<br>(SEQ ID NO:350)  | GCTTTGGATAACATTGACAGGA<br>(SEQ ID NO:850)  |
| RHO-252 | GCCAUUGCAAAGCUGGGUGACG<br>(SEQ ID NO:351) | GCCATTGCAAAGCTGGGTGACG<br>(SEQ ID NO:851)  |
| RHO-253 | CCUAGGUCUCCUGGCUGUGAUC<br>(SEQ ID NO:352) | CCTAGGTCTCCTGGCTGTGATC<br>(SEQ ID NO:852)  |
| RHO-254 | AACAGAGAGGAAAACUGAGGCA<br>(SEQ ID NO:353) | AACAGAGAGGAAAACCTGAGGCA<br>(SEQ ID NO:853) |
| RHO-255 | AUUACCUGGACCAGCCGGCGAG<br>(SEQ ID NO:354) | ATTACCTGGACCAGCCGGCGAG<br>(SEQ ID NO:854)  |
| RHO-256 | GAGGGGCACCUGAGGACAGGGG<br>(SEQ ID NO:355) | GAGGGGCACCTGAGGACAGGGG<br>(SEQ ID NO:855)  |
| RHO-257 | GGGUUAUUUCAUUUCCCGAGAA<br>(SEQ ID NO:356) | GGGTATTTCATTTCCCGAGAA<br>(SEQ ID NO:856)   |
| RHO-258 | AGGGUGCACUCCCCCUAGACA<br>(SEQ ID NO:357)  | AGGGTGCACTCCCCCTAGACA<br>(SEQ ID NO:857)   |
| RHO-259 | CCAGGAGUGGGAGAGGGAUUUG<br>(SEQ ID NO:358) | CCAGGAGTGGGAGAGGGATTTG<br>(SEQ ID NO:858)  |
| RHO-260 | AGAGGGGAGGCAGAGGAUGCCA<br>(SEQ ID NO:359) | AGAGGGGAGGCAGAGGATGCCA<br>(SEQ ID NO:859)  |
| RHO-261 | CCGCCUGCUGACUGCCUUGCAG<br>(SEQ ID NO:360) | CCGCCTGCTGACTGCCTTGCGAG<br>(SEQ ID NO:860) |
| RHO-262 | GGCUUGGUGCUGCAAACAUGGC<br>(SEQ ID NO:361) | GGCTTGGTGCTGCAAACATGGC<br>(SEQ ID NO:861)  |
| RHO-263 | CAGGUAAUGGCACUGAGCAGAA<br>(SEQ ID NO:362) | CAGGTAATGGCACTGAGCAGAA<br>(SEQ ID NO:862)  |
| RHO-264 | UUGGAACGCGGCAGGGAGGCUG<br>(SEQ ID NO:363) | TTGGAACGCGGCAGGGAGGCTG<br>(SEQ ID NO:863)  |
| RHO-265 | UGUCCGGGUUAUUUCAUUUCCC<br>(SEQ ID NO:364) | TGTCCGGGTTATTTCAATTCCC<br>(SEQ ID NO:864)  |
| RHO-266 | CAGGUAGUACUGUGGGUACUCG<br>(SEQ ID NO:365) | CAGGTAGTACTGTGGGTACTCG<br>(SEQ ID NO:865)  |
| RHO-267 | AUAACAGAUCCACUUAACAGA<br>(SEQ ID NO:366)  | ATAACAGATCCCACTTAACAGA<br>(SEQ ID NO:866)  |
| RHO-268 | AGGGACGGGUGCAGAGUUGAGU<br>(SEQ ID NO:367) | AGGGACGGGTGCAGAGTTGAGT<br>(SEQ ID NO:867)  |
| RHO-269 | GAAGGAGAGAGCUUGGUGCUGG<br>(SEQ ID NO:368) | GAAGGAGAGAGCTTGGTGCTGG<br>(SEQ ID NO:868)  |
| RHO-270 | GGUCAGCCACGGCUAGGUUGAG<br>(SEQ ID NO:369) | GGTCAGCCACGGCTAGGTTGAG<br>(SEQ ID NO:869)  |

|         |                                           |                                             |
|---------|-------------------------------------------|---------------------------------------------|
| RHO-271 | AUUUCACAGCAAGAAAACUGAG<br>(SEQ ID NO:370) | ATTTACACAGCAAGAAAACCTGAG<br>(SEQ ID NO:870) |
| RHO-272 | UCAAAGAAGUCAAGCGCCUGC<br>(SEQ ID NO:371)  | TCAAAGAAGTCAAGCGCCCTGC<br>(SEQ ID NO:871)   |
| RHO-273 | GCUGCUCACCCCAAGAAUGCU<br>(SEQ ID NO:372)  | GCTGCTCCCAACCAAGAAATGCT<br>(SEQ ID NO:872)  |
| RHO-274 | GCAACAAACACCCAAACAUGGC<br>(SEQ ID NO:373) | GCAACAAACACCCAAACAATGGC<br>(SEQ ID NO:873)  |
| RHO-275 | AAAUCCACUCCCCACCCUGAGC<br>(SEQ ID NO:374) | AAATCCACTTCCCACCCTGAGC<br>(SEQ ID NO:874)   |
| RHO-276 | CAGGGAGGCUGGAGGGGCACCU<br>(SEQ ID NO:375) | CAGGGAGGCTGGAGGGGCACCT<br>(SEQ ID NO:875)   |
| RHO-277 | GGGCAAGCCAGACCCCUCCUCU<br>(SEQ ID NO:376) | GGGCAAGCCAGACCCCTCCTCT<br>(SEQ ID NO:876)   |
| RHO-278 | CAGGAAAACAGAUGGGGUGCUG<br>(SEQ ID NO:377) | CAGGAAAACAGATGGGGTGCTG<br>(SEQ ID NO:877)   |
| RHO-279 | UUGGAGAAGGGCACGUAGAAGU<br>(SEQ ID NO:378) | TTGGAGAAGGGCACGTAGAAGT<br>(SEQ ID NO:878)   |
| RHO-280 | AGAGCUUGGUGCUGGGAGGAGG<br>(SEQ ID NO:379) | AGAGCTTGGTGCTGGGAGGAGG<br>(SEQ ID NO:879)   |
| RHO-281 | UAGCUAGGAAGGCAACCAGGAG<br>(SEQ ID NO:380) | TAGCTAGGAAGGCAACCAGGAG<br>(SEQ ID NO:880)   |
| RHO-282 | GGCUAGGUUGAGCAGGAUGUAG<br>(SEQ ID NO:381) | GGCTAGGTTGAGCAGGATGTAG<br>(SEQ ID NO:881)   |
| RHO-283 | CUCACCACCCCAUGAAGUUCCA<br>(SEQ ID NO:382) | CTCACCACCCCATGAAGTTCCA<br>(SEQ ID NO:882)   |
| RHO-284 | AAGCAAUGUGCAAUGUUUUGCC<br>(SEQ ID NO:383) | AAGCAATGTGCAATGTTTGCC<br>(SEQ ID NO:883)    |
| RHO-285 | GGAAGACCCAAUGACUGGAGAA<br>(SEQ ID NO:384) | GGAAGACCCAAATGACTGGAGAA<br>(SEQ ID NO:884)  |
| RHO-286 | UGGCCAGGACCACCAAGGACCA<br>(SEQ ID NO:385) | TGGCCAGGACCACCAAGGACCA<br>(SEQ ID NO:885)   |
| RHO-287 | AAAUAUUGUCCCUUUCACUGUU<br>(SEQ ID NO:386) | AAATATTGTCCCTTTCACTGTT<br>(SEQ ID NO:886)   |
| RHO-288 | CAUGAGCAACUCCGCUUCGGG<br>(SEQ ID NO:387)  | CATGAGCAACTTCCGCTTCGGG<br>(SEQ ID NO:887)   |
| RHO-289 | AGAGAUAUUCCUGGAUCACAGC<br>(SEQ ID NO:388) | AGAGATATTCTGGATCACAGC<br>(SEQ ID NO:888)    |
| RHO-290 | CAUGGAGGGGUCUGGGAGAGUC<br>(SEQ ID NO:389) | CATGGAGGGGTCTGGGAGAGTC<br>(SEQ ID NO:889)   |
| RHO-291 | AUGUUUUGCCAGAGGAAGAAG<br>(SEQ ID NO:390)  | ATGTTTTGCCCAGAGGAAGAAG<br>(SEQ ID NO:890)   |
| RHO-292 | GUGGGUGGGGUGUGCAGGAGCC<br>(SEQ ID NO:391) | GTGGGTGGGGTGTGCAGGAGCC<br>(SEQ ID NO:891)   |
| RHO-293 | CCAGGUAAUGGCACUGAGCAGA<br>(SEQ ID NO:392) | CCAGGTAATGGCACTGAGCAGA<br>(SEQ ID NO:892)   |
| RHO-294 | CCCAACAAUGGCCAGAGAUUCC<br>(SEQ ID NO:393) | CCCAACAATGGCCAGAGATTCC<br>(SEQ ID NO:893)   |
| RHO-295 | GCACCUGAGGACAGGGGCTGAG<br>(SEQ ID NO:394) | GCACCTGAGGACAGGGGCTGAG<br>(SEQ ID NO:894)   |

|         |                                           |                                            |
|---------|-------------------------------------------|--------------------------------------------|
| RHO-296 | GUCAGACCCAGGCUGGGCACUG<br>(SEQ ID NO:395) | GTCAGACCCAGGCTGGGCACTG<br>(SEQ ID NO:895)  |
| RHO-297 | GGGGCACCUGAGGACAGGGGCU<br>(SEQ ID NO:396) | GGGGCACCTGAGGACAGGGGCT<br>(SEQ ID NO:896)  |
| RHO-298 | AGAGGAAAACUGAGGCAGGGAG<br>(SEQ ID NO:397) | AGAGGAAAACAGGAGGCAGGGAG<br>(SEQ ID NO:897) |
| RHO-299 | AGGGAUAACAGAUCCACUUA<br>(SEQ ID NO:398)   | AGGATAACAGATCCCACTTAA<br>(SEQ ID NO:898)   |
| RHO-300 | CUUGGUGCUGGGAGGAGGGGGA<br>(SEQ ID NO:399) | CTTGGTGCTGGGAGGAGGGGGA<br>(SEQ ID NO:899)  |
| RHO-301 | AGAGGGUAGCUAGGAAGGCAAC<br>(SEQ ID NO:400) | AGAGGGTAGCTAGGAAGGCAAC<br>(SEQ ID NO:900)  |
| RHO-302 | UUGCACAUUGCUUCAUGGCUC<br>(SEQ ID NO:401)  | TTGCACATTGCTTCATGGCTCC<br>(SEQ ID NO:901)  |
| RHO-303 | GACCGAGCCCAUUGCCCAGCAC<br>(SEQ ID NO:402) | GACCGAGCCCATGCCCAGCAC<br>(SEQ ID NO:902)   |
| RHO-304 | UGAACACUGCCUUGAUCUUAUU<br>(SEQ ID NO:403) | TGAACACTGCCTTGATCTTATT<br>(SEQ ID NO:903)  |
| RHO-305 | GGUGCACUCCCCCUAGACAGG<br>(SEQ ID NO:404)  | GGTGCACCTCCCCCTAGACAGG<br>(SEQ ID NO:904)  |
| RHO-306 | GCUUGGUGCUGGGAGGAGGGGG<br>(SEQ ID NO:405) | GCTTGGTGCTGGGAGGAGGGGG<br>(SEQ ID NO:905)  |
| RHO-307 | GGAUACUUCGUCUUCGGGCCCA<br>(SEQ ID NO:406) | GGATACTTCGTCTTCGGGCCCA<br>(SEQ ID NO:906)  |
| RHO-308 | AGUCAGACCCAGGCUGGGCACU<br>(SEQ ID NO:407) | AGTCAGACCCAGGCTGGGCACT<br>(SEQ ID NO:907)  |
| RHO-309 | AGCACCAAGCCUCUGUUUCCCU<br>(SEQ ID NO:408) | AGCACCAAGCCTCTGTTTCCCT<br>(SEQ ID NO:908)  |
| RHO-310 | UGGGCAAAGAAAUUCCAGGGAA<br>(SEQ ID NO:409) | TGGGCAAAGAAATTCCAGGGAA<br>(SEQ ID NO:909)  |
| RHO-311 | AGAGGGAUUUGAGGAGGCCUUG<br>(SEQ ID NO:410) | AGAGGGATTTGAGGAGGCCTTG<br>(SEQ ID NO:910)  |
| RHO-312 | GCAAUGUUUUGCCCAGAGGAAG<br>(SEQ ID NO:411) | GCAATGTTTTGCCAGAGGAAG<br>(SEQ ID NO:911)   |
| RHO-313 | CAUGUCCGGGUUAUUUCAUUUC<br>(SEQ ID NO:412) | CATGTCCGGGTATTTCATTTC<br>(SEQ ID NO:912)   |
| RHO-314 | AAGCCCAUGAGCAACUCCGCU<br>(SEQ ID NO:413)  | AAGCCCATGAGCAACTTCCGCT<br>(SEQ ID NO:913)  |
| RHO-315 | UCCACCCUGAGCUUGGGCCCC<br>(SEQ ID NO:414)  | TCCCACCCTGAGCTTGGGCCCC<br>(SEQ ID NO:914)  |
| RHO-316 | GAGAGAGCUUGGUGCUGGGAGG<br>(SEQ ID NO:415) | GAGAGAGCTTGGTGCTGGGAGG<br>(SEQ ID NO:915)  |
| RHO-317 | CUACGUGCCCUUCUCCAAUGCG<br>(SEQ ID NO:416) | CTACGTGCCCTTCTCCAATGCG<br>(SEQ ID NO:916)  |
| RHO-318 | CUUGCAUUUAACAGGAAAACAG<br>(SEQ ID NO:417) | CTTGCATTAAACAGGAAAACAG<br>(SEQ ID NO:917)  |
| RHO-319 | GAAAUAGAAUAACCCGGACAUG<br>(SEQ ID NO:418) | GAAATGAAATAACCCGGACATG<br>(SEQ ID NO:918)  |
| RHO-320 | CGAAGGCCUGAGCUCAGCCACU<br>(SEQ ID NO:419) | CGAAGGCCTGAGCTCAGCCACT<br>(SEQ ID NO:919)  |

|         |                                            |                                           |
|---------|--------------------------------------------|-------------------------------------------|
| RHO-321 | GGAGGGUGCACUCCCCCUAGA<br>(SEQ ID NO:420)   | GGAGGGTGCACCTCCCCCTAGA<br>(SEQ ID NO:920) |
| RHO-322 | CAGCACCAAGCCUCUGUUUCCC<br>(SEQ ID NO:421)  | CAGCACCAAGCCTCTGTTTCCC<br>(SEQ ID NO:921) |
| RHO-323 | GGGCAAAGAAAUUCCAGGGAAU<br>(SEQ ID NO:422)  | GGGCAAAGAAATTCCAGGGAAT<br>(SEQ ID NO:922) |
| RHO-324 | CUUCGGGGAGAACCAUGCCAUC<br>(SEQ ID NO:423)  | CTTCGGGGAGAACCATGCCATC<br>(SEQ ID NO:923) |
| RHO-325 | UGGGAGGAGGGGGAAGGGGCAG<br>(SEQ ID NO:424)  | TGGGAGGAGGGGGAAGGGGCAG<br>(SEQ ID NO:924) |
| RHO-326 | CCUAGACAGGGAGAGGGUAGCU<br>(SEQ ID NO:425)  | CCTAGACAGGGAGAGGGTAGCT<br>(SEQ ID NO:925) |
| RHO-327 | UAACAGAGAGGAAAACUGAGGC<br>(SEQ ID NO:426)  | TAACAGAGAGGAAAACUGAGGC<br>(SEQ ID NO:926) |
| RHO-328 | UCUCAGCCACCACCGCCAAGCC<br>(SEQ ID NO:427)  | TCTCAGCCACCACCGCCAAGCC<br>(SEQ ID NO:927) |
| RHO-329 | GUCAGCACAGACCCACUGCCU<br>(SEQ ID NO:428)   | GTCAGCACAGACCCACTGCCT<br>(SEQ ID NO:928)  |
| RHO-330 | AGGAAAACUGAGGCAGGGAGAG<br>(SEQ ID NO:429)  | AGGAAAACUGAGGCAGGGAGAG<br>(SEQ ID NO:929) |
| RHO-331 | AGCCAUUGCAAAGCUGGGUGAC<br>(SEQ ID NO:430)  | AGCCATTGCAAAGCTGGGTGAC<br>(SEQ ID NO:930) |
| RHO-332 | AAAUGAAAUAAACCCGGACAUGU<br>(SEQ ID NO:431) | AAATGAAATAACCCGGACATGT<br>(SEQ ID NO:931) |
| RHO-333 | UAGCUACCCUCUCCUGUCUAG<br>(SEQ ID NO:432)   | TAGCTACCCTCTCCCTGTCTAG<br>(SEQ ID NO:932) |
| RHO-334 | UGUGGGUGGGUGUGCAGGAGC<br>(SEQ ID NO:433)   | TGTGGGTGGGTGTGCAGGAGC<br>(SEQ ID NO:933)  |
| RHO-335 | UGGGGAAGGAGAGAGCUUGGUG<br>(SEQ ID NO:434)  | TGGGGAAGGAGAGAGCTTGGTG<br>(SEQ ID NO:934) |
| RHO-336 | GACUUGGAACGCGGCAGGGAGG<br>(SEQ ID NO:435)  | GACTTGAACGCGGCAGGGAGG<br>(SEQ ID NO:935)  |
| RHO-337 | AAGGAGAGAGCUUGGUGCUGGG<br>(SEQ ID NO:436)  | AAGGAGAGAGCTTGGTGCTGGG<br>(SEQ ID NO:936) |
| RHO-338 | GGGAAGGAGAGAGCUUGGUGCU<br>(SEQ ID NO:437)  | GGGAAGGAGAGAGCTTGGTGCT<br>(SEQ ID NO:937) |
| RHO-339 | AUUUGAGGAGGCCUUGGGGAAG<br>(SEQ ID NO:438)  | ATTTGAGGAGGCCTTGGGGAAG<br>(SEQ ID NO:938) |
| RHO-340 | AUCCAGCUGGAGCCUGAGUGG<br>(SEQ ID NO:439)   | ATCCAGCTGGAGCCCTGAGTGG<br>(SEQ ID NO:939) |
| RHO-341 | GAGAGCUUGGUGCUGGGAGGAG<br>(SEQ ID NO:440)  | GAGAGCTTGGTGCTGGGAGGAG<br>(SEQ ID NO:940) |
| RHO-342 | UCCUAGCUACCCUCUCCUGUC<br>(SEQ ID NO:441)   | TCCTAGCTACCCTCTCCCTGTC<br>(SEQ ID NO:941) |
| RHO-343 | CCGAGGCAGCAGCCUGGACAUG<br>(SEQ ID NO:442)  | CCGAGGCAGCAGCCTGGACATG<br>(SEQ ID NO:942) |
| RHO-344 | GGGGAAGGAGAGAGCUUGGUGC<br>(SEQ ID NO:443)  | GGGGAAGGAGAGAGCTTGGTG<br>(SEQ ID NO:943)  |
| RHO-345 | UGCUGGGAGGAGGGGGAAGGGG<br>(SEQ ID NO:444)  | TGCTGGGAGGAGGGGGAAGGGG<br>(SEQ ID NO:944) |

|         |                                           |                                           |
|---------|-------------------------------------------|-------------------------------------------|
| RHO-346 | CUUCUUGUGCUGGACGGUGACG<br>(SEQ ID NO:445) | CTTCTTGCTGGACGGTGACG<br>(SEQ ID NO:945)   |
| RHO-347 | UACCACACCCGUCGCAUUGGAG<br>(SEQ ID NO:446) | TACCACACCCGTCGCATTGGAG<br>(SEQ ID NO:946) |
| RHO-348 | AGCAGCCUGGACAUGGGGGAGA<br>(SEQ ID NO:447) | AGCAGCCTGGACATGGGGGAGA<br>(SEQ ID NO:947) |
| RHO-349 | AGCCAGGUAGUACUGUGGGUAC<br>(SEQ ID NO:448) | AGCCAGGTAGTACTGTGGGTAC<br>(SEQ ID NO:948) |
| RHO-350 | GGCUGCUUGCGGUUCUACAC<br>(SEQ ID NO:449)   | GGCTGCTTGCGGTTCTCAACAC<br>(SEQ ID NO:949) |
| RHO-351 | GGACCGAGGCAGCAGCCUGGAC<br>(SEQ ID NO:450) | GGACCGAGGCAGCAGCCTGGAC<br>(SEQ ID NO:950) |
| RHO-352 | CUGGGCAAAGAAUCCAGGGA<br>(SEQ ID NO:451)   | CTGGGCAAAGAAATTCAGGGA<br>(SEQ ID NO:951)  |
| RHO-353 | UGAGAGGGGAGGCAGAGGAUGC<br>(SEQ ID NO:452) | TGAGAGGGGAGGCAGAGGATGC<br>(SEQ ID NO:952) |
| RHO-354 | GAGGGUGCACUCCCCCUAGAC<br>(SEQ ID NO:453)  | GAGGGTGCACTCCCCCTAGAC<br>(SEQ ID NO:953)  |
| RHO-355 | CGGUUCUACACACCAGGAGACU<br>(SEQ ID NO:454) | CGGTTCTCAACACCAGGAGACT<br>(SEQ ID NO:954) |
| RHO-356 | UGUGCAAUGUUUUGCCCAGAGG<br>(SEQ ID NO:455) | TGTGCAATGTTTTGCCAGAGG<br>(SEQ ID NO:955)  |
| RHO-357 | GGGGGAGACAGGGCAAGGCUGG<br>(SEQ ID NO:456) | GGGGGAGACAGGGCAAGGCTGG<br>(SEQ ID NO:956) |
| RHO-358 | GCCGGGUGUGGGUGGGUGUGC<br>(SEQ ID NO:457)  | GCCGGGTGTGGGTGGGGTGTGC<br>(SEQ ID NO:957) |
| RHO-359 | CUGCGUACCACACCCGUCGCAU<br>(SEQ ID NO:458) | CTGCGTACCACACCCGTCGCAT<br>(SEQ ID NO:958) |
| RHO-360 | CACCCAAGAAUGCUGCGAAGGC<br>(SEQ ID NO:459) | CACCCAAGAATGCTGCGAAGGC<br>(SEQ ID NO:959) |
| RHO-361 | CCUAGCUACCCUCUCCUGUCU<br>(SEQ ID NO:460)  | CCTAGCTACCCTCTCCCTGTCT<br>(SEQ ID NO:960) |
| RHO-362 | CACCAGGAGACUUGGAACGCGG<br>(SEQ ID NO:461) | CACCAGGAGACTTGGAACGCGG<br>(SEQ ID NO:961) |
| RHO-363 | UUGGAUAACAUUGACAGGACAG<br>(SEQ ID NO:462) | TTGGATAACATTGACAGGACAG<br>(SEQ ID NO:962) |
| RHO-364 | UUCGGGCCACAGGAUGCAAUU<br>(SEQ ID NO:463)  | TTCGGGCCACAGGATGCAATT<br>(SEQ ID NO:963)  |
| RHO-365 | GAAGUAUCCAUGCAGAGAGGUG<br>(SEQ ID NO:464) | GAAGTATCCATGCAGAGAGGTG<br>(SEQ ID NO:964) |
| RHO-366 | GGUGUGCAGGAGCCCGGGAGCA<br>(SEQ ID NO:465) | GGTGTGCAGGAGCCCGGGAGCA<br>(SEQ ID NO:965) |
| RHO-367 | GGAGCAGCCACGGGUCAGCCAC<br>(SEQ ID NO:466) | GGAGCAGCCACGGGTCAGCCAC<br>(SEQ ID NO:966) |
| RHO-368 | AGCGCCUGCUGGGGCGUCACA<br>(SEQ ID NO:467)  | AGCGCCCTGCTGGGGCGTCACA<br>(SEQ ID NO:967) |
| RHO-369 | GAGCCCGGGAGCAUGGAGGGGU<br>(SEQ ID NO:468) | GAGCCCGGGAGCATGGAGGGGT<br>(SEQ ID NO:968) |
| RHO-370 | AGGGCCACAGCCAUGAAUGGCA<br>(SEQ ID NO:469) | AGGGCCACAGCCATGAATGGCA<br>(SEQ ID NO:969) |

|         |                                           |                                            |
|---------|-------------------------------------------|--------------------------------------------|
| RHO-371 | GCAAUGUGCAAUGUUUUGCCCA<br>(SEQ ID NO:470) | GCAATGTGCAATGTTTTGCCCA<br>(SEQ ID NO:970)  |
| RHO-372 | GAAGAGGUCAGCCACGGCUAGG<br>(SEQ ID NO:471) | GAAGAGGTCAGCCACGGCTAGG<br>(SEQ ID NO:971)  |
| RHO-373 | GGCCUUCGCAGCAUUCUUGGGU<br>(SEQ ID NO:472) | GGCCTTCGCAGCATTCTTGGGT<br>(SEQ ID NO:972)  |
| RHO-374 | UUAACAGAGAGGAAAACUGAGG<br>(SEQ ID NO:473) | TTAACAGAGAGGAAAACCTGAGG<br>(SEQ ID NO:973) |
| RHO-375 | UGAUGGCAUGGUUCUCCCCGAA<br>(SEQ ID NO:474) | TGATGGCATGGTTCTCCCCGAA<br>(SEQ ID NO:974)  |
| RHO-376 | ACCGAGGCAGCAGCCUGGACAU<br>(SEQ ID NO:475) | ACCGAGGCAGCAGCCTGGACAT<br>(SEQ ID NO:975)  |
| RHO-377 | AGGGACCACACGCUGAGGAGAG<br>(SEQ ID NO:476) | AGGGACCACACGCTGAGGAGAG<br>(SEQ ID NO:976)  |
| RHO-378 | UGGAACGCGGCAGGGAGGCUGG<br>(SEQ ID NO:477) | TGGAACGCGGCAGGGAGGCTGG<br>(SEQ ID NO:977)  |
| RHO-379 | UGCACAUUGCUUCAUGGCUCCU<br>(SEQ ID NO:478) | TGCACATTGCTTCATGGCTCCT<br>(SEQ ID NO:978)  |
| RHO-380 | GCGUCCAAGUCUCCUGGUGUU<br>(SEQ ID NO:479)  | GCGTTCCAAGTCTCCTGGTGT<br>(SEQ ID NO:979)   |
| RHO-381 | GGGUGUGCAGGAGCCCGGGAGC<br>(SEQ ID NO:480) | GGGTGTGCAGGAGCCCGGGAGC<br>(SEQ ID NO:980)  |
| RHO-382 | GGCAAAGAAAUUCCAGGGAAUG<br>(SEQ ID NO:481) | GGCAAAGAAATTCCAGGGAATG<br>(SEQ ID NO:981)  |
| RHO-383 | GGCUGGAGGGGCACCUGAGGAC<br>(SEQ ID NO:482) | GGCTGGAGGGGCACCTGAGGAC<br>(SEQ ID NO:982)  |
| RHO-384 | GCGCCUGCUGGGGCGUCACAC<br>(SEQ ID NO:483)  | GCGCCCTGCTGGGGCGTCACAC<br>(SEQ ID NO:983)  |
| RHO-385 | GCGUACCACACCCGUCGCAUUG<br>(SEQ ID NO:484) | GCGTACCACACCCGTCGCATTG<br>(SEQ ID NO:984)  |
| RHO-386 | ACCAGGAGACUUGGAACGCGGC<br>(SEQ ID NO:485) | ACCAGGAGACTTGAACGCGGC<br>(SEQ ID NO:985)   |
| RHO-387 | GCUGCUGCCUCGGUCCCAUUCU<br>(SEQ ID NO:486) | GCTGCTGCCTCGGTCCCATCT<br>(SEQ ID NO:986)   |
| RHO-388 | GAAGCCCUCCAAAUUGCAUCCU<br>(SEQ ID NO:487) | GAAGCCCTCCAAATTGCATCCT<br>(SEQ ID NO:987)  |
| RHO-389 | CGUAGAGCGUGAGGAAGUUGAU<br>(SEQ ID NO:488) | CGTAGAGCGTGAGGAAGTTGAT<br>(SEQ ID NO:988)  |
| RHO-390 | CUGAAGCAGUCCUUUUUGCUU<br>(SEQ ID NO:489)  | CTGAAGCAGTTCCTTTTGCTT<br>(SEQ ID NO:989)   |
| RHO-391 | GCUGGACGGUGACGUAGAGCGU<br>(SEQ ID NO:490) | GCTGGACGGTGACGTAGAGCGT<br>(SEQ ID NO:990)  |
| RHO-392 | UGAGGGCUUUGGAUAACAUUGA<br>(SEQ ID NO:491) | TGAGGGCTTTGGATAACATTGA<br>(SEQ ID NO:991)  |
| RHO-393 | AGCCGGGUGUGGGUGGGUGUG<br>(SEQ ID NO:492)  | AGCCGGGTGTGGGTGGGGTGTG<br>(SEQ ID NO:992)  |
| RHO-394 | CUCAGUUUUCUCUCUGUUAAG<br>(SEQ ID NO:493)  | CTCAGTTTTCTCTCTGTTAAG<br>(SEQ ID NO:993)   |
| RHO-395 | CAAGACAUUAUUCUAAAGCAAA<br>(SEQ ID NO:494) | CAAGACATTATTCTAAAGCAAA<br>(SEQ ID NO:994)  |

|         |                                            |                                            |
|---------|--------------------------------------------|--------------------------------------------|
| RHO-396 | UGGAACUUCAUGGGGUGGUGAG<br>(SEQ ID NO:495)  | TGGAAC TTCATGGGGTGGTGAG<br>(SEQ ID NO:995) |
| RHO-397 | GAGAGGGAUUUGAGGAGGCCUU<br>(SEQ ID NO:496)  | GAGAGGGATTTGAGGAGGCCTT<br>(SEQ ID NO:996)  |
| RHO-398 | CUUCGGGCCCCACAGGAUGCAAU<br>(SEQ ID NO:497) | CTTCGGGCCCCACAGGATGCAAT<br>(SEQ ID NO:997) |
| RHO-399 | ACUUGGAACGCGGCAGGGAGGC<br>(SEQ ID NO:498)  | ACTTGGAACGCGGCAGGGAGGC<br>(SEQ ID NO:998)  |
| RHO-400 | AUGGCCAGAGAUUCCUGAGAA<br>(SEQ ID NO:499)   | ATGGCCAGAGATTCCTGAGAA<br>(SEQ ID NO:999)   |
| RHO-401 | CCUCAGUUUCCUCUCUGUAA<br>(SEQ ID NO:500)    | CCTCAGTTTTCTCTCTGTAA<br>(SEQ ID NO:1000)   |
| RHO-402 | UAACAGAUCCACUUAACAGAG<br>(SEQ ID NO:501)   | TAACAGATCCCACTTAACAGAG<br>(SEQ ID NO:1001) |
| RHO-403 | GGGAGAGGGAUUUGAGGAGGCC<br>(SEQ ID NO:502)  | GGGAGAGGGATTTGAGGAGGCC<br>(SEQ ID NO:1002) |

### Incorporation by Reference

All publications, patents, and patent applications mentioned herein are hereby incorporated by reference in their entirety as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

### Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described herein. Such equivalents are intended to be encompassed by the following claims.

### Additional Sequences

Exemplary sequences that may be used in certain embodiments are set forth below:

#### AAV ITR:

TGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGC  
GACCTTTGGTCGCCCCGCCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCA  
TCACTAGGGGTTCTT (SEQ ID NO:92)

#### U6 Promoter:

AAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAA  
GGCTGTTAGAGAGATAATTAGAAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATA  
CGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAATTTATGTTTTAAATG  
GACTATCATATGCTTACCGTAACTTGAAAGTATTTGATTTCTTGGCTTTATATATCTTGTG  
GAAAGGACGAAACACC (SEQ ID NO:78)

**Exemplary saCas9 gRNA protospacer:**

CCCACACCCGGCTCATACCGCC (SEQ ID NO: 606)

**Guide RNA scaffold sequence:**

5 GTTATAGTACTCTGGAAACAGAATCTACTATAACAAGGCAAAATGCCGTGTTTATCTCGTCA  
 ACTTGTTGGCGAGA (SEQ ID NO: 12)

**Minimal RHO Promoter (250 bp):**

GTCACCTTGGCCCCCTCTTAGAAGCCAATTAGGCCCTCAGTTTCTGCAGCGGGGATTAATATG  
 ATTATGAACACCCCCAATCTCCCAGATGCTGATTTCAGCCAGGAGCTTAGGAGGGGGAGGTCA  
 10 CTTTATAAGGGTCTGGGGGGGTGAGAACCAGAGTCATCCAGCTGGAGCCCTGAGTGGCTGA  
 GCTCAGGCCCTTCGCAGCATTCTTGGGTGGGAGCAGCCACGGGTGAGCCACAAGGGCCACAGC  
 C (SEQ ID NO: 44)

**SV40 Intron:**

TCTAGAGGATCCGGTACTCGAGGAACTGAAAAACCAGAAAGTTAACTGGTAAGTTTATGCTT  
 15 TTTGTCTTTTATTTTTCAGGTCCCGGATCCGGTGGTGGTGCAAATCAAAGAACTGCTCCTCAGT  
 GGATGTTGCCTTTACTTCTAGGCCTGTACGGAAGTGTTAC (SEQ ID NO: 94)

**Codon Optimized RHO-encoding sequence 1 (Codon 1):**

ATGAACGGCACCGAGGGCCCCAACTTCTACGTCCCCTTCAGCAACGCCACCGGCGTTCGTCCG  
 CAGCCCCCTTCGAGTACCCCCAGTACTACCTGGCCGAGCCCTGGCAGTTCAGCATGCTGGCCG  
 20 CCTACATGTTCTGCTGATCGTCCTGGGCTTCCCCATCAACTTCCTGACCCCTGTACGTCACC  
 GTCCAGCACAGAAGCTGCGCACCCCCCTGAACTACATCCTGCTGAACCTGGCCGTGCGCCGA  
 CCTGTTTCATGGTCTGCGGGCTTCACCAGCACCCCTGTACACCAGCCTGCACGGCTACTTCG  
 TCTTCGGCCCCACCGGCTGCAACCTGGAGGGCTTCTTCGCCACCCTGGGCGGCGAGATCGCC  
 CTGTGGAGCCTGGTCTGCTGCTGGCCATCGAGCGCTACGTGCTCGTCTGCAAGCCCATGAGCAA  
 25 CTTCGCTTCGGCGAGAACCACGCCATCATGGGCGTCGCCTTCACCTGGGTTCATGGCCCTGG  
 CCTGCGCCGCCCCCCCCCTGGCCGGCTGGAGCCGCTACATCCCCGAGGGCCTGCAGTGCAGC  
 TGCGGCATCGACTACTACACCCTGAAGCCCCGAGGTCAACAACGAGAGCTTCGTTCATCTACAT  
 GTTCGTGCTCCACTTCACCATCCCCATGATCATCATCTTCTTCTGCTACGGCCAGCTGGTCT  
 TCACCGTCAAGGAGGCCGCCGCCAGCAGCAGGAGAGCGCCACCACCCAGAAGGCCGAGAAG  
 30 GAGGTCAACCGCATGGTCATCATCATGGTCATCGCCTTCCTGATCTGCTGGGTCCCCTACGC  
 CAGCGTCGCCTTCTACATCTTCACCCACCAGGGCAGCAACTTCGGCCCCATCTTCATGACCA  
 TCCCCGCCTTCTTCGCCAAGAGCGCCGCCATCTACAACCCCGTCATCTACATCATGATGAAC  
 AAGCAGTTCGCAACTGCATGCTGACCACCATCTGCTGCGGCAAGAACCCCCCTGGGCGACGA  
 CGAGGCCAGCGCCACCGTCAGCAAGACCGAGACCAGCCAGGTGCCCCCGCCTAA (SEQ  
 35 ID NO: 13)

**Codon Optimized RHO-encoding sequence 2 (Codon 2):**

ATGAACGGCACCGAGGGCCCCAACTTCTACGTGCCCTTCTCCAACGCCACCGGCGTGGTGCG  
 CTCCCCCTTCGAGTACCCCCAGTACTACCTGGCCGAGCCCTGGCAGTTCCTCATGCTGGCCG  
 CCTACATGTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTGACCCCTGTACGTGACC  
 40 GTGCAGCACAGAAGCTGCGCACCCCCCTGAACTACATCCTGCTGAACCTGGCCGTGGCCGA  
 CCTGTTTCATGGTCTGCGGGCTTCACCTCCACCCTGTACACCTCCCTGCACGGCTACTTCG  
 TGTTTCGGCCCCACCGGCTGCAACCTGGAGGGCTTCTTCGCCACCCTGGGCGGCGAGATCGCC  
 CTGTGGTCCCTGGTGGTGGTGGCCATCGAGCGCTACGTGGTGGTGTGCAAGCCCATGTCCAA  
 CTTCGCTTCGGCGAGAACCACGCCATCATGGGCGTGGCCTTCACCTGGGTGATGGCCCTGG  
 45 CCTGCGCCGCCCCCCCCCTGGCCGGCTGGTCCCGCTACATCCCCGAGGGCCTGCAGTGTCTCC

TGCGGCATCGACTACTACACCCTGAAGCCCGAGGTGAACAACGAGTCCTTCGTGATCTACAT  
 GTTCGTGGTGCACCTTACCATCCCCATGATCATCATCTTCTTCTGCTACGGCCAGCTGGTGT  
 TCACCGTGAAGGAGGCCGCCGCCAGCAGCAGGAGTCCGCCACCACCCAGAAGGCCGAGAAG  
 GAGGTGACCCGCATGGTGATCATCATGGTGATCGCCTTCCTGATCTGCTGGGTGCCCTACGC  
 5 CTCCGTGGCCTTCTACATCTTACCCACCAGGGCTCCAACCTTCGGCCCCATCTTCATGACCA  
 TCCCCGCCTTCTTCGCCAAGTCCGCCGCCATCTACAACCCCGTGATCTACATCATGATGAAC  
 AAGCAGTTCCGCAACTGCATGCTGACCACCATCTGCTGCGGCAAGAACCCCTGGGCGACGA  
 CGAGGCCTCCGCCACCGTGTCCAAGACCGAGACCTCCAGGTGGCCCCCGCCTAA (SEQ  
 ID NO: 14)

10 **Codon Optimized RHO-encoding sequence 3 (Codon 3):**

ATGAACGGCACCGAGGGCCCCAACTTCTACGTCCCCTTCAGCAACGCCACCGGGCTCGTCCG  
 CAGCCCCCTTCGAGTACCCCCAGTACTACCTGGCCGAGCCCTGGCAGTTCTCTATGCTGGCCG  
 CCTACATGTTCTGCTGATCGTCCTGGGCTTCCCTATCAACTTCCTCACCTCTACGTCACC  
 GTCCAGCACAAGAAGCTCCGCACCCCTCTCAACTACATCCTCCTTAACCTTGCCGTCGCCGA  
 15 CCTTTTCATGGTCCTTGGCGGGCTTACCTCTACTCTTTACACTTCTTTGCACGGGTACTTCG  
 TGTTCCGTCCTACTGGTTGCAACTTGGAGGGTTTCTTCGCCACTTGGGTGGTGAGATCGCC  
 TTGTGGTCGTTGGTGGTGTAGCTATCGAGCGATACGTGGTGGTGTGCAAGCCTATGTGCAA  
 CTTCCGGTTCGGTGAGAATCATGCTATCATGGGAGTGGCTTTTACTTGGGTGATGGCTTTAG  
 CTTGCGCTGCTCCTCCGTTAGCTGGATGGTCGCGTTATATCCCGGAGGGATTACAGTGCTCA  
 20 TGCGGAATCGACTATTATACTCTAAAGCCGGAAGTTAATAATGAATCATTTGTTATTTATAT  
 GTTTGTTGTTTCAATTTTACAATTCCGATGATTATTATTTTTTTTTTGTATGGACAGCTAGTTT  
 TTACAGTTAAGGAAGCAGCAGCACAGCAACAAGAATCAGCAACAACACAAAAGGCAGAAAAA  
 GAAGTTACAAGGATGGTTATTATTATGGTAATTGCATTTCTAATATGTTGGGTACCGTATGC  
 ATCCGTAGCATTTTATATATTTACACATCAAGGGTCCAATTTTGGGCCAATATTTATGACGA  
 25 TACCAGCGTTTTTTTTGCGAAATCCGCGGCGATATATAATCCAGTAATATATATAATGATGAAT  
 AAACAATTTAGAAATTGTATGCTAACGACGATATGTTGTGGGAAAAATCCACTAGGGGATGA  
 TGAAGCGAGTGCGACGGTAAGTAAAACGGAAACGAGTCAAGTAGCGCCAGCGTAA (SEQ  
 ID NO: 15)

**Codon Optimized RHO-encoding sequence 4 (Codon 4):**

30 ATGAACGGCACCGAGGGTCCCAATTTCTACGTCCCATTTTCCAACGCCACGGGGGTGGTACG  
 CAGCCCTTTCGAATATCCGCAGTACTATCTGGCTGAGCCCTGGCAGTTTTCTATGCTCGCAG  
 CGTACATGTTCTTGCTAATCGTTCTGGGATTTCCAATTAATTTCTCACATTGTATGTCACC  
 GTGCAGCACAAGAAGCTACGGACGCCTCTGAACCTACATCCTCTTGAATCTAGCCGTCGCTGA  
 CCTGTTTATGGTTCTCGGCGGGTTTACATCGACCTTGTATACGTCACTACATGGGTACTTTG  
 35 TCTTCGGACCGACAGGCTGCAACCTGGAAGGTTTTTTTCGCAACCCTCGGGGGAGAGATTGCG  
 TTGTGGTCCCTAGTGGTACTGGCCATCGAAAGGTATGTTGTGCTGTGTAAGCCCATGAGCAA  
 TTTTCGCTTCGGCGAGAACCACGCTATTATGGGTGTAGCATTTACGTGGGTATGGCGCTCG  
 CCTGCGCTGCACCACCTTTGGCGGGGTGGTCTCGGTACATCCCGGAAGGACTACAGTGTTCG  
 TGCGGCATTGATTATTACACACTGAAGCCCGAGGTCAATAACGAATCATTCGTGATCTATAT  
 40 GTTTGTAGTTTCAATTTACCATTCCAATGATCATTATCTTTTTCTGTTACGGTCAGCTCGTCT  
 TTACGGTGAAGGAGGCCGCTGCACAGCAGCAGGAATCCGCGACAACCCAGAAGGCCGAGAAG  
 GAAGTAACGAGGATGGTTATTATCATGGTCATTGCTTTCTTGATCTGCTGGGTGCCCTTATGC  
 AAGCGTAGCGTTTTTACATTTTACACACCAGGGGTCTAATTTTGGACCGATCTTCATGACCA  
 TTCCCGCCTTTTTTCGCTAAGTCGGCAGCGATCTATAACCCAGTTATTTACATCATGATGAAT  
 45 AAGCAGTTTCGCAACTGTATGCTAACGACAATTTGCTGTGGCAAGAATCCTCTGGGTGACGA

TGAGGCCTCAGCTACCGTCTCCAAGACGGAAACAAGCCAGGTGGCACCGGCGTAA (SEQ ID NO: 16)

**Codon Optimized RHO-encoding sequence 5 (Codon 5):**

ATGAATGGGACTGAAGGACCTAATTTCTATGTGCCATTTAGCAATGCTACTGGCGTTGTCAG  
 5 AAGCCCCCTTCGAATATCCACAATACTATCTGGCCGAACCTTGGCAGTTCAGCATGCTCGCTG  
 CCTATATGTTTCTGCTGATTGTGCTGGGCTTTCCCATAAATTTCCCTCACCCTGTATGTTACT  
 GTTCAACACAAAAAGCTGCGGACGCCTCTGAACTACATACTGCTGAACCTGGCCGTCGCCGA  
 CCTGTTTATGGTCCTGGGAGGCTTTACAAGCACTCTGTATACAAGCCTGCACGGCTACTTCG  
 TGTTCCGCCCCACAGGCTGCAACCTCGAAGGCTTCTTTGCCACCCTCGGAGGAGAGATTGCC  
 10 CTGTGGAGCCTGGTGGTGTGCTGGCCATCGAAAGGTATGTGGTGGTGTGTAAACCCATGTCCAA  
 TTTTCCGTTCCGGCGAGAACCACGCTATTATGGGAGTGGCTTTCACTTGGGTGATGGCCCTGG  
 CCTGCGCCGCCCCACCACTGGCCGGGTGGAGCCGGTACATCCAGAGGGGCTGCAATGTAGC  
 TGCGGAATCGACTATTATACCCTGAAACCAGAGGTGAACAACGAGAGCTTTGTGATTTATAT  
 GTTTGTGGTGCATTTTACAATTCCTATGATTATCATTTTCTTCTGTTACGGGCAACTGGTGT  
 15 TTACCGTGAAGGAAGCCGCGCTCAACAGCAGGAGAGCGCCACAACCCAAAAGGCCGAGAAG  
 GAGGTGACCAGAATGGTGATTATTATGGTGATCGCTTTTCTGATTGTGCTGGGTGCCATACGC  
 TAGCGTCGCTTTCTATATTTTCACTCACCAGGGGAGCAACTTCGGCCCCATTTTCATGACAA  
 TCCCTGCCTTTTTTGTAAAAGCGCCGCCATCTATAACCCAGTGATCTACATCATGATGAAC  
 AAACAGTTTAGGAACTGTATGCTCACAACAATCTGCTGTGGAAAGAACCCCTCGGCGATGA  
 20 CGAAGCCAGCGCCACCGTCAGCAAGACAGAAACAAGCCAGGTGGCCCCTGCCTAA (SEQ  
 ID NO: 17)

**Codon Optimized RHO-encoding sequence 6 (Codon 6):**

ATGAATGGCACAGAGGGCCCTAACTTCTACGTGCCCTTTAGCAATGCCACAGGCGTCGTGCG  
 GAGCCCTTTTGAGTACCCTCAGTACTATCTGGCCGAGCCTTGGCAGTTTAGCATGCTGGCCG  
 25 CCTACATGTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTTCTGACCCTGTACGTGACC  
 GTGCAGCACAGAAGCTGCGGACCCCTCTGAACTACATCCTGCTGAATCTGGCCGTGGCCGA  
 CCTGTTTATGGTGCTCGGCGGCTTTACCAGCACACTGTACACAAGCCTGCACGGCTACTTCG  
 TGTTTGGCCCCACCGGCTGCAATCTGGAAGGCTTTTTTGGCACACTCGGCGGCGAAATTGCT  
 CTGTGGTCACTGGTGGTGTGCTGGCCATCGAGAGATACGTGGTGTGTGCAAGCCCATGAGCAA  
 30 CTTCAGATTCCGCGAGAACCACGCCATCATGGGCGTCGCCTTTACATGGGTTATGGCCCTGG  
 CTTGTGCAGCTCCTCCTCTTGCCGGCTGGTCCAGATATATTCTGAGGGCCTGCAGTGCAGC  
 TGCGGCATCGATTACTACACCCTGAAGCCTGAAGTGAACAACGAGAGCTTCGTGATCTACAT  
 GTTTGTGGTGCATTCACGATCCCCATGATCATCATATTCTTTTGTACGGCCAGCTGGTGT  
 TCACCGTGAAAGAAGCCGCTGCTCAGCAGCAAGAGAGCGCCACAACACAGAAAGCCGAGAAA  
 35 GAAGTGACCCGGATGGTCATTATCATGGTTATCGCCTTTCTGATCTGTTGGGTGCCCTACGC  
 CAGCGTGGCCTTCTACATCTTTACCCACCAAGGCAGCAACTTCGGCCCCATCTTTATGACAA  
 TCCCCGCCTTCTTTGCCAAGAGCGCCGCCATCTACAACCCCGTGATCTATATCATGATGAAC  
 AAGCAGTTCGCAACTGCATGCTGACCACCATCTGCTGCGGAAAGAACCCTCTGGGAGATGA  
 TGAGGCCAGCGCCACCGTGTCTAAGACCGAAACATCTCAGGTGGCCCCTGCATGA (SEQ  
 40 ID NO: 18)

**Hemoglobin A1 (HBA1) 3' UTR:**

GCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCAGCCCCCTCCTCCCCTT  
 CCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGCA (SEQ ID  
 NO: 38)

45

**Minimal UTR (minPolyA):**

TAGCAATAAAGGATCGTTTATTTTCATTGGAAGCGTGTGTTGGTTTTTTTGATCAGGCGCG  
(SEQ ID NO:56)

**Inverted ITR sequence:**

5 AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCC  
GGGCGACCAAAGGTCGCCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGC  
GCGCAGCTGCCTGCA (SEQ ID NO:93)

**Exemplary replacement vector (250 bp minimal RHO promoter driving codon-optimized RHO cDNA; U6 promoter driving gRNA targeting RHO) (see Fig. 16 for feature**

10 **annotation):**  
TGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGC  
GACCTTTGGTCGCCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCA  
TCACTAGGGGTTCTCTGCGGCCGCGGTTCTCAGATCTGAATTCGGTACCAAGGTCGGGCAGG  
AAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAG  
15 ATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAA  
GTAATAATTTCTTGGGTAGTTTGCAGTTTTTAAAATTATGTTTTAAAATGGACTATCATATGC  
TTACCGTAACTTGAAAGTATTTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAAC  
ACCGCCACACCCGGCTCATACCGCCGTTATAGTACTCTGGAAACAGAATCTACTATAACAA  
GGCAAAATGCCGTGTTTATCTCGTCAACTTGTTGGCGAGATTTTTTTCGACTTAGTTCGATCG  
20 AAGGAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGAT  
ACAAGGCTGTTAGAGAGATAAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAA  
AATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTTAAAATTATGTTTTAA  
AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTTCGATTTCTTGGCTTTATATATCT  
TGTGGAAAGGACGAAACACCGCCACACCCGGCTCATACCGCCGTTATAGTACTCTGGAAAC  
25 AGAATCTACTATAACAAGGCAAAATGCCGTGTTTATCTCGTCAACTTGTTGGCGAGATTTTT  
TGGTACCGCTAGCGCTGTCACCTTGGCCCCCTCTAGAAGCCAATTAGGCCCTCAGTTTCTGC  
AGCGGGGATTAATATGATTATGAACACCCCCAATCTCCAGATGCTGATTACAGCCAGGAGCT  
TAGGAGGGGGAGGTCACCTTATAAGGGTCTGGGGGGGTGAGAACCAGAGTCATCCAGCTGG  
AGCCCTGAGTGGCTGAGCTCAGGCCTTCGCAGCATTCTTGGGTGGGAGCAGCCACGGGTCAG  
30 CCACAAGGGCCACAGCCTCTAGAGGATCCGGTACTCGAGGAAGTGAACCAAGCAAGTTAA  
CTGGTAAGTTTAGTCTTTTTGTCTTTTATTTTCAGGTCCCGGATCCGGTGGTGGTGCATCA  
AAGAACTGCTCCTCAGTGGATGTTGCCTTTACTTCTAGGCCTGTACGGAAGTGTACTCCGC  
CACCATGAATGGCACAGAGGGCCCTAACTTCTACGTGCCCTTTAGCAATGCCACAGGCGTCG  
TGCGGAGCCCTTTTGGTACCCCTCAGTACTATCTGGCCGAGCCTTGGCAGTTTAGCATGCTG  
35 GCCGCCTACATGTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTTCTGACCCTGTACGT  
GACCGTGCAGCACAAAGAGCTGCGGACCCCTCTGAACTACATCCTGCTGAATCTGGCCGTGG  
CCGACCTGTTTATGGTGCTCGGCGGCTTTACCAGCACACTGTACACAAGCCTGCACGGCTAC  
TTCGTGTTTGGCCCCACCGGCTGCAATCTGGAAGGCTTTTTTGGCACACTCGGCGGCGAAAT  
TGCTCTGTGGTCACTGGTGGTGTGGCCATCGAGAGATACGTGGTCTGTGCAAGCCCATGA  
40 GCAACTTCAGATTCGGCGAGAACCACGCCATCATGGGCGTCGCCTTTACATGGGTTATGGCC  
CTGGCTTGTGCAGCTCCTCCTCTTGCCGGCTGGTCCAGATATATTCCTGAGGGCCTGCAGTG  
CAGCTGCGGCATCGATTACTACACCCTGAAGCCTGAAGTGAACAACGAGAGCTTCGTGATCT  
ACATGTTTGTGGTGCACTTCACGATCCCCATGATCATCATATTCTTTTGCTACGGCCAGCTG  
GTGTTACACCGTGAAAGAAGCCGCTGCTCAGCAGCAAGAGAGCGCCACAACACAGAAAGCCGA  
45 GAAAGAAGTGACCCGGATGGTCATTATCATGGTTATCGCCTTTCTGATCTGTTGGGTGCCCT  
ACGCCAGCGTGGCCTTCTACATCTTTACCCACCAAGGCAGCAACTTCGGCCCCATCTTTATG

ACAATCCCCGCCTTCTTTGCCAAGAGCGCCGCCATCTACAACCCCGTGATCTATATCATGAT  
 GAACAAGCAGTTCCGCAACTGCATGCTGACCACCATCTGCTGCGGAAAGAACCCTCTGGGAG  
 ATGATGAGGCCAGCGCCACCGTGTCTAAGACCGAAACATCTCAGGTGGCCCCTGCATGAGCT  
 GGAGCCTCGGTGGCCATGCTTCTTGCCCCCTTGGGCCTCCCCCAGCCCCTCCTCCCCCTTCCT  
 5 GCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGCACATGCTGGGGAGAGAT  
 CTGCGGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCT  
 CACTGAGGCCGGGCGACCAAAGGTCGCCCAGCGCCGGGCTTTGCCCGGGCGGCCTCAGTGA  
 GCGAGCGAGCGCGCAGCTGCCTGCA (SEQ ID NO:11)

Cas9 Vector 2 (250 bp minimal RHO promoter driving Cas9 w/ alpha globin UTR) (see Fig.  
 10 17 for feature annotation):

CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGG  
 GCGACCTTTGGTTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACCTC  
 CATCACTAGGGGTTCTTAAGCGGGCGCGGTTCTCAGATCTGAATTCGGTACCTGTACCTT  
 GGCCCCCTCTTAGAAGCCAATTAGGCCCTCAGTTTCTGCAGCGGGGATTAATATGATTATGAA  
 15 CACCCCCAATCTCCAGATGCTGATTAGCCAGGAGCTTAGGAGGGGGAGGTCACTTTATAA  
 GGGTCTGGGGGGGTGAGAACCAGAGTCATCCAGCTGGAGCCCTGAGTGGCTGAGCTCAGGC  
 CTTCGCAGCATTCTTGGGTGGGAGCAGCCACGGGTGAGCCACAAGGGCCACAGCCTCTAGAG  
 GATCCGGTACTCGAGGAAGTGAACCAAGGAAAGTTAACTGGTAAGTTTAGTCTTTTTTGTCT  
 TTTATTTTCAAGTCCCGGATCCGGTGGTGGTGCAATCAAAGAACTGCTCCTCAGTGGATGTT  
 20 GCCTTTACTTCTAGGCCTGTACGGAAGTGTTACTCCGCCACCATGGGACCGAAGAAAAAGCG  
 CAAGGTGGAAGCGTCCATGAAAAGGAACTACATTCTGGGGCTGGACATCGGGATTACAAGCG  
 TGGGGTATGGGATTATTGACTATGAAACAAGGGACGTGATCGACGCAGGCGTCAGACTGTTT  
 AAGGAGGCCAACGTGGAAAACAATGAGGGACGGAGAAGCAAGAGGGGAGCCAGGCGCCTGAA  
 ACGACGGAGAAGGCACAGAATCCAGAGGGTGAAGAACTGCTGTTTCGATTACAACCTGCTGA  
 25 CCGACCATTCTGAGCTGAGTGGAATTAATCCTTATGAAGCCAGGGTGAAGGCCTGAGTCAG  
 AAGCTGTCAGAGGAAGAGTTTTCCGCAGCTCTGCTGCACCTGGCTAAGCGCCGAGGAGTGCA  
 TAACGTCAATGAGGTGGAAGAGGACACCGGCAACGAGCTGTCTACAAAGGAACAGATCTCAC  
 GCAATAGCAAAGCTCTGGAAGAGAAGTATGTCGCAGAGCTGCAGCTGGAACGGCTGAAGAAA  
 GATGGCGAGGTGAGAGGGTCAATTAATAGGTTCAAGACAAGCGACTACGTCAAAGAAGCCAA  
 30 GCAGCTGCTGAAAGTGAGAAGGCTTACCACCAGCTGGATCAGAGCTTCATCGATACTTATA  
 TCGACCTGCTGGAGACTCGGAGAACCTACTATGAGGGACCAGGAGAAGGGAGCCCCCTTCGGA  
 TGGAAGACATCAAGGAATGGTACGAGATGCTGATGGGACATTGCACCTATTTTCCAGAAGA  
 GCTGAGAAGCGTCAAGTACGCTTATAACGCAGATCTGTACAACGCCCTGAATGACCTGAACA  
 ACCTGGTCATCACAGGGATGAAAACGAGAACTGGAATACTATGAGAAGTTCCAGATCATC  
 35 GAAAACGTGTTTAAAGCAGAAGAAAAAGCCTACACTGAAACAGATTGCTAAGGAGATCCTGGT  
 CAACGAAGAGGACATCAAGGGCTACCGGGTGACAAGCACTGGAACCAAGAGTTCCACCAATC  
 TGAAAGTGTATCACGATATTAAGGACATCACAGCACGGAAAGAAATCATTGAGAACGCCGAA  
 CTGCTGGATCAGATTGCTAAGATCCTGACTATCTACCAGAGCTCCGAGGACATCCAGGAAGA  
 GCTGACTAACCTGAACAGCGAGCTGACCCAGGAAGAGATCGAACAGATTAGTAATCTGAAGG  
 40 GGTACACCGGAACACACAACCTGTCCCTGAAAGCTATCAATCTGATTCTGGATGAGCTGTGG  
 CATACAAACGACAATCAGATTGCAATCTTTAACCGGCTGAAGCTGGTCCCAAAAAGGTGGA  
 CCTGAGTCAGCAGAAAGAGATCCCAACCACACTGGTGGACGATTTCAATCTGTACCCCGTGG  
 TCAAGCGGAGCTTCATCCAGAGCATCAAAGTGATCAACGCCATCATCAAGAAGTACGGCCTG  
 CCCAATGATATCATTATCGAGCTGGCTAGGGAGAAGAACAGCAAGGACGCACAGAAGATGAT  
 45 CAATGAGATGCAGAAACGAAACCGGCAGACCAATGAACGCATTGAAGAGATTATCCGAACCTA  
 CCGGGAAAGAGAACGCAAAGTACCTGATTGAAAAAATCAAGCTGCACGATATGCAGGAGGGA  
 AAGTGTCTGTATTCTCTGGAGGCCATCCCCCTGGAGGACCTGCTGAACAATCCATTCAACTA

CGAGGTTCGATCATATTATCCCCAGAAGCGTGTCTTCGACAATTCTTTAACAACAAGGTGC  
 TGGTCAAGCAGGAAGAGAACTCTAAAAAGGGCAATAGGACTCCTTTCCAGTACCTGTCTAGT  
 TCAGATTCCAAGATCTCTTACGAAACCTTTAAAAAGCACATTCTGAATCTGGCCAAAGGAAA  
 GGGCCGCATCAGCAAGACCAAAAAGGAGTACCTGCTGGAAGAGCGGGACATCAACAGATTCT  
 5 CCGTCCAGAAGGATTTTATTAACCGGAATCTGGTGGACACAAGATACGCTACTCGCGGCCTG  
 ATGAATCTGCTGCGATCCTATTTCCGGGTGAACAATCTGGATGTGAAAGTCAAGTCCATCAA  
 CGGCGGGTTCACATCTTTTCTGAGGCGCAAATGGAAGTTTAAAAAGGAGCGCAACAAAGGGT  
 ACAAGCACCATGCCGAAGATGCTCTGATTATCGCAAATGCCGACTTCATCTTTAAGGAGTGG  
 AAAAGCTGGACAAAGCCAAGAAAGTGATGGAGAACCAGATGTTTCAAGAGAAGCAGGCCGA  
 10 ATCTATGCCCGAAATCGAGACAGAACAGGAGTACAAGGAGATTTTCATCACTCCTCACCAGA  
 TCAAGCATATCAAGGATTTCAAGGACTACAAGTACTCTCACCAGGTGGATAAAAAGCCCAAC  
 AGAGAGCTGATCAATGACACCCTGTATAGTACAAGAAAAGACGATAAGGGGAATACCCTGAT  
 TGTGAACAATCTGAACGGACTGTACGACAAAGATAATGACAAGCTGAAAAAGCTGATCAACA  
 AAAGTCCCGAGAAGCTGCTGATGTACCACCATGATCCTCAGACATATCAGAACTGAAGCTG  
 15 ATTATGGAGCAGTACGGCGACGAGAAGAACCCACTGTATAAGTACTATGAAGAGACTGGGAA  
 CTACCTGACCAAGTATAGCAAAAAGGATAATGGCCCCGTGATCAAGAAGATCAAGTACTATG  
 GGAACAAGCTGAATGCCCATCTGGACATCACAGACGATTACCCTAACAGTCGCAACAAGGTG  
 GTCAAGCTGTCACTGAAGCCATACAGATTCTGATGTCTATCTGGACAACGGCGTGTATAAATT  
 TGTGACTGTCAAGAATCTGGATGTCATCAAAAAGGAGAACTACTATGAAGTGAATAGCAAGT  
 20 GCTACGAAGAGGCTAAAAAGCTGAAAAAGATTAGCAACCAGGCAGAGTTCATCGCCTCCTTT  
 TACAACAACGACCTGATTAAGATCAATGGCGAACTGTATAGGGTCATCGGGGTGAACAATGA  
 TCTGCTGAACCGCATTGAAGTGAATATGATTGACATCACTTACCGAGAGTATCTGGAAAACA  
 TGAATGATAAGCGCCCCCTCGAATTATCAAAACAATTGCCTCTAAGACTCAGAGTATCAAA  
 AAGTACTCAACCGACATTCTGGGAAACCTGTATGAGGTGAAGAGCAAAAAGCACCCCTCAGAT  
 25 TATCAAAAAGGGCGGATCCCCAAGAAGAAGAGGAAAGTCTCGAGCTAGGCTGGAGCCTCGG  
 TGGCCATGCTTCTTGCCCCCTGGGCCTCCCCCAGCCCCCTCCTCCCCTTCTGCACCCGTAC  
 CCCCCTGGTCTTTGAATAAAGTCTGAGTGGGCGGCACATGCTGGGGAGAGATCTGCGGCCGC  
 CTAGCAATAAAGGATCGTTTATTTTTCATTGGAAGCGTGTGTTGGTTTTTTTGATCAGGCGCGA  
 GGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCG  
 30 GGCGACCAAAGGTGCGCCGACGCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCG  
 CGCAGCTGCCTGCAGG (SEQ ID NO:10)

**Cas9 Vector 1 (550 bp minimal RHO promoter driving wt Cas9 with SV40 polyA signal)**  
 (see **Fig. 18** for feature annotation):

CCTGCAGGCAGCTGCGCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTTCGG  
 35 GCGACCTTTGGTCGCCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTC  
 CATCACTAGGGGTTCTAAGCGGCGCGGTTCTCAGATCTGAATTCTCATGTTACAGGCAG  
 GGAGACGGGCACAAAACACAAATAAAAAGCTTCCATGCTGTCAGAAGCACTATGCAAAAAGC  
 AAGATGCTGAGGTCATGGAGCTCCTCCTGTCAGAGGAGTGTGGGGACTGGATGACTCCAGAG  
 GTAACCTTGTGGGGGAACGAACAGGTAAGGGGCTGTGTGACGAGATGAGAGACTGGGAGAATA  
 40 AACCAGAAAGTCTCTAGCTGTCCAGAGGACATAGCACAGAGGCCCATGGTCCCTATTTCAAA  
 CCCAGGCCACCAGACTGAGCTGGGACCTTGGGACAGACAAGTCATGCAGAAGTTAGGGGACC  
 TTCTCCTCCCTTTTCTGGATCCTGAGTACCTCTCCTCCCTGACCTCAGGCTTCCTCCTAGT  
 GTCACCTTGGCCCCCTCTTAGAAGCCAATTAGGCCCTCAGTTTCTGCAGCGGGGATTAATATG  
 ATTATGAACACCCCCAATCTCCCAGATGCTGATTACAGCCAGGAGCTTAGGAGGGGGAGGTCA  
 45 CTTTATAAGGGTCTGGGGGGGTGAGAACCAGAGTCATCCAGCTGGAGCCCTGAGTGGCTGA  
 GCTCAGGCCCTTCGACGATTCTTGGGTGGGAGCAGCCACGGGTGAGCCACAATCTAGAGGAT  
 CCGGTACTCGAGGAACTGAAAAACCAGAAAGTTAACTGGTAAGTTTAGTCTTTTTGTCTTTT

ATTTTCAGGTCCCGGATCCGGTGGTGGTGCAAATCAAAGAAGCTGCTCCTCAGTGGATGTTGCC  
TTTACTTCTAGGCCTGTACGGAAGTGTTACGCGGCCGCCACCATGGGACCGAAGAAAAAGCG  
CAAGGTCTGAAGCGTCCATGAAAAGGAACTACATTCTGGGGCTGGACATCGGGATTACAAGCG  
TGGGGTATGGGATTATTGACTATGAAACAAGGGACGTGATCGACGCAGGCGTCAGACTGTTT  
5 AAGGAGGCCAACGTGGAAAACAATGAGGGACGGAGAAGCAAGAGGGGAGCCAGGCGCCTGAA  
ACGACGGAGAAGGCACAGAATCCAGAGGGTGAAGAACTGCTGTTTCGATTACAACCTGCTGA  
CCGACCATTCTGAGCTGAGTGGAAATTAATCCTTATGAAGCCAGGGTGAAGGCCTGAGTCAG  
AAGCTGTCAGAGGAAGAGTTTTCCGCAGCTCTGCTGCACCTGGCTAAGCGCCGAGGAGTGCA  
TAACGTCAATGAGGTGGAAGAGGACACCGGCAACGAGCTGTCTACAAAGGAACAGATCTCAC  
10 GCAATAGCAAAGCTCTGGAAGAGAAGTATGTCGCAGAGCTGCAGCTGGAACGGCTGAAGAAA  
GATGGCGAGGTGAGAGGGTCAATTAATAGGTTCAAGACAAGCGACTACGTCAAAGAAGCCAA  
GCAGCTGCTGAAAGTGCAGAAGGCTTACCACCAGCTGGATCAGAGCTTCATCGATACTTATA  
TCGACCTGCTGGAGACTCGGAGAACCTACTATGAGGGACCAGGAGAAGGGAGCCCCCTTCGGA  
TGGAAGACATCAAGGAATGGTACGAGATGCTGATGGGACATTGCACCTATTTTCCAGAAGA  
15 GCTGAGAAGCGTCAAGTACGCTTATAACGCAGATCTGTACAACGCCCTGAATGACCTGAACA  
ACCTGGTCATCACCAGGGATGAAAACGAGAACTGGAATACTATGAGAAGTTCAGATCATC  
GAAAACGTGTTTAAAGCAGAAGAAAAAGCCTACACTGAAACAGATTGCTAAGGAGATCCTGGT  
CAACGAAGAGGACATCAAGGGCTACCGGGTGACAAGCACTGGAAAACCAGAGTTTACCAATC  
TGAAAGTGTATCACGATATTAAGGACATCACAGCACGGAAAGAAATCATTGAGAACGCCGAA  
20 CTGCTGGATCAGATTGCTAAGATCCTGACTATCTACCAGAGCTCCGAGGACATCCAGGAAGA  
GCTGACTAACCTGAACAGCGAGCTGACCCAGGAAGAGATCGAACAGATTAGTAATCTGAAGG  
GGTACACCGGAACACACAACCTGTCCCTGAAAGCTATCAATCTGATTCTGGATGAGCTGTGG  
CATACAAACGACAATCAGATTGCAATCTTTAACCGGCTGAAGCTGGTCCCAAAAAGGTGGA  
CCTGAGTCAGCAGAAAGAGATCCCAACCACACTGGTGGACGATTTTCAATCTGTCACCCGTGG  
25 TCAAGCGGAGCTTCATCCAGAGCATCAAAGTGATCAACGCCATCATCAAGAAGTACGGCCTG  
CCCAATGATATCATTATCGAGCTGGCTAGGGAGAAGAACAGCAAGGACGCACAGAAGATGAT  
CAATGAGATGCAGAAACGAAACCGGCAGACCAATGAACGCATTGAAGAGATTATCCGAACTA  
CCGGGAAAGAGAACGCAAAGTACCTGATTGAAAAAATCAAGCTGCACGATATGCAGGAGGGA  
AAGTGTCTGTATTCTCTGGAGGCCATCCCCCTGGAGGACCTGCTGAACAATCCATTCAACTA  
30 CGAGGTGATCATATTATCCCCAGAAGCGTGTCTTCGACAATTCCTTTAACAACAAGGTGC  
TGGTCAAGCAGGAAGAGAAGCTCTAAAAAGGGCAATAGGACTCCTTTCCAGTACCTGTCTAGT  
TCAGATTCCAAGATCTCTTACGAAACCTTTAAAAAGCACATTCTGAATCTGGCCAAAGGAAA  
GGGCCGCATCAGCAAGACCAAAAAGGAGTACCTGCTGGAAGAGCGGGACATCAACAGATTCT  
CCGTCCAGAAGGATTTTATTAACCGGAATCTGGTGGACACAAGATACGCTACTCGCGGCCCTG  
35 ATGAATCTGCTGCGATCCTATTTCCGGGTGAACAATCTGGATGTGAAAGTCAAGTCCATCAA  
CGGCGGGTTCACATCTTTTCTGAGGCGCAAATGGAAGTTTAAAAAGGAGCGCAACAAAGGT  
ACAAGCACCATGCCGAAGATGCTCTGATTATCGCAAATGCCGACTTCATCTTTAAGGAGTGG  
AAAAAGCTGGACAAAGCCAAGAAAGTGATGGAGAACCAGATGTTTCAAGAGAAGCAGGCCGA  
ATCTATGCCCCGAAATCGAGACAGAACAGGAGTACAAGGAGATTTTCATCACTCCTCACCAGA  
40 TCAAGCATATCAAGGATTTCAAGGACTACAAGTACTCTCACCGGGTGGATAAAAAGCCCAAC  
AGAGAGCTGATCAATGACACCCTGTATAGTACAAGAAAAGACGATAAGGGGAATACCCTGAT  
TGTGAACAATCTGAACGGACTGTACGACAAAGATAATGACAAGCTGAAAAAGCTGATCAACA  
AAAGTCCCGAGAAGCTGCTGATGTACCACCATGATCCTCAGACATATCAGAACTGAAGCTG  
ATTATGGAGCAGTACGGCGACGAGAAGAACCCACTGTATAAGTACTATGAAGAGACTGGGAA  
45 CTACCTGACCAAGTATAGCAAAAAGGATAATGGCCCCGTGATCAAGAAGATCAAGTACTATG  
GGAACAAGCTGAATGCCATCTGGACATCACAGACGATTACCCTAACAGTCGCAACAAGGTG  
GTCAAGCTGTCACTGAAGCCATACAGATTGATGTCTATCTGGACAACGGCGTGTATAAATT

TGTGACTGTCAAGAATCTGGATGTCATCAAAAAGGAGAACTACTATGAAGTGAATAGCAAGT  
 GCTACGAAGAGGCTAAAAAGCTGAAAAAGATTAGCAACCAGGCAGAGTTCATCGCCTCCTTT  
 TACAACAACGACCTGATTAAGATCAATGGCGAACTGTATAGGGTCATCGGGGTGAACAATGA  
 TCTGCTGAACCGCATTGAAGTGAATATGATTGACATCACTTACCGAGAGTATCTGGAAAACA  
 5 TGAATGATAAGCGCCCCCTCGAATTATCAAAACAATTGCCTCTAAGACTCAGAGTATCAAA  
 AAGTACTCAACCGACATTCTGGGAAACCTGTATGAGGTGAAGAGCAAAAAGCACCCCTCAGAT  
 TATCAAAAAGGGCGGATCCCCAAGAAGAAGAGGAAAGTCTCGAGCTAGCAATAAAGGATCG  
 TTTATTTTCATTGGAAGCGTGTGTTGGTTTTTTTGATCAGGCGCGTCCAAGCTTGCATGCTGG  
 GGAGAGATCTGCGGCCCGCTAGCAATAAAGGATCGTTTATTTTCATTGGAAGCGTGTGTTGG  
 10 TTTTTTGATCAGGCGCGAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTC  
 GCTCGCTCACTGAGGCCGGGCGACCAAGGTCGCCCCGACGCCCGGGCTTTGCCCGGGCGGCC  
 TCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGG (SEQ ID NO: 9)

## REFERENCES

- 15 Ambati et al., *Invest Ophthalmol Vis Sci* 41(5):1181-1185 (2000a)  
 Ambati et al., *Invest Ophthalmol Vis Sci* 41(5):1186-1191 (2000b)  
 Amrani et al., *Genome Biol.* 19(1):214 (2018)  
 Bae et al., *Bioinformatics* 30(10):1473-1475 (2014)  
 Berson et al., *N Engl J Med.* 323(19):1302-1307 (1990)  
 20 Briner et al., *Mol Cell* 56(2):333-339 (2014)  
 Burstein et al., *Nature.* 542(7640):237-241 (2017)  
 Casini et al., *Nat Biotechnol.* 36(3):265-271 (2018)  
 Chen et al., *Nature.* 550(7676):407-410 (2017)  
 Cideciyan et al., *PNAS.* 115 (36):E8547-E8556 (2018)  
 25 Cong et al., *Science.* 339(6121):819-23 (2013)  
 Daiger et al., *Arch Ophthalmol.* 125(2):151-8 (2007)  
 Heigwer et al., *Nat Methods* 11(2):122-3 (2014)  
 Hsu et al., *Nat Biotechnol* 31(9):827-832 (2013)  
 Jiang et al., *Nat Biotechnol* 31(3):233-239 (2013)  
 30 Jinek et al., *Science* 337(6096):816-821 (2012)  
 Kim et al., *Nat Commun.* 8:14500 (2017)  
 Kleinstiver et al., *Nat Biotechnol* 33(12):1293-1298 (2015)  
 Kleinstiver et al., *Nature* 529(7587):490-495 (2016)  
 Lee et al., *Nat Commun.* 9(1):3048 (2018)  
 35 Li et al., *The CRISPR Journal* 01:01 (2018)  
 Mali et al., *Science* 339(6121):823-826 (2013)  
 Nishimasu et al., *Cell* 156(5):935-949 (2014)

- Nishimasu et al., Cell 162(5):1113-1126 (2015)
- Nishimasu et al., Science. 361(6408):1259-1262 (2018)
- Pellissier et al., Mol Ther Methods Clin Dev. 1:14009 (2014)
- Ran et al., Cell 154(6):1380-1389 (2013)
- 5 Ran et al., Nature. 520(7546):186-91 (2015)
- Strecker et al., Nat Commun. Jan 22;10(1):212 (2019)
- Teng et al., Cell Discov. 4:63 (2018)
- Wang et al., Plant Biotechnol J. pbi.13053 (2018)
- Xiao et al. Bioinformatics 30(8):1180-1182 (2014)
- 10 Yadav et al., Human Molecular Genetics 23(8):2132-2144 (2014)
- Yan et al., Science 363(6422):88-91 (2019)
- Zetsche et al., Nat Biotechnol 33(2):139-142 (2015)
- Zetsche et al., Nat Biotechnol. 35(1):31-34 (2017)

Other embodiments are within the following claims.

### CLAIMS

What is claimed is:

1. A guide RNA (“gRNA”) molecule comprising a targeting domain that binds a target sequence of a *RHO* gene.
2. The gRNA molecule of claim 1, wherein the targeting domain is complementary to a target domain of a *RHO* gene.
3. The gRNA molecule of claim 1, wherein said targeting domain is configured to provide a cleavage event selected from a double strand break and a single strand break, within 10 nucleotides of a *RHO* target position.
4. The gRNA molecule of claim 1, wherein the *RHO* target position is in the 5' region of the *RHO* gene.
5. The gRNA molecule of claim 4, wherein the 5' region of the *RHO* gene is selected from the group consisting of the 5' untranslated (“UTR”) region, exon 1, the exon 1/intron 1 border, exon 2, and the exon 2/intron 1 border of the *RHO* gene.
6. The gRNA molecule of claim 1, wherein said targeting domain comprises a sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence from any of Tables 1-3 and 18.
7. The gRNA molecule of claim 1, wherein said targeting domain is selected from those in Tables 1-3 and 18.
8. The gRNA molecule of any of claims 1-7, wherein said gRNA is a modular gRNA molecule or a chimeric gRNA molecule.
9. The gRNA molecule of any of claims 1-8, comprising from 5' to 3':
  - a targeting domain;
  - a first complementarity domain;
  - a linking domain;
  - a second complementarity domain;
  - a proximal domain; and
  - a tail domain.
10. A nucleic acid that comprises: (a) sequence that encodes a gRNA molecule comprising a targeting domain that is complementary to a target domain in the *RHO* gene.
11. The nucleic acid of claim 10, wherein said gRNA molecule is a gRNA molecule of any of claims 1-9.

12. The nucleic acid of claim 11, wherein said targeting domain is configured to provide a cleavage event selected from a double strand break and a single strand break, within 10 nucleotides of a *RHO* target position.
13. The nucleic acid of claim 11, wherein said targeting domain comprises a sequence  
5 that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence from any of Tables 1-3 and 18.
14. The nucleic acid of claim 11, wherein said targeting domain is selected from those in Tables 1-3 and 18.
15. The nucleic acid of any of claims 10-14, wherein said gRNA is a modular gRNA  
10 molecule or a chimeric molecule.
16. The nucleic acid of any of claims 10-15, wherein said nucleic acid comprises a promoter operably linked to the sequence that encodes said gRNA molecule of (a).
17. The nucleic acid of claim 16, wherein the promoter operably linked to the sequence that encodes said gRNA molecule of (a) is a U6 promoter.
18. The nucleic acid of any of claims 10-17, further comprising: (b) sequence that  
15 encodes an RNA-guided nuclease molecule.
19. The nucleic acid of claim 18, wherein said RNA-guided nuclease molecule forms a double strand break in a target nucleic acid.
20. The nucleic acid of claim 18, wherein said RNA-guided nuclease molecule forms a  
20 single strand break in a target nucleic acid.
21. The nucleic acid of claim 20, wherein said single strand break is formed in the strand of the target nucleic acid to which the targeting domain of said gRNA molecule is complementary.
22. The nucleic acid of claim 21, wherein said single strand break is formed in the strand  
25 of the target nucleic acid other than the strand to which to which the targeting domain of said gRNA is complementary.
23. The nucleic acid of claim 18, wherein said RNA-guided nuclease molecule is a Cas9 molecule.
24. The nucleic acid of claim 23, wherein said Cas9 molecule comprises a nickase  
30 molecule.
25. The nucleic acid of claim 18, wherein said RNA-guided nuclease molecule is a Cpf1 molecule.

26. The nucleic acid of any of claims 18-25, wherein said nucleic acid comprises a promoter operably linked to the sequence that encodes the RNA-guided nuclease molecule of (b).
- 5 27. The nucleic acid of claim 26, wherein said promoter operably linked to the sequence that encodes the RNA-guided nuclease molecule of (b) comprises a promoter selected from the group consisting of RHO, CMV, EFS, GRK1, CRX, NRL, and RCVRN promoter.
28. The nucleic acid of any of claims 10-27, further comprising: (c) a *RHO* cDNA molecule.
- 10 29. The nucleic acid of claim 24, wherein said *RHO* cDNA molecule is not codon modified to be resistant to hybridization with the gRNA molecule.
30. The nucleic acid of claim 28, wherein said *RHO* cDNA molecule comprises a nucleotide sequence comprising exon 1, exon 2, exon 3, exon 4, and exon 5 of the *RHO* gene.
- 15 31. The nucleic acid of claim 28, wherein said *RHO* cDNA molecule comprises a nucleotide sequence comprising exon 1, intron 1, exon 2, exon 3, exon 4, and exon 5 of the *RHO* gene.
32. The nucleic acid of claim 28, wherein intron 1 comprises one or more truncations at a 5' end of intron 1, a 3' end of intron 1, or both.
- 20 33. The nucleic acid of any of claims 28-32, wherein said nucleic acid comprises a 3' UTR nucleotide sequence downstream of the *RHO* cDNA molecule.
34. The nucleic acid of claim 33, wherein said 3' UTR nucleotide sequence comprises a *RHO* gene 3' UTR nucleotide sequence.
- 25 35. The nucleic acid of claim 33, wherein said 3' UTR nucleotide sequence comprises an  $\alpha$ -globin 3' UTR nucleotide sequence.
36. The nucleic acid of claim 33, wherein said 3' UTR nucleotide sequence comprises a  $\beta$ -globin 3' UTR nucleotide sequence.
37. The nucleic acid of any of claims 33-36, wherein said 3' UTR nucleotide sequence comprises one or more truncations at a 5' end of said 3' UTR nucleotide sequence, a 3' end of said 3' UTR nucleotide sequence, or both.
- 30 38. The nucleic acid of any of claims 28-37, wherein said nucleic acid comprises a promoter operably linked to the *RHO* cDNA molecule (c).
39. The nucleic acid of claim 38, wherein said promoter operably linked to the *RHO* cDNA molecule (c) is a rod-specific promoter.

40. The nucleic acid of claim 39, wherein said rod-specific promoter is a human *RHO* promoter.
41. The nucleic acid of claim 40, wherein said human *RHO* promoter comprises an endogenous *RHO* promoter.
- 5 42. The nucleic acid of claim 41, further comprising: (d) sequence that encodes a second gRNA molecule having a targeting domain that is complementary to a second target domain of the *RHO* gene.
43. The nucleic acid of claim 42, wherein said targeting domain of said second gRNA is configured to provide a cleavage event selected from a double strand break and a  
10 single strand break, within 10 nucleotides of a *RHO* target position.
44. The nucleic acid of any of claims 42 or 43, wherein said second gRNA molecule is a modular gRNA molecule or chimeric gRNA molecule.
45. The nucleic acid of any of claims 42-44, wherein said second gRNA molecule is a chimeric gRNA molecule.
- 15 46. The nucleic acid of any of claims 42-45, wherein said second gRNA molecule comprises from 5' to 3':  
a targeting domain;  
a first complementarity domain;  
a linking domain;  
20 a second complementarity domain;  
a proximal domain; and  
a tail domain.
47. The nucleic acid of any of claims 42-46, further comprising a third gRNA molecule.
48. The nucleic acid of claim 47, further comprising a fourth gRNA molecule.
- 25 49. The nucleic acid of any of claims 18-27, wherein each of (a) and (b) is present on the same nucleic acid molecule.
50. The nucleic acid of claim 49, wherein said nucleic acid molecule is an AAV vector.
51. The nucleic acid of any of claims 18-27, wherein: (a) is present on a first nucleic acid molecule; and (b) is present on a second nucleic acid molecule.
- 30 52. The nucleic acid of claim 51, wherein said first and second nucleic acid molecules are AAV vectors.
53. The nucleic acid of any of claims 18-27, further comprising (c) a *RHO* cDNA molecule of any of claims 28-41.

54. The nucleic acid of claim 53, wherein each of (a) and (c) is present on the same nucleic acid molecule.
55. The nucleic acid of claim 54, wherein said nucleic acid molecule is an AAV vector.
56. The nucleic acid of claim 53, wherein: (a) is present on a first nucleic acid molecule;  
5 and (c) is present on a second nucleic acid molecule.
57. The nucleic acid of claim 56, wherein said first and second nucleic acid molecules are AAV vectors.
58. The nucleic acid of any of claims 10-17, further comprising:  
10 (b) sequence that encodes an RNA-guided nuclease molecule of any of claims 18-27;  
and  
(c) *RHO* cDNA molecule of any of claims 28-41.
59. The nucleic acid of claim 58, wherein each of (a), (b), and (c) are present on the same nucleic acid molecule.
60. The nucleic acid of claim 59, wherein said nucleic acid molecule is an AAV vector.
- 15 61. The nucleic acid of claim 58, wherein:  
one of (a), (b), and (c) are present on a first nucleic acid molecule; and  
and a second and third of (a), (b), and (c) is present on a second nucleic acid molecule.
62. The nucleic acid of claim 61, wherein said first and second nucleic acid molecules are  
20 AAV vectors.
63. The nucleic acid of claim 58, wherein: (a) is present on a first nucleic acid molecule;  
and (b) and (c) are present on a second nucleic acid molecule.
64. The nucleic acid of claim 63, wherein said first and second nucleic acid molecules are AAV vectors.
- 25 65. The nucleic acid of claim 58, wherein: (b) is present on a first nucleic acid molecule;  
and (a) and (c) are present on a second nucleic acid molecule.
66. The nucleic acid of claim 65, wherein said first and second nucleic acid molecules are AAV vectors.
67. The nucleic acid of claim 58, wherein: (c) is present on a first nucleic acid molecule;  
30 and (b) and (a) are present on a second nucleic acid molecule.
68. The nucleic acid of claim 67, wherein said first and second nucleic acid molecules are AAV vectors.

69. The nucleic acid of any of claims 51, 56, 61, 63, 65, and 67, wherein said first nucleic acid molecule is other than an AAV vector and said second nucleic acid molecule is an AAV vector.
70. A composition comprising a gRNA molecule of any of claims 1-17.
- 5 71. The composition of claim 70, further comprising (b) a Cas9 molecule of any of claims 18-27.
72. The composition of claim 71, further comprising (c) a *RHO* cDNA molecule of any of claims 28-41.
73. The composition of claim 72, further comprising a second gRNA molecule.
- 10 74. The composition of claim 73, further comprising a third gRNA molecule.
75. The composition of claim 75, further comprising a fourth gRNA molecule.
76. A method of altering a cell comprising contacting said cell with:
- (a) a gRNA of any of claims 1-17;
- (b) an RNA-guided nuclease molecule of any of claims 18-27;
- 15 (c) a *RHO* cDNA molecule of any of claims 28-41; and
- optionally, (d) a second gRNA molecule of any of claims 42-46.
77. The method of claim 76, further comprising a third gRNA molecule.
78. The method of claim 77, further comprising a fourth gRNA molecule.
79. The method of claim 76, comprising contacting said cell with (a), (b), (c) and
- 20 optionally (d).
80. The method of any of claims 76-79, wherein said cell is from a subject suffering from adRP.
81. The method of any of claims 76-80, wherein said cell is from a subject having a mutation in the *RHO* gene.
- 25 82. The method of any of claims 76-81, wherein said cell is a retinal cell.
83. The method of claim 82, wherein the retinal cell is a rod photoreceptor.
84. The method of any of claims 76-83, wherein said cell is an embryonic stem cell, an induced pluripotent stem cell, a hematopoietic stem cell, a neuronal stem cell or a mesenchymal stem cell.
- 30 85. The method of any of claims 76-83, wherein said contacting is performed *ex vivo*.
86. The method of claim 84, wherein said contacted cell is returned to said subject's body.
87. The method of any of claims 76-83, wherein said contacting is performed *in vivo*.

88. The method of any of claims 80-87, comprising acquiring knowledge of the presence of the mutation in the *RHO* gene in said cell.
89. The method of claim 88, comprising acquiring knowledge of the presence of the presence of the mutation in the *RHO* gene in said cell by sequencing a portion of the *RHO* gene.
90. The method of any of claims 76-89, comprising altering a *RHO* target position to knock-out function of the *RHO* gene.
91. The method of any of claims 76-90, wherein contacting comprises contacting said cell with a nucleic acid that encodes at least one of (a), (b), (c) and optionally (d).
92. The method of any of claims 76-90, wherein contacting comprises delivering to said cell said RNA-guided nuclease molecule of (b) and a nucleic acid which encodes (a) and (c) and optionally (d).
93. The method of any of claims 76-90, wherein contacting comprises delivering to said cell said RNA-guided nuclease molecule of (b), said gRNA molecule of (a), and said *RHO* cDNA molecule of (c).
94. The method of any of claims 76-90, wherein contacting comprises delivering to said cell said gRNA molecule of (a), said *RHO* cDNA molecule of (c) and a nucleic acid that encodes the RNA-guided nuclease molecule of (b).
95. A method of contacting a subject (or a cell from said subject) with:
- (a) a gRNA of any of claims 1-17;
  - (b) an RNA-guided nuclease molecule of any of claims 18-27;
  - (c) a *RHO* cDNA molecule of any of claims 28-41; and
  - optionally, (d) a second gRNA of any of claims 42-46.
96. The method of claim 95, further comprising a third gRNA molecule.
97. The method of claim 96, further comprising a fourth gRNA molecule.
98. The method of claim 97, further comprising contacting said subject with (a), (b), (c) and optionally (d).
99. The method of claims any one of claims 95-98, wherein said subject is suffering from adRP.
100. The method of any of claims 95-99, wherein said subject has a mutation in the *RHO* gene.
101. The method of any of claims 95-100, comprising acquiring knowledge of the presence of the mutation in the *RHO* gene in said subject.

102. The method of claim 101, comprising acquiring knowledge of the presence of the mutation in the *RHO* gene in said subject by sequencing a portion of the *RHO* gene.

103. The method of claims 95-102, comprising altering a *RHO* target position to knock-out function of the *RHO* gene.

104. The method of any of claims 95-103, wherein a cell of said subject is contacted *ex vivo* with (a), (b), (c) and optionally (d).

105. The method of claim 104, wherein said cell is returned to the subject's body.

106. The method of any of claims 95-105, wherein treatment comprises introducing a cell into said subject's body, wherein said cell subject is contacted *ex vivo* with (a), (b), (c), and optionally (d).

107. The method of any of claims 95-106, wherein said contacting is performed *in vivo*.

108. The method of claim 107, wherein said contacting comprises intravenous delivery.

109. The method of any of claims 95-108, wherein contacting comprises contacting said subject with a nucleic acid that encodes at least one of (a), (b), and (c), and optionally (d).

110. The method of any of claims 95-108, wherein contacting comprises contacting said subject with a nucleic acid of any of claims 10-69.

111. The method of any of claims 95-108, wherein contacting comprises delivering to said subject said RNA-guided nuclease molecule of (b) and a nucleic acid which encodes and (a) and (c), and optionally (d).

112. The method of any of claims 95-108, wherein contacting comprises delivering to said subject said RNA-guided nuclease molecule of (b), said gRNA of (a) and said *RHO* cDNA molecule of (c), and optionally said second gRNA of (d).

113. The method of any of claims 95-108, wherein contacting comprises delivering to said subject said gRNA of (a), said *RHO* cDNA molecule of (c) and a nucleic acid that encodes the RNA-guided nuclease molecule of (b).

114. A reaction mixture comprising a gRNA, a nucleic acid, or a composition described herein, and a cell from a subject having adRP, or a subject having a mutation in the *RHO* gene.

115. A kit comprising, (a) gRNA molecule of any of claims 1-17, or nucleic acid that encodes said gRNA, and one or more of the following:

- (b) a Cas9 molecule of any of claims 18-27;  
(c) a *RHO* cDNA molecule of any of claims 28-41;  
optionally, (d) a second gRNA molecule of any of claims 42-46; and  
(e) nucleic acid that encodes one or more of (b) and (c).

116. The kit of claim 115, comprising nucleic acid that encodes one or more of (a), (b) (c) and (d).

117. The kit of claim 116, further comprising a third gRNA molecule targeting a *RHO* target position of the *RHO* gene.

118. The kit of claim 117, further comprising a fourth gRNA molecule targeting a *RHO* target position of the *RHO* gene.

FIG. 1




FIG. 2




FIG. 3




FIG. 4





FIG. 5

| Predicted gRNA-induced <i>rho</i> alleles |                      |                              |                  |                  |                  |
|-------------------------------------------|----------------------|------------------------------|------------------|------------------|------------------|
| Guide                                     | Location             | Target Site<br>Position (AA) | -1 Frame<br>(AA) | -2 Frame<br>(AA) | -3 Frame<br>(AA) |
| RHO-3                                     | Exon 1               | 96                           | 95               | 120              | 347; T97del      |
| RHO-10                                    | Exon 2<br>(Intron 2) | 174                          | 215              | 328              | 347; G174del     |
| RHO-7                                     | Exon 1<br>(Intron 1) | 120                          | 142              | 139              | 347; G120del     |



**FIG. 6**




FIG. 7A




FIG. 7B




FIG. 8




FIG. 9




FIG. 10




FIG. 11A




FIG. 11B




FIG. 12






FIG. 13



**FIG. 14A**



Unpaired t test (two-tailed) P = 2.599e-005

FIG. 14B





FIG. 15



[illegible]

FIG. 17





FIG. 18



## SEQUENCE LISTING

<110> Editas Medicine, Inc.

<120> CRISPR/RNA-Guided Nuclease-Related Methods and Compositions  
for

Treating RHO-Associated Autosomal-Dominant Retinitis  
Pigmentosa  
(ADRP)

<130> 118945-8018.W000 (EM127PCT)

<140> PCT/US2020/019766

<141> 2020-02-25

<150> US 62/810,320

<151> 2019-02-25

<160> 1002

<170> PatentIn version 3.5

<210> 1

<211> 6706

<212> DNA

<213> Artificial Sequence

<220>

<223> RHO genomic

<400> 1

agagtcatcc agctggagcc ctgagtggct gagctcaggc cttcgcagca ttcttgggtg  
60

ggagcagcca cgggtcagcc acaagggcca cagccatgaa tggcacagaa ggcctaact  
120

tctacgtgcc cttctccaat gcgacgggtg tggtagcgag ccccttcgag taccacagt  
180

actacctggc tgagccatgg cagttctcca tgctggccgc ctacatgttt ctgctgatcg  
240

tgctgggctt ccccatcaac ttcttcacgc tctacgtcac cgtccagcac aagaagctgc  
300

gcacgcctct caactacatc ctgctcaacc tagccgtggc tgacctcttc atggtcctag  
360

gtggcttcac cagcaccctc tacacctctc tgcattggata cttcgtcttc gggcccacag  
420

gatgcaattt ggagggcttc tttgccaccc tgggcgggtat gagccgggtg tgggtggggt  
480

gtgcaggagc ccgggagcat ggaggggtct gggagagtcc cgggcttggc ggtggtggct  
540

gagaggcctt ctcccttctc ctgtcctgtc aatgttatcc aaagccctca tatattcagt  
600

caacaaacac cattcatggg gatagccggg ctgctgtttg tgcagggctg gcactgaaca  
660

ctgccttgat cttattttgga gcaatatgcg cttgtctaata ttcacagcaa gaaaactgag  
720

ctgaggctca aagaagtcaa gcgccctgct ggggcgtcac acagggacgg gtgcagagtt  
780

gagttggaag cccgcatcta tctcgggccca tgtttgagc accaagcctc tgtttccctt  
840

ggagcagctg tgctgagtca gaccaggtc gggcactgag ggagagctgg gcaagccaga  
900

cccctcctct ctggggggccc aagctcaggg tgggaagtgg attttccatt ctccagtcatt  
960

tgggtcttcc ctgtgctggg caatgggctc ggtcccctct ggcatcctct gcctcccctc  
1020

tcagcccctg tcctcaggtg cccctccagc ctccctgccg cgttccaagt ctcttggtgt  
1080

tgagaaccgc aagcagccgc tctgaagcag ttcctttttg ctttagaata atgtcttgca  
1140

tttaacagga aaacagatgg ggtgctgcag ggataacaga tcccacttaa cagagaggaa  
1200

aactgaggca gggagagggg aagagactca tttagggatg tggccaggca gcaacaagag  
1260

cctaggtctc ctggctgtga tccaggaata tctctgctga gatgcaggag gagacgctag  
1320

aagcagccat tgcaaagctg ggtgacgggg agagcttacc gccagccaca agcgtctctc  
1380

tgccagcctt gccctgtctc ccccatgtcc aggctgctgc ctcgggtccca ttctcaggga  
1440

atctctggcc attggtgggt gtttgttgca ttcaataatc acagatcact cagttctggc  
1500

cagaaggtgg gtgtgccact tacgggtggt tgttctctgc agggtcagtc ccagtttaca  
1560

aatattgtcc ctttcactgt taggaatgtc ccagtttggt tgattaacta tatggccact  
1620

ctccctatgg aacttcatgg ggtggtgagc aggacagatg tctgaattcc atcatttcct  
1680

tcttcttcct ctgggcaaaa cattgcacat tgcttcatgg ctccctaggag aggccccac  
1740

atgtccgggt tatttcatth cccgagaagg gagagggagg aaggactgcc aattctgggt  
1800

ttccaccacc tctgcattcc ttcccaacaa ggaactctgc cccacattag gatgcattct  
1860

tctgctaaac acacacacac acacacacac acacaacaca cacacacaca cacacacaca  
1920

cacacacaca aaactcccta ccgggttccc agttcaatcc tgacccccctg atctgattcg  
1980

tgtcccttat gggcccagag cgctaagcaa ataacttccc ccattccctg gaatttcttt  
2040

gccagctct cctcagcgtg tggtcctctt gcccttccc cctcctccca gcaccaagct  
2100

ctctccttcc ccaaggcctc ctcaaattccc tctcccactc ctgggttgct tcctagctac  
2160

cctctccctg tctagggggg agtgcaccct ccttaggcag tgggggtctgt gctgaccgcc  
2220

tgctgactgc cttgcagggtg aaattgccct gtggtccttg gtggtcctgg ccatcgagcg  
2280

gtacgtgggtg gtgtgtaagc ccatgagcaa cttccgcttc ggggagaacc atgccatcat  
2340

gggcgttgcc ttcacctggg tcatggcgct ggcctgcgcc gcacccccac tcgccggctg  
2400

gtccaggtaa tggcactgag cagaaggga gaagctccgg gggctctttg tagggtcctc  
2460

cagtcaggac tcaaaccag tagtgtcttg ttccaggcac tgaccttgta tgtctcctgg  
2520

cccaaattgcc cactcagggt aggggtgtag ggcagaagaa gaaacagact ctaatgttgc  
2580

tacaagggtt ggtcccatct cctgagcccc atgtcaaaca gaatccaaga catcccaacc  
2640

cttcaccttg gctgtgcccc taatcctcaa ctaagctagg cgcaaattcc aatcctcttt  
2700

ggtctagtag cccgggggca gccccctcta accttgggcc tcagcagcag gggaggccac  
2760

accttcctag tgcagggtggc catattgtgg ccccttggaa ctgggtccca ctcagcctct  
2820

aggcgattgt ctccaatgg ggctgagatg agacacagtg gggacagtgg tttggacaat  
2880

aggactgggtg actctgggtcc ccagaggcct catgtccctc tgtctccaga aaattccac  
2940

tctcacttcc ctttcctcct cagtcttgct aggggccatt tcttaccct tgctgaattt  
3000

**gagcccaccc cctggacttt ttcccacatct tctccaatct ggcctagttc tatectctgg**  
**3060**

**aagcagagcc gctggacgct ctggggtttcc tgaggcccgt ccactgtcac caatatcagg**  
**3120**

**aaccattgcc acgtcctaata gacgtgacgct ggaagcctct agtttccaga agctgcacaa**  
**3180**

**agatccctta gatactctgt gtgtccatct ttggcctgga aaataactctc accctggggc**  
**3240**

**taggaagacc tcgggtttgta caaacttcct caaatgcaga gcctgagggc tctccccacc**  
**3300**

**tcctcaccaa ccctctgcgt ggcatagccc tagcctcagc gggcagtgga tgctggggct**  
**3360**

**gggcatgcag ggagaggctg ggtggtgtca tctggtaacg cagccaccaa acaatgaagc**  
**3420**

**gacactgatt ccacaaggct catctgcac cccatctgat ccattccatc ctgtcaccca**  
**3480**

**gccatgcaga cgtttatgat ccccttttcc agggagggaa tgtgaagccc cagaaagggc**  
**3540**

**cagcgctcgg cagccacctt ggctgttccc aagtcctca caggcagggt ctccctacct**  
**3600**

**gcctgtcctc aggtacatcc ccgagggcct gcagtgtcgt tgtggaatcg actactacac**  
**3660**

**gctcaagccg gaggtcaaca acgagtcttt tgtcatctac atgttcgtgg tccacttcac**  
**3720**

**catcccatg attatcatct ttttctgcta tgggcagctc gtcttcaccg tcaaggaggt**  
**3780**

**acgggccggg ggggtgggcgg cctcacggct ctgaggggtcc agccccagc atgcatctgc**  
**3840**

**ggctcctgct ccctggagga gccatggtct ggaccgggt cccgtgtcct gcaggccgct**  
**3900**

gcccagcagc aggagtcagc caccacacag aaggcagaga aggaggtcac ccgcatggtc  
3960

atcatcatgg tcatcgcttt cctgatctgc tgggtgccct acgccagcgt ggcatcttac  
4020

atcttcaccc accagggctc caacttcggt cccatcttca tgaccatccc agcggttcttt  
4080

gccaagagcg ccgccatcta caaccctgtc atctatatca tgatgaacaa gcagggtgcct  
4140

actgcgggtg ggaggggcccc agtgccccag gccacaggcg ctgcctgcca aggacaagct  
4200

acttcccagg gcagggggagg gggctccatc agggttactg gcagcagtct tgggtcagca  
4260

gtcccaatgg ggagtgtgtg agaaatgcag attcctggcc ccactcagaa ctgctgaatc  
4320

tcagggtggg cccaggaacc tgcattttcca gcaagccctc cacagggtggc tcagatgctc  
4380

actcagggtg gagaagctcc agtcagctag ttctggaagc ccaatgtcaa agtcagaagg  
4440

acccaagtcg ggaatgggat gggccagtct ccataaagct gaataaggag ctaaaaagtc  
4500

ttattctgag gggtaaaggg gtaaagggtt cctcggagag gtacctccga ggggtaaaca  
4560

gttgggtaaa cagtctctga agtcagctct gccattttct agctgtatgg ccctgggcaa  
4620

gtcaattttc ttctctgtgc tttggttttc tcatccatag aaaggtagaa agggcaaaac  
4680

accaaactct tggattacaa gagataatth acagaacacc cttggcacac agagggcacc  
4740

atgaaatgtc acgggtgaca cagccccctt gtgctcagtc cctggcatct ctaggggtga  
4800

ggagcgtctg cctagcaggt tccctccagg aagctggatt tgagtggatg gggcgctgga  
4860

atcgtgaggg gcagaagcag gcaaagggtc ggggcgaacc tcactaacgt gccagttcca  
4920

agcacactgt gggcagccct ggccctgact caagcctctt gccttccagt tccggaactg  
4980

catgctcacc accatctgct gcggcaagaa cccactgggt gacgatgagg cctctgctac  
5040

cgtgtccaag acggagacga gccagggtggc cccggcctaa gacctgccta ggactctgtg  
5100

gccgactata ggcgtctccc atcccctaca ccttccccca gccacagcca tcccaccagg  
5160

agcagcgcct gtgcagaatg aacgaagtca cataggctcc ttaatTTTTT tttttttttt  
5220

aagaaataat taatgaggct cctcactcac ctgggacagc ctgagaaggg acatccacca  
5280

agacctactg atctggagtc ccacgttccc caaggccagc gggatgtgtg cccctcctcc  
5340

tcccaactca tctttcagga acacgaggat tcttgctttc tggaagagtg tcccagctta  
5400

gggataagtg tctagcacag aatggggcac acagtaggtg ctttaataaat gctggatgga  
5460

tgcaggaagg aatggaggaa tgaatgggaa gggagaacat atctatcctc tcagaccctc  
5520

gcagcagcag caactcatac ttggctaatag atatggagca gttgtttttc cctccctggg  
5580

cctcactttc ttctcctata aaatggaaat cccagatccc tggtcctgcc gacacgcagc  
5640

tactgagaag accaaaagag gtgtgtgtgt gtctatgtgt gtgtttcagc actttgtaaa  
5700

tagcaagaag ctgtacagat tctagttaat gttgtgaata acatcaatta atgtaactag  
5760

ttaattacta tgattatcac ctcctgatag tgaacatttt gagattgggc attcagatga  
5820

tgggggtttca cccaaccttg gggcaggttt ttaaaaatta gctaggcatc aaggccagac  
5880

cagggctggg ggttgggctg taggcaggga cagtcacagg aatgcagaat gcagtcatca  
5940

gacctgaaaa aacaacactg ggggaggggg acggtgaagg ccaagttccc aatgaggggtg  
6000

agattgggcc tgggggtctca cccctagtgt ggggccccag gtcccgtgcc tccccttccc  
6060

aatgtggcct atggagagac aggcctttct ctcagcctct ggaagccacc tgctcttttg  
6120

ctctagcacc tgggtcccag catctagagc atggagcctc tagaagccat gctcaccgcg  
6180

ccacatttaa ttaacagctg agtccctgat gtcatcctta tctcgaagag cttagaaaca  
6240

aagagtggga aattccactg ggcctacctt ccttggggat gttcatgggc cccagtttcc  
6300

agtttccctt gccagacaag cccatcttca gcagttgcta gtccattctc cattctggag  
6360

aatctgctcc aaaaagctgg ccacatctct gaggtgtcag aattaagctg cctcagtaac  
6420

tgctccccct tctccatata agcaaagcca gaagctctag ctttaccag ctctgcctgg  
6480

agactaaggc aaattgggcc attaaaagct cagctcctat gttggtatta acggtggtgg  
6540

gttttgttgc tttcacactc tatccacagg atagattgaa actgccagct tccacctgat  
6600

ccctgaccct gggatggctg gattgagcaa tgagcagagc caagcagcac agagtcacct  
6660

ggggctagag gtggaggagg cagtcctggg aatgggaaaa acccca  
6706

<210> 2

<211> 1047

<212> DNA

<213> Artificial Sequence

<220>

<223> Wild-type RHO cDNA

<400> 2

atgaatggca cagaaggccc taactttctac gtgcccttct ccaatgcgac ggggtgtggta  
60

cgcagcccct tcgagtaccc acagtactac ctggctgagc catggcagtt ctccatgctg  
120

gccgcctaca tgttttctgct gatcgtgctg ggcttcccca tcaacttcct cagcgtctac  
180

gtcacctgcc agcacaagaa gctgcgcacg cctctcaact acatcctgct caacctagcc  
240

gtggctgacc tcttcatggg cctaggtggc ttcaccagca ccctctacac ctctctgcat  
300

ggatacttcg tcttcggggc cacaggatgc aatttggagg gcttctttgc caccctgggc  
360

ggtgaaattg ccctgtggtc cttgggtggc ctggccatcg agcgggtacgt ggtgggtgtgt  
420

aagcccatga gcaacttccg cttcggggag aaccatgcca tcatgggcgt tgccttcacc  
480

tgggtcatgg cgctggcctg cgccgcaccc ccactcgccg gctgggtccag gtacatcccc  
540

gagggcctgc agtgctcgtg tggaatcgac tactacacgc tcaagccgga ggtcaacaac  
600

gagtcttttg tcattctacat gttcgtggtc cacttcacca tccccatgat tatcatcttt  
660

ttctgctatg ggcagctcgt cttcaccgtc aaggaggccg ctgcccagca gcaggagtca  
720

gccaccacac agaaggcaga gaaggaggtc acccgcatgg tcatcatcat ggtcatcgct  
780

ttcctgatct gctgggtgcc ctacgccagc gtggcattct acatcttcac ccaccagggc  
840

tccaacttcg gtcccatctt catgaccatc ccagcgttct ttgccaagag cgccgccatc  
900

tacaaccctg tcattctatat catgatgaac aagcagttcc ggaactgcat gctcaccacc  
960

atctgctgcg gcaagaaccc actgggtgac gatgaggcct ctgctaccgt gtccaagacg  
1020

g a g a c g a g c c a g g t g g c c c c g g c c t a a  
1047

<210> 3

<400> 3  
000

<210> 4

<211> 2828

<212> DNA

<213> Artificial Sequence

<220>

<223> RHO cDNA with intron 1

<400> 4

atgaatggca cagaaggccc taacttctac gtgcccttct ccaatgcgac ggggtgtggta  
60

cgcagcccct tcgagtaccc acagtactac ctggctgagc catggcagtt ctccatgctg  
120

gccgcctaca tgtttctgct gatcgtgctg ggcttcccca tcaacttcct cacgctctac  
180

gtcaccgtcc agcacaagaa gctgcgcacg cctctcaact acatcctgct caacctagcc  
240

gtggctgacc tcttcatggg cctaggtggc ttcaccagca ccctctacac ctctctgcat  
300

ggatacttcg tcttcggggc cacaggatgc aatttggagg gcttctttgc caccctgggc  
360

ggatatgagc ggggtgtgggt ggggtgtgca ggagcccggg agcatggagg ggtctgggag  
420

agtcccgggc ttggcggtgg tggctgagag gccttctccc ttctcctgtc ctgtcaatgt  
480

tatccaaagc cctcatatat tcagtcaaca aacaccattc atggtgatag ccgggctgct  
540

gtttgtgcag ggctggcact gaacactgcc ttgatcttat ttggagcaat atgcgcttgt  
600

ctaatttcac agcaagaaaa ctgagctgag gctcaaagaa gtcaagcgcc ctgctggggc  
660

gtcacacagg gacgggtgca gagttgagtt ggaagcccgc atctatctcg ggccatgttt  
720

gcagcaccaa gcctctgttt cccttggagc agctgtgctg agtcagaccc aggctgggca  
780

ctgagggaga gctgggcaag ccagaccctt cctctctggg ggcccaagct cagggtggga  
840

agtggatttt ccattctcca gtcattgggt cttccctgtg ctgggcaatg ggctcgggcc  
900

cctctggcat cctctgcctc ccctctcagc ccctgtcctc aggtgcccct ccagcctccc  
960

tgccgcgttc caagtctcct ggtgttgaga accgcaagca gccgctctga agcagttcct  
1020

ttttgcttta gaataatgtc ttgcatttaa caggaaaaca gatggggtgc tgcagggata  
1080

acagatccca cttaacagag aggaaaactg aggcaggag aggggaagag actcatttag  
1140

ggatgtggcc aggcagcaac aagagcctag gtctcctggc tgtgatccag gaatatctct  
1200

gctgagatgc aggaggagac gctagaagca gccattgcaa agctgggtga cggggagagc  
1260

ttaccgccag ccacaagcgt ctctctgccca gccttgccct gtctcccca tgtccaggct  
1320

gctgcctcgg tcccattctc agggaatctc tggccattgt tgggtgtttg ttgcattcaa  
1380

taatcacaga tcactcagtt ctggccagaa ggtgggtgtg ccacttacgg gtggttggtc  
1440

tctgcagggt cagtcccagt ttacaaatat tgtccctttc actgttagga atgtcccagt  
1500

ttggttgatt aactatatgg ccactctccc tatggaactt catggggtgg tgagcaggac  
1560

agatgtctga attccatcat ttccttcttc ttcctctggg caaaacattg cacattgctt  
1620

catggctcct aggagaggcc cccacatgtc cgggttattt catttcccga gaaggagag  
1680

ggaggaagga ctgccaattc tgggtttcca ccacctctgc attccttccc aacaaggaac  
1740

tctgccccac attaggatgc attcttctgc taaacacaca cacacacaca cacacacaca  
1800

acacacacac acacacacac acacacacac acacaaaact ccctaccggg ttcccagttc  
1860

aatcctgacc ccctgatctg attcgtgtcc cttatgggcc cagagcgcta agcaaataac  
1920

ttccccatt ccctggaatt tctttgccca gctctcctca gcgtgtggtc cctctgcccc  
1980

ttccccctcc tcccagcacc aagctctctc cttccccaag gcctcctcaa atccctctcc  
2040

cactcctggg tgccttccta gctaccctct ccctgtctag gggggagtgc accctcctta  
2100

ggcagtgggg tctgtgctga ccgcctgctg actgccttgc aggtgaaatt gccctgtggg  
2160

ccttggtggg cctggccatc gagcggtagc tgggtgggtg taagcccatg agcaacttcc  
2220

gcttcgggga gaaccatgcc atcatgggag ttgccttcac ctgggtcatg gcgctggcct  
2280

gcgccgcacc cccactcgcc ggctgggtcca ggtacatccc cgagggcctg cagtgtctgt  
2340

gtggaatcga ctactacacg ctcaagccgg aggtcaacaa cgagtctttt gtcattctaca  
2400

tgttcgtggg ccacttcacc atcccatga ttatcatctt tttctgctat gggcagctcg  
2460

tcttcaccgt caaggaggcc gctgcccagc agcaggagtc agccaccaca cagaaggcag  
2520

agaaggaggt caccgcgatg gtcattcatca tgggtcatcg tttcctgatc tgctgggtgc  
2580

cctacgccag cgtggcattc tacatcttca cccaccaggg ctccaacttc ggtcccatct  
2640

tcatgaccat cccagcggtc tttgcccaaga gcgccgcat ctacaaccct gtcattctata  
2700

tcatgatgaa caagcagttc cggaactgca tgctcaccac catctgctgc ggcaagaacc  
2760

cactgggtga cgatgaggcc tctgctaccg tgtccaagac ggagacgagc cagggtggccc  
2820

c                    g                    g                    c                    c                    t                    a                    a  
2828

<210> 5

<211> 2253

<212> DNA

<213> Artificial Sequence

<220>

<223> RHO cDNA with intron 2

<400> 5

atgaatggca cagaaggccc taacttctac gtgcccttct ccaatgcgac ggggtgtggta  
60

cgcagcccct tcgagtaccc acagtactac ctggctgagc catggcagtt ctccatgctg  
120

gccgcctaca tgtttctgct gatcgtgctg ggcttcccca tcaacttcct cacgctctac  
180

gtcacCGtcc agcacaagaa gctgcgcacg cctctcaact acatcctgct caacctagcc  
240

gtggctgacc tcttcatggc cctagggtggc ttcaccagca ccctctacac ctctctgcat  
300

ggatacttcg tcttcggggc cacaggatgc aatttggagg gcttctttgc caccctgggc  
360

ggtgaaattg ccctgtggtc cttggtggtc ctggccatcg agcggtacgt ggtggtgtgt  
420

aagcccatga gcaacttcCG cttcggggag aaccatgcca tcatgggcgt tgccttcacc  
480

tgggtcatgg cgctggcctg cgccgcaccc ccactcgccg gctgggtccag gtaatggcac  
540

tgagcagaag ggaagaagct ccgggggctc tttgtagggt cctccagtca ggactcaaac  
600

ccagtagtgt ctggttccag gcactgacct tgtatgtctc ctggcccaaa tgcccactca  
660

gggtaggggt gtagggcaga agaagaaaca gactctaata ttgctacaag ggctgggtccc  
720

atctcctgag ccccatgtca aacagaatcc aagacatccc aacccttcac cttggctgtg  
780

cccctaatacc tcaactaagc taggcgcaaa ttccaatcct ctttgggtcta gtaccccggg  
840

ggcagcccc tctaaccttg ggcctcagca gcaggggagg ccacaccttc ctagtgcagg  
900

tggccatatt gtggcccctt ggaactgggt cccactcagc ctctaggcga ttgtctccta  
960

atggggctga gatgagacac agtggggaca gtggtttgga caataggact ggtgactctg  
1020

gtccccagag gcctcatgtc cctctgtctc cagaaaattc ccactctcac ttccctttcc  
1080

tcctcagtct tgctagggtc catttcttac cccttgctga atttgagccc accccctgga  
1140

ctttttcccc atctttctcca atctggccta gttctatcct ctggaagcag agccgctgga  
1200

cgctctgggt ttccctgaggc ccgtccactg tcaccaatat caggaaccat tgccacgtcc  
1260

taatgacgtg cgctggaagc ctctagtttc cagaagctgc acaaagatcc cttagatact  
1320

ctgtgtgtcc atctttggcc tggaaaatac tctcaccctg gggctaggaa gacctcggtt  
1380

tgtacaaact tcctcaaata cagagcctga gggctctccc cacctcctca ccaaccctct  
1440

gcgtggcata gccctagcct cagcgggcag tggatgctgg ggctgggcat gcagggagag  
1500

gctgggtgggt gtcactctgggt aacgcagcca ccaaacaatg aagcgacact gattccacaa  
1560

ggtgcatctg catccccatc tgatccattc catcctgtca cccagccatg cagacgttta  
1620

tgatcccctt ttccagggag ggaatgtgaa gccccagaaa gggccagcgc tcggcagcca  
1680

ccttggctgt tcccaagtcc ctcacaggca gggctctccct acctgcctgt cctcaggtac  
1740

atccccgagg gcctgcagtg ctcgtgtgga atcgactact acacgctcaa gccggaggtc  
1800

aacaacgagt cttttgtcat ctacatgttc gtgggtccact tcaccatccc catgattatc  
1860

atctttttct gctatgggca gctcgtcttc accgtcaagg aggccgctgc ccagcagcag  
1920

gagtcagcca ccacacagaa ggcagagaag gaggtcaccc gcatgggtcat catcatggtc  
1980

atcgctttcc tgatctgctg ggtgccctac gccagcgtgg cattctacat cttcacccac  
2040

cagggctcca acttcgggtcc catcttcatg accatcccag cgttctttgc caagagcgcc  
2100

gccatctaca accctgtcat ctatatcatg atgaacaagc agttccggaa ctgcatgctc  
2160

accaccatct gctgcggcaa gaaccactg ggtgacgatg aggcctctgc taccgtgtcc  
2220

a a g a c g g a g a                    c g a g c c a g g t                    g g c c c c g g c c                    t a a  
2253

<210> 6

<211> 1163

<212> DNA

<213> Artificial Sequence

<220>

<223> RHO cDNA with intron 3

<400> 6

atgaatggca cagaaggccc taacttctac gtgcccttct ccaatgcgac ggggtgtggta  
60

cgcagcccct tcgagtaccc acagtactac ctggctgagc catggcagtt ctccatgctg  
120

gccgcctaca tgtttctgct gatcgtgctg ggcttcccca tcaacttcct cacgctctac  
180

gtcaccgtcc agcacaagaa gctgcgcacg cctctcaact acatcctgct caacctagcc  
240

gtggctgacc tcttcatggc cctaggtggc ttcaccagca ccctctacac ctctctgcat  
300

ggatacttcg tcttcgggcc cacaggatgc aatttggagg gcttctttgc caccctgggc  
360

ggtgaaattg ccctgtggtc cttgggtggc ctggccatcg agcggtagct ggtgggtgtgt  
420

aagcccatga gcaacttccg cttcggggag aaccatgcca tcatgggcgt tgccttcacc  
480

tgggtcatgg cgctggcctg cgccgcaccc ccactcgccg gctgggtccag gtacatcccc  
540

gagggcctgc agtgctcgtg tggaatcgac tactacacgc tcaagccgga ggtcaacaac  
600

gagtcttttg tcatctacat gttcgtggtc cacttcacca tccccatgat tatcatcttt  
660

ttctgctatg ggcagctcgt cttcaccgtc aaggaggtag gggccggggg gtgggcggcc  
720

tcacggctct gaggggtccag cccccagcat gcatctgcgg ctctgctcc ctggaggagc  
780

catgggtctg acccggttcc cgtgtcctgc aggccgctgc ccagcagcag gagtcagcca  
840

ccacacagaa ggcagagaag gaggtcaccc gcatgggtcat catcatggtc atcgctttcc  
900

tgatctgctg ggtgccctac gccagcgtgg cattctacat cttcacccac cagggctcca  
960

acttcggtcc catcttcatg accatcccag cgttctttgc caagagcgcc gccatctaca  
1020

accctgtcat ctatatcatg atgaacaagc agttccggaa ctgcatgctc accaccatct  
1080

gctgcggcaa gaacccactg ggtgacgatg aggcctctgc taccgtgtcc aagacggaga  
1140

c g a g c c a g g t                      g g c c c c g g c c                      t a a  
1163

<210> 7

<211> 1882

<212> DNA

<213> Artificial Sequence

<220>

<223> RHO cDNA with intron 4

<400> 7

atgaatggca cagaaggccc taacttctac gtgcccttct ccaatgcgac ggggtgtggta  
60

cgcagcccct tcgagtaccc acagtactac ctggctgagc catggcagtt ctccatgctg  
120

gccgcctaca tgtttctgct gatcgtgctg ggcttcccca tcaacttcct cacgctctac  
180

gtcacctgcc agcacaagaa gctgcgcacg cctctcaact acatcctgct caacctagcc  
240

gtggctgacc tcttcatggc cctaggtggc ttcaccagca ccctctacac ctctctgcat  
300

ggatacttcg tcttcggggc cacaggatgc aatttgagg gcttctttgc caccctgggc  
360

ggtgaaattg ccctgtggtc cttggtggtc ctggccatcg agcgggtacgt ggtgggtgtgt  
420

aagcccatga gcaacttccg cttcggggag aaccatgcca tcatgggcgt tgccttcacc  
480

tgggtcatgg cgctggcctg cgccgcaccc ccactcgccg gctgggtccag gtacatcccc  
540

gagggcctgc agtgctcgtg tggaatcgac tactacacgc tcaagccgga ggtcaacaac  
600

gagtcctttg tcatctacat gttcgtggtc cacttcacca tccccatgat tatcatcttt  
660

ttctgctatg ggcagctcgt cttcacccgtc aaggaggccg ctgcccagca gcaggagtca  
720

gccaccacac agaaggcaga gaaggaggtc acccgcatgg tcatcatcat ggtcatcgct  
780

ttcctgatct gctgggtgcc ctacgccagc gtggcattct acatcttcac ccaccagggc  
840

tccaacttcg gtcccatctt catgaccatc ccagcgttct ttgccaagag cgccgccatc  
900

tacaaccctg tcatctatat catgatgaac aagcagggtgc ctactgcggg tgggagggcc  
960

ccagtgcgcc aggccacagg cgctgcctgc caaggacaag ctacttccca gggcagggga  
1020

gggggctcca tcagggttac tggcagcagt cttgggtcag cagtcccaat ggggagtgtg  
1080

tgagaaatgc agattcctgg cccactcag aactgctgaa tctcagggtg ggcccaggaa  
1140

cctgcatttc cagcaagccc tccacagggtg gctcagatgc tcactcaggt gggagaagct  
1200

ccagtcagct agttctggaa gcccaatgtc aaagtcagaa ggaccaaggt cgggaatggg  
1260

atgggccagt ctccataaag ctgaataagg agctaaaaag tcttattctg aggggtaaag  
1320

gggtaaaggg ttcctcggag aggtacctcc gaggggtaaa cagttgggta aacagtctct  
1380

gaagtcagct ctgccatttt ctagctgtat ggccctgggc aagtcaattt ccttctctgt  
1440

gctttggttt cctcatccat agaaaggtag aaagggcaaa acaccaaact cttggattac  
1500

aagagataat ttacagaaca cccttggcac acagagggca ccatgaaatg tcacgggtga  
1560

cacagccccc ttgtgctcag tccctggcat ctctaggggt gaggagcgtc tgcctagcag  
1620

gttccctcca ggaagctgga tttgagtgga tggggcgctg gaatcgtgag gggcagaagc  
1680

aggcaaaggg tcggggcgaa cctcactaac gtgccagttc caagcacact gtgggcagcc  
1740

ctggccctga ctcaagcctc ttgccttcca gttccggaac tgcattgctca ccaccatctg  
1800

ctgcggcaag aaccactgg gtgacgatga ggcctctgct accgtgtcca agacggagac  
1860

g a g c c a g g t g g c c c c g g c c t a a  
1882

<210> 8

<211> 1670

<212> DNA

<213> Artificial Sequence

<220>

<223> Vector 2

<400> 8

ccacgtcaga atcaaaccct caccttaacc tcattagcgt tgggcataat caccaggcca  
60

agcgccttaa actacgagag gcccacatccc acccgccctg ccttagccct gccacgtgtg  
120

ccaaacgctg ttagacccaa caccaccag gccaggtagg gggctggagc ccagggtgggc  
180

atttgagtca ccaaccccca ggcagtctcc cttttcctgg atcctgagta cctctcctcc  
240

ctgacctcag gcttcctcct agtgtcacct tggcccctct tagaagccaa ttaggccctc  
300

agttttctgca gcgggggatta atatgattat gaacaccccc aatctcccag atgctgattc  
360

agccaggagc ttaggagggg gaggtcactt tataagggtc tgggggggtc agaaccaga  
420

gtcatccagc tggagccctg agtggctgag ctcaggcctt cgcagcattc ttgggtggga  
480

gcagccacgg gtcagccaca agggccacca ccatgaatgg cacagaaggc cctaacttct  
540

acgtgccctt ctccaatgcg acgggtgtgg tacgcagccc cttcgagtac ccacagtact  
600

acctggctga gccatggcag ttctccatgc tggccgccta catgtttctg ctgatcgtgc  
660

tgggcttccc catcaacttc ctcacgctct acgtcacctg ccagcacaag aagctgcgca  
720

cgcctctcaa ctacatcctg ctcaacctag ccgtggctga cctcttcatg gtcctagggtg  
780

gcttcaccag caccctctac acctctctgc atggatactt cgtcttcggg cccacaggat  
840

gcaatttgga gggcttcttt gccaccctgg gcggtgaaat tgccctgtgg tccttggtgg  
900

tcctggccat cgagcggtac gtggtggtgt gtaagcccat gagcaacttc cgcttcgggg  
960

agaaccatgc catcatgggc gttgccttca cctgggtcat ggcgctggcc tgcgccgcac  
1020

ccccactcgc cggctggtcc aggtacatcc ccgagggcct gcagtgctcg tgtggaatcg  
1080

actactacac gctcaagccg gaggtcaaca acgagtcctt tgtcatctac atgttcgtgg  
1140

tccacttcac catcccatg attatcatct ttttctgcta tgggcagctc gtcttcaccg  
1200

tcaaggaggc cgctgcccag cagcaggagt cagccaccac acagaaggca gagaaggagg  
1260

tcacccgcat ggtcatcatc atgggtcatcg ctttcctgat ctgctgggtg ccctacgcca  
1320

gcgtggcatt ctacatcttc acccaccagg gctccaactt cgggtcccatc ttcatgacca  
1380

tcccagcggt ctttgccaag agcgccgcca tctacaaccc tgtcatctat atcatgatga  
1440

acaagcagtt ccggaactgc atgctcacca ccatctgctg cggcaagaac ccactgggtg  
1500

acgatgaggc ctctgctacc gtgtccaaga cggagacgag ccagggtggcc ccggcctaag  
1560

ctggagcctc ggtggccatg cttcttgccc cttgggcctc cccccagccc ctctccct  
1620

tcctgcaccc gtacccccgt ggtctttgaa taaagtctga gtgggcggca  
1670

<210> 9

<211> 4498

<212> DNA

<213> Artificial Sequence

<220>

<223> Vector 1: 550 bp minimal RHO promoter driving wt Cas9 with  
SV40  
polyA signal

<220>  
<221> misc\_feature  
<222> (1)..(141)  
<223> ITR

<220>  
<221> misc\_feature  
<222> (172)..(796)  
<223> MinRHO promoter

<220>  
<221> misc\_feature  
<222> (797)..(960)  
<223> SV40 SA/SD

<220>  
<221> misc\_feature  
<222> (964)..(976)  
<223> Kozak start

<220>  
<221> misc\_feature  
<222> (979)..(1008)  
<223> NLS

<220>  
<221> misc\_feature  
<222> (1009)..(4167)  
<223> Sa Cas9

<220>  
<221> misc\_feature  
<222> (4174)..(4194)  
<223> SV40 NLS

<220>  
<221> misc\_feature  
<222> (4201)..(4260)  
<223> Minimal polyA

<220>  
<221> misc\_feature  
<222> (4358)..(4498)  
<223> ITR

<400> 9

cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccggggcaaag cccggggcgtc  
60

gggcgacctt tggtcgcccc gcctcagtga gcgagcgagc gcgcagagag ggagtggcca  
120

actccatcac taggggttcc taagcggccg cggttcctca gatctgaatt ctcatgttac  
180

aggcaggag acgggcacaa aacacaaata aaaagcttcc atgctgtcag aagcactatg  
240

caaaaagcaa gatgctgagg tcatggagct cctcctgtca gaggagtgtg gggactggat  
300

gactccagag gtaacttgtg ggggaacgaa caggtaaggg gctgtgtgac gagatgagag  
360

actgggagaa taaaccagaa agtctctagc tgtccagagg acatagcaca gaggcccatg  
420

gtccctattht caaaccagc ccaccagact gagctgggac cttgggacag acaagtcatg  
480

cagaagttag gggaccttct cctccctttt cctggatcct gagtacctct cctccctgac  
540

ctcaggcttc ctccatagtgt caccttggcc cctcttagaa gccaattagg ccctcagttt  
600

ctgcagcggg gattaatatg attatgaaca cccccaatct cccagatgct gattcagcca  
660

ggagcttagg agggggaggt cactttataa gggctctgggg gggtcagaac ccagagtcac  
720

ccagctggag ccctgagtgg ctgagctcag gccttcgcag cattcttggg tgggagcagc  
780

cacgggtcag ccacaatcta gaggatccgg tactcgagga actgaaaaac cagaaagtta  
840

actggtaagt ttagtctttt tgtcttttat ttcagggtccc ggatccggtg gtgggtgcaaa  
900

tcaaagaact gctcctcagt ggatgttgcc tttacttcta ggcctgtacg gaagtgttac  
960

gcggccgcca ccatgggacc gaagaaaaag cgcaagggtcg aagcgtccat gaaaaggaac  
1020

tacattctgg ggctggacat cgggattaca agcgtgggggt atgggattat tgactatgaa  
1080

acaagggacg tgatcgacgc aggcgtcaga ctgttcaagg aggccaacgt ggaaaacaat  
1140

gagggacgga gaagcaagag gggagccagg cgcctgaaac gacggagaag gcacagaatc  
1200

cagaggggtga agaaactgct gttcgattac aacctgctga ccgaccattc tgagctgagt  
1260

ggaattaatc cttatgaagc cagggtgaaa ggcctgagtc agaagctgtc agaggaagag  
1320

ttttccgcag ctctgctgca cctggctaag cgccgaggag tgcataacgt caatgaggtg  
1380

gaagaggaca ccggcaacga gctgtctaca aaggaacaga tctcacgcaa tagcaaagct  
1440

ctggaagaga agtatgtcgc agagctgcag ctggaacggc tgaagaaaga tggcgaggtg  
1500

agaggggtcaa ttaatagggt caagacaagc gactacgtca aagaagccaa gcagctgctg  
1560

aaagtgcaga aggcttacca ccagctggat cagagcttca tcgataactta tatcgacctg  
1620

ctggagactc ggagaacctt ctatgagggg ccaggagaag ggagcccctt cggatggaaa  
1680

gacatcaagg aatgggtacga gatgctgatg ggacattgca cctatttttcc agaagagctg  
1740

agaagcgtca agtacgctta taacgcagat ctgtacaacg ccctgaatga cctgaacaac  
1800

ctgggtcatca ccaggggatga aaacgagaaa ctggaatact atgagaagtt ccagatcatc  
1860

gaaaacgtgt ttaagcagaa gaaaaagcct acactgaaac agattgctaa ggagatcctg  
1920

gtcaacgaag aggacatcaa gggctaccgg gtgacaagca ctggaaaacc agagttcacc  
1980

aatctgaaag tgtatcacga tattaaggac atcacagcac ggaaagaaat cattgagaac  
2040

gccgaactgc tggatcagat tgctaagatc ctgactatct accagagctc cgaggacatc  
2100

caggaagagc tgactaacct gaacagcgag ctgacccagg aagagatcga acagattagt  
2160

aatctgaagg ggtacaccgg aacacacaac ctgtccctga aagctatcaa tctgattctg  
2220

gatgagctgt ggcatacaaa cgacaatcag attgcaatct ttaaccggct gaagctggtc  
2280

ccaaaaaagg tggacctgag tcagcagaaa gagatcccaa ccacactggg ggacgatttc  
2340

attctgtcac ccgtgggtcaa gcggagcttc atccagagca tcaaagtgat caacgccatc  
2400

atcaagaagt acggcctgcc caatgatatc attatcgagc tggctaggga gaagaacagc  
2460

aaggacgcac agaagatgat caatgagatg cagaaacgaa accggcagac caatgaacgc  
2520

attgaagaga ttatccgaac taccgggaaa gagaacgcaa agtacctgat tgaaaaaatc  
2580

aagctgcacg atatgcagga gggaaagtgt ctgtattctc tggaggccat ccccctggag  
2640

gacctgctga acaatccatt caactacgag gtcgatcata ttatccccag aagcgtgtcc  
2700

ttcgacaatt cctttaacaa caaggtgctg gtcaagcagg aagagaactc taaaaagggc  
2760

aataggactc ctttccagta cctgtctagt tcagattcca agatctctta cgaaaccttt  
2820

aaaaagcaca ttctgaatct ggccaaagga aagggccgca tcagcaagac caaaaaggag  
2880

tacctgctgg aagagcggga catcaacaga ttctccgtcc agaaggattt tattaaccgg  
2940

aatctggtgg acacaagata cgctactcgc ggctgatga atctgctgcg atcctatttc  
3000

cgggtgaaca atctggatgt gaaagtcaag tccatcaacg gcgggttcac atcttttctg  
3060

aggcgcaa at ggaagtttaa aaaggagcgc aacaaaggg tacaagcacca tgccgaagat  
3120

gctctgatta tcgcaa atgc cgacttcac ttttaaggagt ggaaaaagct ggacaaagcc  
3180

aagaaagtga tggagaacca gatgttcgaa gagaagcagg ccgaatctat gcccgaaatc  
3240

gagacagaac aggagtacaa ggagattttc atcactcctc accagatcaa gcatatcaag  
3300

gatttcaagg actacaagta ctctcaccgg gtggataaaa agcccaacag agagctgac  
3360

aatgacaccc tgtatagtac aagaaaagac gataagggga atacctgat tgtgaacaat  
3420

ctgaacggac tgtacgacaa agataatgac aagctgaaaa agctgatcaa caaaagtccc  
3480

gagaagctgc tgatgtacca ccatgac tct cagacat atc agaaactgaa gctgattatg  
3540

gagcagtacg gcgacgagaa gaaccactg tataagtact atgaagagac tgggaactac  
3600

ctgaccaagt atagcaaaaa ggataatggc cccgtgatca agaagatcaa gtactatggg  
3660

aacaagctga atgcccattct ggacatcaca gacgattacc ctaacagtcg caacaagggtg  
3720

gtcaagctgt cactgaagcc atacagattc gatgtctatc tggacaacgg cgtgtataaa  
3780

tttgtgactg tcaagaatct ggatgtcatc aaaaaggaga actactatga agtgaatagc  
3840

aagtgctacg aagaggctaa aaagctgaaa aagattagca accaggcaga gttcatcgcc  
3900

tcctttttaca acaacgacct gattaagatc aatggcgaac tgtatagggt catcgggggtg  
3960

aacaatgatc tgctgaaccg cattgaagtg aatatgattg acatcactta ccgagagtat  
4020

ctggaaaaca tgaatgataa gcgccccctt cgaattatca aaacaattgc ctctaagact  
4080

cagagtatca aaaagtactc aaccgacatt ctgggaaacc tgtatgaggt gaagagcaaa  
4140

aagcaccctc agattatcaa aaagggcgga tcccccaaga agaagaggaa agtctcgagc  
4200

tagcaataaa ggatcgttta ttttcattgg aagcgtgtgt tggttttttg atcaggcgcg  
4260

tccaagcttg catgctgggg agagatctgc ggccgcctag caataaagga tcgtttatatt  
4320

tcattggaag cgtgtgttgg ttttttgatc aggcgcgagg aacccttagt gatggagtgtg  
4380

gccactccct ctctgcgcgc tcgctcgctc actgaggccg ggcgaccaa ggtcgcccga  
4440

cgcccgggct ttgcccgggc ggcctcagtg agcgagcgag cgcgagctg cctgcagg  
4498

<210> 10  
<211> 4170  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Cas9 Vector 2: 250 bp minimal RHO promoter driving Cas9 w/  
alpha  
globin UTR

<220>  
<221> misc\_feature  
<222> (1)..(141)  
<223> ITR

<220>  
<221> misc\_feature  
<222> (179)..(427)  
<223> MinRHO promoter (250bp)

<220>  
<221> misc\_feature  
<222> (428)..(590)  
<223> SV40 intron

<220>  
<221> misc\_feature  
<222> (607)..(636)  
<223> NLS

<220>  
<221> misc\_feature  
<222> (637)..(3795)  
<223> Sa Cas9

<220>  
<221> misc\_feature  
<222> (3802)..(3822)  
<223> SV40 NLS

<220>  
<221> misc\_feature

<222> (3832)..(3942)

<223> HBA1 UTR

<220>

<221> misc\_feature

<222> (4030)..(4170)

<223> ITR

<400> 10

cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcaaag cccgggcgtc  
60

gggcgacctt tggtcgcccc gcctcagtga gcgagcgagc gcgcagagag ggagtggcca  
120

actccatcac taggggttcc taagcggccg cggttcctca gatctgaatt cggtacctgt  
180

caccttggcc cctcttagaa gccaattagg ccctcagttt ctgcagcggg gattaatatg  
240

attatgaaca cccccaatct cccagatgct gattcagcca ggagcttagg agggggaggt  
300

cactttataa gggctctgggg gggtcagaac ccagagtcac ccagctggag ccctgagtgg  
360

ctgagctcag gccttcgcag cattcttggg tgggagcagc cacgggtcag ccacaagggc  
420

cacagcctct agaggatccg gtactcgagg aactgaaaaa ccagaaagtt aactggtaag  
480

tttagtcttt ttgtctttta tttcagggtcc cggatccggt ggtgggtgcaa atcaaagaac  
540

tgctcctcag tggatgttgc ctttacttct aggcctgtac ggaagtgtta ctccgccacc  
600

atgggaccga agaaaaagcg caaggtcgaa gcgtccatga aaaggaacta cattctgggg  
660

ctggacatcg ggattacaag cgtgggggtat gggattattg actatgaaac aaggggacgtg  
720

atcgacgcag gcgtcagact gttcaaggag gccaacgtgg aaaacaatga gggacggaga  
780

agcaagaggg gagccaggcg cctgaaacga cggagaaggc acagaatcca gaggggtgaag  
840

aaactgctgt tcgattacaa cctgctgacc gaccattctg agctgagtgg aattaatcct  
900

tatgaagcca gggtgaaagg cctgagtcag aagctgtcag aggaagagtt ttccgcagct  
960

ctgctgcacc tggctaagcg ccgaggagtg cataacgtca atgagggtgga agaggacacc  
1020

ggcaacgagc tgtctacaaa ggaacagatc tcacgcaata gcaaagctct ggaagagaag  
1080

tatgtcgcag agctgcagct ggaacggctg aagaaagatg gcgagggtgag aggggtcaatt  
1140

aataggttca agacaagcga ctacgtcaaa gaagccaagc agctgctgaa agtgcagaag  
1200

gcttaccacc agctggatca gagcttcacg gatacttata tcgacctgct ggagactcgg  
1260

agaacctact atgagggacc aggagaaggg agccccttcg gatggaaaga catcaaggaa  
1320

tggtacgaga tgctgatggg acattgcacc tattttccag aagagctgag aagcgtcaag  
1380

tacgcttata acgcagatct gtacaacgcc ctgaatgacc tgaacaacct ggtcatcacc  
1440

agggatgaaa acgagaaact ggaatactat gagaagttcc agatcatcga aaacgtgttt  
1500

aagcagaaga aaaagcctac actgaaacag attgctaagg agatcctggg caacgaagag  
1560

gacatcaagg gctaccgggt gacaagcact ggaaaaccag agttcaccaa tctgaaagtg  
1620

tatcacgata ttaaggacat cacagcacgg aaagaaatca ttgagaacgc cgaactgctg  
1680

gatcagattg ctaagatcct gactatctac cagagctccg aggacatcca ggaagagctg  
1740

actaacctga acagcgagct gacccaggaa gagatcgaac agattagtaa tctgaagggg  
1800

tacaccggaa cacacaacct gtccctgaaa gctatcaatc tgattctgga tgagctgtgg  
1860

catacaaacg acaatcagat tgcaatcttt aaccggctga agctgggtccc aaaaaagggtg  
1920

gacctgagtc agcagaaaga gatcccaacc acactgggtgg acgatttcat tctgtcaccc  
1980

gtgggtcaagc ggagcttcat ccagagcatc aaagtgatca acgccatcat caagaagtac  
2040

ggcctgcccc atgatatcat tatcgagctg gctagggaga agaacagcaa ggacgcacag  
2100

aagatgatca atgagatgca gaaacgaaac cggcagacca atgaacgcat tgaagagatt  
2160

atccgaacta ccgggaaaga gaacgcaaag tacctgattg aaaaaatcaa gctgcacgat  
2220

atgcaggagg gaaagtgtct gtatttctctg gaggccatcc ccctggagga cctgctgaac  
2280

aatccattca actacgaggt cgatcatatt atccccagaa gcgtgtcctt cgacaattcc  
2340

tttaacaaca aggtgctgggt caagcaggaa gagaactcta aaaagggcaa taggactcct  
2400

ttccagtacc tgtctagttc agattccaag atctcttacg aaacctttaa aaagcacatt  
2460

ctgaatctgg ccaaaggaaa gggccgcac cagcaagacca aaaaggagta cctgctggaa  
2520

**gagcgggaca tcaacagatt ctccgtccag aaggatttta ttaaccggaa tctggtggac**  
**2580**

**acaagatacg ctactcgcgg cctgatgaat ctgctgcgat cctattttccg ggtgaacaat**  
**2640**

**ctggatgtga aagtcaagtc catcaacggc gggttcacat cttttctgag gcgcaaattg**  
**2700**

**aagtttaaaa aggagcgcaa caaaggggtac aagcaccatg ccgaagatgc tctgattatc**  
**2760**

**gcaaattgccg acttcatctt taaggagtgg aaaaagctgg acaaagccaa gaaagtgatg**  
**2820**

**gagaaccaga tgttcgaaga gaagcaggcc gaatctatgc ccgaaatcga gacagaacag**  
**2880**

**gagtacaagg agattttcat cactcctcac cagatcaagc atatcaagga tttcaaggac**  
**2940**

**tacaagtact ctcaccgggt ggataaaaag cccaacagag agctgatcaa tgacaccctg**  
**3000**

**tatagtacaa gaaaagacga taaggggaat accctgattg tgaacaatct gaacggactg**  
**3060**

**tacgacaaag ataatgacaa gctgaaaaag ctgatcaaca aaagtcccga gaagctgctg**  
**3120**

**atgtaccacc atgatcctca gacatatcag aaactgaagc tgattatgga gcagtacggc**  
**3180**

**gacgagaaga acccactgta taagtactat gaagagactg ggaactacct gaccaagtat**  
**3240**

**agcaaaaagg ataatggccc cgtgatcaag aagatcaagt actatgggaa caagctgaat**  
**3300**

**gcccattctgg acatcacaga cgattaccct aacagtcgca acaagggtgg caagctgtca**  
**3360**

**ctgaagccat acagattcga tgtctatctg gacaacggcg tgtataaatt tgtgactgtc**  
**3420**

aagaatctgg atgtcatcaa aaaggagAAC tactatgaag tgaatagcaa gtgctacgaa  
3480

gaggctaaaa agctgaaaaa gattagcaac caggcagagt tcatcgccctc cttttacaac  
3540

aacgacctga ttaagatcaa tggcgaactg tataggggtca tcgggggtgaa caatgatctg  
3600

ctgaaccgca ttgaagtgaa tatgattgac atcacttacc gagagtatct ggaaaacatg  
3660

aatgataagc gccccctcg aattatcaaa acaattgcct ctaagactca gagtatcaaa  
3720

aagtactcaa ccgacattct gggaaacctg tatgagggtga agagcaaaaa gcaccctcag  
3780

attatcaaaa agggcggatc cccaagaag aagaggaaag tctcgagcta ggctggagcc  
3840

tcggtggcca tgcttcttgc cccttgggcc tccccccagc ccctcctccc cttcctgcac  
3900

ccgtaccccc gtggtctttg aataaagtct gagtgggcgg cacatgctgg ggagagatct  
3960

gcggccgcct agcaataaag gatcgtttat tttcattgga agcgtgtgtt ggttttttga  
4020

tcaggcgcgga ggaacccta gtgatggagt tggccactcc ctctctgcgc gctcgctcgc  
4080

tcactgaggc cgggcgacca aaggtcgccc gacgcccggg ctttgcccgg gcggcctcag  
4140

t g a g c g a g c g                      a g c g c g c a g c                      t g c c t g c a g g  
4170

<210> 11

<211> 2691

<212> DNA

<213> Artificial Sequence

<220>  
<223> Exemplary replacement vector: 250 bp minimal RHO promoter driving  
codon-optimized RHO cDNA; U6 promoter driving gRNA targeting  
RHO

<220>  
<221> misc\_feature  
<222> (1)..(139)  
<223> ITR

<220>  
<221> misc\_feature  
<222> (174)..(437)  
<223> U6 promoter

<220>  
<221> misc\_feature  
<222> (439)..(460)  
<223> RHO-7 gRNA targeting domain

<220>  
<221> misc\_feature  
<222> (461)..(536)  
<223> Sa gRNA scaffold

<220>  
<221> misc\_feature  
<222> (563)..(826)  
<223> U6 promoter

<220>  
<221> misc\_feature  
<222> (828)..(849)  
<223> RHO-7 gRNA targeting domain

<220>  
<221> misc\_feature  
<222> (850)..(925)  
<223> Sa gRNA scaffold

<220>  
<221> misc\_feature  
<222> (947)..(1195)

<223> minRHO promoter (250bp)

<220>

<221> misc\_feature

<222> (1196)..(1359)

<223> SV40 intron

<220>

<221> misc\_feature

<222> (1369)..(2412)

<223> Codon Optimized RHO cDNA

<220>

<221> misc\_feature

<222> (2416)..(2526)

<223> HBA1 UTR

<220>

<221> misc\_feature

<222> (2553)..(2691)

<223> ITR

<400> 11

tgcaggcagc tgcgcgctcg ctcgctcact gaggccgccc gggcaaagcc cgggcgctcgg  
60

gcgacctttg gtcgcccggc ctcagtgagc gagcgagcgc gcagagaggg agtggccaac  
120

tccatcacta ggggttcctg cggccgcggt tcctcagatc tgaattcggg accaaggctc  
180

ggcaggaaga gggcctatth cccatgattc cttcatatth gcatatacga tacaaggctg  
240

ttagagagat aattagaatt aatttgactg taaacacaaa gatattagta caaaatacgt  
300

gacgtagaaa gtaataatth cttgggtagt ttgcagthtt aaaattatgt tttaaaatgg  
360

actatcatat gcttaccgta acttgaaagt atttcgattt cttggcttta tataatcttgt  
420

ggaaaggacg aaacaccgcc cacaccggc tcataccgcc gttatagtag tctggaaaca  
480

gaatctacta taacaaggca aaatgccgtg tttatctcgt caacttgttg gcgagatttt  
540

ttcgacttag ttcgatcgaa ggaaggctcg gcaggaagag ggcctatttc ccatgattcc  
600

ttcatatttg catatacgat acaaggctgt tagagagata attagaatta atttgactgt  
660

aaacacaaag atattagtag aaaatacgtg acgtagaaag taataatttc ttgggtagtt  
720

tgcagtttta aaattatggt ttaaaatgga ctatcatatg cttaccgtaa cttgaaagta  
780

tttcgatttc ttggctttat atatcttggt gaaaggacga aacaccgccc acaccggct  
840

cataccgccg ttatagtact ctggaaacag aatctactat aacaaggcaa aatgccgtgt  
900

ttatctcgtc aacttgttgg cgagattttt tggtagcgt agcgctgtca ccttggcccc  
960

tcttagaagc caattaggcc ctcagtttct gcagcgggga ttaatatgat tatgaacacc  
1020

cccaatctcc cagatgctga ttcagccagg agcttaggag ggggaggtca ctttataagg  
1080

gtctgggggg gtcagaaccc agagtcaccc agctggagcc ctgagtggtt gagctcaggc  
1140

cttcgcagca ttcttgggtg ggagcagcca cgggtcagcc acaagggccca cagcctctag  
1200

aggatccggt actcgaggaa ctgaaaaacc agaaagttaa ctggtaagtt tagtcttttt  
1260

gtcttttatt tcagggtccc gatccggtgg tgggtgcaaat caaagaactg ctctcagtg  
1320

gatgttgccct ttacttctag gcctgtacgg aagtgttact ccgccaccat gaatggcaca  
1380

**gagggcccta acttctacgt gcccttttagc aatgccacag gcgtcgtgcg gagccctttt**  
**1440**

**gagtaccctc agtactatct ggccgagcct tggcagttta gcatgctggc cgcctacatg**  
**1500**

**ttcctgctga tcgtgctggg cttccccatc aacttttctga ccctgtacgt gaccgtgcag**  
**1560**

**cacaagaagc tgcggacccc tctgaactac atcctgctga atctggccgt ggccgacctg**  
**1620**

**tttatggtgc tcggcggtt taccagcaca ctgtacacaa gcctgcacgg ctacttcgtg**  
**1680**

**tttgccccca ccggctgcaa tctggaaggc ttttttgcca cactcggcgg cgaaattgct**  
**1740**

**ctgtggtcac tgggtggtgct ggccatcgag agatacgtgg tcgtgtgcaa gcccatgagc**  
**1800**

**aacttcagat tcggcgagaa ccacgccatc atgggcgtcg cctttacatg ggttatggcc**  
**1860**

**ctggcttggtg cagctcctcc tcttgccggc tgggtccagat atattcctga gggcctgcag**  
**1920**

**tgcagctgcg gcatcgatta ctacaccctg aagcctgaag tgaacaacga gagcttcgtg**  
**1980**

**atctacatgt ttgtggtgca cttcacgatc cccatgatca tcatattctt ttgctacggc**  
**2040**

**cagctggtgt tcaccgtgaa agaagccgct gctcagcagc aagagagcgc cacaacacag**  
**2100**

**aaagccgaga aagaagtgac ccggatggtc attatcatgg ttatcgcctt tctgatctgt**  
**2160**

**tgggtgccct acgccagcgt ggccttctac atctttaccc accaaggcag caacttcggc**  
**2220**

**cccatcttta tgacaatccc cgccttcttt gccaaagagcg ccgccatcta caaccccgctg**  
**2280**

atctatatca tgatgaacaa gcagttccgc aactgcatgc tgaccaccat ctgctgcgga  
2340

aagaaccctc tgggagatga tgaggccagc gccaccgtgt ctaagaccga aacatctcag  
2400

gtggcccctg catgagctgg agcctcgggtg gccatgcttc ttgccccttg ggcctcccc  
2460

cagcccctcc tccccttcct gcacccgtag ccccgtaggtc tttgaataaa gtctgagtgg  
2520

gcggcacatg ctggggagag atctgcggcc gcaggaaccc ctagtgatgg agttggccac  
2580

tccctctctg cgcgctcgct cgctcactga ggccggggcga ccaaaggtag cccgacgccc  
2640

gggctttgcc cgggcggcct cagtgcgcga gcgagcgcgc agctgcctgc a  
2691

<210> 12

<211> 76

<212> DNA

<213> Artificial Sequence

<220>

<223> gRNA scaffold sequence

<400> 12

gttatagtac tctggaaaca gaatctacta taacaaggca aaatgccgtg tttatctcgt  
60

c a a c t t g t t g  
76

g c g a g a

<210> 13

<211> 1047

<212> DNA

<213> Artificial Sequence

<220>

**<223> Codon optimized RHO-encoding sequence 1 (Codon 1)**

**<400> 13**

**atgaacggca ccgagggccc caacttctac gtccccttca gcaacgccac cggcgtcgtc**  
**60**

**cgcagcccct tcgagtaccc ccagtactac ctggccgagc cctggcagtt cagcatgctg**  
**120**

**gccgcctaca tgttcctgct gatcgtcctg ggcttcccca tcaacttcct gaccctgtac**  
**180**

**gtcacctgcc agcacaagaa gctgcgcacc cccctgaact acatcctgct gaacctggcc**  
**240**

**gtcgccgacc tgttcatggc cctggggcggc ttcaccagca ccctgtacac cagcctgcac**  
**300**

**ggctacttcg tcttcggccc caccggctgc aacctggagg gcttcttcgc caccctgggc**  
**360**

**ggcgagatcg ccctgtggag cctggtcgtc ctggccatcg agcgctacgt cgtcgtctgc**  
**420**

**aagcccatga gcaacttcg cttcggcgag aaccacgcca tcatgggcgt cgccttcacc**  
**480**

**tgggtcatgg ccctggcctg cgccgcccc cccctggccg gctggagccg ctacatcccc**  
**540**

**gagggcctgc agtgcagctg cggcatcgac tactacaccc tgaagcccga ggtcaacaac**  
**600**

**gagagcttcg tcatctacat gttcgtcgtc cacttcacca tccccatgat catcatcttc**  
**660**

**ttctgctacg gccagctggc cttcaccgtc aaggaggccg ccgcccagca gcaggagagc**  
**720**

**gccaccaccc agaaggccga gaaggaggtc acccgcatgg tcatcatcat ggtcatcgcc**  
**780**

**ttcctgatct gctgggtccc ctacgccagc gtcgccttct acatcttcac ccaccagggc**  
**840**

agcaacttcg gccccatctt catgaccatc cccgccttct tcgccaagag cgccgccatc  
900

tacaaccccg tcatctacat catgatgaac aagcagttcc gcaactgcat gctgaccacc  
960

atctgctgcg gcaagaaccc cctgggcgac gacgaggcca gcgccaccgt cagcaagacc  
1020

g a g a c c a g c c                      a g g t c g c c c c                      c g c c t a a  
1047

<210> 14

<211> 1047

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon optimized RHO-encoding sequence 2 (Codon 2)

<400> 14

atgaacggca ccgagggccc caacttctac gtgcccttct ccaacgccac cggcgtggtg  
60

cgctccccct tcgagtaccc ccagtactac ctggccgagc cctggcagtt ctccatgctg  
120

gccgcctaca tgttcctgct gatcgtgctg ggcttcccca tcaacttcct gaccctgtac  
180

gtgaccgtgc agcacaagaa gctgcgcacc cccctgaact acatcctgct gaacctggcc  
240

gtggccgacc tgttcatggt gctgggcggc ttcacctcca ccctgtacac ctccctgcac  
300

ggctacttcg tgttcggccc caccggctgc aacctggagg gcttcttcgc caccctgggc  
360

ggcgagatcg ccctgtggtc cctgggtggtg ctggccatcg agcgctacgt ggtggtgtgc  
420

aagcccatgt ccaacttccg cttcggcgag aaccacgcca tcatgggcgt ggccttcacc  
480

tggggtgatgg ccctggcctg cgccgcccc cccctggccg gctgggtcccg ctacatcccc  
540

gagggcctgc agtgctcctg cggcatcgac tactacaccc tgaagcccga ggtgaacaac  
600

gagtccttcg tgatctacat gttcgtgggtg cacttcacca tccccatgat catcatcttc  
660

ttctgctacg gccagctggg gttcaccgtg aaggaggccg ccgcccagca gcaggagtcc  
720

gccaccaccc agaaggccga gaaggagggtg acccgcatgg tgatcatcat ggtgatcgcc  
780

ttcctgatct gctgggtgcc ctacgcctcc gtggccttct acatcttcac ccaccagggc  
840

tccaacttcg gcccacatctt catgaccatc cccgccttct tcgccaagtc cgccgccatc  
900

tacaaccccg tgatctacat catgatgaac aagcagttcc gcaactgcat gctgaccacc  
960

atctgctgcg gcaagaaccc cctggggcgac gacgaggcct ccgccaccgt gtccaagacc  
1020

g a g a c c t c c c                      a g g t g g c c c c                      c g c c t a a  
1047

<210> 15

<211> 1047

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon Optimized RHO-encoding sequence 3 (Codon 3)

<400> 15

atgaacggca ccgagggccc caacttctac gtcccccttca gcaacgccac cggcgctcgtc  
60

cgcagcccct tcgagtaccc ccagtactac ctggccgagc cctggcagtt ctctatgctg  
120

gccgcctaca tgttcctgct gatcgtcctg ggcttcccta tcaacttcct caccctctac  
180

gtcaccgtcc agcacaagaa gctccgcacc cctctcaact acatcctcct taaccttgcc  
240

gtcgccgacc ttttcatggg ccttggcggc ttcacctcta ctctttacac ttctttgcac  
300

gggtacttcg tgttcgggtcc tactgggttg aacttggagg gtttcttcgc cactttgggt  
360

ggtgagatcg ccttgtgggc gttgggtggtg ttagctatcg agcgatacgt ggtgggtgtgc  
420

aagcctatgt cgaacttccg gttcgggtgag aatcatgcta tcatgggagt ggcttttact  
480

tgggtgatgg ctttagcttg cgctgctcct ccgttagctg gatggtcgcg ttatatcccg  
540

gagggattac agtgctcatg cggaatcgac tattatactc taaagccgga agttaataat  
600

gaatcatttg ttattttatat gtttggttgtt cattttacaa ttccgatgat tattattttt  
660

ttttgttatg gacagctagt ttttacagtt aaggaagcag cagcacagca acaagaatca  
720

gcaacaacac aaaaggcaga aaaagaagtt acaaggatgg ttattattat ggtaattgca  
780

tttctaatat gttgggtacc gtatgcatcc gtagcatttt atatatttac acatcaaggg  
840

tccaattttg ggccaatatt tatgacgata ccagcgtttt ttgcgaaatc cgcggcgata  
900

tataatccag taatatatat aatgatgaat aaacaattta gaaattgtat gctaacgacg  
960

atatgttggt ggaaaaatcc actaggggat gatgaagcga gtgcgacggg aagtaaaacg  
1020

g a a a c g a g t c  
1047

a a g t a g c g c c

a g c g t a a

<210> 16

<211> 1047

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon Optimized RHO-encoding sequence 4 (Codon 4)

<400> 16

atgaacggca ccgaggggtcc caatttctac gtcccathtt ccaacgccac ggggggtggta  
60

cgcagccctt tcgaatatcc gcagtactat ctggctgagc cctggcagtt ttctatgctc  
120

gcagcgtaca tgttcttgct aatcgttctg ggattttcaa ttaatttcct cacattgtat  
180

gtcacctgtc agcacaagaa gctacggacg cctctgaact acatcctctt gaatctagcc  
240

gtcgctgacc tgtttatggg tctcggcggt ttcacatcga ccttggtatac gtcactacat  
300

gggtactttg tcttcggacc gacaggctgc aacctggaag gttttttcgc aaccctcggg  
360

ggagagattg cgttgtggtc cctagtggta ctggccatcg aaaggatatgt tgcgtgtgt  
420

aagcccatga gcaattttcg cttcggcgag aaccacgcta ttatgggtgt agcatttacg  
480

tgggttatgg cgctcgccctg cgctgcacca cctttggcgg ggtgggtctcg gtacatcccg  
540

gaaggactac agtgttcgtg cggcattgat tattacacac tgaagcccga ggtcaataac  
600

gaatcattcg tgatctatat gtttgtagtt catttcacca ttccaatgat cattatcttt  
660

ttctgttacg gtcagctcgt ctttacggtg aaggaggccg ctgcacagca gcaggaatcc  
720

gcgacaaccc agaaggccga gaaggaagta acgaggatgg ttattatcat ggtcattgct  
780

ttcttgatct gctgggtgcc ttatgcaagc gtagcgtttt acattttcac acaccagggg  
840

tctaattttg gaccgatctt catgaccatt cccgcctttt tcgctaagtc ggcagcgatc  
900

tataaccag ttattttacat catgatgaat aagcagtttc gcaactgtat gctaacgaca  
960

atttgctgtg gcaagaatcc tctgggtgac gatgaggcct cagctaccgt ctccaagacg  
1020

g a a a c a a g c c a g g t g g c a c c g g c g t a a  
1047

<210> 17

<211> 1047

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon Optimized RHO-encoding sequence 5 (Codon 5)

<400> 17

atgaatggga ctgaaggacc taattttctat gtgccattta gcaatgctac tggcgttgtc  
60

agaagcccct tcgaatatcc acaatactat ctggccgaac cttggcagtt cagcatgctc  
120

gctgcctata tgttttctgct gattgtgctg ggctttccca taaatttcct caccctgtat  
180

gttactgttc aacacaaaaa gctgcggacg cctctgaact acatactgct gaacctggcc  
240

gtcgccgacc tgttttatggc cctgggaggc ttacaagca ctctgtatac aagcctgcac  
300

ggctacttcg tgttcggccc cacaggctgc aacctcgaag gcttcctttgc caccctcgga  
360

ggagagattg ccctgtggag cctgggtggtg ctggccatcg aaaggatatgt ggtgggtgtgt  
420

aaacccatgt ccaatttttcg gttcggcgag aaccacgcta ttatgggagt ggctttcact  
480

tgggtgatgg ccctggcctg cgccgccccca ccactggccg ggtggagccg gtacatccca  
540

gaggggctgc aatgtagctg cggaatcgac tattataccc tgaaaccaga ggtgaacaac  
600

gagagctttg tgatttatat gtttgtggtg cattttacaa ttcctatgat tatcattttc  
660

ttctgttacg ggcaactggg gtttaccgtg aaggaagccg ccgctcaaca gcaggagagc  
720

gccacaaccc aaaaggccga gaaggagggtg accagaatgg tgattattat ggtgatcgct  
780

tttctgattt gctgggtgcc atacgctagc gtcgctttct atattttcac tcaccagggg  
840

agcaacttcg gccccatttt catgacaatc cctgcctttt ttgctaaaag cgccgccatc  
900

tataaccag tgatctacat catgatgaac aaacagttta ggaactgtat gctcacaaca  
960

atctgctgtg gaaagaaccc cctcggcgat gacgaagcca gcgccaccgt cagcaagaca  
1020

g a a a c a a g c c a g g t g g c c c c t g c c t a a  
1047

<210> 18

<211> 1047

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon Optimized RHO-encoding sequence 6 (Codon 6)

<400> 18

atgaatggca cagaggggcc taacttctac gtgcccttta gcaatgccac aggcgtcgtg  
60

cggagccctt ttgagtaccc tcagtactat ctggccgagc cttggcagtt tagcatgctg  
120

gccgcctaca tgttcctgct gatcgtgctg ggcttcccca tcaactttct gaccctgtac  
180

gtgaccgtgc agcacaagaa gctgcggacc cctctgaact acatcctgct gaatctggcc  
240

gtggccgacc tgtttatggg gctcggcggc tttaccagca cactgtacac aagcctgcac  
300

ggctacttcg tgtttgcccc caccggctgc aatctggaag gcttttttgc cacactcggc  
360

ggcgaaattg ctctgtggtc actggtggtg ctggccatcg agagatacgt ggtcgtgtgc  
420

aagcccatga gcaacttcag attcggcgag aaccacgcca tcatgggcgt cgcctttaca  
480

tgggttatgg ccctggcttg tgcagctcct cctcttgccg gctgggtccag atatattcct  
540

gagggcctgc agtgcagctg cggcatcgat tactacaccc tgaagcctga agtgaacaac  
600

gagagcttcg tgatctacat gtttgtggtg cacttcacga tccccatgat catcatattc  
660

ttttgctacg gccagctggg gttcaccgtg aaagaagccg ctgctcagca gcaagagagc  
720

gccacaacac agaaagccga gaaagaagtg acccggatgg tcattatcat ggttatcgcc  
780

tttctgatct gttgggtgcc ctacgccagc gtggccttct acatctttac ccaccaaggc  
840

agcaacttcg gccccatctt tatgacaatc cccgccttct ttgccaagag cgccgccatc  
900

tacaaccccg tgatctatat catgatgaac aagcagttcc gcaactgcat gctgaccacc  
960

atctgctgcg gaaagaaccc tctgggagat gatgaggcca gcgccaccgt gtctaagacc  
1020

g a a a c a t c t c                      a g g t g g c c c c                      t g c a t g a  
1047

<210> 19

<400> 19  
000

<210> 20

<400> 20  
000

<210> 21

<400> 21  
000

<210> 22

<400> 22  
000

<210> 23

<400> 23  
000

<210> 24

<400> 24  
000

<210> 25

**<400> 25  
000**

**<210> 26**

**<400> 26  
000**

**<210> 27**

**<400> 27  
000**

**<210> 28**

**<400> 28  
000**

**<210> 29**

**<400> 29  
000**

**<210> 30**

**<400> 30  
000**

**<210> 31**

**<400> 31  
000**

**<210> 32**

**<400> 32  
000**

**<210> 33**

**<400> 33  
000**

**<210> 34**

<400> 34  
000

<210> 35

<400> 35  
000

<210> 36

<400> 36  
000

<210> 37

<400> 37  
000

<210> 38

<211> 111

<212> DNA

<213> Artificial Sequence

<220>

<223> HBA1 3'UTR

<400> 38

gctggagcct cggtggccat gcttcttgcc ccttgggcct cccccagcc cctcctcccc  
60

ttcctgcacc cgtacccccg tggctcttga ataaagtctg agtgggcggc a  
111

<210> 39

<211> 101

<212> DNA

<213> Artificial Sequence

<220>

<223> short HBA1 3'UTR

<400> 39

gctggagcct cggtggccat gcttcttgcc ccttgggcct cccccagcc cctcctcccc  
60



cagacaagca acccaaactg aacccccctca aaagccaaaa aatgggagac aatttcacat  
120

ggactttgga aaatatTTTT ttcctttgca ttcattcttc aaacttagtt tttatctttg  
180

accaaccgaa catgaccaaa aaccaaagt gcattcaacc ttaccaaaaa aaaaaaaaaa  
240

aaaagaataa ataaataact ttttaaaaaa ggaagcttgg tccacttgct tgaagacca  
300

tgcgggggta agtccctttc tgcccgttgg gcttatgaaa cccaatgct gccctttctg  
360

ctcctttctc cacaccccc ttggggcctc ccctccactc cttcccaaat ctgtctcccc  
420

agaagacaca ggaaacaatg tattgtctgc ccagcaatca aaggcaatgc tcaaacaccc  
480

aagtggcccc caccctcagc ccgctcctgc ccgcccagca ccccaggcc ctgggggacc  
540

tggggttctc agactgccaa agaagccttg ccattctggcg ctcccatggc tcttgcaaca  
600

tctccccttc gtttttgagg gggtcattgc gggggagcca ccagcccctc actgggttcg  
660

gaggagagtc aggaagggcc acgacaaagc agaaacatcg gatttgggga acgcgtgtca  
720

atcccttggt ccgcagggct gggcgggaga gactgttctg ttccttggtg aactgtgttg  
780

ctgaaagact acctcgttct tgtcttgatg tgtcaccggg gcaactgcct gggggcgggg  
840

atgggggcag ggtggaagcg gctccccatt ttataccaaa ggtgctacat ctatgtgatg  
900

ggtggggtgg ggagggaatc actggtgcta tagaaattga gatgcccccc caggccagca  
960

aatgttcctt tttgttcaaa gtctatTTTT attccttgat atTTTTcttt tTTTTTTTTT  
1020

TTTTTgtgg atggggactt gtgaatTTTT ctaaaggTgc tattaacat gggaggagag  
1080

cgtgtgcggc tccagcccag cccgctgctc actttccacc ctctctccac ctgcctctgg  
1140

cttctcaggc ctctgctctc cgacctctct cctctgaaac cctcctccac agctgcagcc  
1200

catcctcccg gctccctcct agtctgtcct gcgtcctctg tccccgggtt tcagagacaa  
1260

cttcccaaag cacaaagcag tttttccccc taggggtggg aggaagcaaa agactctgta  
1320

cctatTTTgt atgtgtataa taatttgaga tgtTTTTaat tattttgatt gctggaataa  
1380

a g c a t g t g g a                      a a t g a c c c a a                      a c a t a a  
1406

<210> 42

<211> 681

<212> DNA

<213> Artificial Sequence

<220>

<223> ALOX15 3'UTR

<400> 42

gcgtcgccac cctttgggta tttcagcccc catcacccaa gccacaagct gacccttcg  
60

tggttatagc cctgccctcc caagtcccac cctcttccca tgtcccaccc tccctagagg  
120

ggcacctttt catgggtctct gcacccagtg aacacatTTT actctagagg catcacctgg  
180

gaccttactc ctctttcctt ccttcctcct ttcctatctt ccttcctctc tctcttcctc  
240

tttcttcatt cagatctata tggcaaatag ccacaattat ataaatcatt tcaagactag  
300

aataggggga tataatacat attactccac accttttatg aatcaaatat gatttttttg  
360

ttgttggttaa gacagagtct cactttgaca cccaggctgg agtgcagtgg tgccatcacc  
420

acggctcact gcagcctcag cgtcctgggc tcaaatagat ctcccacctc agcctcctga  
480

gtagctggga ctacaggctc atgccatcat gccagctaa tattttttta ttttcgtgga  
540

gacggggcct cactatgttg cctaggctgg aaataggatt ttgaacccaa attgagttta  
600

acaataataa aaagttgttt tacgctaaag atggaaaaga actaggactg aactatttta  
660

a a t a a a a t a t t g g c a a a a g a a  
681

<210> 43

<211> 516

<212> DNA

<213> Artificial Sequence

<220>

<223> Human rhodopsin promoter

<400> 43

ccacgtcaga atcaaaccct caccttaacc tcattagcgt tgggcataat caccaggcca  
60

agcgccttaa actacgagag gcccacatccc acccgccctg ccttagccct gccacgtgtg  
120

ccaaacgctg ttagacccaa caccacccag gccaggtagg gggctggagc ccagggtgggc  
180

atttgagtca ccaacccccca ggcagtctcc cttttcctgg atcctgagta cctctcctcc  
240

ctgacctcag gcttcctcct agtgtcacct tggcccctct tagaagccaa ttaggccctc  
300

agtttctgca gcgggggatta atatgattat gaacaccccc aatctcccag atgctgattc  
360

agccaggagc ttaggagggg gaggtcactt tataagggtc tggggggggtc agaaccaga  
420

gtcatccagc tggagccctg agtggctgag ctcaggcctt cgcagcattc ttgggtggga  
480

g c a g c c a c g g            g t c a g c c a c a            a g g g c c a c c a            c c a t g g  
516

<210> 44

<211> 249

<212> DNA

<213> Artificial Sequence

<220>

<223> Minimal Human rhodopsin promoter

<400> 44

gtcaccttgg cccctcttag aagccaatta ggccctcagt ttctgcagcg gggattaata  
60

tgattatgaa ccccccaat ctcccagatg ctgattcagc caggagctta ggagggggag  
120

gtcactttat aaggggtctgg gggggtcaga acccagagtc atccagctgg agccctgagt  
180

ggctgagctc aggccttcgc agcattcttg ggtgggagca gccacgggtc agccacaagg  
240

g            c            c            a            c            a            g            c            c  
249

<210> 45

<211> 617

<212> DNA

<213> Artificial Sequence

<220>

<223> CMV promoter

<400> 45

cattgattat tgactagtta ttaatagtaa tcaattacgg ggtcattagt tcatagccca  
60

tatatggagt tccgcgttac ataacttacg gttaaattggcc cgcctggctg accgcccac  
120

gacccccgcc cattgacgtc aataatgacg tatgtttccca tagtaacgcc aatagggact  
180

ttccattgac gtcaatgggt ggactattta cggtaaaactg cccacttggc agtacatcaa  
240

gtgtatcata tgccaagtac gccccctatt gacgtcaatg acggtaaagt gccgcctgg  
300

cattatgccc agtacatgac cttatgggac tttcctactt ggcagtacat ctacgtatta  
360

gtcatcgcta ttaccatgggt gatgcgggtt tggcagtaca tcaatgggag tggatagcgg  
420

tttgactcac ggggatttcc aagtctccac cccattgacg tcaatgggag tttgttttgg  
480

cacaaaaatc aacgggactt tccaaaatgt cgtaacaact ccgccccatt gacgcaaagt  
540

ggcggtaggc gtgtacgggt ggaggtctat ataagcagag ctggtttagt gaaccgtcag  
600

a t c c g c t a g a  
617

g a t c c g c

<210> 46

<211> 252

<212> DNA

<213> Artificial Sequence

<220>

<223> EFS promoter

<400> 46

tcgagtggct ccggtgcccc tcagtgggca gagcgcacat cggccacagt ccccgagaag  
60

ttgggggggag gggtcggcaa ttgaaccggt gcctagagaa ggtggcgcgg ggtaaactgg  
120

gaaagtgatg tcgtgtactg gctccgcctt tttcccagg gtgggggaga accgtatata  
180

agtgcagtag tcgccgtgaa cgttcttttt cgcaacgggt ttgccgccag aacacagggtg  
240

t c g t g a c c g c g g  
252

<210> 47

<211> 292

<212> DNA

<213> Artificial Sequence

<220>

<223> Human GRK1 (rhodopsin kinase) promoter

<400> 47

gggccccaga agcctggtgg ttgtttgtcc ttctcagggg aaaagtgagg cggcccccttg  
60

gaggaagggg ccgggcagaa tgatctaata ggattccaag cagctcaggg gattgtcttt  
120

ttctagcacc ttcttgccac tcctaagcgt cctccgtgac cccggctggg atttcgcctg  
180

gtgctgtgtc agccccggtc tcccaggggc ttcccagtgg tccccaggaa ccctcgacag  
240

ggccccggtct ctctcgtcca gcaagggcag ggacggggcca caggccaagg gc  
292

<210> 48  
<211> 113  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Human CRX (cone rod homeobox transcription factor) promoter

<400> 48  
gcctgtagcc ttaatctctc ctagcagggg gtttggggga gggaggagga gaaagaaagg  
60

gccccttatg gctgagacac aatgaccag ccacaaggag ggattaccgg gcg  
113

<210> 49  
<211> 281  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Human NRL (neural retina leucine zipper transcription factor  
enhance upstream of the human TK terminal promoter)

<400> 49  
aggtaggaag tggcctttaa ctccatagac cctattttaa cagcttcgga caggtttaa  
60

catctccttg gataattcct agtatccctg ttcccactcc tactcaggga tgatagctct  
120

aagaggtggt aggggattag gctgaaaatg taggtcaccc ctcagccatc tgggaactag  
180

aatgagtgag agaggagaga ggggcagaga cacacacatt cgcatattaa ggtgacgcgt  
240

gtggcctcga acaccgagcg accctgcagc gaccgcctta a  
281

<210> 50  
<211> 235  
<212> DNA

<213> Artificial Sequence

<220>

<223> Human RCVRN (recoverin) promoter

<400> 50

attttaatct cactaggggtt ctgggagcac cccccccac cgctcccgcc ctccacaaag  
60

ctcctggggcc cctcctccct tcaaggattg cgaagagctg gtcgcaaata ctccctaagcc  
120

accagcatct cgggtcttcag ctacacaccag ccttgagccc agcctgcggc caggggacca  
180

cgcacgtccc acccaccag cgactcccca gccgctgccc actcttcctc actca  
235

<210> 51

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> 3X Flag tag

<400> 51

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Tyr | Lys | Asp | His | Asp | Gly | Asp | Tyr | Lys | Asp | His | Asp | Ile | Asp | Tyr |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|
| Lys | Asp | Asp | Asp | Asp | Lys |
|     |     |     |     | 20  |     |

<210> 52

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Flag tag (single)

<400> 52

Asp Tyr Lys Asp Asp Asp Asp Lys  
1 5

<210> 53

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HA tag

<400> 53

Tyr Pro Tyr Asp Val Pro Asp Tyr Ala  
1 5

<210> 54

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Myc tag

<400> 54

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu  
1 5 10

<210> 55

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> HIS tag

<400> 55

His His His His His His

<210> 56  
<211> 60  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Mini polyA

<400> 56  
tagcaataaa ggatcgttta ttttcattgg aagcgtgtgt tggttttttg atcaggcgcg  
60

<210> 57  
<211> 228  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> bGH polyA

<400> 57  
gctgcaggat gaccggtcat catcaccatc accattgagt ttaaaccgc tgatcagcct  
60

cgactgtgcc ttctagttgc cagccatctg ttgtttgccc ctcccccgctg ccttccttga  
120

ccctggaagg tgccactccc actgtccttt cctaataaaa tgaggaaatt gcatcgcatt  
180

gtctgagtag gtgtcattct attctggggg gtgggggtggg gcaggaca  
228

<210> 58  
<211> 134  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> SV40 polyA

<400> 58  
atgctttatt tgtgaaattt gtgatgctat tgctttattt gtaaccatta taagctgcaa  
60  
  
taaacaagtt aacaacaaca attgcattca ttttatgttt caggttcagg gggagggtgtg  
120  
  
g g a g g t t t t t t t a a a  
134

<210> 59  
<211> 143  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AAV1 Left ITR

<400> 59  
ttgcccactc cctctctgcg cgctcgctcg ctcggtgggg cctgcggacc aaagggtccgc  
60  
  
agacggcaga gctctgctct gccggcccca ccgagcgagc gagcgcgagc agagggagtg  
120  
  
g g c a a c t c c a t c a c t a g g g g t a a  
143

<210> 60  
<211> 145  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AAV2 Left ITR

<400> 60  
ttggccactc cctctctgcg cgctcgctcg ctcactgagg ccggggcgacc aaagggtcgcc  
60  
  
cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgagc agagggagtg  
120

g c c a a c t c c a                      t c a c t a g g g g                      t t c c t  
145

<210> 61  
<211> 142  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AAV3B Left ITR

<400> 61  
tggccactcc ctctatgcgc actcgcctcgc tcggtggggc ctggcgacca aaggctcgcca  
60

gacggacgtg ctttgcacgt ccggccccac cgagcgagcg agtgcgcata gagggagtgg  
120

c c a a c t c c a t                      c a c t a g a g g t                      a t  
142

<210> 62  
<211> 146  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AAV4 Left ITR

<400> 62  
ttggccactc cctctatgcg cgctcgcctca ctcactcggc cctggagacc aaaggctctcc  
60

agactgccgg cctctggccg gcagggccga gtgagtgagc gagcgcgcat agagggagtg  
120

g c c a a c t c c a                      t c a t c t a g g t                      t t g c c c  
146

<210> 63  
<211> 155

<212> DNA  
<213> Artificial Sequence

<220>  
<223> AAV5 Left ITR

<400> 63  
ctctccccc tgtcgcgttc gctcgtcgc tggctcgttt gggggggtgg cagctcaaag  
60  
  
agctgccaga cgacggccct ctggccgtcg ccccccaaa cgagccagcg agcgagcgaa  
120  
  
c g c g a c a g g g g g g a g a g t g c c a c a c t c t c a a g c a a  
155

<210> 64  
<211> 143  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AAV6 Left ITR

<400> 64  
atacccttag tgatggagtt gccactccc tctatgcgcg ctcgctcgct cgggtggggcc  
60  
  
ggcagagcag agctctgccg tctgcggacc tttggtccgc aggccccacc gagcgagcga  
120  
  
g c g c g c a t a g a g g g a g t g g g c a a  
143

<210> 65  
<211> 145  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AAV7 Left ITR

<400> 65

ttggccactc cctctatgcg cgctcgctcg ctcggtgggg cctgcggacc aaaggtccgc  
60

agacggcaga gctctgctct gccggcccca ccgagcgagc gagcgcgcat agagggagtg  
120

g c c a a c t c c a t c a c t a g g g g t a c c g  
145

<210> 66

<211> 145

<212> DNA

<213> Artificial Sequence

<220>

<223> AAV8 Left ITR

<400> 66

cagagaggga gtggccaact ccatcactag gggtagcgcg aagcgcctcc cacgctgccg  
60

cgtcagcgct gacgtaaatt acgtcatagg ggagtgggcc tgtattagct gtcacgtgag  
120

t g c t t t t g c g g c a t t t t g c g a c a c c  
145

<210> 67

<211> 145

<212> DNA

<213> Artificial Sequence

<220>

<223> AAV9 Left ITR

<400> 67

cagagaggga gtggccaact ccatcactag gggtaatcgc gaagcgcctc ccacgctgcc  
60

gcgtcagcgc tgacgtagat tacgtcatag gggagtggtc ctgtattagc tgtcacgtga  
120

g t g c t t t t g c g a c a t t t t g c g a c a c  
145

<210> 68  
<211> 143  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AAV1 Right ITR

<400> 68  
ttaccacctag tgatggagtt gccactccc tctctgcgcg ctcgctcgct cgggtggggcc  
60  
  
ggcagagcag agctctgccg tctgcggacc tttggtccgc aggccccacc gagcgagcga  
120  
  
g c g c g c a g a g a g g g a g t g g g c a a  
143

<210> 69  
<211> 145  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AAV2 Right ITR

<400> 69  
aggaaccct agtgatggag ttggccactc cctctctgcg cgctcgctcg ctcactgagg  
60  
  
ccgcccgggc aaagcccggg cgtcgggcga cctttggtcg cccggcctca gtgagcgagc  
120  
  
g a g c g c g c a g a g a g g g a g t g g c c a a  
145

<210> 70  
<211> 142  
<212> DNA  
<213> Artificial Sequence

<220>

<223> AAV3B Right ITR

<400> 70

atacctctag tgatggagtt ggccactccc tctatgcgca ctcgctcgct cggtagggcc  
60

ggacgtgcaa agcacgtccg tctggcgacc tttggtcgcc aggccccacc gagcgagcga  
120

g t g c g c a t a g a g g g a g t g g c c a  
142

<210> 71

<211> 146

<212> DNA

<213> Artificial Sequence

<220>

<223> AAV4 Right ITR

<400> 71

gggcaaacct agatgatgga gttggccact ccctctatgc gcgctcgctc actcactcgg  
60

ccctgccggc cagaggccgg cagtctggag acctttggtc tccagggccg agtgagtgag  
120

c g a g c g c g c a t a g a g g g a g t g g c c a a  
146

<210> 72

<211> 155

<212> DNA

<213> Artificial Sequence

<220>

<223> AAV5 Right ITR

<400> 72

ttgcttgaga gtgtggcact ctccccctg tcgcgttcgc tcgctcgctg gctcgtttgg  
60

gggggcgacg gccagagggc cgtcgtcttg cagctctttg agctgccacc cccccaacg  
120

agccagcgag cgagcgaaag cgacaggggg gagag  
155

<210> 73

<211> 143

<212> DNA

<213> Artificial Sequence

<220>

<223> AAV6 Right ITR

<400> 73

ttgccactc cctctatgcg cgctcgctcg ctcggtgggg cctgcggacc aaagggtccgc  
60

agacggcaga gctctgctct gccggcccca ccgagcgagc gagcgcgcat agagggagtg  
120

ggcaactcca tcactagggg tat  
143

<210> 74

<211> 145

<212> DNA

<213> Artificial Sequence

<220>

<223> AAV7 Right ITR

<400> 74

cggtaccct agtgatggag ttggccactc cctctatgcg cgctcgctcg ctcggtgggg  
60

ccggcagagc agagctctgc cgtctgcgga cctttggtcc gcaggcccca ccgagcgagc  
120

gagcgcgcat agaggagtg gccaa  
145

<210> 75  
<211> 145  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AAV8 Right ITR

<400> 75  
gggtgtcgcaa aatgccgcaa aagcactcac gtgacagcta atacaggacc actcccctat  
60

gacgtaattt acgtcagcgc tgacgcggca gcgtgggagg cgcttcgcgc taccctagt  
120

g a t g g a g t t g g c c a c t c c c t c t c t g  
145

<210> 76  
<211> 145  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AAV9 Right ITR

<400> 76  
gtgtcgcaaa atgtcgcaaa agcactcacg tgacagctaa tacaggacca ctcccctatg  
60

acgtaatcta cgtcagcgct gacgcggcag cggtgggaggc gcttcgcgat taccctagt  
120

g a t g g a g t t g g c c a c t c c c t c t c t g  
145

<210> 77  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Spacer

<400> 77  
c a g a t c t g a a t t c g g t a c c  
19

<210> 78  
<211> 264  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> U6 Promoter

<400> 78  
aaggctcgggc aggaagaggg cctattttccc atgattcctt catatttgca tatacgatac  
60

aaggctgtta gagagataat tagaattaat ttgactgtaa acacaaagat attagtacaa  
120

aatacgtgac gtagaaagta ataatttctt gggtagtttg cagttttaaa attatgtttt  
180

aaaatggact atcatatgct taccgtaact tgaaagtatt tcgatttctt ggctttatat  
240

a t c t t g t g g a a a g g a c g a a a c a c c  
264

<210> 79  
<211> 82  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> gRNA scaffold domain

<400> 79  
gttttagtac tctggaaaca gaatctacta aaacaaggca aaatgccgtg tttatctcgt  
60

c a a c t t g t t g g c g a g a t t t t t t  
82

<210> 80  
<211> 50  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Spacer

<400> 80  
ggtaccgcta gcgcttaagt cgcgatgtac gggccagata tacgcgttga  
50

<210> 81  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> N-ter NLS nucleotide sequence

<400> 81  
c c g a a g a a a a a g c g c a a g g t c g a a g c g t c c  
30

<210> 82  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> N-ter NLS amino acid sequence

<400> 82  
Pro Lys Lys Lys Arg Lys Val  
1 5

<210> 83  
<211> 21  
<212> DNA

<213> Artificial Sequence

<220>

<223> C-ter NLS sequence

<400> 83

c c c a a g a a g a  
21

a g a g g a a a g t

c

<210> 84

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> C-ter NLS amino acid sequence

<400> 84

Pro Lys Lys Lys Arg Lys Val  
1 5

<210> 85

<211> 86

<212> DNA

<213> Artificial Sequence

<220>

<223> Spacer

<400> 85

tc caagcttc gcaggaaaga acatgtgagc aaaaggccag caaaaggcgt taactctaga  
60

t t t a a a t g c a  
86

t g c t g g g g a g

a g a t c t

<210> 86

<211> 66

<212> DNA

<213> Artificial Sequence

<220>

<223> 3X FLAG nucleotide sequence

<400> 86

gactacaaag accatgacgg tgattataaa gatcatgaca tcgattacaa ggatgacgat  
60

g                    a                    c                    a                    a                    g  
66

<210> 87

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Spacer

<400> 87

c g a c t t a g t t                    c g a t c g a a g g  
20

<210> 88

<211> 106

<212> DNA

<213> Artificial Sequence

<220>

<223> Unimolecular *S. aureus* gRNA

<220>

<221> misc\_feature

<222> (1)..(16)

<223> a, c, t, g, unknown or other

<220>

<221> misc\_feature

<222> (1)..(24)

<223> targeting domain (between 16 and 24 bases in length)

<220>

<221> misc\_feature

<222> (17)..(24)  
<223> a, c, t, g, unknown, absent or other

<220>  
<221> misc\_feature  
<222> (25)..(38)  
<223> crRNA

<220>  
<221> misc\_feature  
<222> (39)..(42)  
<223> GAAA linker

<220>  
<221> misc\_feature  
<222> (43)..(106)  
<223> tracrRNA

<400> 88  
nnnnnnnnnnn nnnnnnnnnn nnnngtttta gtactctgga aacagaatct actaaaacaa  
60

ggcaaaatgc cgtgtttatc tcgtcaactt gttggcgaga tttttt  
106

<210> 89  
<211> 106  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> Unimolecular *S. aureus* gRNA

<220>  
<221> misc\_feature  
<222> (1)..(16)  
<223> a, c, g, u, unknown or other

<220>  
<221> misc\_feature  
<222> (1)..(24)  
<223> targeting domain (between 16 and 24 bases in length)

<220>  
<221> misc\_feature  
<222> (17)..(24)  
<223> a, c, g, u, unknown, absent or other

<220>  
<221> misc\_feature  
<222> (25)..(38)  
<223> crRNA

<220>  
<221> misc\_feature  
<222> (39)..(42)  
<223> GAAA linker

<220>  
<221> misc\_feature  
<222> (43)..(106)  
<223> tracrRNA

<400> 89  
nnnnnnnnnnn nnnnnnnnnnn nnnnguuaa guacucugga aacagaaucu acuaaaacaa  
60

ggcaaaaugc cguguuauc ucgucaacuu guuggcgaga uuuuuu  
106

<210> 90  
<211> 106  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Unimolecular S. aureus gRNA

<220>  
<221> misc\_feature  
<222> (1)..(16)  
<223> a, c, t, g, unknown or other

<220>  
<221> misc\_feature  
<222> (1)..(24)

<223> targeting domain (between 16 and 24 bases in length)

<220>

<221> misc\_feature

<222> (17)..(24)

<223> a, c, t, g, unknown, absent or other

<220>

<221> misc\_feature

<222> (25)..(38)

<223> crRNA

<220>

<221> misc\_feature

<222> (39)..(42)

<223> GAAA linker

<220>

<221> misc\_feature

<222> (43)..(106)

<223> tracrRNA

<400> 90

nnnnnnnnnn nnnnnnnnnn nnnngttata gtactctgga aacagaatct actataacaa  
60

ggcaaaatgc cgtgtttatc tcgtcaactt gttggcgaga tttttt  
106

<210> 91

<211> 106

<212> RNA

<213> Artificial Sequence

<220>

<223> Unimolecular *S. aureus* gRNA

<220>

<221> misc\_feature

<222> (1)..(16)

<223> a, c, u, g, unknown or other

<220>

<221> misc\_feature  
<222> (1)..(24)  
<223> targeting domain (between 16 and 24 bases in length)

<220>  
<221> misc\_feature  
<222> (17)..(24)  
<223> a, c, u, g, unknown, absent or other

<220>  
<221> misc\_feature  
<222> (25)..(38)  
<223> crRNA

<220>  
<221> misc\_feature  
<222> (39)..(42)  
<223> GAAA linker

<220>  
<221> misc\_feature  
<222> (43)..(106)  
<223> tracrRNA

<400> 91  
nnnnnnnnnnn nnnnnnnnnnn nnnnguuaa guacucugga aacagaaucu acuauaaca  
60

ggcaaaaugc cguguuuau ucgucaacuu guuggcgaga uuuuuu  
106

<210> 92  
<211> 139  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AAV Left ITR

<400> 92  
tgcaggcagc tgcgcgctcg ctcgctcact gaggccgccc gggcaaagcc cgggcgctcg  
60

gcgacctttg gtcgcccggc ctcagtgagc gagcgagcgc gcagagaggg agtggccaac  
120

t c c a t c a c t a  
139

g g g g t t c c t

<210> 93  
<211> 139  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AAV Right ITR

<400> 93  
aggaaccct agtgatggag ttggccactc cctctctgcg cgctcgctcg ctcactgagg  
60

ccgggcgacc aaaggtcgcc cgacgcccg gctttgcccg ggcggcctca gtgagcgagc  
120

g a g c g c g c a g  
139

c t g c c t g c a

<210> 94  
<211> 164  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> SV40 intron

<400> 94  
tctagaggat ccggtactcg aggaactgaa aaaccagaaa gttaactggt aagtttagtc  
60

tttttgtctt ttatttcagg tcccggatcc ggtggtggtg caaatcaaag aactgctcct  
120

cagtggatgt tgcctttact tctaggcctg tacggaagtg ttac  
164

<210> 95

<400> 95  
000

<210> 96

<400> 96  
000

<210> 97

<400> 97  
000

<210> 98

<400> 98  
000

<210> 99

<400> 99  
000

<210> 100

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-1 targeting domain

<400> 100

g u c a g c c a c a  
22

a g g g c c a c a g

c c

<210> 101

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-2 targeting domain

<400> 101

c c g a a g a c g a  
22

a g u a u c c a u g

c a

<210> 102

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-3 targeting domain

<400> 102

a g u a u c c a u g  
22

c a g a g a g g u g

u a

<210> 103

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-4 targeting domain

<400> 103

c u a g g u u g a g  
22

c a g g a u g u a g

u u

<210> 104

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-5 targeting domain

<400> 104

c a u g g c u c a g  
22

c c a g g u a g u a

c u

<210> 105

<211> 22

<212> RNA  
<213> Artificial Sequence  
  
<220>  
<223> RH0-6 targeting domain

<400> 105  
a c g g g u g u g g u a c g c a g c c c c u  
22

<210> 106  
<211> 22  
<212> RNA  
<213> Artificial Sequence  
  
<220>  
<223> RH0-7 targeting domain

<400> 106  
c c c a c a c c c g g c u c a u a c c g c c  
22

<210> 107  
<211> 22  
<212> RNA  
<213> Artificial Sequence  
  
<220>  
<223> RH0-8 targeting domain

<400> 107  
c c c u g g g c g g u a u g a g c c g g g u  
22

<210> 108  
<211> 22  
<212> RNA  
<213> Artificial Sequence  
  
<220>  
<223> RH0-9 targeting domain

<400> 108  
c c a u c a u g g g c g u u g c c u u c a c  
22

<210> 109  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-10 targeting domain

<400> 109  
g u g c c a u u a c c u g g a c c a g c c g  
22

<210> 110  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-11 targeting domain

<400> 110  
u u a c c u g g a c c a g c c g g c g a g u  
22

<210> 111  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-12 targeting domain

<400> 111  
g c a u u c u u g g g u g g g a g c a g c c  
22

<210> 112

<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-13 targeting domain

<400> 112  
g c u c a g c c a c u c a g g g c u c c a g  
22

<210> 113  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-14 targeting domain

<400> 113  
u g a c c c g u g g c u g c u c c c a c c c  
22

<210> 114  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-15 targeting domain

<400> 114  
a g c u c a g g c c u u c g c a g c a u u c  
22

<210> 115  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-16 targeting domain

<400> 115  
u a g c a g a a g a a u g c a u c c u a a u  
22

<210> 116  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-17 targeting domain

<400> 116  
a c a c g c u g a g g a g a g c u g g g c a  
22

<210> 117  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-18 targeting domain

<400> 117  
g c a a a u a a c u u c c c c c a u u c c c  
22

<210> 118  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-19 targeting domain

<400> 118  
a g a c c c a g g c u g g g c a c u g a g g  
22

<210> 119  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-20 targeting domain

<400> 119  
c u a g g u c u c c u g g c u g u g a u c c  
22

<210> 120  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-21 targeting domain

<400> 120  
c c a g a a g g u g g g u g u g c c a c u u  
22

<210> 121  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-22 targeting domain

<400> 121  
a a c a a g g a a c u c u g c c c c a c a u  
22

<210> 122  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-23 targeting domain

<400> 122

c a g g a u u g a a  
22

c u g g g a a c c c

g g

<210> 123

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-24 targeting domain

<400> 123

g g g c g u c a c a  
22

c a g g g a c g g g

u g

<210> 124

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-25 targeting domain

<400> 124

c u g u g a u c c a  
22

g g a a u a u c u c

u g

<210> 125

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-26 targeting domain

<400> 125

u u g c a u u u a a  
22

c a g g a a a a c a

g a

<210> 126  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-27 targeting domain

<400> 126  
g g a g u g c a c c c c u c c u u a g g c a g  
22

<210> 127  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-28 targeting domain

<400> 127  
c a u c u g u c c u g c u c a c c a c c c c  
22

<210> 128  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-29 targeting domain

<400> 128  
g a g g g g a g g c a g a g g a u g c c a g  
22

<210> 129  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-30 targeting domain

<400> 129

c u c a g g g a a u  
22

c u c u g g c c a u

u g

<210> 130

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-31 targeting domain

<400> 130

u g c a c u c c c c  
22

c c u a g a c a g g

g a

<210> 131

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-32 targeting domain

<400> 131

u g c u g u u u g u  
22

g c a g g g c u g g

c a

<210> 132

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-33 targeting domain

<400> 132

a c u g g g a c a u  
22

u c c u a a c a g u

g a

<210> 133  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-34 targeting domain

<400> 133  
a u c a g g g g g u c a g g a u u g a a c u  
22

<210> 134  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-35 targeting domain

<400> 134  
c u c c u c u c u g g g g g c c c a a g c u  
22

<210> 135  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-36 targeting domain

<400> 135  
c u g c a u c u c a g c a g a g a u a u u c  
22

<210> 136  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-37 targeting domain

<400> 136

u g u u u c c c u u  
22

g g a g c a g c u g

u g

<210> 137

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-38 targeting domain

<400> 137

g c g c u c u g g g  
22

c c c a u a a g g g

a c

<210> 138

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-39 targeting domain

<400> 138

a g g a u u g a a c  
22

u g g g a a c c c g

g u

<210> 139

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-40 targeting domain

<400> 139

c c u a g g a g a g  
22

g c c c c c a c a u

g u

<210> 140  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-41 targeting domain

<400> 140  
a u c a c u c a g u u c u g g c c a g a a g  
22

<210> 141  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-42 targeting domain

<400> 141  
a g a g c u g g g c a a a g a a a u u c c a  
22

<210> 142  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-43 targeting domain

<400> 142  
c c a c c c c a u g a a g u u c c a u a g g  
22

<210> 143  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-44 targeting domain

<400> 143

c c a c c c u g a g  
22

c u u g g g c c c c

c a

<210> 144

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-45 targeting domain

<400> 144

c a g a g g a a g a  
22

a g a a g g a a a u

g a

<210> 145

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-46 targeting domain

<400> 145

a a a c a g c a g c  
22

c c g g c u a u c a

c c

<210> 146

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-47 targeting domain

<400> 146

g g a u u g a a c u  
22

g g g a a c c c g g

u a

|       |                     |
|-------|---------------------|
| <210> | 147                 |
| <211> | 22                  |
| <212> | RNA                 |
| <213> | Artificial Sequence |

**<220>**  
**<223> RH0-48 targeting domain**

**<400>    147**

**u g u g u g u g u g                  u g u g u u u a g c                  a g**

**22**

|                    |                            |
|--------------------|----------------------------|
| <b>&lt;210&gt;</b> | <b>148</b>                 |
| <b>&lt;211&gt;</b> | <b>22</b>                  |
| <b>&lt;212&gt;</b> | <b>RNA</b>                 |
| <b>&lt;213&gt;</b> | <b>Artificial Sequence</b> |

**<220>**  
**<223> RH0-49 targeting domain**

**<400> 148**  
**u c a c a c a g g g** **a c g g g u g c a g** **a g**  
**22**

|       |                     |
|-------|---------------------|
| <210> | 149                 |
| <211> | 22                  |
| <212> | RNA                 |
| <213> | Artificial Sequence |

**<220>**  
**<223> RHO-50 targeting domain**

**<400> 149**  
**g u g u g u g u g u** **g u g u g u g u u u** **a g**  
**22**

|                    |                            |
|--------------------|----------------------------|
| <b>&lt;210&gt;</b> | <b>150</b>                 |
| <b>&lt;211&gt;</b> | <b>22</b>                  |
| <b>&lt;212&gt;</b> | <b>RNA</b>                 |
| <b>&lt;213&gt;</b> | <b>Artificial Sequence</b> |

<220>

<223> RH0-51 targeting domain

<400> 150

u g a g c u u g g g  
22

c c c c c a g a g a

g g

<210> 151

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-52 targeting domain

<400> 151

a a u a u c u c u g  
22

c u g a g a u g c a

g g

<210> 152

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-53 targeting domain

<400> 152

g g a g a g g g g a  
22

a g a g a c u c a u

u u

<210> 153

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-54 targeting domain

<400> 153

a g a a c u g a g u  
22

g a u c u g u g a u

u a

<210> 154  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-55 targeting domain

<400> 154  
c c a c u c u c c c u a u g g a a c u u c a  
22

<210> 155  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-56 targeting domain

<400> 155  
a u a a g g g a c a c g a a u c a g a u c a  
22

<210> 156  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-57 targeting domain

<400> 156  
u g g a u u u u c c a u u c u c c a g u c a  
22

<210> 157  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-58 targeting domain

<400> 157

g u g c a g g a g c  
22

c c g g g a g c a u

g g

<210> 158

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-59 targeting domain

<400> 158

g g g u g g u g a g  
22

c a g g a c a g a u

g u

<210> 159

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-60 targeting domain

<400> 159

c a g c u c u c c c  
22

u c a g u g c c c a

g c

<210> 160

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-61 targeting domain

<400> 160

c c u g c u g g g g  
22

c g u c a c a c a g

g g

<210> 161  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-62 targeting domain

<400> 161  
c a c a c a c a c a c a a a a c u c c c u a  
22

<210> 162  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-63 targeting domain

<400> 162  
a c u u a c g g g u g g u u g u u c u c u g  
22

<210> 163  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-64 targeting domain

<400> 163  
c a c a g g g a a g a c c c a a u g a c u g  
22

<210> 164  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-65 targeting domain

<400> 164

a g c a c a g a c c  
22

c c a c u g c c u a

a g

<210> 165

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-66 targeting domain

<400> 165

a c c u g a g g a c  
22

a g g g g c u g a g

a g

<210> 166

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-67 targeting domain

<400> 166

c a a c a a u g g c  
22

c a g a g a u u c c

c u

<210> 167

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-68 targeting domain

<400> 167

u g c u g c c u c g  
22

g u c c c a u u c u

c a

<210> 168  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-69 targeting domain

<400> 168  
u g c u g c c u g g c c a c a u c c c u a a  
22

<210> 169  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-70 targeting domain

<400> 169  
g c c a c u c u c c c u a u g g a a c u u c  
22

<210> 170  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-71 targeting domain

<400> 170  
g a g g g a g g a a g g a c u g c c a a u u  
22

<210> 171  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-72 targeting domain

<400> 171

g a g g g u a g c u  
22

a g g a a g g c a a

c c

<210> 172

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-73 targeting domain

<400> 172

g g a a g g c a a c  
22

c a g g a g u g g g

a g

<210> 173

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-74 targeting domain

<400> 173

g c u g a g a u g c  
22

a g g a g g a g a c

g c

<210> 174

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-75 targeting domain

<400> 174

a g g c u g g a g g  
22

g g c a c c u g a g

g a

<210> 175  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-76 targeting domain

<400> 175  
a g g a a g g c a a c c a g g a g u g g g a  
22

<210> 176  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-77 targeting domain

<400> 176  
c c g g g a g c a u g g a g g g g u c u g g  
22

<210> 177  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-78 targeting domain

<400> 177  
g g a u a a c a g a u c c c a c u u a a c a  
22

<210> 178  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-79 targeting domain

<400> 178

a g g c a g a g g a  
22

u g c c a g a g g g

g a

<210> 179

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-80 targeting domain

<400> 179

g g g c c c a a g c  
22

u c a g g g u g g g

a a

<210> 180

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-81 targeting domain

<400> 180

u a a c u a u a u g  
22

g c c a c u c u c c

c u

<210> 181

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-82 targeting domain

<400> 181

u c c c a c u u a a  
22

c a g a g a g g a a

a a

<210> 182  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-83 targeting domain

<400> 182  
g a a u g c a g a g                      g u g g u g g a a a                      c c  
22

<210> 183  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-84 targeting domain

<400> 183  
g g g a g a c a g g                      g c a a g g c u g g                      c a  
22

<210> 184  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-85 targeting domain

<400> 184  
c a c c a c c c c a                      u g a a g u u c c a                      u a  
22

<210> 185  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-86 targeting domain

<400> 185

g c c a u a u a g u  
22

u a a u c a a c c a

a a

<210> 186

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-87 targeting domain

<400> 186

g u a g c u a g g a  
22

a g g c a a c c a g

g a

<210> 187

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-88 targeting domain

<400> 187

c a c a u u g c u u  
22

c a u g g c u c c u

a g

<210> 188

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-89 targeting domain

<400> 188

c u g a g c u u g g  
22

g c c c c c a g a g

a g

<210> 189  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-90 targeting domain

<400> 189  
a c c g a g c c c a u u g c c c a g c a c a  
22

<210> 190  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-91 targeting domain

<400> 190  
c u c a a a g a a g u c a a g c g c c c u g  
22

<210> 191  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-92 targeting domain

<400> 191  
g c u a c c c u c u c c c u g u c u a g g g  
22

<210> 192  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-93 targeting domain

<400> 192

a c c c u g a g c u  
22

u g g g c c c c c a

g a

<210> 193

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-94 targeting domain

<400> 193

g g c a g a g g g a  
22

c c a c a c g c u g

a g

<210> 194

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-95 targeting domain

<400> 194

u c u g a c u c a g  
22

c a c a g c u g c u

c c

<210> 195

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-96 targeting domain

<400> 195

c u c u c a g c c a  
22

c c a c c g c c a a

g c

<210> 196  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-97 targeting domain

<400> 196  
a g g g a u g u g g c c a g g c a g c a a c  
22

<210> 197  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-98 targeting domain

<400> 197  
c a c c u g a g g a c a g g g g c u g a g a  
22

<210> 198  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-99 targeting domain

<400> 198  
g c c c a u g a u g g c a u g g u u c u c c  
22

<210> 199  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-100 targeting domain

<400> 199

g a a g g g g c a g  
22

a g g g a c c a c a

c g

<210> 200

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-101 targeting domain

<400> 200

a g c a c c c u c u  
22

a c a c c u c u c u

g c

<210> 201

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-102 targeting domain

<400> 201

c u u u g g a u a a  
22

c a u u g a c a g g

a c

<210> 202

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-103 targeting domain

<400> 202

g g u g a a g c c a  
22

c c u a g g a c c a

u g

<210> 203  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-104 targeting domain

<400> 203  
u a a c a u u g a c a g g a c a g g a g a a  
22

<210> 204  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-105 targeting domain

<400> 204  
g g g a g a g g g g a a g a g a c u c a u u  
22

<210> 205  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-106 targeting domain

<400> 205  
g c u g u g c u g a g u c a g a c c c a g g  
22

<210> 206  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-107 targeting domain

<400> 206

u u g a g g a g g c  
22

c u u g g g g a a g

g a

<210> 207

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-108 targeting domain

<400> 207

g c c c g g g a g c  
22

a u g g a g g g g u

c u

<210> 208

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-109 targeting domain

<400> 208

g u a a a c u g g g  
22

a c u g a c c c u g

c a

<210> 209

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-110 targeting domain

<400> 209

a u a a c a u u g a  
22

c a g g a c a g g a

g a

<210> 210  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-111 targeting domain

<400> 210  
g g c a g g g a g g c u g g a g g g g c a c  
22

<210> 211  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-112 targeting domain

<400> 211  
g c a a a c a u g g c c c g a g a u a g a u  
22

<210> 212  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-113 targeting domain

<400> 212  
g g a c c g a g c c c a u u g c c c a g c a  
22

<210> 213  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-114 targeting domain

<400> 213

g c u c u a c g u c  
22

a c c g u c c a g c

a c

<210> 214

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-115 targeting domain

<400> 214

a g c a c a g c u g  
22

c u c c a a g g g a

a a

<210> 215

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-116 targeting domain

<400> 215

c u a a a g c a a a  
22

a a g g a a c u g c

u u

<210> 216

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-117 targeting domain

<400> 216

g a g a g g a a a a  
22

c u g a g g c a g g

g a

<210> 217  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-118 targeting domain

<400> 217  
c a u u g c a a a g c u g g g u g a c g g g  
22

<210> 218  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-119 targeting domain

<400> 218  
u u g c c a c c c u g g g c g g u a u g a g  
22

<210> 219  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-120 targeting domain

<400> 219  
a g c u a g g a a g g c a a c c a g g a g u  
22

<210> 220  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-121 targeting domain

<400> 220

u c u c u g g g g g  
22

c c c a a g c u c a

g g

<210> 221

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-122 targeting domain

<400> 221

a g c a c a g g g a  
22

a g a c c c a a u g

a c

<210> 222

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-123 targeting domain

<400> 222

g u u g a c u g a a  
22

u a u a u g a g g g

c u

<210> 223

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-124 targeting domain

<400> 223

u u g u a a a c u g  
22

g g a c u g a c c c

u g

<210> 224  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-125 targeting domain

<400> 224  
c a c a c c c a c c u u c u g g c c a g a a  
22

<210> 225  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-126 targeting domain

<400> 225  
c c a g a g g a a g a a g a a a u g  
22

<210> 226  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-127 targeting domain

<400> 226  
g a g a u a u u c c u g g a u c a c a g c c  
22

<210> 227  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-128 targeting domain

<400> 227

a g g g g c a g a g  
22

g g a c c a c a c g

c u

<210> 228

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-129 targeting domain

<400> 228

a a c u a u a u g g  
22

c c a c u c u c c c

u a

<210> 229

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-130 targeting domain

<400> 229

g c u g c u u g c g  
22

g u u c u c a a c a

c c

<210> 230

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-131 targeting domain

<400> 230

c a c c a u g a a u  
22

g g u g u u u g u u

g a

<210> 231  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-132 targeting domain

<400> 231  
g c a g c c a u u g c a a a g c u g g g u g  
22

<210> 232  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-133 targeting domain

<400> 232  
u g a c u c a g c a c a g c u g c u c c a a  
22

<210> 233  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-134 targeting domain

<400> 233  
c u g g g a g g a g g g g g a a g g g g c a  
22

<210> 234  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-135 targeting domain

<400> 234

g a u a a c a u u g  
22

a c a g g a c a g g

a g

<210> 235

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-136 targeting domain

<400> 235

c c a a a c u g g g  
22

a c a u u c c u a a

c a

<210> 236

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-137 targeting domain

<400> 236

a g g a a a a c a g  
22

a u g g g g u g c u

g c

<210> 237

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-138 targeting domain

<400> 237

c g g a c a u g u g  
22

g g g g c c u c u c

c u

<210> 238  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-139 targeting domain

<400> 238  
g c a a a g a a a u u c c a g g g a a u g g  
22

<210> 239  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-140 targeting domain

<400> 239  
c c a g g a g a c u u g g a a c g c g g c a  
22

<210> 240  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-141 targeting domain

<400> 240  
u g g u c c u u g g u g g u c c u g g c c a  
22

<210> 241  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-142 targeting domain

<400> 241

a a u g g a a a a u  
22

c c a c u u c c c a

c c

<210> 242

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-143 targeting domain

<400> 242

g c c c g a a g a c  
22

g a a g u a u c c a

u g

<210> 243

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-144 targeting domain

<400> 243

g u g c u g g a c g  
22

g u g a c g u a g a

g c

<210> 244

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-145 targeting domain

<400> 244

a g a a a c a u g u  
22

a g g c g g c c a g

c a

<210> 245  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-146 targeting domain

<400> 245  
c c g c u c g a u g g c c a g g a c c a c c  
22

<210> 246  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-147 targeting domain

<400> 246  
u c a g c a c a g a c c c c a c u g c c u a  
22

<210> 247  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-148 targeting domain

<400> 247  
g a a u a u c u c u g c u g a g a u g c a g  
22

<210> 248  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-149 targeting domain

<400> 248

g a g u a c c c a c  
22

a g u a c u a c c u

g g

<210> 249

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-150 targeting domain

<400> 249

c a a c c a g g a g  
22

u g g g a g a g g g

a u

<210> 250

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-151 targeting domain

<400> 250

u u g a g a a c c g  
22

c a a g c a g c c g

c u

<210> 251

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-152 targeting domain

<400> 251

g c a a g c c a g a  
22

c c c c u c c u c u

c u

<210> 252  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-153 targeting domain

<400> 252  
g a g a g c u g g g c a a a g a a a u u c c  
22

<210> 253  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-154 targeting domain

<400> 253  
c g a g g c a g c a g c c u g g a c a u g g  
22

<210> 254  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-155 targeting domain

<400> 254  
a g g a a u a u c u c u g c u g a g a u g c  
22

<210> 255  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-156 targeting domain

<400> 255

u u c c c g a g a a  
22

g g g a g a g g g a

g g

<210> 256

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-157 targeting domain

<400> 256

u c c u u c c u c c  
22

c u c u c c c u u c

u c

<210> 257

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-158 targeting domain

<400> 257

u g u u u u g c c c  
22

a g a g g a a g a a

g a

<210> 258

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-159 targeting domain

<400> 258

c c g g c u g g u c  
22

c a g g u a a u g g

c a

<210> 259  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-160 targeting domain

<400> 259  
c a g c a c a g g g a a g a c c c a a u g a  
22

<210> 260  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-161 targeting domain

<400> 260  
a c c a g g a g u g g g a g a g g g a u u u  
22

<210> 261  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-162 targeting domain

<400> 261  
g c u g g u g a a g c c a c c u a g g a c c  
22

<210> 262  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-163 targeting domain

<400> 262

g g c g g u a u g a  
22

g c c g g g u g u g

g g

<210> 263

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-164 targeting domain

<400> 263

c a g c c a u u g c  
22

a a a g c u g g g u

g a

<210> 264

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-165 targeting domain

<400> 264

a c a u u g a c a g  
22

g a c a g g a g a a

g g

<210> 265

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-166 targeting domain

<400> 265

u g g g u c u u c c  
22

c u g u g c u g g g

c a

<210> 266  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-167 targeting domain

<400> 266  
g u a c g u g g u g                      g u g u g u a a g c                      c c  
22

<210> 267  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-168 targeting domain

<400> 267  
a g c a a a u a a c                      u u c c c c c a u u                      c c  
22

<210> 268  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-169 targeting domain

<400> 268  
g g a u u u g a g g                      a g g c c u u g g g                      g a  
22

<210> 269  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-170 targeting domain

<400> 269

c c c u g a g c u u  
22

g g g c c c c a g

a g

<210> 270

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-171 targeting domain

<400> 270

c a g a g a u u c c  
22

c u g a g a a u g g

g a

<210> 271

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-172 targeting domain

<400> 271

g a g u u g g a a g  
22

c c c g c a u c u a

u c

<210> 272

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-173 targeting domain

<400> 272

a g u c c u u c c u  
22

c c c u c u c c c u

u c

<210> 273  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-174 targeting domain

<400> 273  
g u u a u u u c a u u u c c c g a g a a g g  
22

<210> 274  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-175 targeting domain

<400> 274  
a u u u c a u u u c c c g a g a a g g g a g  
22

<210> 275  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-176 targeting domain

<400> 275  
g a c g u a g a g c g u g a g g a a g u u g  
22

<210> 276  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-177 targeting domain

<400> 276

c a u u c c c g a  
22

g a a g g g a g a g

g g

<210> 277

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-178 targeting domain

<400> 277

g u a g a g c g u g  
22

a g g a a g u u g a

u g

<210> 278

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-179 targeting domain

<400> 278

c a g g c c u u c g  
22

c a g c a u u c u u

g g

<210> 279

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-180 targeting domain

<400> 279

a g g u a g u a c u  
22

g u g g g u a c u c

g a

<210> 280  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-181 targeting domain

<400> 280  
a a a c a u g u a g g c g g c c a g c a u g  
22

<210> 281  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-182 targeting domain

<400> 281  
u u u c a u u u c c c g a g a a g g g a g a  
22

<210> 282  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-183 targeting domain

<400> 282  
g g g a a g a c c c a a u g a c u g g a g a  
22

<210> 283  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-184 targeting domain

<400> 283

a a a a c u g a g g  
22

c a g g g a g a g g

g g

<210> 284

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-185 targeting domain

<400> 284

u g a g u c a g a c  
22

c c a g g c u g g g

c a

<210> 285

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-186 targeting domain

<400> 285

g g g a u u u g a g  
22

g a g g c c u u g g

g g

<210> 286

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-187 targeting domain

<400> 286

u c u g g g g g c c  
22

c a a g c u c a g g

g u

<210> 287  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-188 targeting domain

<400> 287  
c g g g c c c a c a g g a u g c a a u u u g  
22

<210> 288  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-189 targeting domain

<400> 288  
a c g u a g a g c g u g a g g a a g u u g a  
22

<210> 289  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-190 targeting domain

<400> 289  
g a c c g a g g c a g c a g c c u g g a c a  
22

<210> 290  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-191 targeting domain

<400> 290

c a g g c u g g g c  
22

a c u g a g g g a g

a g

<210> 291

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-192 targeting domain

<400> 291

u a u u u c a u u u  
22

c c c g a g a a g g

g a

<210> 292

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-193 targeting domain

<400> 292

g u c c c g g g c u  
22

u g g c g g u g g u

g g

<210> 293

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-194 targeting domain

<400> 293

c u g c u g c c u c  
22

g g u c c c a u u c

u c

<210> 294  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-195 targeting domain

<400> 294  
a g c g u c u c c u c c u g c a u c u c a g  
22

<210> 295  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-196 targeting domain

<400> 295  
u c a g a c c c a g g c u g g g c a c u g a  
22

<210> 296  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-197 targeting domain

<400> 296  
a g c u a c c c u c u c c c u g u c u a g g  
22

<210> 297  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-198 targeting domain

<400> 297

c a g a g a g g a a  
22

a a c u g a g g c a

g g

<210> 298

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-199 targeting domain

<400> 298

g g a g a g g g a u  
22

u u g a g g a g g c

c u

<210> 299

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-200 targeting domain

<400> 299

g u c c u u c c u c  
22

c c u c u c c c u u

c u

<210> 300

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-201 targeting domain

<400> 300

a g a g a g c u u g  
22

g u g c u g g g a g

g a

<210> 301  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-202 targeting domain

<400> 301  
c c u u c u c g g g a a a u g a a a u a a c  
22

<210> 302  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-203 targeting domain

<400> 302  
g c g g u u c u c a a c a c c a g g a g a c  
22

<210> 303  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-204 targeting domain

<400> 303  
c u c u g g g g g c c c a a g c u c a g g g  
22

<210> 304  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-205 targeting domain

<400> 304

u g u g c a g g a g  
22

c c c g g g a g c a

u g

<210> 305

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-206 targeting domain

<400> 305

c a g a g a g g u g  
22

u a g a g g g u g c

u g

<210> 306

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-207 targeting domain

<400> 306

c u c c c c g a a g  
22

c g g a a g u u g c

u c

<210> 307

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-208 targeting domain

<400> 307

g c u a g a a g c a  
22

g c c a u u g c a a

a g

<210> 308  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-209 targeting domain

<400> 308  
c a a a c a c c a u u c a u g g u g a u a g  
22

<210> 309  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-210 targeting domain

<400> 309  
u c a u u u c c c g a g a a g g g a g a g g  
22

<210> 310  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-211 targeting domain

<400> 310  
u c a c c a c c c c a u g a a g u u c c a u  
22

<210> 311  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-212 targeting domain

<400> 311

g g g a g u g c a c  
22

c c u c c u u a g g

c a

<210> 312

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-213 targeting domain

<400> 312

a a u g g c c a g a  
22

g a u u c c c u g a

g a

<210> 313

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-214 targeting domain

<400> 313

a g a a u g g g a c  
22

c g a g g c a g c a

g c

<210> 314

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-215 targeting domain

<400> 314

g g c a a g c c a g  
22

a c c c c u c c u c

u c

<210> 315  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-216 targeting domain

<400> 315  
c c c g g g c u u g g c g g u g g u g g c u  
22

<210> 316  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-217 targeting domain

<400> 316  
a g c c c g g g a g c a u g g a g g g g u c  
22

<210> 317  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-218 targeting domain

<400> 317  
c c g g g u u a u u u c a u u u c c c g a g  
22

<210> 318  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-219 targeting domain

<400> 318

g g u g u u u g u u  
22

g a c u g a a u a u

a u

<210> 319

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-220 targeting domain

<400> 319

c c g u c c c u g u  
22

g u g a c g c c c c

a g

<210> 320

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-221 targeting domain

<400> 320

g g a c a g g g g c  
22

u g a g a g g g g a

g g

<210> 321

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-222 targeting domain

<400> 321

a g a g g g u g c u  
22

g g u g a a g c c a

c c

<210> 322  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-223 targeting domain

<400> 322  
a u u g c a u c c u g u g g g c c c g a a g  
22

<210> 323  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-224 targeting domain

<400> 323  
c g g g u u a u u u c a u u u c c c g a g a  
22

<210> 324  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-225 targeting domain

<400> 324  
g g a a a u g a a a u a a c c c g g a c a u  
22

<210> 325  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-226 targeting domain

<400> 325

c u g a c u c a g c  
22

a c a g c u g c u c

c a

<210> 326

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-227 targeting domain

<400> 326

g g c a c c u g a g  
22

g a c a g g g g c u

g a

<210> 327

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-228 targeting domain

<400> 327

g g a g a g c u g g  
22

g c a a a g a a a u

u c

<210> 328

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-229 targeting domain

<400> 328

g g g c g g u a u g  
22

a g c c g g g u g u

g g

<210> 329  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-230 targeting domain

<400> 329  
c c u c c c u c u c c c u u c u c g g g a a  
22

<210> 330  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-231 targeting domain

<400> 330  
u c c a g g u a a u g g c a c u g a g c a g  
22

<210> 331  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-232 targeting domain

<400> 331  
g u g g g g c c u c u c c u a g g a g c c  
22

<210> 332  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-233 targeting domain

<400> 332

g a u g g c a u g g  
22

u u c u c c c c g a

a g

<210> 333

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-234 targeting domain

<400> 333

c g u c g c a u u g  
22

g a g a a g g g c a

c g

<210> 334

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-235 targeting domain

<400> 334

u g g g u g g g g u  
22

g u g c a g g a g c

c c

<210> 335

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-236 targeting domain

<400> 335

c u g g a c g g u g  
22

a c g u a g a g c g

u g

<210> 336  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-237 targeting domain

<400> 336  
g a g g a a a a c u g a g g c a g g g a g a  
22

<210> 337  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-238 targeting domain

<400> 337  
c u g a a c a c u g c c u u g a u c u u a u  
22

<210> 338  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-239 targeting domain

<400> 338  
c a u u a c c u g g a c c a g c c g g c g a  
22

<210> 339  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-240 targeting domain

<400> 339

g g a g a g a g c u  
22

u g g u g c u g g g

a g

<210> 340

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-241 targeting domain

<400> 340

a g a a u a a u g u  
22

c u u g c a u u u a

a c

<210> 341

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-242 targeting domain

<400> 341

c u a g g a a g g c  
22

a a c c a g g a g u

g g

<210> 342

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-243 targeting domain

<400> 342

u c u c c c a g a c  
22

c c c u c c a u g c

u c

<210> 343  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-244 targeting domain

<400> 343  
a c a g g g g c u g a g a g g g g a g g c a  
22

<210> 344  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-245 targeting domain

<400> 344  
g g g g c a g a g g g a c c a c a c g c u g  
22

<210> 345  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-246 targeting domain

<400> 345  
a g g g g a g g c a g a g g a u g c c a g a  
22

<210> 346  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-247 targeting domain

<400> 346

u g g u c c a g g u  
22

a a u g g c a c u g

a g

<210> 347

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-248 targeting domain

<400> 347

c c g g a c a u g u  
22

g g g g g c c u c u

c c

<210> 348

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-249 targeting domain

<400> 348

g c a g g c c a g c  
22

g c c a u g a c c c

a g

<210> 349

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-250 targeting domain

<400> 349

c u a g c u a c c c  
22

u c u c c c u g u c

u a

<210> 350  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-251 targeting domain

<400> 350  
g c u u u g g a u a a c a u u g a c a g g a  
22

<210> 351  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-252 targeting domain

<400> 351  
g c c a u u g c a a a g c u g g g u g a c g  
22

<210> 352  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-253 targeting domain

<400> 352  
c c u a g g u c u c c u g g c u g u g a u c  
22

<210> 353  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-254 targeting domain

<400> 353

a a c a g a g a g g  
22

a a a a c u g a g g

c a

<210> 354

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-255 targeting domain

<400> 354

a u u a c c u g g a  
22

c c a g c c g g c g

a g

<210> 355

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-256 targeting domain

<400> 355

g a g g g g c a c c  
22

u g a g g a c a g g

g g

<210> 356

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-257 targeting domain

<400> 356

g g g u u a u u u c  
22

a u u u c c c g a g

a a

<210> 357  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-258 targeting domain

<400> 357  
a g g g u g c a c u c c c c c c u a g a c a  
22

<210> 358  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-259 targeting domain

<400> 358  
c c a g g a g u g g g a g a g g g a u u u g  
22

<210> 359  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-260 targeting domain

<400> 359  
a g a g g g g a g g c a g a g g a u g c c a  
22

<210> 360  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-261 targeting domain

<400> 360

c c g c c u g c u g  
22

a c u g c c u u g c

a g

<210> 361

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-262 targeting domain

<400> 361

g g c u u g g u g c  
22

u g c a a a c a u g

g c

<210> 362

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-263 targeting domain

<400> 362

c a g g u a a u g g  
22

c a c u g a g c a g

a a

<210> 363

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-264 targeting domain

<400> 363

u u g g a a c g c g  
22

g c a g g g a g g c

u g

<210> 364  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-265 targeting domain

<400> 364  
u g u c c g g g u u a u u u c a u u u c c c  
22

<210> 365  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-266 targeting domain

<400> 365  
c a g g u a g u a c u g u g g g u a c u c g  
22

<210> 366  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-267 targeting domain

<400> 366  
a u a a c a g a u c c c a c u u a a c a g a  
22

<210> 367  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-268 targeting domain

<400> 367

a g g g a c g g g u  
22

g c a g a g u u g a

g u

<210> 368

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-269 targeting domain

<400> 368

g a a g g a g a g a  
22

g c u u g g u g c u

g g

<210> 369

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-270 targeting domain

<400> 369

g g u c a g c c a c  
22

g g c u a g g u u g

a g

<210> 370

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-271 targeting domain

<400> 370

a u u u c a c a g c  
22

a a g a a a a c u g

a g

<210> 371  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-272 targeting domain

<400> 371  
u c a a a g a a g u c a a g c g c c c u g c  
22

<210> 372  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-273 targeting domain

<400> 372  
g c u g c u c c c a c c c a a g a a u g c u  
22

<210> 373  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-274 targeting domain

<400> 373  
g c a a c a a a c a c c c a a c a a u g g c  
22

<210> 374  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-275 targeting domain

<400> 374

a a a u c c a c u u  
22

c c c a c c c u g a

g c

<210> 375

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-276 targeting domain

<400> 375

c a g g g a g g c u  
22

g g a g g g g c a c

c u

<210> 376

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-277 targeting domain

<400> 376

g g g c a a g c c a  
22

g a c c c c u c c u

c u

<210> 377

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-278 targeting domain

<400> 377

c a g g a a a a c a  
22

g a u g g g g u g c

u g

<210> 378  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-279 targeting domain

<400> 378  
u u g g a g a a g g g c a c g u a g a a g u  
22

<210> 379  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-280 targeting domain

<400> 379  
a g a g c u u g g u g c u g g g a g g a g g  
22

<210> 380  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-281 targeting domain

<400> 380  
u a g c u a g g a a g g c a a c c a g g a g  
22

<210> 381  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-282 targeting domain

<400> 381

g g c u a g g u u g  
22

a g c a g g a u g u

a g

<210> 382

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-283 targeting domain

<400> 382

c u c a c c a c c c  
22

c a u g a a g u u c

c a

<210> 383

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-284 targeting domain

<400> 383

a a g c a a u g u g  
22

c a a u g u u u u g

c c

<210> 384

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-285 targeting domain

<400> 384

g g a a g a c c c a  
22

a u g a c u g g a g

a a

<210> 385  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-286 targeting domain

<400> 385  
u g g c c a g g a c c a c c a a g g a c c a  
22

<210> 386  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-287 targeting domain

<400> 386  
a a a u a u u g u c c c u u u c a c u g u u  
22

<210> 387  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-288 targeting domain

<400> 387  
c a u g a g c a a c u u c c g c u u c g g g  
22

<210> 388  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-289 targeting domain

<400> 388

a g a g a u a u u c  
22

c u g g a u c a c a

g c

<210> 389

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-290 targeting domain

<400> 389

c a u g g a g g g g  
22

u c u g g g a g a g

u c

<210> 390

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-291 targeting domain

<400> 390

a u g u u u u g c c  
22

c a g a g g a a g a

a g

<210> 391

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-292 targeting domain

<400> 391

g u g g g u g g g g  
22

u g u g c a g g a g

c c

<210> 392  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-293 targeting domain

<400> 392  
c c a g g u a a u g g c a c u g a g c a g a  
22

<210> 393  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-294 targeting domain

<400> 393  
c c c a a c a a u g g c c a g a g a u u c c  
22

<210> 394  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-295 targeting domain

<400> 394  
g c a c c u g a g g a c a g g g g c u g a g  
22

<210> 395  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-296 targeting domain

<400> 395

g u c a g a c c c a  
22

g g c u g g g c a c

u g

<210> 396

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-297 targeting domain

<400> 396

g g g g c a c c u g  
22

a g g a c a g g g g

c u

<210> 397

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-298 targeting domain

<400> 397

a g a g g a a a a c  
22

u g a g g c a g g g

a g

<210> 398

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-299 targeting domain

<400> 398

a g g g a u a a c a  
22

g a u c c c a c u u

a a

<210> 399  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-300 targeting domain

<400> 399  
c u u g g u g c u g g g a g g a g g g g g a  
22

<210> 400  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-301 targeting domain

<400> 400  
a g a g g g u a g c u a g g a a g g c a a c  
22

<210> 401  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-302 targeting domain

<400> 401  
u u g c a c a u u g c u u c a u g g c u c c  
22

<210> 402  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-303 targeting domain

<400> 402

g a c c g a g c c c  
22

a u u g c c c a g c

a c

<210> 403

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-304 targeting domain

<400> 403

u g a a c a c u g c  
22

c u u g a u c u u a

u u

<210> 404

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-305 targeting domain

<400> 404

g g u g c a c u c c  
22

c c c c u a g a c a

g g

<210> 405

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-306 targeting domain

<400> 405

g c u u g g u g c u  
22

g g g a g g a g g g

g g

<210> 406  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-307 targeting domain

<400> 406  
g g a u a c u u c g u c u u c g g g c c c a  
22

<210> 407  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-308 targeting domain

<400> 407  
a g u c a g a c c c a g g c u g g g c a c u  
22

<210> 408  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-309 targeting domain

<400> 408  
a g c a c c a a g c c u c u g u u u c c c u  
22

<210> 409  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-310 targeting domain

<400> 409

u g g g c a a a g a  
22

a a u u c c a g g g

a a

<210> 410

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-311 targeting domain

<400> 410

a g a g g g a u u u  
22

g a g g a g g c c u

u g

<210> 411

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-312 targeting domain

<400> 411

g c a a u g u u u u  
22

g c c c a g a g g a

a g

<210> 412

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-313 targeting domain

<400> 412

c a u g u c c g g g  
22

u u a u u u c a u u

u c

<210> 413  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-314 targeting domain

<400> 413  
a a g c c c a u g a g c a a c u u c c g c u  
22

<210> 414  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-315 targeting domain

<400> 414  
u c c c a c c c u g a g c u u g g g c c c c  
22

<210> 415  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-316 targeting domain

<400> 415  
g a g a g a g c u u g g u g c u g g g a g g  
22

<210> 416  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-317 targeting domain

<400> 416

c u a c g u g c c c  
22

u u c u c c a a u g

c g

<210> 417

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-318 targeting domain

<400> 417

c u u g c a u u u a  
22

a c a g g a a a a c

a g

<210> 418

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-319 targeting domain

<400> 418

g a a a u g a a a u  
22

a a c c c g g a c a

u g

<210> 419

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-320 targeting domain

<400> 419

c g a a g g c c u g  
22

a g c u c a g c c a

c u

<210> 420  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-321 targeting domain

<400> 420  
g g a g g g u g c a c u c c c c c c u a g a  
22

<210> 421  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-322 targeting domain

<400> 421  
c a g c a c c a a g c c u c u g u u u c c c  
22

<210> 422  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-323 targeting domain

<400> 422  
g g g c a a a g a a a u u c c a g g g a a u  
22

<210> 423  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-324 targeting domain

<400> 423

c u u c g g g g a g  
22

a a c c a u g c c a

u c

<210> 424

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-325 targeting domain

<400> 424

u g g g a g g a g g  
22

g g g a a g g g g c

a g

<210> 425

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-326 targeting domain

<400> 425

c c u a g a c a g g  
22

g a g a g g g u a g

c u

<210> 426

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-327 targeting domain

<400> 426

u a a c a g a g a g  
22

g a a a a c u g a g

g c

<210> 427  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-328 targeting domain

<400> 427  
u c u c a g c c a c c a c c g c c a a g c c  
22

<210> 428  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-329 targeting domain

<400> 428  
g u c a g c a c a g a c c c c a c u g c c u  
22

<210> 429  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-330 targeting domain

<400> 429  
a g g a a a a c u g a g g c a g g g a g a g  
22

<210> 430  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-331 targeting domain

<400> 430

a g c c a u u g c a  
22

a a g c u g g g u g

a c

<210> 431

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-332 targeting domain

<400> 431

a a a u g a a a u a  
22

a c c c g g a c a u

g u

<210> 432

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-333 targeting domain

<400> 432

u a g c u a c c c u  
22

c u c c c u g u c u

a g

<210> 433

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-334 targeting domain

<400> 433

u g u g g g u g g g  
22

g u g u g c a g g a

g c

<210> 434  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-335 targeting domain

<400> 434  
u g g g g a a g g a g a g a g c u u g g u g  
22

<210> 435  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-336 targeting domain

<400> 435  
g a c u u g g a a c g c g g c a g g g a g g  
22

<210> 436  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-337 targeting domain

<400> 436  
a a g g a g a g a g c u u g g u g c u g g g  
22

<210> 437  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-338 targeting domain

<400> 437

g g g a a g g a g a  
22

g a g c u u g g u g

c u

<210> 438

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-339 targeting domain

<400> 438

a u u u g a g g a g  
22

g c c u u g g g g a

a g

<210> 439

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-340 targeting domain

<400> 439

a u c c a g c u g g  
22

a g c c c u g a g u

g g

<210> 440

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-341 targeting domain

<400> 440

g a g a g c u u g g  
22

u g c u g g g a g g

a g

<210> 441  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-342 targeting domain

<400> 441  
u c c u a g c u a c c c u c u c c c u g u c  
22

<210> 442  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-343 targeting domain

<400> 442  
c c g a g g c a g c a g c c u g g a c a u g  
22

<210> 443  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-344 targeting domain

<400> 443  
g g g g a a g g a g a g a g c u u g g u g c  
22

<210> 444  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-345 targeting domain

<400> 444

u g c u g g g a g g  
22

a g g g g g a a g g

g g

<210> 445

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-346 targeting domain

<400> 445

c u u c u u g u g c  
22

u g g a c g g u g a

c g

<210> 446

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-347 targeting domain

<400> 446

u a c c a c a c c c  
22

g u c g c a u u g g

a g

<210> 447

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-348 targeting domain

<400> 447

a g c a g c c u g g  
22

a c a u g g g g g a

g a

<210> 448  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-349 targeting domain

<400> 448  
a g c c a g g u a g u a c u g u g g g u a c  
22

<210> 449  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-350 targeting domain

<400> 449  
g g c u g c u u g c g g u u c u c a a c a c  
22

<210> 450  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-351 targeting domain

<400> 450  
g g a c c g a g g c a g c a g c c u g g a c  
22

<210> 451  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-352 targeting domain

<400> 451

c u g g g c a a a g  
22

a a a u u c c a g g

g a

<210> 452

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-353 targeting domain

<400> 452

u g a g a g g g g a  
22

g g c a g a g g a u

g c

<210> 453

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-354 targeting domain

<400> 453

g a g g g u g c a c  
22

u c c c c c c u a g

a c

<210> 454

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-355 targeting domain

<400> 454

c g g u u c u c a a  
22

c a c c a g g a g a

c u

<210> 455  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-356 targeting domain

<400> 455  
u g u g c a a u g u u u u g c c c a g a g g  
22

<210> 456  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-357 targeting domain

<400> 456  
g g g g g a g a c a g g g c a a g g c u g g  
22

<210> 457  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-358 targeting domain

<400> 457  
g c c g g g u g u g g g u g g g u g u g c  
22

<210> 458  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-359 targeting domain

<400> 458

c u g c g u a c c a  
22

c a c c c g u c g c

a u

<210> 459

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-360 targeting domain

<400> 459

c a c c c a a g a a  
22

u g c u g c g a a g

g c

<210> 460

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-361 targeting domain

<400> 460

c c u a g c u a c c  
22

c u c u c c c u g u

c u

<210> 461

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-362 targeting domain

<400> 461

c a c c a g g a g a  
22

c u u g g a a c g c

g g

<210> 462  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-363 targeting domain

<400> 462  
u u g g a u a a c a u u g a c a g g a c a g  
22

<210> 463  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-364 targeting domain

<400> 463  
u u c g g g c c c a c a g g a u g c a a u u  
22

<210> 464  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-365 targeting domain

<400> 464  
g a a g u a u c c a u g c a g a g a g g u g  
22

<210> 465  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-366 targeting domain

<400> 465

g g u g u g c a g g  
22

a g c c c g g g a g

c a

<210> 466

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-367 targeting domain

<400> 466

g g a g c a g c c a  
22

c g g g u c a g c c

a c

<210> 467

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-368 targeting domain

<400> 467

a g c g c c c u g c  
22

u g g g g c g u c a

c a

<210> 468

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-369 targeting domain

<400> 468

g a g c c c g g g a  
22

g c a u g g a g g g

g u

<210> 469  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-370 targeting domain

<400> 469  
a g g g c c a c a g c c a u g a a u g g c a  
22

<210> 470  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-371 targeting domain

<400> 470  
g c a a u g u g c a a u g u u u u g c c c a  
22

<210> 471  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-372 targeting domain

<400> 471  
g a a g a g g u c a g c c a c g g c u a g g  
22

<210> 472  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-373 targeting domain

<400> 472

g g c c u u c g c a  
22

g c a u u c u u g g

g u

<210> 473

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-374 targeting domain

<400> 473

u u a a c a g a g a  
22

g g a a a a c u g a

g g

<210> 474

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-375 targeting domain

<400> 474

u g a u g g c a u g  
22

g u u c u c c c c g

a a

<210> 475

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-376 targeting domain

<400> 475

a c c g a g g c a g  
22

c a g c c u g g a c

a u

<210> 476  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-377 targeting domain

<400> 476  
a g g g a c c a c a c g c u g a g g a g a g  
22

<210> 477  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-378 targeting domain

<400> 477  
u g g a a c g c g g c a g g g a g g c u g g  
22

<210> 478  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-379 targeting domain

<400> 478  
u g c a c a u u g c u u c a u g g c u c c u  
22

<210> 479  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-380 targeting domain

<400> 479

g c g u u c c a a g  
22

u c u c c u g g u g

u u

<210> 480

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-381 targeting domain

<400> 480

g g g u g u g c a g  
22

g a g c c c g g g a

g c

<210> 481

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-382 targeting domain

<400> 481

g g c a a a g a a a  
22

u u c c a g g g a a

u g

<210> 482

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-383 targeting domain

<400> 482

g g c u g g a g g g  
22

g c a c c u g a g g

a c

<210> 483  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-384 targeting domain

<400> 483  
g c g c c c u g c u g g g g c g u c a c a c  
22

<210> 484  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-385 targeting domain

<400> 484  
g c g u a c c a c a c c c g u c g c a u u g  
22

<210> 485  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-386 targeting domain

<400> 485  
a c c a g g a g a c u u g g a a c g c g g c  
22

<210> 486  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-387 targeting domain

<400> 486

g c u g c u g c c u  
22

c g g u c c c a u u

c u

<210> 487

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-388 targeting domain

<400> 487

g a a g c c c u c c  
22

a a a u u g c a u c

c u

<210> 488

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-389 targeting domain

<400> 488

c g u a g a g c g u  
22

g a g g a a g u u g

a u

<210> 489

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-390 targeting domain

<400> 489

c u g a a g c a g u  
22

u c c u u u u u g c

u u

<210> 490  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-391 targeting domain

<400> 490  
g c u g g a c g g u g a c g u a g a g c g u  
22

<210> 491  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-392 targeting domain

<400> 491  
u g a g g g c u u u g g a u a a c a u u g a  
22

<210> 492  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-393 targeting domain

<400> 492  
a g c c g g g u g u g g g u g g g g u g u g  
22

<210> 493  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-394 targeting domain

<400> 493

c u c a g u u u u c  
22

c u c u c u g u u a

a g

<210> 494

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-395 targeting domain

<400> 494

c a a g a c a u u a  
22

u u c u a a a g c a

a a

<210> 495

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-396 targeting domain

<400> 495

u g g a a c u u c a  
22

u g g g g u g g u g

a g

<210> 496

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-397 targeting domain

<400> 496

g a g a g g g a u u  
22

u g a g g a g g c c

u u

<210> 497  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-398 targeting domain

<400> 497  
c u u c g g g c c c a c a g g a u g c a a u  
22

<210> 498  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-399 targeting domain

<400> 498  
a c u u g g a a c g c g g c a g g g a g g c  
22

<210> 499  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> RH0-400 targeting domain

<400> 499  
a u g g c c a g a g a u u c c c u g a g a a  
22

<210> 500  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<223> RH0-401 targeting domain

<400> 500

c c u c a g u u u u  
22

c c u c u c u g u u

a a

<210> 501

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-402 targeting domain

<400> 501

u a a c a g a u c c  
22

c a c u u a a c a g

a g

<210> 502

<211> 22

<212> RNA

<213> Artificial Sequence

<220>

<223> RH0-403 targeting domain

<400> 502

g g g a g a g g g a  
22

u u u g a g g a g g

c c

<210> 503

<400> 503

000

<210> 504

<400> 504

000

**<210> 505**

**<400> 505  
000**

**<210> 506**

**<400> 506  
000**

**<210> 507**

**<400> 507  
000**

**<210> 508**

**<400> 508  
000**

**<210> 509**

**<400> 509  
000**

**<210> 510**

**<400> 510  
000**

**<210> 511**

**<400> 511  
000**

**<210> 512**

**<400> 512  
000**

**<210> 513**

**<400> 513  
000**

**<210> 514**

**<400> 514  
000**

**<210> 515**

**<400> 515  
000**

**<210> 516**

**<400> 516  
000**

**<210> 517**

**<400> 517  
000**

**<210> 518**

**<400> 518  
000**

**<210> 519**

**<400> 519  
000**

**<210> 520**

**<400> 520  
000**

**<210> 521**

**<400> 521  
000**

**<210> 522**

**<400> 522  
000**

**<210> 523**

**<400> 523  
000**

**<210> 524**

**<400> 524  
000**

**<210> 525**

**<400> 525  
000**

**<210> 526**

**<400> 526  
000**

**<210> 527**

**<400> 527  
000**

**<210> 528**

**<400> 528  
000**

**<210> 529**

**<400> 529  
000**

**<210> 530**

**<400> 530  
000**

**<210> 531**

**<400> 531  
000**

**<210> 532**

**<400> 532  
000**

**<210> 533**

**<400> 533  
000**

**<210> 534**

**<400> 534  
000**

**<210> 535**

**<400> 535  
000**

**<210> 536**

**<400> 536  
000**

**<210> 537**

**<400> 537  
000**

**<210> 538**

**<400> 538  
000**

**<210> 539**

**<400> 539  
000**

**<210> 540**

**<400> 540  
000**

**<210> 541**

**<400> 541  
000**

**<210> 542**

**<400> 542  
000**

**<210> 543**

**<400> 543  
000**

**<210> 544**

**<400> 544  
000**

**<210> 545**

**<400> 545  
000**

**<210> 546**

**<400> 546  
000**

**<210> 547**

**<400> 547  
000**

**<210> 548**

**<400> 548  
000**

**<210> 549**

**<400> 549  
000**

**<210> 550**

**<400> 550  
000**

**<210> 551**

**<400> 551  
000**

**<210> 552**

**<400> 552  
000**

**<210> 553**

**<400> 553  
000**

**<210> 554**

**<400> 554  
000**

**<210> 555**

**<400> 555  
000**

**<210> 556**

**<400> 556  
000**

**<210> 557**

**<400> 557  
000**

**<210> 558**

**<400> 558  
000**

**<210> 559**

**<400> 559  
000**

**<210> 560**

**<400> 560  
000**

**<210> 561**

**<400> 561  
000**

**<210> 562**

**<400> 562  
000**

**<210> 563**

**<400> 563  
000**

**<210> 564**

**<400> 564  
000**

**<210> 565**

**<400> 565  
000**

**<210> 566**

**<400> 566  
000**

**<210> 567**

**<400> 567  
000**

**<210> 568**

**<400> 568  
000**

**<210> 569**

**<400> 569  
000**

**<210> 570**

**<400> 570  
000**

**<210> 571**

**<400> 571  
000**

**<210> 572**

**<400> 572  
000**

**<210> 573**

**<400> 573  
000**

**<210> 574**

**<400> 574  
000**

**<210> 575**

**<400> 575  
000**

**<210> 576**

**<400> 576  
000**

**<210> 577**

**<400> 577  
000**

**<210> 578**

**<400> 578  
000**

**<210> 579**

**<400> 579  
000**

**<210> 580**

**<400> 580  
000**

**<210> 581**

**<400> 581  
000**

**<210> 582**

**<400> 582  
000**

**<210> 583**

**<400> 583  
000**

**<210> 584**

**<400> 584  
000**

**<210> 585**

**<400> 585  
000**

**<210> 586**

**<400> 586  
000**

**<210> 587**

**<400> 587  
000**

**<210> 588**

**<400> 588  
000**

**<210> 589**

**<400> 589  
000**

**<210> 590**

**<400> 590  
000**

**<210> 591**

**<400> 591  
000**

**<210> 592**

**<400> 592  
000**

**<210> 593**

**<400> 593  
000**

**<210> 594**

**<400> 594  
000**

<210> 595

<400> 595  
000

<210> 596

<400> 596  
000

<210> 597

<400> 597  
000

<210> 598

<400> 598  
000

<210> 599

<400> 599  
000

<210> 600

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-1 targeting domain

<400> 600

g t c a g c c a c a  
22

a g g g c c a c a g

c c

<210> 601

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-2 targeting domain

<400> 601  
c c g a a g a c g a a g t a t c c a t g c a  
22

<210> 602  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-3 targeting domain

<400> 602  
a g t a t c c a t g c a g a g a g g t g t a  
22

<210> 603  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-4 targeting domain

<400> 603  
c t a g g t t g a g c a g g a t g t a g t t  
22

<210> 604  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-5 targeting domain

<400> 604  
c a t g g c t c a g c c a g g t a g t a c t  
22

<210> 605  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-6 targeting domain

<400> 605  
a c g g g t g t g g t a c g c a g c c c c t  
22

<210> 606  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-7 targeting domain

<400> 606  
c c c a c a c c c g g c t c a t a c c g c c  
22

<210> 607  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-8 targeting domain

<400> 607  
c c c t g g g c g g t a t g a g c c g g g t  
22

<210> 608  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-9 targeting domain

<400> 608

c c a t c a t g g g  
22

c g t t g c c t t c

a c

<210> 609

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-10 targeting domain

<400> 609

g t g c c a t t a c  
22

c t g g a c c a g c

c g

<210> 610

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-11 targeting domain

<400> 610

t t a c c t g g a c  
22

c a g c c g g c g a

g t

<210> 611

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-12 targeting domain

<400> 611

g c a t t c t t g g  
22

g t g g g a g c a g

c c

<210> 612  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-13 targeting domain

<400> 612  
g c t c a g c c a c t c a g g g c t c c a g  
22

<210> 613  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-14 targeting domain

<400> 613  
t g a c c c g t g g c t g c t c c c a c c c  
22

<210> 614  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-15 targeting domain

<400> 614  
a g c t c a g g c c t t c g c a g c a t t c  
22

<210> 615  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-16 targeting domain

<400> 615

t a g c a g a a g a

a t g c a t c c t a

a t

22

<210> 616

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-17 targeting domain

<400> 616

a c a c g c t g a g

g a g a g c t g g g

c a

22

<210> 617

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-18 targeting domain

<400> 617

g c a a a t a a c t

t c c c c c a t t c

c c

22

<210> 618

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-19 targeting domain

<400> 618

a g a c c c a g g c

t g g g c a c t g a

g g

22

<210> 619  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-20 targeting domain

<400> 619  
c t a g g t c t c c t g g c t g t g a t c c  
22

<210> 620  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-21 targeting domain

<400> 620  
c c a g a a g g t g g g t g t g c c a c t t  
22

<210> 621  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-22 targeting domain

<400> 621  
a a c a a g g a a c t c t g c c c c a c a t  
22

<210> 622  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-23 targeting domain

<400> 622

c a g g a t t g a a  
22

c t g g g a a c c c

g g

<210> 623

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-24 targeting domain

<400> 623

g g g c g t c a c a  
22

c a g g g a c g g g

t g

<210> 624

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-25 targeting domain

<400> 624

c t g t g a t c c a  
22

g g a a t a t c t c

t g

<210> 625

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-26 targeting domain

<400> 625

t t g c a t t t a a  
22

c a g g a a a a c a

g a

<210> 626  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-27 targeting domain

<400> 626  
g g a g t g c a c c c c t c c t t a g g c a g  
22

<210> 627  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-28 targeting domain

<400> 627  
c a t c t g t c c t g c t c a c c a c c c c c  
22

<210> 628  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-29 targeting domain

<400> 628  
g a g g g g a g g c a g a g g a t g c c a g  
22

<210> 629  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-30 targeting domain

<400> 629

c t c a g g g a a t  
22

c t c t g g c c a t

t g

<210> 630

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-31 targeting domain

<400> 630

t g c a c t c c c c  
22

c c t a g a c a g g

g a

<210> 631

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-32 targeting domain

<400> 631

t g c t g t t t g t  
22

g c a g g g c t g g

c a

<210> 632

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-33 targeting domain

<400> 632

a c t g g g a c a t  
22

t c c t a a c a g t

g a

<210> 633  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-34 targeting domain

<400> 633  
a t c a g g g g g t c a g g a t t g a a c t  
22

<210> 634  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-35 targeting domain

<400> 634  
c t c c t c t c t g g g g g c c c a a g c t  
22

<210> 635  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-36 targeting domain

<400> 635  
c t g c a t c t c a g c a g a g a t a t t c  
22

<210> 636  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-37 targeting domain

<400> 636

t g t t t c c c t t  
22

g g a g c a g c t g

t g

<210> 637

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-38 targeting domain

<400> 637

g c g c t c t g g g  
22

c c c a t a a g g g

a c

<210> 638

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-39 targeting domain

<400> 638

a g g a t t g a a c  
22

t g g g a a c c c g

g t

<210> 639

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-40 targeting domain

<400> 639

c c t a g g a g a g  
22

g c c c c c a c a t

g t

<210> 640  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-41 targeting domain

<400> 640  
a t c a c t c a g t t c t g g c c a g a a g  
22

<210> 641  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-42 targeting domain

<400> 641  
a g a g c t g g g c a a a g a a a t t c c a  
22

<210> 642  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-43 targeting domain

<400> 642  
c c a c c c c a t g a a g t t c c a t a g g  
22

<210> 643  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-44 targeting domain

<400> 643

c c a c c c t g a g  
22

c t t g g g c c c c

c a

<210> 644

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-45 targeting domain

<400> 644

c a g a g g a a g a  
22

a g a a g g a a a t

g a

<210> 645

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-46 targeting domain

<400> 645

a a a c a g c a g c  
22

c c g g c t a t c a

c c

<210> 646

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-47 targeting domain

<400> 646

g g a t t g a a c t  
22

g g g a a c c c g g

t a

<210> 647  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-48 targeting domain

<400> 647  
t g t g t g t g t g t g t t a g c a g  
22

<210> 648  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-49 targeting domain

<400> 648  
t c a c a c a g g g a c g g g t g c a g a g  
22

<210> 649  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-50 targeting domain

<400> 649  
g t g t g t g t g t g t g t t t a g  
22

<210> 650  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-51 targeting domain

<400> 650

t g a g c t t g g g  
22

c c c c c a g a g a

g g

<210> 651

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-52 targeting domain

<400> 651

a a t a t c t c t g  
22

c t g a g a t g c a

g g

<210> 652

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-53 targeting domain

<400> 652

g g a g a g g g g a  
22

a g a g a c t c a t

t t

<210> 653

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-54 targeting domain

<400> 653

a g a a c t g a g t  
22

g a t c t g t g a t

t a

<210> 654  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-55 targeting domain

<400> 654  
c c a c t c t c c c                      t a t g g a a c t t                      c a  
22

<210> 655  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-56 targeting domain

<400> 655  
a t a a g g g a c a                      c g a a t c a g a t                      c a  
22

<210> 656  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-57 targeting domain

<400> 656  
t g g a t t t t c c                      a t t c t c c a g t                      c a  
22

<210> 657  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-58 targeting domain

<400> 657

g t g c a g g a g c  
22

c c g g g a g c a t

g g

<210> 658

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-59 targeting domain

<400> 658

g g g t g g t g a g  
22

c a g g a c a g a t

g t

<210> 659

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-60 targeting domain

<400> 659

c a g c t c t c c c  
22

t c a g t g c c c a

g c

<210> 660

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-61 targeting domain

<400> 660

c c t g c t g g g g  
22

c g t c a c a c a g

g g

<210> 661  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-62 targeting domain

<400> 661  
c a c a c a c a c a c a a a a c t c c c t a  
22

<210> 662  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-63 targeting domain

<400> 662  
a c t t a c g g g t g g t t g t t c t c t g  
22

<210> 663  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-64 targeting domain

<400> 663  
c a c a g g g a a g a c c c a a t g a c t g  
22

<210> 664  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-65 targeting domain

<400> 664

a g c a c a g a c c  
22

c c a c t g c c t a

a g

<210> 665

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-66 targeting domain

<400> 665

a c c t g a g g a c  
22

a g g g g c t g a g

a g

<210> 666

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-67 targeting domain

<400> 666

c a a c a a t g g c  
22

c a g a g a t t c c

c t

<210> 667

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-68 targeting domain

<400> 667

t g c t g c c t c g  
22

g t c c c a t t c t

c a

<210> 668  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-69 targeting domain

<400> 668  
t g c t g c c t g g c c a c a t c c c t a a  
22

<210> 669  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-70 targeting domain

<400> 669  
g c c a c t c t c c c t a t g g a a c t t c  
22

<210> 670  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-71 targeting domain

<400> 670  
g a g g g a g g a a g g a c t g c c a a t t  
22

<210> 671  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-72 targeting domain

<400> 671

g a g g g t a g c t  
22

a g g a a g g c a a

c c

<210> 672

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-73 targeting domain

<400> 672

g g a a g g c a a c  
22

c a g g a g t g g g

a g

<210> 673

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-74 targeting domain

<400> 673

g c t g a g a t g c  
22

a g g a g g a g a c

g c

<210> 674

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-75 targeting domain

<400> 674

a g g c t g g a g g  
22

g g c a c c t g a g

g a

<210> 675  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-76 targeting domain

<400> 675  
a g g a a g g c a a c c a g g a g t g g g a  
22

<210> 676  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-77 targeting domain

<400> 676  
c c g g g a g c a t g g a g g g g t c t g g  
22

<210> 677  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-78 targeting domain

<400> 677  
g g a t a a c a g a t c c c a c t t a a c a  
22

<210> 678  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-79 targeting domain

<400> 678

a g g c a g a g g a  
22

t g c c a g a g g g

g a

<210> 679

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-80 targeting domain

<400> 679

g g g c c c a a g c  
22

t c a g g g t g g g

a a

<210> 680

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-81 targeting domain

<400> 680

t a a c t a t a t g  
22

g c c a c t c t c c

c t

<210> 681

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-82 targeting domain

<400> 681

t c c c a c t t a a  
22

c a g a g a g g a a

a a

<210> 682  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-83 targeting domain

<400> 682  
g a a t g c a g a g g t g g t g g a a a c c  
22

<210> 683  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-84 targeting domain

<400> 683  
g g g a g a c a g g g c a a g g c t g g c a  
22

<210> 684  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-85 targeting domain

<400> 684  
c a c c a c c c c a t g a a g t t c c a t a  
22

<210> 685  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-86 targeting domain

<400> 685

g c c a t a t a g t  
22

t a a t c a a c c a

a a

<210> 686

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-87 targeting domain

<400> 686

g t a g c t a g g a  
22

a g g c a a c c a g

g a

<210> 687

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-88 targeting domain

<400> 687

c a c a t t g c t t  
22

c a t g g c t c c t

a g

<210> 688

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-89 targeting domain

<400> 688

c t g a g c t t g g  
22

g c c c c c a g a g

a g

<210> 689  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-90 targeting domain

<400> 689  
a c c g a g c c c a t t g c c c a g c a c a  
22

<210> 690  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-91 targeting domain

<400> 690  
c t c a a a g a a g t c a a g c g c c c t g  
22

<210> 691  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-92 targeting domain

<400> 691  
g c t a c c c t c t c c c t g t c t a g g g  
22

<210> 692  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-93 targeting domain

<400> 692

a c c c t g a g c t  
22

t g g g c c c c c a

g a

<210> 693

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-94 targeting domain

<400> 693

g g c a g a g g g a  
22

c c a c a c g c t g

a g

<210> 694

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-95 targeting domain

<400> 694

t c t g a c t c a g  
22

c a c a g c t g c t

c c

<210> 695

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-96 targeting domain

<400> 695

c t c t c a g c c a  
22

c c a c c g c c a a

g c

<210> 696  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-97 targeting domain

<400> 696  
a g g g a t g t g g c c a g g c a g c a a c  
22

<210> 697  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-98 targeting domain

<400> 697  
c a c c t g a g g a c a g g g g c t g a g a  
22

<210> 698  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-99 targeting domain

<400> 698  
g c c c a t g a t g g c a t g g t t c t c c  
22

<210> 699  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-100 targeting domain

<400> 699

g a a g g g g c a g  
22

a g g g a c c a c a

c g

<210> 700

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-101 targeting domain

<400> 700

a g c a c c c t c t  
22

a c a c c t c t c t

g c

<210> 701

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-102 targeting domain

<400> 701

c t t t g g a t a a  
22

c a t t g a c a g g

a c

<210> 702

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-103 targeting domain

<400> 702

g g t g a a g c c a  
22

c c t a g g a c c a

t g

<210> 703  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-104 targeting domain

<400> 703  
t a a c a t t g a c a g g a c a g g a g a a  
22

<210> 704  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-105 targeting domain

<400> 704  
g g g a g a g g g g a a g a g a c t c a t t  
22

<210> 705  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-106 targeting domain

<400> 705  
g c t g t g c t g a g t c a g a c c c a g g  
22

<210> 706  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-107 targeting domain

<400> 706

t t g a g g a g g c  
22

c t t g g g g a a g

g a

<210> 707

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-108 targeting domain

<400> 707

g c c c g g g a g c  
22

a t g g a g g g g t

c t

<210> 708

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-109 targeting domain

<400> 708

g t a a a c t g g g  
22

a c t g a c c c t g

c a

<210> 709

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-110 targeting domain

<400> 709

a t a a c a t t g a  
22

c a g g a c a g g a

g a

<210> 710  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-111 targeting domain

<400> 710  
g g c a g g g a g g c t g g a g g g g c a c  
22

<210> 711  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-112 targeting domain

<400> 711  
g c a a a c a t g g c c c g a g a t a g a t  
22

<210> 712  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-113 targeting domain

<400> 712  
g g a c c g a g c c c a t t g c c c a g c a  
22

<210> 713  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-114 targeting domain

<400> 713

g c t c t a c g t c  
22

a c c g t c c a g c

a c

<210> 714

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-115 targeting domain

<400> 714

a g c a c a g c t g  
22

c t c c a a g g g a

a a

<210> 715

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-116 targeting domain

<400> 715

c t a a a g c a a a  
22

a a g g a a c t g c

t t

<210> 716

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-117 targeting domain

<400> 716

g a g a g g a a a a  
22

c t g a g g c a g g

g a

<210> 717  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-118 targeting domain

<400> 717  
c a t t g c a a a g c t g g g t g a c g g g  
22

<210> 718  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-119 targeting domain

<400> 718  
t t g c c a c c c t g g g c g g t a t g a g  
22

<210> 719  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-120 targeting domain

<400> 719  
a g c t a g g a a g g c a a c c a g g a g t  
22

<210> 720  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-121 targeting domain

<400> 720

t c t c t g g g g g  
22

c c c a a g c t c a

g g

<210> 721

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-122 targeting domain

<400> 721

a g c a c a g g g a  
22

a g a c c c a a t g

a c

<210> 722

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-123 targeting domain

<400> 722

g t t g a c t g a a  
22

t a t a t g a g g g

c t

<210> 723

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-124 targeting domain

<400> 723

t t g t a a a c t g  
22

g g a c t g a c c c

t g

<210> 724  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-125 targeting domain

<400> 724  
c a c a c c c a c c t t c t g g c c a g a a  
22

<210> 725  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-126 targeting domain

<400> 725  
c c a g a g g a a g a a g a a a t g  
22

<210> 726  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-127 targeting domain

<400> 726  
g a g a t a t t c c t g g a t c a c a g c c  
22

<210> 727  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-128 targeting domain

<400> 727

a g g g g c a g a g  
22

g g a c c a c a c g

c t

<210> 728

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-129 targeting domain

<400> 728

a a c t a t a t g g  
22

c c a c t c t c c c

t a

<210> 729

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-130 targeting domain

<400> 729

g c t g c t t g c g  
22

g t t c t c a a c a

c c

<210> 730

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-131 targeting domain

<400> 730

c a c c a t g a a t  
22

g g t g t t t g t t

g a

<210> 731  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-132 targeting domain

<400> 731  
g c a g c c a t t g c a a a g c t g g g t g  
22

<210> 732  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-133 targeting domain

<400> 732  
t g a c t c a g c a c a g c t g c t c c a a  
22

<210> 733  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-134 targeting domain

<400> 733  
c t g g g a g g a g g g g g a a g g g g c a  
22

<210> 734  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-135 targeting domain

<400> 734

g a t a a c a t t g  
22

a c a g g a c a g g

a g

<210> 735

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-136 targeting domain

<400> 735

c c a a a c t g g g  
22

a c a t t c c t a a

c a

<210> 736

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-137 targeting domain

<400> 736

a g g a a a a c a g  
22

a t g g g g t g c t

g c

<210> 737

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-138 targeting domain

<400> 737

c g g a c a t g t g  
22

g g g g c c t c t c

c t

<210> 738  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-139 targeting domain

<400> 738  
g c a a a g a a a t t c c a g g g a a t g g  
22

<210> 739  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-140 targeting domain

<400> 739  
c c a g g a g a c t t g g a a c g c g g c a  
22

<210> 740  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-141 targeting domain

<400> 740  
t g g t c c t t g g t g g t c c t g g c c a  
22

<210> 741  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-142 targeting domain

<400> 741

a a t g g a a a a t  
22

c c a c t t c c c a

c c

<210> 742

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-143 targeting domain

<400> 742

g c c c g a a g a c  
22

g a a g t a t c c a

t g

<210> 743

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-144 targeting domain

<400> 743

g t g c t g g a c g  
22

g t g a c g t a g a

g c

<210> 744

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-145 targeting domain

<400> 744

a g a a a c a t g t  
22

a g g c g g c c a g

c a

<210> 745  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-146 targeting domain

<400> 745  
c c g c t c g a t g g c c a g g a c c a c c  
22

<210> 746  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-147 targeting domain

<400> 746  
t c a g c a c a g a c c c c a c t g c c t a  
22

<210> 747  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-148 targeting domain

<400> 747  
g a a t a t c t c t g c t g a g a t g c a g  
22

<210> 748  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-149 targeting domain

<400> 748

g a g t a c c c a c  
22

a g t a c t a c c t

g g

<210> 749

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-150 targeting domain

<400> 749

c a a c c a g g a g  
22

t g g g a g a g g g

a t

<210> 750

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-151 targeting domain

<400> 750

t t g a g a a c c g  
22

c a a g c a g c c g

c t

<210> 751

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-152 targeting domain

<400> 751

g c a a g c c a g a  
22

c c c c t c c t c t

c t

<210> 752  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-153 targeting domain

<400> 752  
g a g a g c t g g g c a a a g a a a t t c c  
22

<210> 753  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-154 targeting domain

<400> 753  
c g a g g c a g c a g c c t g g a c a t g g  
22

<210> 754  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-155 targeting domain

<400> 754  
a g g a a t a t c t c t g c t g a g a t g c  
22

<210> 755  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-156 targeting domain

<400> 755

t t c c c g a g a a  
22

g g g a g a g g g a

g g

<210> 756

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-157 targeting domain

<400> 756

t c c t t c c t c c  
22

c t c t c c c t t c

t c

<210> 757

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-158 targeting domain

<400> 757

t g t t t t g c c c  
22

a g a g g a a g a a

g a

<210> 758

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-159 targeting domain

<400> 758

c c g g c t g g t c  
22

c a g g t a a t g g

c a

<210> 759  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-160 targeting domain

<400> 759  
c a g c a c a g g g a a g a c c c a a t g a  
22

<210> 760  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-161 targeting domain

<400> 760  
a c c a g g a g t g g g a g a g g g a t t t  
22

<210> 761  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-162 targeting domain

<400> 761  
g c t g g t g a a g c c a c c t a g g a c c  
22

<210> 762  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-163 targeting domain

<400> 762

g g c g g t a t g a  
22

g c c g g g t g t g

g g

<210> 763

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-164 targeting domain

<400> 763

c a g c c a t t g c  
22

a a a g c t g g g t

g a

<210> 764

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-165 targeting domain

<400> 764

a c a t t g a c a g  
22

g a c a g g a g a a

g g

<210> 765

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-166 targeting domain

<400> 765

t g g g t c t t c c  
22

c t g t g c t g g g

c a

<210> 766  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-167 targeting domain

<400> 766  
g t a c g t g g t g g t g t g t a a g c c c  
22

<210> 767  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-168 targeting domain

<400> 767  
a g c a a a t a a c t t c c c c c a t t c c  
22

<210> 768  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-169 targeting domain

<400> 768  
g g a t t t g a g g a g g c c t t g g g g a  
22

<210> 769  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-170 targeting domain

<400> 769

c c c t g a g c t t  
22

g g g c c c c a g

a g

<210> 770

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-171 targeting domain

<400> 770

c a g a g a t t c c  
22

c t g a g a a t g g

g a

<210> 771

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-172 targeting domain

<400> 771

g a g t t g g a a g  
22

c c c g c a t c t a

t c

<210> 772

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-173 targeting domain

<400> 772

a g t c c t t c c t  
22

c c c t c t c c c t

t c

<210> 773  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-174 targeting domain

<400> 773  
g t t a t t t c a t t t c c c g a g a a g g  
22

<210> 774  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-175 targeting domain

<400> 774  
a t t t c a t t t c c c g a g a a g g g a g  
22

<210> 775  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-176 targeting domain

<400> 775  
g a c g t a g a g c g t g a g g a a g t t g  
22

<210> 776  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-177 targeting domain

<400> 776

c a t t t c c c g a  
22

g a a g g g a g a g

g g

<210> 777

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-178 targeting domain

<400> 777

g t a g a g c g t g  
22

a g g a a g t t g a

t g

<210> 778

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-179 targeting domain

<400> 778

c a g g c c t t c g  
22

c a g c a t t c t t

g g

<210> 779

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-180 targeting domain

<400> 779

a g g t a g t a c t  
22

g t g g g t a c t c

g a

<210> 780  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-181 targeting domain

<400> 780  
a a a c a t g t a g g c g g c c a g c a t g  
22

<210> 781  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-182 targeting domain

<400> 781  
t t t c a t t t c c c g a g a a g g g a g a  
22

<210> 782  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-183 targeting domain

<400> 782  
g g g a a g a c c c a a t g a c t g g a g a  
22

<210> 783  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-184 targeting domain

<400> 783

a a a a c t g a g g  
22

c a g g g a g a g g

g g

<210> 784

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-185 targeting domain

<400> 784

t g a g t c a g a c  
22

c c a g g c t g g g

c a

<210> 785

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-186 targeting domain

<400> 785

g g g a t t t g a g  
22

g a g g c c t t g g

g g

<210> 786

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-187 targeting domain

<400> 786

t c t g g g g g c c  
22

c a a g c t c a g g

g t

<210> 787  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-188 targeting domain

<400> 787  
c g g g c c c a c a g g a t g c a a t t t g  
22

<210> 788  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-189 targeting domain

<400> 788  
a c g t a g a g c g t g a g g a a g t t g a  
22

<210> 789  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-190 targeting domain

<400> 789  
g a c c g a g g c a g c a g c c t g g a c a  
22

<210> 790  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-191 targeting domain

<400> 790

c a g g c t g g g c  
22

a c t g a g g g a g

a g

<210> 791

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-192 targeting domain

<400> 791

t a t t t c a t t t  
22

c c c g a g a a g g

g a

<210> 792

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-193 targeting domain

<400> 792

g t c c c g g g c t  
22

t g g c g g t g g t

g g

<210> 793

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-194 targeting domain

<400> 793

c t g c t g c c t c  
22

g g t c c c a t t c

t c

<210> 794  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-195 targeting domain

<400> 794  
a g c g t c t c c t c c t g c a t c t c a g  
22

<210> 795  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-196 targeting domain

<400> 795  
t c a g a c c c a g g c t g g g c a c t g a  
22

<210> 796  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-197 targeting domain

<400> 796  
a g c t a c c c t c t c c c t g t c t a g g  
22

<210> 797  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-198 targeting domain

<400> 797

c a g a g a g g a a  
22

a a c t g a g g c a

g g

<210> 798

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-199 targeting domain

<400> 798

g g a g a g g g a t  
22

t t g a g g a g g c

c t

<210> 799

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-200 targeting domain

<400> 799

g t c c t t c c t c  
22

c c t c t c c c t t

c t

<210> 800

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-201 targeting domain

<400> 800

a g a g a g c t t g  
22

g t g c t g g g a g

g a

<210> 801  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-202 targeting domain

<400> 801  
c c t t c t c g g g a a a t g a a a t a a c  
22

<210> 802  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-203 targeting domain

<400> 802  
g c g g t t c t c a a c a c c a g g a g a c  
22

<210> 803  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-204 targeting domain

<400> 803  
c t c t g g g g g c c c a a g c t c a g g g  
22

<210> 804  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-205 targeting domain

<400> 804

t g t g c a g g a g  
22

c c c g g g a g c a

t g

<210> 805

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-206 targeting domain

<400> 805

c a g a g a g g t g  
22

t a g a g g g t g c

t g

<210> 806

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-207 targeting domain

<400> 806

c t c c c c g a a g  
22

c g g a a g t t g c

t c

<210> 807

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-208 targeting domain

<400> 807

g c t a g a a g c a  
22

g c c a t t g c a a

a g

<210> 808  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-209 targeting domain

<400> 808  
c a a a c a c c a t t c a t g g t g a t a g  
22

<210> 809  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-210 targeting domain

<400> 809  
t c a t t t c c c g a g a a g g g a g a g g  
22

<210> 810  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-211 targeting domain

<400> 810  
t c a c c a c c c c a t g a a g t t c c a t  
22

<210> 811  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-212 targeting domain

<400> 811

g g g a g t g c a c  
22

c c t c c t t a g g

c a

<210> 812

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-213 targeting domain

<400> 812

a a t g g c c a g a  
22

g a t t c c c t g a

g a

<210> 813

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-214 targeting domain

<400> 813

a g a a t g g g a c  
22

c g a g g c a g c a

g c

<210> 814

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-215 targeting domain

<400> 814

g g c a a g c c a g  
22

a c c c c t c c t c

t c

<210> 815  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-216 targeting domain

<400> 815  
c c c g g g c t t g g c g g t g g t g g c t  
22

<210> 816  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-217 targeting domain

<400> 816  
a g c c c g g g a g c a t g g a g g g g t c  
22

<210> 817  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-218 targeting domain

<400> 817  
c c g g g t t a t t t c a t t t c c c g a g  
22

<210> 818  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-219 targeting domain

<400> 818

g g t g t t t g t t  
22

g a c t g a a t a t

a t

<210> 819

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-220 targeting domain

<400> 819

c c g t c c c t g t  
22

g t g a c g c c c c

a g

<210> 820

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-221 targeting domain

<400> 820

g g a c a g g g g c  
22

t g a g a g g g g a

g g

<210> 821

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-222 targeting domain

<400> 821

a g a g g g t g c t  
22

g g t g a a g c c a

c c

<210> 822  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-223 targeting domain

<400> 822  
a t t g c a t c c t g t g g g c c c g a a g  
22

<210> 823  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-224 targeting domain

<400> 823  
c g g g t t a t t t c a t t t c c c g a g a  
22

<210> 824  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-225 targeting domain

<400> 824  
g g a a a t g a a a t a a c c c g g a c a t  
22

<210> 825  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-226 targeting domain

<400> 825

c t g a c t c a g c  
22

a c a g c t g c t c

c a

<210> 826

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-227 targeting domain

<400> 826

g g c a c c t g a g  
22

g a c a g g g g c t

g a

<210> 827

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-228 targeting domain

<400> 827

g g a g a g c t g g  
22

g c a a a g a a a t

t c

<210> 828

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-229 targeting domain

<400> 828

g g g c g g t a t g  
22

a g c c g g g t g t

g g

<210> 829  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-230 targeting domain

<400> 829  
c c t c c c t c t c c c t t c t c g g g a a  
22

<210> 830  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-231 targeting domain

<400> 830  
t c c a g g t a a t g g c a c t g a g c a g  
22

<210> 831  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-232 targeting domain

<400> 831  
g t g g g g c c t c t c c t a g g a g c c  
22

<210> 832  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-233 targeting domain

<400> 832

g a t g g c a t g g  
22

t t c t c c c c g a

a g

<210> 833

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-234 targeting domain

<400> 833

c g t c g c a t t g  
22

g a g a a g g g c a

c g

<210> 834

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-235 targeting domain

<400> 834

t g g g t g g g g t  
22

g t g c a g g a g c

c c

<210> 835

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-236 targeting domain

<400> 835

c t g g a c g g t g  
22

a c g t a g a g c g

t g

<210> 836  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-237 targeting domain

<400> 836  
g a g g a a a a c t g a g g c a g g g a g a  
22

<210> 837  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-238 targeting domain

<400> 837  
c t g a a c a c t g c c t t g a t c t t a t  
22

<210> 838  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-239 targeting domain

<400> 838  
c a t t a c c t g g a c c a g c c g g c g a  
22

<210> 839  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-240 targeting domain

<400> 839

g g a g a g a g c t  
22

t g g t g c t g g g

a g

<210> 840

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-241 targeting domain

<400> 840

a g a a t a a t g t  
22

c t t g c a t t t a

a c

<210> 841

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-242 targeting domain

<400> 841

c t a g g a a g g c  
22

a a c c a g g a g t

g g

<210> 842

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-243 targeting domain

<400> 842

t c t c c c a g a c  
22

c c c t c c a t g c

t c

<210> 843  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-244 targeting domain

<400> 843  
a c a g g g g c t g a g a g g g g a g g c a  
22

<210> 844  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-245 targeting domain

<400> 844  
g g g g c a g a g g g a c c a c a c g c t g  
22

<210> 845  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-246 targeting domain

<400> 845  
a g g g g a g g c a g a g g a t g c c a g a  
22

<210> 846  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-247 targeting domain

<400> 846

t g g t c c a g g t  
22

a a t g g c a c t g

a g

<210> 847

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-248 targeting domain

<400> 847

c c g g a c a t g t  
22

g g g g g c c t c t

c c

<210> 848

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-249 targeting domain

<400> 848

g c a g g c c a g c  
22

g c c a t g a c c c

a g

<210> 849

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-250 targeting domain

<400> 849

c t a g c t a c c c  
22

t c t c c c t g t c

t a

<210> 850  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-251 targeting domain

<400> 850  
g c t t t g g a t a a c a t t g a c a g g a  
22

<210> 851  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-252 targeting domain

<400> 851  
g c c a t t g c a a a g c t g g g t g a c g  
22

<210> 852  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-253 targeting domain

<400> 852  
c c t a g g t c t c c t g g c t g t g a t c  
22

<210> 853  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-254 targeting domain

<400> 853

a a c a g a g a g g  
22

a a a a c t g a g g

c a

<210> 854

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-255 targeting domain

<400> 854

a t t a c c t g g a  
22

c c a g c c g g c g

a g

<210> 855

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-256 targeting domain

<400> 855

g a g g g g c a c c  
22

t g a g g a c a g g

g g

<210> 856

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-257 targeting domain

<400> 856

g g g t t a t t t c  
22

a t t t c c c g a g

a a

<210> 857  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-258 targeting domain

<400> 857  
a g g g t g c a c t c c c c c c t a g a c a  
22

<210> 858  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-259 targeting domain

<400> 858  
c c a g g a g t g g g a g a g g g a t t t g  
22

<210> 859  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-260 targeting domain

<400> 859  
a g a g g g g a g g c a g a g g a t g c c a  
22

<210> 860  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-261 targeting domain

<400> 860

c c g c c t g c t g  
22

a c t g c c t t g c

a g

<210> 861

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-262 targeting domain

<400> 861

g g c t t g g t g c  
22

t g c a a a c a t g

g c

<210> 862

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-263 targeting domain

<400> 862

c a g g t a a t g g  
22

c a c t g a g c a g

a a

<210> 863

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-264 targeting domain

<400> 863

t t g g a a c g c g  
22

g c a g g g a g g c

t g

<210> 864  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-265 targeting domain

<400> 864  
t g t c c g g g t t a t t t c a t t t c c c  
22

<210> 865  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-266 targeting domain

<400> 865  
c a g g t a g t a c t g t g g g t a c t c g  
22

<210> 866  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-267 targeting domain

<400> 866  
a t a a c a g a t c c c a c t t a a c a g a  
22

<210> 867  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-268 targeting domain

<400> 867

a g g g a c g g g t  
22

g c a g a g t t g a

g t

<210> 868

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-269 targeting domain

<400> 868

g a a g g a g a g a  
22

g c t t g g t g c t

g g

<210> 869

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-270 targeting domain

<400> 869

g g t c a g c c a c  
22

g g c t a g g t t g

a g

<210> 870

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-271 targeting domain

<400> 870

a t t t c a c a g c  
22

a a g a a a a c t g

a g

<210> 871  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-272 targeting domain

<400> 871  
t c a a a g a a g t c a a g c g c c c t g c  
22

<210> 872  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-273 targeting domain

<400> 872  
g c t g c t c c c a c c c a a g a a t g c t  
22

<210> 873  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-274 targeting domain

<400> 873  
g c a a c a a a c a c c c a a c a a t g g c  
22

<210> 874  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-275 targeting domain

<400> 874

a a a t c c a c t t  
22

c c c a c c c t g a

g c

<210> 875

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-276 targeting domain

<400> 875

c a g g g a g g c t  
22

g g a g g g g c a c

c t

<210> 876

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-277 targeting domain

<400> 876

g g g c a a g c c a  
22

g a c c c c t c c t

c t

<210> 877

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-278 targeting domain

<400> 877

c a g g a a a c a  
22

g a t g g g g t g c

t g

<210> 878  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-279 targeting domain

<400> 878  
t t g g a g a a g g g c a c g t a g a a g t  
22

<210> 879  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-280 targeting domain

<400> 879  
a g a g c t t g g t g c t g g g a g g a g g  
22

<210> 880  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-281 targeting domain

<400> 880  
t a g c t a g g a a g g c a a c c a g g a g  
22

<210> 881  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-282 targeting domain

<400> 881

g g c t a g g t t g  
22

a g c a g g a t g t

a g

<210> 882

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-283 targeting domain

<400> 882

c t c a c c a c c c  
22

c a t g a a g t t c

c a

<210> 883

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-284 targeting domain

<400> 883

a a g c a a t g t g  
22

c a a t g t t t t g

c c

<210> 884

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-285 targeting domain

<400> 884

g g a a g a c c c a  
22

a t g a c t g g a g

a a

<210> 885  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-286 targeting domain

<400> 885  
t g g c c a g g a c c a c c a a g g a c c a  
22

<210> 886  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-287 targeting domain

<400> 886  
a a a t a t t g t c c c t t t c a c t g t t  
22

<210> 887  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-288 targeting domain

<400> 887  
c a t g a g c a a c t t c c g c t t c g g g  
22

<210> 888  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-289 targeting domain

<400> 888

a g a g a t a t t c  
22

c t g g a t c a c a

g c

<210> 889

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-290 targeting domain

<400> 889

c a t g g a g g g g  
22

t c t g g g a g a g

t c

<210> 890

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-291 targeting domain

<400> 890

a t g t t t t g c c  
22

c a g a g g a a g a

a g

<210> 891

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-292 targeting domain

<400> 891

g t g g g t g g g g  
22

t g t g c a g g a g

c c

<210> 892  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-293 targeting domain

<400> 892  
c c a g g t a a t g g c a c t g a g c a g a  
22

<210> 893  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-294 targeting domain

<400> 893  
c c c a a c a a t g g c c a g a g a t t c c  
22

<210> 894  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-295 targeting domain

<400> 894  
g c a c c t g a g g a c a g g g g c t g a g  
22

<210> 895  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-296 targeting domain

<400> 895

g t c a g a c c c a  
22

g g c t g g g c a c

t g

<210> 896

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-297 targeting domain

<400> 896

g g g g c a c c t g  
22

a g g a c a g g g g

c t

<210> 897

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-298 targeting domain

<400> 897

a g a g g a a a a c  
22

t g a g g c a g g g

a g

<210> 898

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-299 targeting domain

<400> 898

a g g g a t a a c a  
22

g a t c c c a c t t

a a

<210> 899  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-300 targeting domain

<400> 899  
c t t g g t g c t g g g a g g a g g g g g a  
22

<210> 900  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-301 targeting domain

<400> 900  
a g a g g g t a g c t a g g a a g g c a a c  
22

<210> 901  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-302 targeting domain

<400> 901  
t t g c a c a t t g c t t c a t g g c t c c  
22

<210> 902  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-303 targeting domain

<400> 902

g a c c g a g c c c  
22

a t t g c c c a g c

a c

<210> 903

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-304 targeting domain

<400> 903

t g a a c a c t g c  
22

c t t g a t c t t a

t t

<210> 904

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-305 targeting domain

<400> 904

g g t g c a c t c c  
22

c c c c t a g a c a

g g

<210> 905

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-306 targeting domain

<400> 905

g c t t g g t g c t  
22

g g g a g g a g g g

g g

<210> 906  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-307 targeting domain

<400> 906  
g g a t a c t t c g t c t t c g g g c c c a  
22

<210> 907  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-308 targeting domain

<400> 907  
a g t c a g a c c c a g g c t g g g c a c t  
22

<210> 908  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-309 targeting domain

<400> 908  
a g c a c c a a g c c t c t g t t t c c c t  
22

<210> 909  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-310 targeting domain

<400> 909

t g g g c a a a g a  
22

a a t t c c a g g g

a a

<210> 910

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-311 targeting domain

<400> 910

a g a g g g a t t t  
22

g a g g a g g c c t

t g

<210> 911

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-312 targeting domain

<400> 911

g c a a t g t t t t  
22

g c c c a g a g g a

a g

<210> 912

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-313 targeting domain

<400> 912

c a t g t c c g g g  
22

t t a t t t c a t t

t c

<210> 913  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-314 targeting domain

<400> 913  
a a g c c c a t g a g c a a c t t c c g c t  
22

<210> 914  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-315 targeting domain

<400> 914  
t c c c a c c c t g a g c t t g g g c c c c  
22

<210> 915  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-316 targeting domain

<400> 915  
g a g a g a g c t t g g t g c t g g g a g g  
22

<210> 916  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-317 targeting domain

<400> 916

c t a c g t g c c c  
22

t t c t c c a a t g

c g

<210> 917

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-318 targeting domain

<400> 917

c t t g c a t t t a  
22

a c a g g a a a a c

a g

<210> 918

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-319 targeting domain

<400> 918

g a a a t g a a a t  
22

a a c c c g g a c a

t g

<210> 919

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-320 targeting domain

<400> 919

c g a a g g c c t g  
22

a g c t c a g c c a

c t

<210> 920  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-321 targeting domain

<400> 920  
g g a g g g t g c a c t c c c c c c t a g a  
22

<210> 921  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-322 targeting domain

<400> 921  
c a g c a c c a a g c c t c t g t t t c c c  
22

<210> 922  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-323 targeting domain

<400> 922  
g g g c a a a g a a a t t c c a g g g a a t  
22

<210> 923  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-324 targeting domain

<400> 923

c t t c g g g g a g  
22

a a c c a t g c c a

t c

<210> 924

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-325 targeting domain

<400> 924

t g g g a g g a g g  
22

g g g a a g g g g c

a g

<210> 925

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-326 targeting domain

<400> 925

c c t a g a c a g g  
22

g a g a g g g t a g

c t

<210> 926

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-327 targeting domain

<400> 926

t a a c a g a g a g  
22

g a a a a c t g a g

g c

<210> 927  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-328 targeting domain

<400> 927  
t c t c a g c c a c c a c c g c c a a g c c  
22

<210> 928  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-329 targeting domain

<400> 928  
g t c a g c a c a g a c c c c a c t g c c t  
22

<210> 929  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-330 targeting domain

<400> 929  
a g g a a a a c t g a g g c a g g g a g a g  
22

<210> 930  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-331 targeting domain

<400> 930

a g c c a t t g c a  
22

a a g c t g g g t g

a c

<210> 931

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-332 targeting domain

<400> 931

a a a t g a a a t a  
22

a c c c g g a c a t

g t

<210> 932

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-333 targeting domain

<400> 932

t a g c t a c c c t  
22

c t c c c t g t c t

a g

<210> 933

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-334 targeting domain

<400> 933

t g t g g g t g g g  
22

g t g t g c a g g a

g c

<210> 934  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-335 targeting domain

<400> 934  
t g g g g a a g g a g a g a g c t t g g t g  
22

<210> 935  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-336 targeting domain

<400> 935  
g a c t t g g a a c g c g g c a g g g a g g  
22

<210> 936  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-337 targeting domain

<400> 936  
a a g g a g a g a g c t t g g t g c t g g g  
22

<210> 937  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-338 targeting domain

<400> 937

g g g a a g g a g a  
22

g a g c t t g g t g

c t

<210> 938

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-339 targeting domain

<400> 938

a t t t g a g g a g  
22

g c c t t g g g g a

a g

<210> 939

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-340 targeting domain

<400> 939

a t c c a g c t g g  
22

a g c c c t g a g t

g g

<210> 940

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-341 targeting domain

<400> 940

g a g a g c t t g g  
22

t g c t g g g a g g

a g

<210> 941  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-342 targeting domain

<400> 941  
t c c t a g c t a c c c t c t c c c t g t c  
22

<210> 942  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-343 targeting domain

<400> 942  
c c g a g g c a g c a g c c t g g a c a t g  
22

<210> 943  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-344 targeting domain

<400> 943  
g g g g a a g g a g a g a g c t t g g t g c  
22

<210> 944  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-345 targeting domain

<400> 944

t g c t g g g a g g  
22

a g g g g g a a g g

g g

<210> 945

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-346 targeting domain

<400> 945

c t t c t t g t g c  
22

t g g a c g g t g a

c g

<210> 946

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-347 targeting domain

<400> 946

t a c c a c a c c c  
22

g t c g c a t t g g

a g

<210> 947

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-348 targeting domain

<400> 947

a g c a g c c t g g  
22

a c a t g g g g g a

g a

<210> 948  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-349 targeting domain

<400> 948  
a g c c a g g t a g t a c t g t g g g t a c  
22

<210> 949  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-350 targeting domain

<400> 949  
g g c t g c t t g c g g t t c t c a a c a c  
22

<210> 950  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-351 targeting domain

<400> 950  
g g a c c g a g g c a g c a g c c t g g a c  
22

<210> 951  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-352 targeting domain

<400> 951

c t g g g c a a a g  
22

a a a t t c c a g g

g a

<210> 952

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-353 targeting domain

<400> 952

t g a g a g g g g a  
22

g g c a g a g g a t

g c

<210> 953

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-354 targeting domain

<400> 953

g a g g g t g c a c  
22

t c c c c c c t a g

a c

<210> 954

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-355 targeting domain

<400> 954

c g g t t c t c a a  
22

c a c c a g g a g a

c t

<210> 955  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-356 targeting domain

<400> 955  
t g t g c a a t g t t t t g c c c a g a g g  
22

<210> 956  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-357 targeting domain

<400> 956  
g g g g g a g a c a g g g c a a g g c t g g  
22

<210> 957  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-358 targeting domain

<400> 957  
g c c g g g t g t g g g t g g g t g t g c  
22

<210> 958  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-359 targeting domain

<400> 958

c t g c g t a c c a  
22

c a c c c g t c g c

a t

<210> 959

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-360 targeting domain

<400> 959

c a c c c a a g a a  
22

t g c t g c g a a g

g c

<210> 960

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-361 targeting domain

<400> 960

c c t a g c t a c c  
22

c t c t c c c t g t

c t

<210> 961

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-362 targeting domain

<400> 961

c a c c a g g a g a  
22

c t t g g a a c g c

g g

<210> 962  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-363 targeting domain

<400> 962  
t t g g a t a a c a t t g a c a g g a c a g  
22

<210> 963  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-364 targeting domain

<400> 963  
t t c g g g c c c a c a g g a t g c a a t t  
22

<210> 964  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-365 targeting domain

<400> 964  
g a a g t a t c c a t g c a g a g a g g t g  
22

<210> 965  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-366 targeting domain

<400> 965

g g t g t g c a g g  
22

a g c c c g g g a g

c a

<210> 966

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-367 targeting domain

<400> 966

g g a g c a g c c a  
22

c g g g t c a g c c

a c

<210> 967

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-368 targeting domain

<400> 967

a g c g c c c t g c  
22

t g g g g c g t c a

c a

<210> 968

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-369 targeting domain

<400> 968

g a g c c c g g g a  
22

g c a t g g a g g g

g t

<210> 969  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-370 targeting domain

<400> 969  
a g g g c c a c a g c c a t g a a t g g c a  
22

<210> 970  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-371 targeting domain

<400> 970  
g c a a t g t g c a a t g t t t t g c c c a  
22

<210> 971  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-372 targeting domain

<400> 971  
g a a g a g g t c a g c c a c g g c t a g g  
22

<210> 972  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-373 targeting domain

<400> 972

g g c c t t c g c a  
22

g c a t t c t t g g

g t

<210> 973

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-374 targeting domain

<400> 973

t t a a c a g a g a  
22

g g a a a a c t g a

g g

<210> 974

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-375 targeting domain

<400> 974

t g a t g g c a t g  
22

g t t c t c c c c g

a a

<210> 975

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-376 targeting domain

<400> 975

a c c g a g g c a g  
22

c a g c c t g g a c

a t

<210> 976  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-377 targeting domain

<400> 976  
a g g g a c c a c a c g c t g a g g a g a g  
22

<210> 977  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-378 targeting domain

<400> 977  
t g g a a c g c g g c a g g g a g g c t g g  
22

<210> 978  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-379 targeting domain

<400> 978  
t g c a c a t t g c t t c a t g g c t c c t  
22

<210> 979  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-380 targeting domain

<400> 979

g c g t t c c a a g  
22

t c t c c t g g t g

t t

<210> 980

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-381 targeting domain

<400> 980

g g g t g t g c a g  
22

g a g c c c g g g a

g c

<210> 981

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-382 targeting domain

<400> 981

g g c a a a g a a a  
22

t t c c a g g g a a

t g

<210> 982

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-383 targeting domain

<400> 982

g g c t g g a g g g  
22

g c a c c t g a g g

a c

<210> 983  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-384 targeting domain

<400> 983  
g c g c c c t g c t g g g g c g t c a c a c  
22

<210> 984  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-385 targeting domain

<400> 984  
g c g t a c c a c a c c c g t c g c a t t g  
22

<210> 985  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-386 targeting domain

<400> 985  
a c c a g g a g a c t t g g a a c g c g g c  
22

<210> 986  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-387 targeting domain

<400> 986

g c t g c t g c c t  
22

c g g t c c c a t t

c t

<210> 987

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-388 targeting domain

<400> 987

g a a g c c c t c c  
22

a a a t t g c a t c

c t

<210> 988

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-389 targeting domain

<400> 988

c g t a g a g c g t  
22

g a g g a a g t t g

a t

<210> 989

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-390 targeting domain

<400> 989

c t g a a g c a g t  
22

t c c t t t t t g c

t t

<210> 990  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-391 targeting domain

<400> 990  
g c t g g a c g g t g a c g t a g a g c g t  
22

<210> 991  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-392 targeting domain

<400> 991  
t g a g g g c t t t g g a t a a c a t t g a  
22

<210> 992  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-393 targeting domain

<400> 992  
a g c c g g g t g t g g g t g g g g t g t g  
22

<210> 993  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-394 targeting domain

<400> 993

c t c a g t t t t c  
22

c t c t c t g t t a

a g

<210> 994

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-395 targeting domain

<400> 994

c a a g a c a t t a  
22

t t c t a a a g c a

a a

<210> 995

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-396 targeting domain

<400> 995

t g g a a c t t c a  
22

t g g g g t g g t g

a g

<210> 996

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-397 targeting domain

<400> 996

g a g a g g g a t t  
22

t g a g g a g g c c

t t

<210> 997  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-398 targeting domain

<400> 997  
c t t c g g g c c c a c a g g a t g c a a t  
22

<210> 998  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-399 targeting domain

<400> 998  
a c t t g g a a c g c g g c a g g g a g g c  
22

<210> 999  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RH0-400 targeting domain

<400> 999  
a t g g c c a g a g a t t c c c t g a g a a  
22

<210> 1000  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> RH0-401 targeting domain

<400> 1000

c c t c a g t t t t  
22

c c t c t c t g t t

a a

<210> 1001

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-402 targeting domain

<400> 1001

t a a c a g a t c c  
22

c a c t t a a c a g

a g

<210> 1002

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> RH0-403 targeting domain

<400> 1002

g g g a g a g g g a  
22

t t t g a g g a g g

c c